0001171843-15-006357.txt : 20151116 0001171843-15-006357.hdr.sgml : 20151116 20151116132756 ACCESSION NUMBER: 0001171843-15-006357 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151116 DATE AS OF CHANGE: 20151116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOINT Corp CENTRAL INDEX KEY: 0001612630 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 900544160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36724 FILM NUMBER: 151233191 BUSINESS ADDRESS: STREET 1: 16767 N PERIMETER DRIVE STREET 2: SUITE 240 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 BUSINESS PHONE: 480 245 5960 MAIL ADDRESS: STREET 1: 16767 N PERIMETER DRIVE STREET 2: SUITE 240 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 10-Q 1 gff10q_111315p.htm FORM 10-Q



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2015

 

OR

 

[   ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the transition period from __________________ to _________________

 

Commission file number: 001-36724

 

The Joint Corp.

(Exact name of registrant as specified in its charter)

 

Delaware 90-0544160

(State or other jurisdiction of incorporation or

organization)

(IRS Employer Identification No.)

 

16767 N. Perimeter Drive, Suite 240, Scottsdale

Arizona

85260
(Address of principal executive offices) (Zip Code)

 

(480) 245-5960

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes þ   No  o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes þ     No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company þ

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)   Yes o     No þ

 

As of November 9, 2015, the registrant had 9,906,491 shares of Common Stock ($0.001 par value) outstanding.

 

 

THE JOINT CORP.

FORM 10-Q

 

TABLE OF CONTENTS

 

      PAGE NO.
PART I FINANCIAL INFORMATION  
       
  Item 1. Financial Statements:  
    Condensed Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014 1
    Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015 and 2014 (unaudited) 2
    Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014 (unaudited) 3
    Notes to Condensed Consolidated Financial Statements (unaudited) 5
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
       
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 28
       
  Item 4 Controls and Procedures 28
     
PART II OTHER INFORMATION  
       
  Item 1. Legal Proceedings 28
       
  Item 1A. Risk Factors 29
       
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29
       
  Item 6. Exhibits 29
       
  SIGNATURES 29
       
  EXHIBIT INDEX 30
       
Part II, Items 3, 4, and 5 - Not applicable  

 

 

 
 

PART I: FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

THE JOINT CORP. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS 

 

  

September 30,

2015

 

December 31,

2014

ASSETS  (unaudited)   
Current assets:          
Cash and cash equivalents  $9,522,013   $20,796,783 
Restricted cash   188,431    224,576 
Accounts receivable, net   605,876    704,905 
Income taxes receivable   449,803    395,814 
Note receivable - current portion   61,533    27,528 
Deferred franchise costs - current portion   548,400    622,800 
Deferred tax asset - current portion   61,000    208,800 
Prepaid expenses and other current assets   151,794    375,925 
Total current assets   11,588,850    23,357,131 
Property and equipment, net   3,602,217    1,134,452 
Note receivable, net of current portion and reserve   26,024    31,741 
Deferred franchise costs, net of current portion   1,799,000    2,574,450 
Intangible assets, net   2,317,484    153,000 
Goodwill   2,948,363    636,104 
Deposits and other assets   203,244    585,150 
Total assets  $22,485,182   $28,472,028 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $1,436,350   $1,271,405 
Co-op funds liability   159,770    186,604 
Payroll liabilities   1,397,215    617,944 
Notes payable - current portion   466,850    - 
Deferred rent - current portion   101,498    93,398 
Deferred revenue - current portion   2,275,035    1,957,500 
Other current liabilities   48,254    50,735 
Total current liabilities   5,884,972    4,177,586 
Notes payable, net of current portion   167,500    - 
Deferred rent, net of current portion   488,746    451,766 
Deferred revenue, net of current portion   4,820,259    7,915,918 
Other liabilities   266,592    299,405 
Total liabilities   11,628,069    12,844,675 
Commitments and contingencies          
Stockholders' equity:          
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of September 30, 2015, and  December 31, 2014   -    - 
Common stock, $0.001 par value; 20,000,000 shares authorized, 10,402,047 shares issued and 9,868,047 shares outstanding as of September 30, 2015 and 10,196,502 shares issued and 9,662,502 outstanding as of December 31, 2014   10,402    10,197 
Additional paid-in capital   22,066,847    21,420,975 
Treasury stock (534,000 shares as of September 30, 2015 and December 31, 2014, at cost)   (791,638)   (791,638)
Accumulated deficit   (10,428,498)   (5,012,181)
Total stockholders' equity   10,857,113    15,627,353 
Total liabilities and stockholders' equity  $22,485,182   $28,472,028 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 1 
 

 

THE JOINT CORP. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

  

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

   2015  2014  2015  2014
Revenues:                    
Royalty fees  $1,150,574   $871,462   $3,264,278   $2,233,053 
Franchise fees   638,000    435,000    1,862,259    1,469,500 
Revenues and management fees from company clinics   1,198,397    -    2,368,866    - 
Advertising fund revenue   330,502    88,031    955,480    204,141 
IT related income and software fees   197,569    218,400    598,758    629,225 
Regional developer fees   531,350    152,250    799,600    377,000 
Other revenues   91,623    51,452    223,419    148,347 
Total revenues   4,138,015    1,816,595    10,072,660    5,061,266 
Cost of revenues:                    
Franchise cost of revenues   697,170    556,495    1,948,328    1,505,569 
IT cost of revenues   48,312    97,900    134,233    233,563 
Cost of revenues   745,482    654,395    2,082,561    1,739,132 
Selling and marketing expenses   693,953    324,177    2,450,976    723,955 
Depreciation and amortization   421,390    52,823    822,489    141,707 
General and administrative expenses   4,328,089    1,096,025    10,528,817    3,146,666 
Total selling, general and administrative expenses   5,443,432    1,473,025    13,802,282    4,012,328 
Loss from operations   (2,050,899)   (310,825)   (5,812,183)   (690,194)
                     
Other income (expense):                    
Bargain purchase gain   384,214    -    384,214    - 
Other income (expense), net   16,111    (54,599)   17,800    (58,399)
Total other income (expense)   400,325    (54,599)   402,014    (58,399)
                     
Loss before income tax (expense) benefit   (1,650,574)   (365,424)   (5,410,169)   (748,593)
                     
Income tax (expense) benefit   (6,148)   163,051    (6,148)   284,574 
                     
Net loss and comprehensive loss  $(1,656,722)  $(202,373)  $(5,416,317)  $(464,019)
                     
Loss per share:                    
Basic and diluted loss per share  $(0.17)  $(0.04)  $(0.55)  $(0.10)
                     
Weighted average shares   9,844,964    4,828,122    9,777,119    4,819,861 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

  

 2 
 

THE JOINT CORP. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

  

Nine Months Ended

September 30,

   2015  2014
Cash flows from operating activities:          
Net loss  $(5,416,317)  $(464,019)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:          
Provision for bad debts   4,344    91,831 
Regional developer fees recognized upon acquisition of development rights   (254,250)   - 
Net franchise fees recognized upon termination of franchise agreements   (480,250)   - 
Notes receivable issued for payment of transfer fees   (49,850)   - 
Depreciation and amortization   822,489    141,707 
Gain on sale of property and equipment   (11,500)   - 
Deferred income taxes   147,800    - 
Bargain purchase gain   (384,214)   - 
Stock based compensation expense   646,077    42,047 
Changes in operating assets and liabilities, net of effects from acquisitions:          
Restricted cash   36,145    (158,950)
Accounts receivable   94,684    (8,582)
Income taxes receivable   (53,989)   (320,290)
Prepaid expenses and other current assets   224,131    (45,230)
Deferred franchise costs   (18,100)   178,000 
Deposits and other assets   (125,594)   - 
Accounts payable and accrued expenses   164,945    450,515 
Co-op funds liability   (26,834)   44,971 
Payroll liabilities   779,271    188,159 
Other liabilities   (35,294)   56,547 
Deferred rent   62,549    543,563 
Income taxes payable   -    (419,297)
Deferred revenue   (134,925)   (435,354)
Net cash used in operating activities   (4,008,682)   (114,382)
           
Cash flows from investing activities:          
Cash paid for acquisitions   (4,652,525)   - 
Reacquisition and termination of regional developer rights   (1,075,500)   - 
Purchase of property and equipment   (1,461,125)   (538,323)
Proceeds received on sale of property and equipment   11,500    2,500 
Payments received on notes receivable   21,562    19,301 
Net cash used in investing activities   (7,156,088)   (516,522)
           
Cash flows from financing activities:          
Deferred offering costs   -    (511,921)
Repayments on note payable   (110,000)   - 
Net cash used in financing activities   (110,000)   (511,921)
           
Net decrease in cash   (11,274,770)   (1,142,825)
Cash at beginning of period   20,796,783    3,516,750 
Cash at end of period  $9,522,013   $2,373,925 
           
Supplemental cash flow disclosures:          
Cash paid for income taxes  $-   $420,250 
Cash paid for interest  $1,445   $- 

 

 3 
 

Supplemental disclosure of non-cash activity:

 

In connection with our acquisitions of franchises during the nine months ended September 30, 2015, we acquired $1,539,321 of property and equipment, intangible assets of $1,531,041, goodwill of $2,312,259, favorable leases of $17,469 and assumed deferred revenue associated with membership packages paid in advance of $117,301 in exchange for $4,652,525 in cash and an aggregate amount of $744,350 in notes payable to the sellers. Additionally, at the time of these transactions, we carried deferred revenue of $976,500, representing franchise fees collected upon the execution of franchise agreements, and deferred costs of $478,200, related to our acquisition of undeveloped franchises. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 2).

 

In connection with our reacquisition and termination of regional developer rights during the nine months ended September 30, 2015, we had deferred revenue of $914,000, representing license fees collected upon the execution of the regional developer agreements. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 5).

  

As of December 31, 2014, we recorded a deposit of $507,500 for the reacquisition and termination of regional developer rights, which were paid in advance. During the nine months ended September 30, 2015, we reclassified $507,500 from deposits to intangible assets.

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 4 
 

 

THE JOINT CORP. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

Note 1: Nature of Operations and Summary of Significant Accounting Policies

 

Basis of Presentation

 

These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”) and its wholly owned subsidiary The Joint Corporate Unit No. 1, LLC (collectively, the “Company”). These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary consolidated financial statements and the notes thereto as set forth in The Joint Corp.’s Form 10-K, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company’s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended September 30, 2015 and 2014 is unaudited.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the “Company”), which was dormant for all periods presented.

 

All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation.

 

Comprehensive Loss

 

 Net loss and comprehensive loss are the same for the three and nine months ended September 30, 2015 and 2014.

 

Nature of Operations

 

The Joint Corp., a Delaware corporation, was formed on March 10, 2010. Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.

 

 5 
 

The following table summarizes the number of clinics in operation under franchise agreements or that are company-owned or managed for the three and nine months ended September 30, 2015 and 2014:

 

   Three Months Ended
 September 30,
  Nine Months Ended
 September 30,
Franchised clinics:  2015  2014  2015  2014
Clinics open at beginning of period   239    215    242    175 
Opened during the period   13    16    36    57 
Acquired during the period   (2)   -    (23)   - 
Closed during the period   (2)   (1)   (7)   (2)
Clinics in operation at the end of the period   248    230    248    230 

 

   Three Months Ended
 September 30,
  Nine Months Ended
 September 30,
Company-owned or managed clinics:  2015  2014  2015  2014
Clinics open at beginning of period   23    -    4    - 
Opened during the period   4    -    4    - 
Acquired during the period   2    -    23    - 
Closed during the period   -    -    (2)   - 
Clinics in operation at the end of the period   29    -    29    - 
                     
Total clinics in operation at the end of the period   277    230    277    230 
                     
Clinic licenses sold but not yet developed   180    248    180    248 

 

Variable Interest Entities

 

An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a variable interest entity (“VIE”) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.

 

Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs. Such PCs are VIEs. In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice.  The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the PCs. As such, the activity of the PCs is not included in the Company’s consolidated financial statements.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its IPO in short-term bank deposits. The Company had no cash equivalents as of September 30, 2015 and December 31, 2014.

 

 6 
 

Restricted Cash

 

Restricted cash relates to cash franchisees and corporate clinics contribute to the Company’s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.

 

Concentrations of Credit Risk

 

From time to time the Company grants credit in the normal course of business to franchisees related to the collection of royalties and other operating revenues. The Company periodically performs credit analysis and monitors the financial condition of the franchisees to reduce credit risk.  As of December 31, 2014, six franchisees represented 56% of outstanding accounts receivable. The Company did not have any customers that represented greater than 10% of its accounts receivable or revenues during the three and nine months ended September 30, 2015 and 2014.

 

Accounts Receivable

 

Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees and marketing and advertising expenses. The Company considers a reserve for doubtful accounts based on the creditworthiness of the franchisee. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management’s best estimate of uncollectible amounts and is determined based on specific identification and historical performance that the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of September 30, 2015 and December 31, 2014, the Company had an allowance for doubtful accounts of $85,376 and $81,032, respectively.

 

Deferred Franchise Costs

 

Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.

 

Property and Equipment

 

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.

 

Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

 

Software Developed

 

The Company capitalizes most software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally 5 years.

 

 7 
 

Intangible Assets

 

Intangible assets consist primarily of re-acquired franchise rights and customer relationships.  The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from six to seven years. The fair value of customer relationships is amortized over their estimated useful life of 2 years.

 

Goodwill

 

Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note 2.  Under ASC 350-10, goodwill and intangible assets deemed to have indefinite lives are no longer amortized but are subject to annual impairment tests. As required, the Company performs an annual impairment test of goodwill as of the first day of the fourth quarter or more frequently if events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.

 

Long-Lived Assets

 

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. No impairments of long-lived assets were recorded for the periods ended September 30, 2015 and 2014.

 

Advertising Fund

 

The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee was increased to 2% in January 2015. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense properly eliminating intercompany transactions. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company’s consolidated balance sheets.

 

Co-Op Marketing Funds

 

Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops’ officers. The marketing funds are included in restricted cash on the Company’s consolidated balance sheets.

 

Deferred Rent

 

The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which may include rent holidays and rent escalation clauses.  It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.  The Company records tenant improvement allowances as deferred rent liabilities and amortizes the allowance over the term of the lease, as a reduction to rent expense.

 

Revenue Recognition

 

The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.

 

Franchise Fees. The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of ten years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.  The Company’s services under the franchise agreement include: training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.

 

 8 
 

During the three and nine months ended September 30, 2015, the Company terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, the Company recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.

  

Regional Developer Fees. During 2011, the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from $7,250 to 25% of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from $14,500 to $19,950 which are collected upon the sale of franchises within their region and a royalty of 3% of sales generated by franchised clinics in their region. Regional developer fees are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. When the Company anticipates that the number of franchised clinics to be opened will exceed the contracted minimum, the license fee on a per-clinic basis is determined by dividing the total fee collected from the regional developer by the number of clinics expected to be opened within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the fee per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. The franchisor’s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer’s license.

 

Revenues and Management Fees from Company Clinics.  The Company earns revenues from clinics that it owns and operates or manages throughout the United States.  In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.  Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.  In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor’s PC.  Under the management agreement, the Company provides administrative and business management services to the doctor’s PC in return for a monthly management fee.  When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.

 

Royalties. The Company collects royalties, as stipulated in the franchise agreement, equal to 7% of gross sales, and a marketing and advertising fee currently equal to 2% of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly two working days after each sales period has ended.

 

IT Related Income and Software Fees.  The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic’s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue upon receipt of equipment by the franchisee.

 

Advertising Costs

 

The Company incurs advertising costs in addition to those included in the advertising fund. The Company’s policy is to expense all operating advertising costs as incurred. Advertising expenses were $377,122 and $853,110 for the three and nine months ended September 30, 2015, respectively. Advertising expenses were $53,691 and $93,730 for the three and nine months ended September 30, 2014, respectively. 

 

 9 
 

Income Taxes

 

The Company accounts for income taxes in accordance with the ASC 740 that requires the recognition of deferred income taxes for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.

 

At September 30, 2015 and December 31, 2014, the Company maintained a liability for income taxes for uncertain tax positions of approximately $142,000 and $122,000, respectively, of which $36,000 and $30,000, respectively, represent penalties and interest and are recorded in the  “other liabilities” section of the accompanying condensed consolidated balance sheets. Interest and penalties associated with tax positions are recorded in the period assessed as general and administrative expenses. The Company’s tax returns for tax years subject to examination by tax authorities include 2011 through the current period for state and 2012-through the current period for federal reporting purposes.

 

Loss per Common Share

 

Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.

 

  

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

   2015  2014  2015  2014
             
Net loss  $(1,656,722)  $(202,373)  $(5,416,317)  $(464,019)
                     
Weighted average common shares outstanding - basic   9,844,964    4,828,122    9,777,119    4,819,861 
Effect of dilutive securities:                    
Stock options   -    -    -    - 
Weighted average common shares outstanding - diluted   9,844,964    4,828,122    9,777,119    4,819,861 
                     
Basic and diluted loss per share  $(0.17)  $(0.04)  $(0.55)  $(0.10)

 

The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:

 

   Three Months Ended
September 30,
  Nine Months Ended
September 30,
   2015  2014  2015  2014
Unvested restricted stock   393,339    542,354    393,339    542,354 
Stock options   524,600    266,555    524,600    266,555 
Warrants   90,000    -    90,000    - 

 

 10 
 

Stock-Based Compensation

 

The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Prior to the IPO the grant date fair value was determined by the Board of Directors. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.

  

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs and the related deferred tax assets and liabilities as long-term or current, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets and purchase price allocations.

 

Recent Accounting Pronouncements

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern: Disclosures about an Entity’s Ability to Continue as a Going Concern.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The new guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU No. 2014-15 on its consolidated financial statements.

 

In April 2015, the FASB issued ASU 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.”  The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.  Debt disclosures will include the face amount of the debt liability and the effective interest rate.  The update requires retrospective application and represents a change in accounting principle.  The update is effective for fiscal years beginning after December 15, 2015.  Early adoption is permitted for financial statements that have not been previously issued.  ASU 2015-03 is not expected to have a material impact on the Company’s consolidated financial statements.

 

In April 2015, FASB issued ASU No. 2015-05, “Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.”  The guidance provides clarification on whether a cloud computing arrangement includes a software license.  If a software license is included, the customer should account for the license consistent with its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a service contract.  The update is effective for reporting periods beginning after December 15, 2015.  The Company is currently evaluating the impact of the adoption of ASU No. 2015-05 on its consolidated financial statements. 

 

 11 
 

In September 2015, the FASB issued Accounting Standards Update ("ASU") 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the three months ended September 30, 2015. Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the three months ended September 30, 2015 with no material effect on previous-period or current-period earnings. See "Note 2—Acquisitions" for more information regarding adjustments to provisional amounts that occurred during the three months ended September 30, 2015.

 

Note 2:Acquisitions

 

Franchises acquired during 2014

 

During 2014, the Company acquired substantially all the assets and certain liabilities of six franchises including franchises that manage four clinics operating in Los Angeles County, for a purchase price of $900,000 which was paid in cash. The Company is operating four of the acquired franchises as managed company clinics and has terminated the two remaining franchises. On January 1, 2015, the Company acquired an additional three undeveloped franchises.  This resulted in a net deferred revenue adjustment of $41,100 to the net purchase price.  No additional consideration was paid on January 1, 2015. The remaining $858,900 was accounted for as the total consideration paid for the acquired franchises.

 

The purchase price allocation for these acquisitions is complete. The following summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date:

 

Property and equipment  $297,630 
Intangible assets   153,000 
Goodwill   636,104 
Total assets acquired   1,086,734 
Unfavorable leases   (227,834)
Net assets acquired  $858,900 

 

Intangible assets consist of reacquired franchise rights of $81,000 and customer relationships of $72,000 and will be amortized over their estimated useful lives of seven years and two years, respectively.

 

Unfavorable leases consist of leases with rents that are in excess of market value. This liability will be amortized over the lives of the associated leases.

 

Goodwill recorded in connection with this acquisition was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible.

 

The Company has retrospectively adjusted the condensed consolidated balance sheet as of December 31, 2014 related to adjustments to the purchase price allocation of the above acquisition.  The impacts are adjustments to deferred franchise costs, goodwill and deferred revenue, with no changes to total net assets.  There were no impacts on the consolidated statements of operations or cash flows for any prior periods as a result of these adjustments.  The balance sheet impacts are as follows:

 

   December 31, 2014
   As reported  As revised
       
Deferred franchise costs - current portion  $668,700   $622,800 
Goodwill  $677,204   $636,104 
Deferred revenue - current portion  $2,044,500   $1,957,500 

 

 12 
 

 

Franchises acquired during 2015

 

During the nine months ended September 30, 2015, the Company continued to execute its growth strategy and entered into a series of unrelated transactions with existing franchisees to re-acquire an aggregate of 23 developed and 34 undeveloped franchises throughout Arizona, California, and New York for an aggregate purchase price of $5,396,875, subject to certain adjustments, consisting of cash of $4,652,525 and notes payable of $744,350. Of the 23 developed franchises, the Company is operating 21 as company-owned or managed clinics and has closed the remaining two clinics. The 34 undeveloped franchises have been terminated and the Company may relocate them. At the time these transactions were consummated, the Company carried a deferred revenue balance of $976,500, representing franchise fees collected upon the execution of the franchise agreements, and deferred franchise costs of $478,200, related to undeveloped franchises.  In accordance with ASC 952-605, the Company accounted for the franchise rights associated with the undeveloped franchise as a cancellation, and the respective deferred revenue and deferred franchise costs were netted against the aggregate purchase price.  The remaining $4,898,575 was accounted for as consideration paid for the acquired franchises.

  

Additionally, in January 2015, in connection with the default by a franchisee under its franchise agreement, the Company assumed substantially all of the assets of a clinic in Tempe, Arizona in exchange for $25,000.  The Company has accounted for this as a business combination.  The Company completed its valuation of the fair value of the assets acquired, including intangible assets, in September 2015. Because the net assets acquired exceeded the consideration paid, the Company recognized a bargain purchase gain of $384,214 during the three months ended September 30, 2015.

 

The Company incurred $361,997 of transaction costs related to these acquisitions for the nine months ended September 30, 2015.

 

Purchase Price Allocation

 

The purchase price allocations for these acquisitions are preliminary and subject to further adjustment upon finalization of the opening balance sheet. The following summarizes the aggregate fair values of the assets acquired and liabilities assumed during 2015 as of the acquisition date:

 

Property and equipment  $1,539,321 
Intangible assets   1,531,041 
Favorable leases   17,469 
Goodwill   2,312,259 
Total assets acquired   5,400,090 
Deferred membership revenue   (117,301)
Net assets acquired  $5,282,789 
Bargain purchase gain   (384,214)
Net purchase price  $4,898,575 

 

Intangible assets in the table above consist of reacquired franchise rights of $1,215,248 and customer relationships of $315,793, and will be amortized over their estimated useful lives ranging from six to seven years and two years, respectively.

 

The estimates of the fair value of the assets or rights acquired and liabilities assumed at the date of the applicable acquisition are subject to adjustment during the measurement period (up to one year from the particular acquisition date). The primary areas of the accounting for the acquisitions that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired, residual goodwill and any related tax impact. The fair value of these net assets acquired are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. While the Company believes that such preliminary estimates provide a reasonable basis for estimating the fair value of assets acquired and liabilities assumed, it evaluates any necessary information prior to finalization of the fair value. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the revised estimated values of those assets or liabilities as of that date. The effect of measurement period adjustments to the estimated fair value is reflected as if the adjustments had been completed on the acquisition date. The impact of all changes that do not qualify as measurement period adjustments are included in current period earnings. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could be subject to a possible impairment of the intangible assets or goodwill, or require acceleration of the amortization expense of intangible assets in subsequent periods. During the three months ended September 30, 2015, the Company made certain measurement period adjustments related to several acquisitions consummated in period. Property and equipment was increased by $47,859, intangible assets increased by $72,400, favorable leases increased by $17,469 and deferred membership revenue decreased by $7,032 with the resulting offset to goodwill of $130,696.

 

 13 
 

Goodwill recorded in connection with these acquisitions was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible. 

 

Pro Forma Results of Operations (Unaudited)

 

The following table summarizes selected unaudited pro forma condensed consolidated statements of operations data for the three and nine months ended September 30, 2015 and 2014 as if the acquisitions had been completed on January 1, 2014.

 

   Pro Forma for the Three Months Ended  Pro Forma for the Nine Months Ended
   September 30, 2015  September 30, 2014  September 30, 2015  September 30, 2014
Revenues, net  $4,159,975   $2,668,562   $11,030,264   $7,465,179 
Net loss  $(2,064,297)  $(814,369)  $(6,338,663)  $(2,811,855)

 

This selected unaudited pro forma consolidated financial data is included only for the purpose of illustration and does not necessarily indicate what the operating results would have been if the acquisitions had been completed on that date. Moreover, this information does not indicate what the Company’s future operating results will be. The information for 2014 and 2015 prior to the acquisitions is included based on prior accounting records maintained by the acquired companies. In some cases, accounting policies differed materially from accounting policies adopted by the Company following the acquisitions. For 2015, this information includes actual data recorded in its financial statements for the period subsequent to the date of the acquisition. The Company’s consolidated statement of operations for the three months ended September 30, 2015 includes net revenue and net loss of $1,198,397 and $(854,948), respectively, attributable to the 2015 acquisitions. The Company’s consolidated statement of operations for the nine months ended September 30, 2015 includes net revenue and net loss of $2,368,866 and $(1,209,682), respectively, attributable to the acquisitions. As the 2014 acquisition occurred on the last day of the period, there were no net revenues or income attributable to the acquisitions.

 

The pro forma amounts included in the table above reflect the application of accounting policies and adjustment of the results of the clinics to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied from January 1, 2014, together with the consequential tax impacts.

 

Note 3: Notes Receivable

 

Effective July 2012, the Company sold a company-owned clinic, including the license agreement, equipment, and customer base, in exchange for a $90,000 unsecured promissory note. The note bears interest at 6% per annum for fifty-four months and requires monthly principal and interest payments over forty-two months, beginning August 2013 and maturing January 2017.

 

Effective July 2015, the Company entered into two license transfer agreements, in exchange for $10,000 and $29,925 in separate unsecured promissory notes.  The non-interest bearing notes require monthly principal payments over 24 months, beginning on September 1, 2015 and maturing on August 1, 2017. Effective July 2015, the Company entered into a license transfer agreement, in exchange for $29,925 in an unsecured promissory note.  The note bearings interest at 4.0% per annum, and requires monthly principal payments over 12 months, beginning on August 1, 2015 and maturing on July 1, 2016.

 

The outstanding balance of the notes as of September 30, 2015 and December 31, 2014 were $87,557 and $59,269, respectively.

 

 14 
 

  

Note 4: Property and Equipment

 

Property and equipment consists of the following:

 

   September 30,
2015
  December 31,
2014
       
Office and computer equipment  $470,251   $209,575 
Leasehold improvements   2,330,927    665,961 
Software developed   688,471    564,560 
    3,489,649    1,440,096 
Accumulated depreciation   (838,325)   (305,644)
    2,651,324    1,134,452 
Assets in progress   950,893    - 
   $3,602,217   $1,134,452 

 

Depreciation expense was $257,197 and $532,682 for the three and nine months ended September 30, 2015, respectively. Depreciation expense was $52,823 and $141,707 for the three and nine months ended September 30, 2014, respectively.

 

Assets in progress relate to the ongoing development of company-owned or managed clinics, which are not yet placed in service.

 

Note 5: Intangible Assets

 

During the nine months ended September 30, 2015, the Company entered into several agreements to repurchase regional developer licenses, reacquiring rights in Los Angeles County, San Diego, and Orange County, all located in the state of California, Erie County, Monroe County, Nassau County, Suffolk County, and Albany County, all located in the state of New York, and the regional developer license in New Jersey in exchange for cash consideration of $1,583,000, of which $507,500 was recorded as a cash advance at December 31, 2014.  The Company carried a deferred revenue balance associated with these transactions of $914,000, representing license fees collected upon the execution of the regional developer agreements.  In accordance with ASC 952-605, the Company accounted for the development rights associated with the unsold or undeveloped franchises as a cancellation, and the respective deferred revenue was netted against the aggregate purchase price or recognized as revenue to the extent deferred revenue was in excess of the cash consideration paid.   During the nine months ended September 30, 2015, the revenue recognized as excess deferred regional developer fees totaled $254,250. The remaining balance was accounted for as consideration paid for the reacquired development rights. As the deferred revenue with respect to these regional developer rights had previously been taken into account for income tax purposes, the tax basis in the reacquired development rights is equal to the cash consideration paid.

 

Intangible assets which remain subject to adjustment upon receipt of final valuation information consisted of the following:

 

 

   As of September 30, 2015
  

Gross Carrying

Amount

 

Accumulated

Amortization

 

Net Carrying

Value

Amortized intangible assets:               
Reacquired franchise rights  $1,296,248   $108,916   $1,187,332 
Customer relationships   387,793    101,652    286,141 
Reacquired development rights   923,250    79,239    844,011 
  $2,607,291   $289,807   $2,317,484 
Unamortized intangible assets:              
Goodwill             2,948,363 
Total intangible assets            $5,265,847 

 

Amortization expense was $164,193 and $289,807 for the three and nine months ended September 30, 2015, respectively. There was no amortization expense for the three and nine months ended September 30, 2014.

 

 15 
 

Estimated amortization expense for 2015 and subsequent years is as follows:

 

2015  $129,101 
2016   518,896 
2017   368,634 
2018   325,000 
2019   325,000 
Thereafter   650,853 
Total  $2,317,484 

 

 

Note 6: Notes Payable

 

On February 17, 2015, the Company delivered a $155,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and a license to develop one additional franchise from Roth & Pelan Enterprises, LLC.  This note bears interest at 1.5% per annum with a principal payment of $25,000 plus interest due on June 17, 2015, and the remaining principal and interest due February 17, 2017.  While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.

 

On March 3, 2015, the Company delivered a $60,000 note payable as a portion of the consideration paid in connection with the acquisition of four existing franchises and a license to develop one additional franchise from TJSC, LLC. This note bears interest at 4.5% per annum with a principal payment of $30,000 plus interest due on July 30, 2015, and the remaining principal plus interest due on January 30, 2016.

 

On March 6, 2015, the Company delivered a $30,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop seven additional franchises from The Joint San Gabriel Valley Inc. This note bears interest at 1.5% per annum with principal and interest due on November 19, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.

 

On March 23, 2015, the Company delivered a $10,000 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Arrowhead Ranch LLC. This note bears interest at 1.5% per annum with principal and interest due September 20, 2016.  The seller fully performed its duties under the agreement and one half of the principal plus interest was paid on September 21, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.

 

On April 1, 2015, the Company delivered a $58,500 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Chiropractic Bell Towne LLC. This note bears interest at 1.50% per annum with the principal and interest due September 30, 2015.  The seller fully performed its duties under the agreement and $25,000 plus interest was paid on August 18, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.

 

On May 1, 2015, the Company delivered a $80,900 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop six additional franchises from San Diego Joint Development Inc. This note bears interest at 4.25% per annum with the principal and interest due April 30, 2016.  The seller fully performed its duties under the agreement and $25,000 plus interest was paid on September 1, 2015. An additional $15,500 plus interest is payable on November 1, 2015 and $40,450 plus interest will be paid on April 30, 2016.

 

On May 18, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop two additional franchises from First Light Junction. This note bears interest at 4.0% per annum with the principal and interest due November 18, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable September 18, 2015, $25,000 plus interest will be paid on February 18, 2016 and $25,000 plus interest will be paid on November 18, 2016.

 

 16 
 

On June 3, 2015, the Company delivered a $100,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop four additional franchises from WHB Franchise, Inc. This note bears interest at 5.25% per annum with the principal and interest due April 3, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable October 3, 2015, $25,000 plus interest will be paid on December 3, 2015 and $50,000 plus interest will be paid on April 3, 2016.

 

On June 5, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop three additional franchises from Clear Path Ventures, Inc. This note bears interest at 4.25% per annum with the principal and interest due June 4, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable on October 5, 2015, $12,500 plus interest will be paid on December 5, 2015 and $37,500 plus interest will be paid on June 4, 2016.

 

On July 1, 2015, the Company delivered a $53,000 note payable as a portion of the consideration paid in connection with the acquisition of one franchise from Chiro Novo, LLC. This note bears interest at 4.00% per annum with the principal and interest due January 1, 2016. If the seller has fully performed its duties under the agreement, $15,000 plus interest is payable on November 1, 2015.

 

On August 10, 2015, the Company delivered a $46,950 note payable as a portion of the consideration paid in connection with the acquisition of three franchises from Chiro Group. This note bears interest at 4.25% per annum with the principal and interest due June 10, 2016. If the seller has fully performed its duties under the agreement, $25,000 plus interest will be paid on December 10, 2015.

 

Maturities of the Company’s notes payable are as follows as of September 30, 2015: 

 

2015  $231,500 
2016   272,850 
2017   130,000 
Total  $634,350 

 

Note 7:       Equity

 

Initial Public Offering

 

The Company completed its initial public offering of 3,000,000 shares of common stock at a price to the public of $6.50 per share on November 14, 2014, whereupon it received aggregate net proceeds of approximately $17,065,000 after deducting underwriting discounts, commissions and other offering expenses. The Company’s underwriters exercised their option to purchase 450,000 additional shares of common stock to cover over-allotments on November 18, 2014, pursuant to which it received aggregate net proceeds of approximately $2,710,000, after deducting underwriting discounts, commissions and expenses.  Also, in conjunction with the IPO, the Company issued warrants to the underwriters for the purchase of 90,000 shares of common stock, which can be exercised between November 10, 2015 and November 10, 2018 at an exercise price of $8.125 per share.

 

Stock Options

 

In the nine months ended September 30, 2015, the Company granted 211,660 stock options to employees and certain non-employee members of its board of directors with exercise prices ranging from $6.31 - $9.62.

 

The fair value of the Company’s common stock prior to its IPO was estimated by the Board of Directors at or about the time of grant for each share-based award. At each grant, the board considered a number of factors in establishing a value for the Company’s common stock including its EBITDA, assessments of an amount its shareholders would accept in the private sale of the company, discussions with its investment bankers regarding pricing of the Company’s common stock in an initial public offering and the probability of successfully completing an IPO. Although the methods for determining the fair value of the Company’s common stock are not complex, the board’s estimate of the fair value of the common stock did involve subjectivity, especially assessments of value in a private sale and estimates of value in the public stock market.

 

 17 
 

Upon the completion of the Company’s IPO, its stock trading price became the basis of fair value of its common stock used in determining the value of share based awards. To the extent the value of the Company’s share based awards involves a measure of volatility, it will rely upon the volatilities from publicly traded companies with similar business models until its common stock has accumulated enough trading history for it to utilize its own historical volatility. The expected life of the options granted is based on the average of the vesting term and the contractual term of the option. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury 10-year yield curve in effect at the date of the grant.

 

The Company has computed the fair value of all options granted during the nine months ended September 30, 2015 and 2014, using the following assumptions:

 

   Nine Months Ended September 30,
   2015  2014
Expected volatility   45% - 50%    43% - 46% 
Expected dividends     None        None   
Expected term (years)   5.5 - 7    5.5 - 7.5 
Risk-free rate   1.66% - 1.92%    0.07% - 2.05% 
Forfeiture rate     20%        None   

 

The information below summarizes the stock options:

 

   Number of
Shares
  Weighted
Average
Exercise
Price
  Weighted
Average
Fair
Value
  Weighted
Average
Remaining
Contractual Life
Outstanding at December 31, 2014   314,775   $2.23   $0.92    9.2 
Granted at market price   211,660    8.35           
Exercised   -    -           
Cancelled   (1,835)   3.49           
Outstanding at September 30, 2015   524,600   $4.69   $2.21    9.0 
Exercisable at September 30, 2015   111,502   $1.81   $0.82    8.4 

 

The intrinsic value of the Company’s stock options outstanding was $1,336,454 at September 30, 2015.

 

For the three and nine months ended September 30, 2015, stock based compensation expense for stock options was $129,704, and $240,701, respectively.  For the three and nine months ended September 30, 2014, stock based compensation expense for stock options was $7,440 and $15,538, respectively.  Unrecognized stock-based compensation expense for stock options as of September 30, 2015 was $613,406, which is expected to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $23,031 to reflect accounting for certain performance based options.

 

 18 
 

Restricted Stock

 

The information below summaries the restricted stock activity:

 

Restricted Stock Awards  Shares
Outstanding at December 31, 2014   662,375 
Restricted stock awards granted   8,000 
Awards forfeited or exercised   - 
Outstanding  at September 30, 2015   670,375 

 

For the three and nine months ended September 30, 2015, stock based compensation expense for restricted stock was $226,875, and $405,376, respectively.  For the three and nine months ended September 30, 2014, stock based compensation expense for restricted stock was $10,115, and $32,508, respectively.   Unrecognized stock based compensation expense for restricted stock awards as of September 30, 2015 was $663,525 to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $122,841 to reflect accounting for certain performance based awards.

 

Note 8:      Income Taxes

 

During the three and nine months ended September 30, 2015, the Company recorded income tax expense of approximately $6,100 due to state tax expense stemming from current year state income taxes and  an increase to uncertain tax positions related to unresolved state apportionment of taxable income. 

 

Note 9:       Related Party Transactions

 

The Company entered into consulting and legal agreements with certain common stockholders related to services performed for the operations and transaction related activities of the Company.  Amounts paid to or for the benefit of these stockholders was approximately $100,000 and $471,000 for the three and nine months ended September 30, 2015, respectively. Amounts paid to or for the benefit of these stockholders was approximately $293,000 and $671,000 for the three and nine months ended September 30, 2014, respectively.

 

Note 10:      Commitments and Contingencies

 

Operating Leases

 

The Company leases its corporate office space with 66 monthly payments increasing from $10,500 to $22,000, beginning February 3, 2014, the date it took occupancy of the new office space.  Between December 31, 2014 and September 30, 2015, the Company assumed 46 additional leases for clinic locations.  These leases vary in length from 18 to 124 months and have monthly payments ranging from $1,432 to $13,213.

 

Total rent expense for the three and nine months ended September 30, 2015 was $402,061 and $756,678, respectively. Total rent expense for the three and nine months ended September 30, 2014 was $33,860 and $100,942, respectively.

 

Future minimum annual lease payments are as follows:

 

2015  $431,526 
2016   2,548,329 
2017   2,513,975 
2018   1,948,791 
2019   1,601,175 
Thereafter   8,443,060 
   $17,486,856 

 

 19 
 

Litigation

 

In the normal course of business, the Company is party to litigation from time to time. The Company maintains insurance to cover certain actions and believe that resolution of such litigation will not have a material adverse effect on the Company.

  

On July 7, 2015, a group of 13 franchisees, whose licenses had been terminated by the Company due to defaults in performance, commenced a collective arbitration proceeding in San Diego, California. The claimants’ demand for arbitration asserts claims for breach of contract, promissory fraud, negligent misrepresentation, breach of the implied covenant of good faith and fair dealing, wrongful termination of franchise agreements and “wrongful competition” pursuant to unspecified state business practices, unfair competition and franchise statutes. The claimants also seek “a preliminary and permanent injunction prohibiting the Company from seeking to operate corporate clinics within 25 miles of any franchise clinic.” Although commenced in California, the arbitration proceeding has been moved to Arizona, pursuant to the franchise agreements in dispute, which include clauses that make it mandatory for any arbitration proceeding to be conducted in Phoenix, Arizona. Each agreement also requires claims to be arbitrated on an individual, not class-wide basis. Additionally, some of the claimants may be unauthorized assignees of franchisees and, therefore, may not have standing to assert certain claims. The Company does not believe any of the claims, either collectively or individually, have any legal merit and intends to vigorously defend the arbitration proceeding.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q, the audited consolidated financial statements and notes thereto and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K.

 

Forward-Looking Statements

 

The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, (“the Exchange Act”), which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management; and accounting estimates and the impact of new or recently issued accounting pronouncements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “should,” “could,” “predicts,” “potential,” “continue,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements. All forward-looking statements in this Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions, and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations as described from time to time in our SEC reports, including those risks outlined under “Risk Factors” which are contained in Item 1A of our Form 10-K for the year ended December 31, 2014. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Form 10-Q. You should carefully consider these risk and uncertainties and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. Some of the important factors that could cause our actual results to differ materially from those projected in any forward-looking statements include, but are not limited to, the following:

 

  we may not be able to successfully implement our growth strategy if we or our franchisees are unable to locate and secure appropriate sites for clinic locations, obtain favorable lease terms, and attract patients to our clinics;

 

 20 
 

 

  we have limited experience operating company-owned or managed clinics, and we may not be able to duplicate the success of some of our franchisees;

 

  we may not be able to acquire operating clinics from existing franchisees or develop company-owned or managed clinics on attractive terms;

 

  any acquisitions that we make could disrupt our business and harm our financial condition;

 

  we may not be able to continue to sell franchises to qualified franchisees;

 

  we may not be able to identify, recruit and train enough qualified chiropractors to staff our clinics;

 

  new clinics may not be profitable, and we may not be able to maintain or improve revenues and franchise fees from existing franchised clinics;

 

  the chiropractic industry is highly competitive, with many well-established competitors;

 

  recent administrative actions and rulings regarding the corporate practice of medicine and joint employer responsibility may jeopardize our business model;

 

  we may face negative publicity or damage to our reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models;
  legislation and regulations, as well as new medical procedures and techniques could reduce or eliminate our competitive advantages;

 

  we face increased costs as a result of being a public company; and

 

  we have identified material weaknesses in our internal control over financial reporting, and our business and stock price may be adversely affected if we do not adequately address those weaknesses.

 

Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the Securities and Exchange Commission. Any forward-looking statements in this report should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others.

 

Overview

 

The principal business of The Joint Corp., a Delaware corporation, is to develop, own, operate, support and manage chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States.

 

As used in this Form 10-Q:

 

  · “we,”  “us,” and “our” refer to The Joint Corp.
     
  · a “clinic” refers to a chiropractic clinic operating under our “Joint” brand, which may be (i) owned by a franchisee, (ii) owned by a professional corporation or limited liability company and managed by a franchisee; (iii) owned directly by us; or (iv) owned by a professional corporation or limited liability company and managed by us.

 

 21 
 

 

  · when we identify an “operator” of a clinic, a party that is “operating” a clinic, or a party by whom a clinic is “operated,” we are referring to the party that operates all aspects of the clinic in certain jurisdictions, and to the party that manages all aspects of the clinic other than the practice of chiropractic in certain other jurisdictions.

 

We seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and abroad.

 

Key Performance Measures.  We receive both weekly and monthly performance reports from our clinics which include key performance indicators including gross clinic revenues, total royalty income, and patient office visits. We believe these indicators provide us with useful data with which to measure our performance and to measure our franchisees’ and clinics’ performance.

 

Key Clinic Development Trends.   As of September 30, 2015, we or our franchisees operated 277 clinics. Of the 277 clinics in operation, 224 were originally awarded through our regional developer program. We repurchased 17 of the 224 clinics awarded through our regional developer program, which we now operate as company-owned or managed clinics. Our regional developer program is one in which we sold licenses to third parties to develop franchises in particular geographic areas.  In addition, 49 of the 277 clinics in operation were awarded through direct sales. We repurchased eight of the 49 clinics awarded through direct sales, which we now operate as company-owned or managed clinics bringing the total of corporate clinics to 29 as of September 30, 2015.

 

Our future growth strategy will increasingly focus on acquiring and developing clinics that are directly owned operated, or managed by us, while continuing to grow through the sale of additional franchises.  

 

We expect to repurchase or to develop up to 42 franchises or clinics to be operated or managed as company-owned or managed clinics during the year ending December 31, 2015.

 

We expect to open up to 55 new franchised clinics during the year ending December 31, 2015. We generally expect a franchised clinic to open within 9 to 12 months from the date a franchise agreement is signed. This development timeline applies both to clinics franchised directly with us and for clinics franchised through a regional developer. In addition, our regional developers are required, under their respective regional developer agreements, to obtain franchises and open the minimum number of clinics prescribed in their regional developer agreement within a negotiated time period, which takes into account the number of clinics, as well as the size, geography and demographics pertaining to each relevant region. This negotiated time period may differ among regional developers.

 

We may encounter difficulty in finding suitable locations for our planned company-owned or managed clinics, and our franchisees may encounter difficulty in finding and funding suitable locations for their franchised clinics. In addition, we and our franchisees may not be able to secure the services of chiropractors who share our vision and philosophy regarding the practice of chiropractic and are therefore appropriate candidates to provide services at a Joint clinic. Our ability to take full advantage of advertising and public awareness initiatives will depend on the speed with which we can develop either company-owned or franchised clinics in clusters with sufficient density to justify the use of mass media and other strategic media.

 

Recent Developments

 

On December 31, 2014, we reacquired six franchised clinics, closed two clinics and retained the remaining four clinics as company-managed clinics.

 

During the nine months ended September 30, 2015, we acquired an aggregate of 21 clinics, opened four company-owned or managed clinics and terminated regional developer rights in one territory. As of September 30, 2015 we had 29 company-owned or managed clinics. As part of our company-owned or managed clinic strategy, we may seek to reacquire additional franchises as circumstances permit. We are in process of negotiating lease agreements for additional company clinics which we expect to open later in the year.

 

 22 
 

Development of company-owned or managed clinics will be our principal focus, and we have used and will use a significant amount of the proceeds from our IPO to pursue this strategy. We believe we can leverage the experience we have gained in supporting our demonstrated franchisee growth and our senior management’s experience in rapidly and effectively growing other well-known high velocity specialty retail concepts to successfully develop and profitably operate company-owned or managed clinics. Since commencing operations as a franchisor of chiropractic clinics, we have gained significant experience in identifying the business systems and practices that are required to profitably operate our clinics, validate our model and demonstrate proof of concept.

 

We believe that applying our operating standards to company-owned or managed clinics will enable us to more effectively apply these business systems and practices than in our franchised clinics and to collect more revenue per clinic than would otherwise be available to us solely through the collection of royalty fees, franchise sales fees, and regional developer fees. We intend to develop company-owned or managed clinics in geographic clusters where we are able to increase efficiencies through a consolidated real estate penetration strategy, leverage aggregated advertisement and marketing, and attain general corporate and administrative operating efficiencies. We believe that our management’s experience in this area readily translates to our business model.

 

During the three and nine months ended September 30, 2015, we terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, we recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.

 

Factors Affecting Our Performance

 

Our quarterly operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic openings, markets in which they are contained and related expenses, general economic conditions, consumer confidence in the economy, consumer preferences, and competitive factors.

 

Significant Accounting Policies and Estimates

 

We adopted accounting policies for revenues and management fees for company clinics in conjunction with our acquisitions of company-owned or managed clinics during the nine months ended September 30, 2015.

 

There were no additional changes in our significant accounting policies and estimates during the nine months ended September 30, 2015 from those set forth in “Significant Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2014.

 

 23 
 

Results of Operations

 

Total Revenues

 

Components of revenues for the three months ended September 30, 2015 as compared to the three months ended September 30, 2014, are as follows:

 

   Three Months Ended      
   September 30,      
   2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
Revenues:                    
Royalty fees  $1,150,574   $871,462   $279,112    32.0%
Franchise fees   638,000    435,000    203,000    46.7%
Revenues and management fees from company clinics   1,198,397    -    1,198,397    100.0%
Advertising fund revenue   330,502    88,031    242,471    275.4%
IT related income and software fees   197,569    218,400    (20,831)   (9.5)%
Regional developer fees   531,350    152,250    379,100    249.0%
Other revenues   91,623    51,452    40,171    78.1%
                     
Total revenues  $4,138,015   $1,816,595   $2,321,420    127.8%

 

The reasons for the significant changes in our components of total revenues are as follows:

 

  · Royalty fees have increased due to an increase in the number of clinics in operation during the current quarter along with continued growth of existing clinics.  As of September 30, 2015 and 2014, there were 248 and 230 franchised clinics in operation, respectively.  
  · Franchise fees are recognized when a clinic is opened. Franchise fees have increased due to the recognition of $290,000 in revenues from terminated franchise licenses, partially offset by lower franchise openings in the quarter. For the three months ended September 30, 2015 and 2014, 13 and 16 new clinics opened, respectively.
  · Revenue and management fees from company clinics increased due to our recent acquisition of franchises and their subsequent operation as company-owned or managed clinics.  No such company-owned or managed clinics were in operation during 2014.
  · Advertising fund revenue increased due to an increase in the monthly marketing fee from 1% to 2% in January 2015, as well as continued growth of existing clinics.
  · Regional developer fees increased largely due to revenue recognition on the default and termination of regional developer rights and fees associated with license transfers.
  · IT related income and software fee revenues declined in the aggregate primarily due to lower franchise computer build fee income.
  · Other revenue increased due to merchant income attributed to the growth in quarterly sales compared to 2014.

 

Components of revenues for the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, are as follows:

 

   Nine Months Ended      
   September 30,      
   2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
Revenues:                    
Royalty fees  $3,264,278   $2,233,053   $1,031,225    46.2%
Franchise fees   1,862,259    1,469,500    392,759    26.7%
Revenues and management fees from company clinics   2,368,866    -    2,368,866    100.0%
Advertising fund revenue   955,480    204,141    751,339    368.0%
IT related income and software fees   598,758    629,225    (30,467)   (4.8)%
Regional developer fees   799,600    377,000    422,600    112.1%
Other revenues   223,419    148,347    75,072    50.6%
                     
Total revenues  $10,072,660   $5,061,266   $5,011,394    99.0%

 

The reasons for the significant changes in our components of total revenues are as follows:

 

  · Royalty fees have increased due to an increase in the number of clinics in operation during the current quarter along with continued growth of existing clinics.  As of September 30, 2015 and 2014, there were 248 and 230 franchised clinics in operation, respectively.  

 

 24 
 

 

  · Franchise fees are recognized when a clinic is opened. Franchise fees have increased due to the recognition of $870,000 in revenues from terminated franchise licenses, partially offset by lower franchise clinic openings in the period.  For the nine months ended September 30, 2015 and 2014, 36 and 55 new franchise clinics opened, respectively.
  · Revenue and management fees from company clinics increased due to our recent acquisition of franchises and their subsequent operation as company-owned or managed clinics.  No such company-owned or managed clinics were in operation during 2014.
  · Advertising fund revenue increased due to an increase in the monthly marketing fee from 1% to 2% in January 2015, as well as continued growth of existing clinics.
  · Regional developer fees increased largely due to revenue recognition on the default and termination of regional developer rights and fees associated with license transfers.
  · IT related income and software fee and revenue declined in the aggregate primarily due to lower franchise computer build fee income.
  · Other revenue increased due to merchant income attributed to the growth in quarterly sales compared to 2014.

 

Cost of Revenues

 

Cost of Revenues  2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
             
Three Months Ended September 30,  $745,482   $654,395   $91,087    13.9%
Nine Months Ended September 30,  $2,082,561   $1,739,132   $343,429    19.7%

 

For the three months ended September 30, 2015, as compared with the same period last year, the total cost of revenues increased primarily due to an increase in regional developer commissions on franchise license terminations in the quarter.

 

For the nine months ended September 30, 2015, as compared with the same period last year, the total cost of revenues increased primarily due to an increase in regional developer commissions recognized in connection with the franchise license terminations in the period, and an increase in regional developer royalties due to corresponding increased royalty revenue earned in regional developer territories.

 

Selling and Marketing Expenses

 

Selling and Marketing Expenses  2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
             
Three Months Ended September 30,  $693,953   $324,177   $369,776    114.1%
Nine Months Ended September 30,  $2,450,976   $723,955   $1,727,021    238.6%

 

Selling and marketing expenses increased for the three and nine months ended September 30, 2015, as compared to the three and nine months ended September 30, 2014, due to increased system wide sales and the associated contribution to the advertising fund, and due to the expenses of opening Company-owned or managed clinics.

  

Depreciation and Amortization Expenses

 

Depreciation and Amortization Expenses  2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
             
Three Months Ended September 30,  $421,390   $52,823   $368,567    697.7%
Nine Months Ended September 30,  $822,489   $141,707   $680,782    480.4%

 

Depreciation and amortization expenses increased for the three months ended September 30, 2015 as compared to the three months ended September 30, 2014, primarily due to fixed assets additions of $1,163,372 and intangible asset additions of $460,541 relating to our acquisitions of franchises and regional developer rights.

 

 25 
 

Depreciation and amortization expenses increased for the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, primarily due to fixed assets additions of $3,000,446 and intangible asset additions of $2,454,293 relating to our acquisitions of franchises and regional developer rights.

 

General and Administrative Expenses

 

General and Administrative Expenses  2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
             
Three Months Ended September 30,  $4,328,089   $1,096,025   $3,232,064    294.9%
Nine Months Ended September 30,  $10,528,817   $3,146,666   $7,382,151    234.6%

 

General and administrative expenses increased during the three months ended September 30, 2015 compared to the three months ended September 30, 2014, primarily due to the following:

 

  · An increase of approximately $1,840,000 of employment expense which includes salaries and wages, stock based compensation, health insurance expense and payroll taxes. This is primarily due to an increase in support staff at the corporate level to support the Company’s strategy of operating and managing company clinics, plus the addition of employees in the Company owned/managed clinics.
     
  · An increase of approximately $277,000 in professional fees, primarily related to franchising and acquisition related services, public company costs, and staff placement fees.

 

  · An increase of approximately $466,000 in occupancy costs, primarily due to acquisition of company clinics.

 

  ·

An increase of approximately $566,000 in general administrative expenses, primarily made up of general liability and professional insurance and miscellaneous corporate office expenses.

.

  · An increase of approximately $83,000 in costs related to the acquiring of franchise clinics.

 

General and administrative expenses increased during the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014, primarily due to the following:

 

  · An increase of approximately $4,132,000 of employment expense which includes salaries and wages, stock based compensation, executive relocation costs, health insurance expense and payroll taxes. This is primarily due to an increase in support staff at the corporate level to support the Company’s strategy of operating and managing company clinics, plus the addition of employees in the Company owned/managed clinics.
     
  · An increase of approximately $895,000 in professional fees, primarily related to franchising and acquisition related services, public company costs, and staff placement fees.

 

  · An increase of approximately $831,000 in occupancy costs, primarily due to acquisition of company clinics.
     
  · An increase of approximately $1,162,000 in general administrative expenses, primarily made up of general liability and professional insurance and miscellaneous corporate office expenses.
     
  · An increase of approximately $362,000 in costs related to the acquiring of franchise clinics.

 

Income Tax (Provision) Benefit

 

Income Tax (Provision) Benefit  2015  2014  Change from
Prior Year
  Percent Change
from Prior Year
             
Three Months Ended September 30,  $(6,148)  $163,051   $(169,199)   (103.8)%
Nine Months Ended September 30,  $(6,148)  $284,574   $(290,722)   (102.2)%

 

Changes in our income tax (provision) benefit related primarily to changes in pretax loss during the three and nine months ended September 30, 2015 as compared to the three and nine months ended September 30, 2014.  For the three and nine months ending September 30, 2015, the effective rate was 0% as we have established a valuation allowance against all deferred tax assets.  For the three and nine months ended September 30, 2014, the effective rate was 38.6% and 31.7%. The difference is due to uncertain tax positions that were recorded during the period and the impact of certain permanent differences on taxable income.

 26 
 

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

Since 2012, we have financed our business primarily through existing cash on hand and cash flows from operations until 2014 when we completed an initial public offering.

 

On November 14, 2014, we closed on our initial public offering (“IPO”) of 3,000,000 shares of common stock at a price to the public of $6.50 per share. As a result of the IPO, we received aggregate net proceeds, after deducting underwriting discounts, commissions and other offering expenses, of approximately $17,065,000.  On November 18, 2014, our underwriters exercised their option to purchase 450,000 additional shares of common stock to cover over-allotments, pursuant to which we received aggregate net proceeds of approximately $2,710,000, after deducting underwriting discounts, commissions and expenses.

 

We are using a significant amount of the net proceeds from our IPO for the development of company-owned or managed clinics.  We may accomplish this by developing new clinics, by repurchasing existing franchises or by acquiring existing chiropractic practices. In addition, we are using these proceeds to repurchase existing regional developer licenses.  Other than to pursue this growth strategy, we have not allocated a specific amount of our net proceeds from the offering to any particular purpose. The net proceeds we actually expend for the development of company-owned or managed clinics and the acquisition of franchises or regional developer licenses may vary significantly depending on a number of factors, including the timing of our identification and leasing of suitable sites for company-owned or managed clinics and, in respect of the acquisition of franchises or regional developer licenses, our ability to enter into a binding acquisition agreement on favorable terms and the negotiated purchase price. In addition, the net proceeds we actually expend for general corporate purposes may vary significantly depending on a number of factors, including future revenue growth and our cash flows. As a result, we will retain broad discretion over the allocation of the net proceeds from these offerings. Pending use of the net proceeds from these offerings, we are holding the net proceeds in cash or investments in short-term, investment-grade securities.

 

As of September 30, 2015, we had cash and short-term bank deposits of $9,522,013.

 

Analysis of Cash Flows

 

Net cash used in operating activities increased by $3,894,300 to $4,008,682 for the nine months ended September 30, 2015, compared to $114,382 for the nine months ended September 30, 2014.  The cash used in operating activities was attributable primarily to increased expenses caused by the addition of senior level and support staff and changes in net working capital and other adjustments.

 

Net cash used in investing activities was $7,156,088 and $516,522 during the nine months ended September 30, 2015, and 2014, respectively.  For the nine months ended September 30, 2015 this includes acquisitions of franchises of $4,652,525, reacquisition and termination of regional developer rights of $1,075,000, purchases of fixed assets of $1,461,125, proceeds received on sale of property and equipment of $11,500, and payments received on notes receivable of $21,562.  For the nine months ended September 30, 2014 this includes investments in property and equipment of $538,323, proceeds received on sale of property and equipment of $2,500 and payments received on notes receivable of $19,301. 

 

Net cash used in financing activities was $110,000 and $511,921 for the nine months ended September 30, 2015, and 2014, respectively. For the nine months ended September 30, 2015 this includes repayments on notes payable of $110,000. For the nine months ended September 30, 2014 this includes $511,921 of deferred offering costs.

 

 27 
 

Contractual Obligations and Risk

 

The following table summarizes our contractual obligations at September 30, 2015 and the effect that such obligations are expected to have on our liquidity and cash flows in future periods:

 

   Payments Due by Fiscal Year
   Total  2015  2016  2017  2018  2019  Thereafter
Operating leases  $17,486,856   $431,526   $2,548,329   $2,513,975   $1,948,791   $1,601,175    8,443,060 
Notes payable   634,350    231,500    272,850    130,000    -    -    - 
   $18,121,206   $663,026   $2,821,179   $2,643,975   $1,948,791   $1,601,175   $8,443,060 

 

Off-Balance Sheet Arrangements

 

During the nine months ended September 30, 2015, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q.  Based on such evaluation, our Chief Executive Officer and Chief Operating Officer have concluded that, as of such date, our disclosure controls and procedures were not effective.

 

We continue to implement certain controls over the Company’s financial reporting cycle. These areas included properly segregating duties and increasing the size of our accounting department. However, even with these improvements one or more material weaknesses or significant deficiencies could be present and result in errors in our financial statements.

 

Changes in Internal Control over Financial Reporting

 

We are currently in the process of addressing and remediating the control weaknesses described above which included the hiring of additional personnel and continued integration of a new general ledger system.  

  

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

In the normal course of business, we are party to litigation from time to time. We maintain insurance to cover certain actions and believe that resolution of such litigation will not have a material adverse effect on the Company.

 

On July 7, 2015, a group of 13 franchisees, whose licenses had been terminated by us due to defaults in performance, commenced a collective arbitration proceeding in San Diego, California. The claimants’ demand for arbitration asserts claims for breach of contract, promissory fraud, negligent misrepresentation, breach of the implied covenant of good faith and fair dealing, wrongful termination of franchise agreements and “wrongful competition” pursuant to unspecified state business practices, unfair competition and franchise statutes. The claimants also seek “a preliminary and permanent injunction prohibiting us from seeking to operate corporate clinics within 25 miles of any franchise clinic.” Although commenced in California, the arbitration proceeding has been moved to Arizona, pursuant to the franchise agreements in dispute, which include clauses that make it mandatory for any arbitration proceeding to be conducted in Phoenix, Arizona. Each agreement also requires claims to be arbitrated on an individual, not class-wide basis. Additionally, some of the claimants may be unauthorized assignees of franchisees and, therefore, may not have standing to assert certain claims. We do not believe any of the claims, either collectively or individually, have any legal merit and intend to vigorously defend the arbitration proceeding 

 

 28 
 

ITEM 1A. RISK FACTORS

 

There have been no material changes from the risk factors disclosed in Item 1A of our Form 10-K for the year ended December 31, 2014.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Recent Sales of Unregistered Securities 

 

On July 15, 2015, the Registrant granted options to purchase an aggregate of 52,250 shares of its common stock at an exercise price of $9.62 per share to 21 individuals who were either employees of or service providers to the Registrant. The foregoing option grants were exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof on the basis that the transaction did not involve a public offering.

 

On July 15, 2015, the Registrant issued 4,000 restricted shares of its common stock to each of 2 individuals who were either employees of or service providers to the Registrant pursuant to a restricted stock purchase agreement. The Board of Directors of the Company determined that the fair market value of its common stock as of that date was $9.62 per share, based on the Registrant’s stock trading price. The foregoing restricted stock grants were exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof on the basis that the transaction did not involve a public offering.

 

On August 4, 2015, the Registrant granted options to purchase 7,500 shares of its common stock to each of Craig P. Colmar, Steven P. Colmar and John Leonesio and 10,000 options to purchase common stock to each of Bret Sanders, William R. Fields and Ronald V. DaVella. The Board of Directors of the Company determined that the fair market value of its common stock as of that date was $9.08 per share, based on the Registrant’s stock trading price. The foregoing option grants were exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof on the basis that the transaction did not involve a public offering.

 

On September 28, 2015, the Registrant granted options to purchase an aggregate of 45,410 shares of its common stock at an exercise price of $6.31 per share to 23 individuals who were either employees of or service providers to the Registrant. The foregoing option grants were exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof on the basis that the transaction did not involve a public offering.

 

Use of Proceeds from Registered Securities

 

On July 1, 2015, the Company completed its repurchase of one operating franchise and one undeveloped franchise in Maricopa County, Arizona (the “Repurchase Transaction”) from Chiro-Novo, LLC. The total consideration for the Repurchase Transaction was $265,000, $212,000 of which was funded from the proceeds of the Company’s initial public offering (IPO). The Company is operating the operating franchise as a Company-owned clinic.

 

On August 10, 2015, the Company repurchased one operating franchise and two undeveloped franchises in Erie County, New York (the “Repurchase Transaction”) from the Chiro Group. The Company is operating the operating franchise to manage an affiliated Company clinic. In a related transaction, the Company terminated a regional developer agreement (the “Termination Transaction”) relating to development rights in Erie County, Monroe County, Nassau County, Suffolk County, and Albany County, all located in the state of New York. The Company terminated the regional developer license as a prelude to developing Company-managed clinics in the region. The total consideration for the Repurchase Transaction and the Termination Transaction was $350,000, $303,050 of which was funded from the proceeds of the Company’s IPO.

 

Our reasonable estimate of net proceeds from the IPO in the amount of $2.7 million were also expended during the quarter for general corporate purposes, including compensation of officers and non-employee directors.

 

ITEM 6. EXHIBITS

 

The Exhibit Index immediately following the Signatures to this Form 10-Q is hereby incorporated by reference into this Form 10-Q.

 

 

 

THE JOINT CORP.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  THE JOINT CORP.
       
Dated: November 16, 2015 By:  /s/ John B. Richards  
    John B. Richards  
    Chief Executive Officer
    (Principal Executive Officer)
       
  By: /s/ Francis T. Joyce  
    Francis T. Joyce  
    Chief Financial Officer and Treasurer
    (Principal Financial and Accounting Officer)

 

 29 
 

EXHIBIT INDEX

 

Exhibit

Number

  Description of Document
     
     
31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, (filed herewith).
     
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, (filed herewith).
     
32   Certifications of Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
     
101.INS   XBRL Instance Document.
     
101.SCH   XBRL Taxonomy Extension Schema Document.
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

 

 

 

 

 

30

 
EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

  

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14(a) AND 15a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, John B. Richards, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 of The Joint Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 16, 2015

 

/s/ John B. Richards

John B. Richards

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(a) AND 15a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934 

 

I, Francis T. Joyce, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 of The Joint Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 16, 2015

 

/s/ Francis T. Joyce

Francis T. Joyce

Chief Financial Officer and Treasurer

(Principal Financial and Accounting Officer)

EX-32 4 exh_32.htm EXHIBIT 32

Exhibit 32

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of The Joint Corp. (the “Company”), for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, John B. Richards, Principal Executive Officer of the Company, and Francis T. Joyce, Principal Financial and Accounting Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

  

By:  /s/ John B. Richards
  John B. Richards
  Chief Executive Officer
  (Principal Executive Officer) 
   
Dated November 16, 2015
   
By: /s/ Francis T. Joyce
  Francis T. Joyce
  Chief Financial Officer and Treasurer
  (Principal Financial and Accounting Officer)

 

Dated November 16, 2015

EX-101.INS 5 jynt-20150930.xml XBRL INSTANCE FILE false --12-31 Q3 2015 2015-09-30 10-Q 0001612630 9906491 Yes Smaller Reporting Company JOINT Corp No No jynt 46 1075500 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Advertising Fund</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee was increased to 2%&nbsp;in January 2015. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense properly eliminating intercompany transactions. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company&#x2019;s consolidated balance sheets.</div></div></div></div></div></div></div></div></div> 858900 4898575 7032 17469 72400 47859 130696 17469 17469 227834 507500 2 23 -2 -23 2 1 7 2 2 13 16 36 57 4 4 180 248 159770 186604 478200 548400 622800 668700 478200 1799000 2574450 254250 0.02 0.07 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">IT Related Income and Software Fees.</div>&nbsp;&nbsp;The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic&#x2019;s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue&nbsp;upon receipt of equipment by the franchisee.</div></div></div></div></div> -26834 44971 18100 -178000 P10Y 507500 0.02 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Nature of Operations</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Joint Corp., a Delaware corporation, was formed on March 10, 2010. Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0">The following table summarizes the number of clinics in operation under franchise agreements or that are company-owned or managed for the three and nine months ended September 30, 2015 and 2014:</div><div style=" font-size: 10pt; margin: 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Franchised clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">239</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">215</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">242</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">175</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">13</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">36</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">57</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(23</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" margin: 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Company-owned or managed clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">23</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">4</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Clinics licenses sold but not yet developed</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">182</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">182</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div> 480250 41100 P2Y P4Y180D P2Y P1Y 0.06 0.04 49850 P3Y180D 1 1 7 6 2 4 3 3 23 10 30 13 6 2 4 2 2 3 2 3 1 3 6 4 2 2 4 66 21 34 34 10500 22000 1432 13213 153000 389750 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Regional Developer Fees</div>. During 2011, the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from $7,250 to 25% of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from $14,500 to $19,950 which are collected upon the sale of franchises within their region and a royalty of 3% of sales generated by franchised clinics in their region. Regional developer fees are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. When the Company anticipates that the number of franchised clinics to be opened will exceed the contracted minimum, the license fee on a per-clinic basis is determined by dividing the total fee collected from the regional developer by the number of clinics expected to be opened within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the fee per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. The franchisor&#x2019;s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer&#x2019;s license.</div></div></div></div></div> 254250 531350 152250 799600 377000 14500 19950 7250 0.25 0.03 290000 870000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Revenues and Management Fees from Company Clinics.&nbsp;&nbsp;</div>The Company earns revenues from clinics that it owns and operates or manages throughout the United States.&nbsp; In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.&nbsp; Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.&nbsp;&nbsp;In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor&#x2019;s PC.&nbsp; Under the management agreement, the Company provides administrative and business management services to the doctor&#x2019;s PC in return for a monthly management fee.&nbsp; When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.</div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Royalties.</div> The Company collects royalties, as stipulated in the franchise agreement, equal to 7% of gross sales, and a marketing and advertising fee currently equal to 2% of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly two working days after each sales period has ended.</div></div></div></div></div> 0.2 0 6.31 9.62 0.82 1436350 1271405 605876 704905 838325 305644 22066847 21420975 122841 23031 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Advertising Costs</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company incurs advertising costs in addition to those included in the advertising fund. The Company&#x2019;s policy is to expense all operating advertising costs as incurred. Advertising expenses were $377,122 and $853,110 for the three and nine months ended September 30, 2015, respectively. Advertising expenses were $53,691 and $93,730 for the three and nine months ended September 30, 2014, respectively.&nbsp;</div></div></div></div></div> 377122 853110 53691 93730 330502 88031 955480 204141 129704 240701 7440 15538 226875 405376 10115 32508 85376 81032 0 0 164193 289807 393339 542354 393339 542354 524600 266555 524600 266555 90000 90000 22485182 28472028 11588850 23357131 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (&#x201c;The Joint&#x201d;) and its wholly owned subsidiary The Joint Corporate Unit No. 1, LLC (collectively, the &#x201c;Company&#x201d;). These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary consolidated financial statements and the notes thereto as set forth in The Joint Corp.&#x2019;s Form 10-K, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&#x2019;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended September 30, 2015 and 2014 is unaudited.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif;; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma for the Three Months Ended</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma for the Nine Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Revenues, net</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">4,159,975</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">2,668,562</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,030,264</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">7,465,179</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(2,064,297</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(814,369</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(6,338,663</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(2,811,855</td> <td style="text-align: left">)</td> </tr> </table></div> -2064297 -814369 -6338663 -2811855 4159975 2668562 11030264 7465179 361997 384214 384214 384214 384214 0 5396875 25000 4898575 744350 744350 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 2:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Acquisitions</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Franchises acquired during 2014</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During 2014, the Company acquired substantially all the assets and certain liabilities of&nbsp;six franchises including franchises that manage four clinics operating in Los Angeles County, for a purchase price of&nbsp;$900,000 which was paid in cash. The Company is operating four of the acquired franchises as managed company clinics and has terminated the two remaining franchises. On January 1, 2015, the Company acquired an additional three undeveloped franchises.&nbsp;&nbsp;This resulted in a net deferred revenue adjustment of $41,100 to the net purchase price.&nbsp;&nbsp;No additional consideration was paid on January 1, 2015. The remaining $858,900 was accounted for as the total consideration paid for the acquired franchises.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The purchase price allocation for these acquisitions is complete. The following summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date:</div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%; font-size: 10pt; text-align: left">Property and equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">297,630</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Intangible assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">153,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Goodwill</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">636,104</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total assets acquired</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,086,734</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Unfavorable leases</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(227,834</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net assets acquired</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">858,900</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0; color: red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Intangible assets consist of reacquired franchise rights of $81,000 and customer relationships of $72,000 and will be amortized over their estimated useful lives of seven years and two years, respectively.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Unfavorable leases consist of leases with rents that are in excess of market value. This liability will be amortized over the lives of the associated leases.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Goodwill recorded in connection with this acquisition was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company has retrospectively adjusted the condensed consolidated balance sheet as of December 31, 2014 related to adjustments to the purchase price allocation of the above acquisition.&nbsp;&nbsp;The impacts are adjustments to deferred franchise costs, goodwill and deferred revenue, with no changes to total net assets.&nbsp;&nbsp;There were no impacts on the consolidated statements of operations or cash flows for any prior periods as a result of these adjustments.&nbsp;&nbsp;The balance sheet impacts are as follows:</div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As reported</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As revised</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Deferred franchise costs - current portion</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">668,700</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">622,800</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Goodwill</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">677,204</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">636,104</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred revenue - current portion</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,044,500</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">1,957,500</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <!-- Field: Page; Sequence: 14 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Franchises acquired during 2015</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During the nine months ended September 30, 2015, the Company continued to execute its growth strategy and entered into a series of unrelated transactions with existing franchisees to re-acquire an aggregate of 23 developed and 34 undeveloped franchises throughout Arizona, California, and New York for an aggregate purchase price of $5,396,875, subject to certain adjustments, consisting of cash of $4,652,525 and notes payable of $744,350. Of the 23 developed franchises, the Company is operating 21 as company-owned or managed clinics and has closed the remaining two clinics. The 34 undeveloped franchises have been terminated and the Company may relocate them. At the time these transactions were consummated, the Company carried <div style="display: inline; background-color: white">a deferred revenue balance of $976,500, representing franchise fees collected upon the execution of the franchise agreements, and deferred franchise costs of $478,200, related to undeveloped franchises.&nbsp;&nbsp;In accordance with ASC 952-605, the Company accounted for the franchise rights associated with the undeveloped franchise as a cancellation, and the respective deferred revenue and deferred franchise costs were netted against the aggregate purchase price.&nbsp;&nbsp;The remaining $4,898,575 was accounted for as consideration paid for the acquired franchises.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Additionally, in January 2015, in connection with the default by a franchisee under its franchise agreement, the Company assumed substantially all of the assets of a clinic in Tempe, Arizona in exchange for $25,000.&nbsp; The Company has accounted for this as a business combination.&nbsp; The Company completed its valuation of the fair value of the assets acquired, including intangible assets, in September 2015. Because the net assets acquired exceeded the consideration paid, the Company recognized a bargain purchase gain of $384,214 during the three months ended September 30, 2015.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company incurred $361,997 of transaction costs related to these acquisitions for the nine months ended September 30, 2015.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-style: italic;">Purchase Price Allocation</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The purchase price allocations for these acquisitions are preliminary and subject to further adjustment upon finalization of the opening balance sheet. The following summarizes the aggregate fair values of the assets acquired and liabilities assumed during 2015 as of the acquisition date:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-size: 10pt; text-align: left">Property and equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">1,539,321</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Intangible assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,531,041</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Favorable leases</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">17,469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Goodwill</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,312,259</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total assets acquired</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,400,090</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Deferred membership revenue</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(117,301</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net assets acquired</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">5,282,789</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bargain purchase gain</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(384,214</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net purchase price</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right; border-bottom: Black 2.25pt double">4,898,575</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Intangible assets in the table above consist of reacquired franchise rights of $1,215,248 and customer relationships of $315,793, and will be amortized over their estimated useful lives ranging from six to seven years and two years, respectively.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The estimates of the fair value of the assets or rights acquired and liabilities assumed at the date of the applicable acquisition are subject to adjustment during the measurement period (up to one year from the particular acquisition date). The primary areas of the accounting for the acquisitions that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired, residual goodwill and any related tax impact. The fair value of these net assets acquired are based on management&#x2019;s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. While the Company believes that such preliminary estimates provide a reasonable basis for estimating the fair value of assets acquired and liabilities assumed, it evaluates any necessary information prior to finalization of the fair value. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the revised estimated values of those assets or liabilities as of that date. The effect of measurement period adjustments to the estimated fair value is reflected as if the adjustments had been completed on the acquisition date. The impact of all changes that do not qualify as measurement period adjustments are included in current period earnings. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could be subject to a possible impairment of the intangible assets or goodwill, or require acceleration of the amortization expense of intangible assets in subsequent periods. During the three months ended September&nbsp;30, 2015, the Company made certain measurement period adjustments related to several acquisitions consummated in period. Property and equipment was increased by $47,859, intangible assets increased by $72,400, favorable leases increased by $17,469 and deferred membership revenue decreased by $7,032 with the resulting offset to goodwill of $130,696.</div> <!-- Field: Page; Sequence: 15 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Goodwill recorded in connection with these acquisitions was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible.&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Pro Forma Results of Operations (Unaudited)</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The following table summarizes selected unaudited pro forma condensed consolidated statements of operations data for the three and nine months ended September&nbsp;30, 2015 and 2014 as if the acquisitions had been completed on January 1, 2014.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma for the Three Months Ended</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma for the Nine Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Revenues, net</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">4,159,975</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">2,668,562</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">11,030,264</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">7,465,179</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(2,064,297</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(814,369</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(6,338,663</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(2,811,855</td> <td style="text-align: left">)</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">This selected unaudited pro forma consolidated financial data is included only for the purpose of illustration and does not necessarily indicate what the operating results would have been if the acquisitions had been completed on that date. Moreover, this information does not indicate what the Company&#x2019;s future operating results will be. The information for 2014 and 2015 prior to the acquisitions is included based on prior accounting records maintained by the acquired companies. In some cases, accounting policies differed materially from accounting policies adopted by the Company following the acquisitions. For 2015, this information includes actual data recorded in its financial statements for the period subsequent to the date of the acquisition. The Company&#x2019;s consolidated statement of operations for the three months ended September&nbsp;30, 2015 includes net revenue and net loss of $1,198,397 and $(854,948), respectively, attributable to the 2015 acquisitions. The Company&#x2019;s consolidated statement of operations for the nine months ended September&nbsp;30, 2015 includes net revenue and net loss of $2,368,866 and $(1,209,682), respectively, attributable to the acquisitions. As the 2014 acquisition occurred on the last day of the period, there were no net revenues or income attributable to the acquisitions.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The pro forma amounts included in the table above reflect the application of accounting policies and adjustment of the results of the clinics to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied from January 1, 2014, together with the consequential tax impacts.</div></div> 0 -854948 -1209682 0 1198397 2368866 1086734 5400090 117301 117301 1531041 153000 1531041 858900 5282789 1539321 297630 1539321 9522013 20796783 3516750 2373925 -11274770 -1142825 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its IPO in short-term bank deposits. The Company had no cash equivalents as of September 30, 2015 and December 31, 2014.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Restricted cash relates to cash franchisees and corporate clinics contribute to the Company&#x2019;s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.</div></div></div></div></div></div></div></div></div> 0 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">Supplemental disclosure of non-cash activity:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">In connection with our acquisitions of franchises during the nine months ended September 30, 2015, we acquired $1,539,321 of property and equipment, intangible assets of $1,531,041, goodwill of $2,312,259, favorable leases of $17,469 and assumed deferred revenue associated with membership packages paid in advance of $117,301 in exchange for $4,652,525 in cash and an aggregate amount of $744,350 in notes payable to the sellers. Additionally, at the time of these transactions, we carried deferred revenue of $976,500, representing franchise fees collected upon the execution of franchise agreements, and deferred costs of $478,200, related to our acquisition of undeveloped franchises. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 2).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">In connection with our reacquisition and termination of regional developer rights during the nine months ended September 30, 2015, we had deferred revenue of $914,000, representing license fees collected upon the execution of the regional developer agreements. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 5).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">&nbsp;&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-size: 8pt">As of December 31, 2014, we recorded a deposit of $507,500 for the reacquisition and termination of regional developer rights, which were paid in advance. During the nine months ended September 30, 2015, we reclassified $507,500 from deposits to intangible assets.</div></div></div> 8.125 90000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Note 10: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Operating Leases</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company leases its corporate office space with 66 monthly payments increasing from $10,500 to $22,000, beginning February 3, 2014, the date it took occupancy of the new office space.&nbsp;&nbsp;Between December 31, 2014 and September 30, 2015, the Company assumed 46 additional leases for clinic locations. &nbsp;These leases vary in length from 18 to 124 months and have monthly payments ranging from $1,432 to $13,213.</div> <div style=" font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Total rent expense for the three and nine months ended September 30, 2015 was $402,061 and $756,678, respectively. Total rent expense for the three and nine months ended September 30, 2014 was $33,860 and $100,942, respectively.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">Future minimum annual lease payments are as follows:</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-size: 10pt; text-align: left">2015</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 16%; font-size: 10pt; text-align: right">431,526</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2016</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,548,329</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,513,975</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2018</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,948,791</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,601,175</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,443,060</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,486,856</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <!-- Field: Page; Sequence: 21 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Litigation</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In the normal course of business, the Company is party to litigation from time to time. The Company maintains insurance to cover certain actions and believe that resolution of such litigation will not have a material adverse effect on the Company.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On July 7, 2015, a group of 13 franchisees, whose licenses had been terminated by the Company due to defaults in performance, commenced a collective arbitration proceeding in San Diego, California. The claimants&#x2019; demand for arbitration asserts claims for breach of contract, promissory fraud, negligent misrepresentation, breach of the implied covenant of good faith and fair dealing, wrongful termination of franchise agreements and &#x201c;wrongful competition&#x201d; pursuant to unspecified state business practices, unfair competition and franchise statutes. The claimants also seek &#x201c;a preliminary and permanent injunction prohibiting the Company from seeking to operate corporate clinics within 25 miles of any franchise clinic.&#x201d; Although commenced in California, the arbitration proceeding has been moved to Arizona, pursuant to the franchise agreements in dispute, which include clauses that make it mandatory for any arbitration proceeding to be conducted in Phoenix, Arizona. Each agreement also requires claims to be arbitrated on an individual, not class-wide basis. Additionally, some of the claimants may be unauthorized assignees of franchisees and, therefore, may not have standing to assert certain claims. The Company does not believe any of the claims, either collectively or individually, have any legal merit and intends to vigorously defend the arbitration proceeding.</div></div> 0.001 0.001 20000000 20000000 10402047 10196502 9868047 9662502 10402 10197 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive Loss</div></div></div><div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;Net loss and comprehensive loss are the same for the three and nine months ended September 30, 2015 and 2014.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">From time to time the Company grants credit in the normal course of business to franchisees related to the collection of royalties and other operating revenues. The Company periodically performs credit analysis and monitor the financial condition of the franchisees to reduce credit risk.&nbsp;&nbsp;As of December 31, 2014, six franchisees represented 56% of outstanding accounts receivable. The Company did not have any customers that represented greater than 10% of its accounts receivable or revenues during the three and nine months ended September 30, 2015 and 2014.</div></div></div></div></div></div></div></div></div> 0.56 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the &#x201c;Company&#x201d;), which was dormant for all periods presented.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Variable Interest Entities</div></div></div><div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a&nbsp;variable interest entity&nbsp;(&#x201c;VIE&#x201d;) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.</div><div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs.&nbsp; In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice.&nbsp; The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the VIE.&nbsp; As such, the activity of the PCs is not included in the Company&#x2019;s consolidated financial statements.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Co-Op Marketing Funds</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops&#x2019; officers. The marketing funds are included in restricted cash on the Company&#x2019;s consolidated balance sheets.</div></div></div></div></div></div></div></div></div> 745482 654395 2082561 1739132 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 6:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"> Notes Payable</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On February 17, 2015, the Company delivered a $155,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and a license to develop one additional franchise from Roth &amp; Pelan Enterprises, LLC.&nbsp;&nbsp;This note bears interest at 1.5% per annum with a principal payment of $25,000 plus interest due on June 17, 2015, and the remaining principal and interest due February 17, 2017.&nbsp;&nbsp;While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On March 3, 2015, the Company delivered a $60,000 note payable as a portion of the consideration paid in connection with the acquisition of four existing franchises and a license to develop one additional franchise from TJSC, LLC. This note bears interest at 4.5% per annum with a principal payment of $30,000 plus interest due on July 30, 2015, and the remaining principal plus interest due on January 30, 2016.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On March 6, 2015, the Company delivered a $30,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop seven additional franchises from The Joint San Gabriel Valley Inc. This note bears interest at 1.5% per annum with principal and interest due on November 19, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On March 23, 2015, the Company delivered a $10,000 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Arrowhead Ranch LLC. This note bears interest at 1.5% per annum with principal and interest due September 20, 2016.&nbsp;&nbsp;The seller fully performed its duties under the agreement and one half of the principal plus interest was paid on September 21, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On April 1, 2015, the Company delivered a $58,500 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Chiropractic Bell Towne LLC. This note bears interest at 1.50% per annum with the principal and interest due September 30, 2015.&nbsp;&nbsp;The seller fully performed its duties under the agreement and $25,000 plus interest was paid on August 18, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On May 1, 2015, the Company delivered a $80,900 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop six additional franchises from San Diego Joint Development Inc. This note bears interest at 4.25% per annum with the principal and interest due April 30, 2016.&nbsp;&nbsp;The seller fully performed its duties under the agreement and $25,000 plus interest was paid on September 1, 2015. An additional $15,500 plus interest is payable on November 1, 2015 and $40,450 plus interest will be paid on April 30, 2016.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On May 18, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop two additional franchises from First Light Junction. This note bears interest at 4.0% per annum with the principal and interest due November 18, 2016.&nbsp;&nbsp;If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable September 18, 2015, $25,000 plus interest will be paid on February 18, 2016 and $25,000 plus interest will be paid on November 18, 2016.</div> <!-- Field: Page; Sequence: 18 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On June 3, 2015, the Company delivered a $100,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop four additional franchises from WHB Franchise, Inc. This note bears interest at 5.25% per annum with the principal and interest due April 3, 2016.&nbsp;&nbsp;If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable October 3, 2015, $25,000 plus interest will be paid on December 3, 2015 and $50,000 plus interest will be paid on April 3, 2016.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On June 5, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop three additional franchises from Clear Path Ventures, Inc. This note bears interest at 4.25% per annum with the principal and interest due June 4, 2016.&nbsp;&nbsp;If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable on October 5, 2015, $12,500 plus interest will be paid on December 5, 2015 and $37,500 plus interest will be paid on June 4, 2016.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On July 1, 2015, the Company delivered a $53,000 note payable as a portion of the consideration paid in connection with the acquisition of one franchise from Chiro Novo, LLC. This note bears interest at 4.00% per annum with the principal and interest due January 1, 2016. If the seller has fully performed its duties under the agreement, $15,000 plus interest is payable on November 1, 2015.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">On August 10, 2015, the Company delivered a $46,950 note payable as a portion of the consideration paid in connection with the acquisition of three franchises from Chiro Group. This note bears interest at 4.25% per annum with the principal and interest due June 10, 2016. If the seller has fully performed its duties under the agreement, $25,000 plus interest will be paid on December 10, 2015.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Maturities of the Company&#x2019;s notes payable are as follows as of September 30, 2015:&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: right">2015</td> <td style="width: 48%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 20%; font-size: 10pt; text-align: right">231,500</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">2016</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">272,850</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt">2017</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130,000</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">634,350</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div> 155000 60000 30000 10000 58500 80900 75000 100000 75000 53000 46950 0.015 0.045 0.015 0.015 0.015 0.0425 0.04 0.0525 0.0425 0.04 0.0425 147800 101498 93398 488746 451766 976500 914000 914000 2275035 1957500 2044500 4820259 7915918 61000 208800 507500 203244 585150 257197 532682 52823 141707 421390 52823 822489 141707 -0.17 -0.04 -0.55 -0.10 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Loss per Common Share</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-size: 10pt">&nbsp;</div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"></div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Three Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Nine Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(1,656,722</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(202,373</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(5,416,317</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(464,019</td> <td style="width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average common shares outstanding - basic</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,844,964</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,828,122</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,777,119</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,819,861</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.25pt">Weighted average common shares outstanding - diluted</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,844,964</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,828,122</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,777,119</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,819,861</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted loss per share</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.17</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.04</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.55</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.10</td> <td style="text-align: left">)</td> </tr> </table> </div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div><div> <table style="border-collapse: collapse; width: 700px;" align="center" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left">Unvested restricted stock</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock options</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div> 1397215 617944 P2Y255D P2Y255D 663525 613406 P7Y P2Y P6Y P7Y P2Y 108916 101652 79239 289807 650853 129101 325000 325000 368634 518896 1296248 387793 923250 2607291 2317484 1187332 286141 844011 81000 72000 1215248 315793 1583000 697170 556495 1948328 1505569 638000 435000 1862259 1469500 11500 4328089 1096025 10528817 3146666 636104 2312259 2948363 636104 677204 2312259 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Goodwill</div></div></div><div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note 2.&nbsp;&nbsp;Under ASC 350-10, goodwill and intangible assets deemed to have indefinite lives are no longer amortized but are subject to annual impairment tests, and tests between annual tests in certain circumstances, based on estimated fair value in accordance with ASC 350-10, and are written down when impaired.</div></div></div></div></div></div></div></div></div> 0 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company reviews our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. No impairments of long-lived assets were recorded for the periods ended September 30, 2015 and 2014.</div></div></div></div></div></div></div></div></div> -1650574 -365424 -5410169 -748593 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Note 8: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes</div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During the three and nine months ended September 30, 2015, the Company recorded income tax expense of approximately $6,100 due to state tax expense stemming from current year state income taxes and &nbsp;an increase to uncertain tax positions related to unresolved state apportionment of taxable income.&nbsp;</div></div> 6148 6148 -163051 -284574 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for income taxes in accordance with the ASC 740 that requires the recognition of deferred income taxes for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">At September 30, 2015 and December 31, 2014, the Company maintained a liability for income taxes for uncertain tax positions of approximately $142,000 and $122,000, respectively, of which $36,000 and $30,000, respectively, represent penalties and interest and are recorded in the&nbsp;&nbsp;&#x201c;other liabilities&#x201d; section of the accompanying condensed consolidated balance sheets. Interest and penalties associated with tax positions are recorded in the period assessed as general and administrative expenses. The Company&#x2019;s tax returns for tax years subject to examination by tax authorities include 2011 through the current period for state and 2012-through the current period for federal reporting purposes.</div></div></div></div></div> 420250 449803 395814 164945 450515 -94684 8582 -419297 -134925 -435354 125594 779271 188159 53989 320290 62549 543563 -35294 56547 -224131 45230 -36145 158950 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 5:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"> Intangible Assets</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During the nine month<div style="display: inline; background-color: white">s ended September 30, 2015, the Company entered into several agreements to repurchase regional developer licenses, reacquiring rights in Los Angeles County, San Diego, and Orange County, all located in the state of California, Erie County, Monroe County, Nassau County, Suffolk County, and Albany County, all located in the state of New York, and the regional developer license in New Jersey in exchange for cash consideration of $1,583,000, of which $507,500 was recorded as a cash advance at December 31, 2014.&nbsp; The Company carried a deferred revenue balance associated with these transactions of $914,000, representing license fees collected upon the execution of the regional developer agreements.&nbsp;&nbsp;In accordance with ASC 952-605, the Company accounted for the development rights associated with the unsold or undeveloped franchises as a cancellation, and the respective deferred revenue was netted against the aggregate purchase price or recognized as revenue to the extent deferred revenue was in excess of the cash consideration paid.&nbsp;&nbsp; During the nine months ended September 30, 2015, the revenue recognized as excess deferred regional developer fees totaled $254,250. The remaining balance was accounted for as consideration paid for the reacquired development rights. As the deferred revenue with respect to these regional developer rights had previously been taken into account for income tax purposes, the tax basis in the reacquired development rights is equal to the cash consideration paid. </div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Intangible assets which remain subject to adjustment upon receipt of final valuation information consisted of the following:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"></div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Gross Carrying</div> <div style=" margin-top: 0; margin-bottom: 0">Amount</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Accumulated</div> <div style=" margin-top: 0; margin-bottom: 0">Amortization</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Net Carrying</div> <div style=" margin-top: 0; margin-bottom: 0">Value</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortized intangible assets:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Reacquired franchise rights</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">1,296,248</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">108,916</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">1,187,332</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">387,793</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">101,652</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">286,141</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reacquired development rights</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">923,250</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">79,239</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">844,011</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"></td> <td>&nbsp;</td> <td style="text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="text-align: right; border-bottom: Black 2.25pt double">2,607,291</td> <td style="text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="text-align: right; border-bottom: Black 2.25pt double">289,807</td> <td style="text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">2,317,484</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Unamortized intangible assets:</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; text-align: right"></td> <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">2,948,363</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total intangible assets</td> <td style="font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">5,265,847</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: Red">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Amortization expense was $164,193 and $289,807 for the three and nine months ended September 30, 2015, respectively. There was no amortization expense for the three and nine months ended September 30, 2014.</div> <!-- Field: Page; Sequence: 17 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">Estimated amortization expense for 2015 and subsequent years is as follows:</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 81%; text-align: left">2015</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">129,101</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">518,896</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">368,634</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">325,000</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">325,000</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">650,853</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">2,317,484</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div></div><div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Intangible assets consist primarily of re-acquired franchise rights and customer relationships.&nbsp;&nbsp;The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from six to seven years. The fair value of customer relationships is amortized over their estimated useful life of&nbsp;2&nbsp;years.</div></div></div></div></div></div></div></div></div> 2317484 153000 5265847 1445 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Software Developed</div></div></div><div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company capitalizes most software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally 5 years.</div></div></div></div></div></div></div></div></div> 402061 756678 33860 100942 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred Rent</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which may include rent holidays and rent escalation clauses.&nbsp; It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.&nbsp; The Company records tenant improvement allowances as deferred rent liabilities and amortizes the allowance over the term of the lease, as a reduction to rent expense.</div></div></div></div></div></div></div></div></div> P1Y180D P10Y120D 11628069 12844675 22485182 28472028 5884972 4177586 142000 122000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 3:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"> Notes Receivable</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Effective July 2012, the Company sold a company-owned clinic, including the license agreement, equipment, and customer base, in exchange for a $90,000 unsecured promissory note. The note bears interest at 6% per annum for fifty-four months and requires monthly principal and interest payments over forty-two months, beginning August 2013 and maturing January 2017.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Effective July 2015, the Company entered into two license transfer agreements, in exchange for $10,000 and $29,925 in separate unsecured promissory notes.&nbsp; The non-interest bearing notes require monthly principal payments over 24 months, beginning on September 1, 2015 and maturing on August 1, 2017. Effective July 2015, the Company entered into a license transfer agreement, in exchange for $29,925 in an unsecured promissory note.&nbsp; The note bearings interest at 4.0% per annum, and requires monthly principal payments over 12 months, beginning on August 1, 2015 and maturing on July 1, 2016.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The outstanding balance of the notes as of September 30, 2015 and December 31, 2014 were $87,557 and $59,269, respectively.</div></div> 634350 130000 40450 25000 25000 50000 37500 272850 25000 30000 25000 25000 15500 25000 25000 25000 25000 12500 15000 25000 231500 167500 -110000 -511921 -7156088 -516522 -4008682 -114382 -1656722 -202373 -5416317 -464019 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In August 2014, the FASB issued ASU No. 2014-15, &#x201c;Presentation of Financial Statements - Going Concern: Disclosures about an Entity&#x2019;s Ability to Continue as a Going Concern.&#x201d; The new standard requires management to perform interim and annual assessments of an entity&#x2019;s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. The new guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU No. 2014-15 on its consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In April 2015, the FASB issued&nbsp;ASU 2015-03, &#x201c;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&#x201d;&nbsp; The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.&nbsp; Debt disclosures will include the face amount of the debt liability and the effective interest rate.&nbsp; The update requires retrospective application and represents a change in accounting principle.&nbsp; The update is effective for fiscal years beginning after December&nbsp;15, 2015.&nbsp; Early adoption is permitted for financial statements that have not been previously issued.&nbsp; ASU 2015-03 is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In April 2015, FASB issued ASU No. 2015-05, &#x201c;Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.&#x201d; &nbsp;The guidance provides clarification on whether a cloud computing arrangement includes a software license.&nbsp;&nbsp;If a software license is included, the customer should account for the license consistent with its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a service contract.&nbsp;&nbsp;The update is effective for reporting periods beginning after December 15, 2015.&nbsp;&nbsp;The Company is currently evaluating the impact of the adoption of ASU No. 2015-05 on its consolidated financial statements.&nbsp;</div><div style=" font-size: 10pt; text-align: justify; margin: 0"></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In September 2015, the FASB issued Accounting Standards Update (&quot;ASU&quot;) 2015-16, &quot;Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments.&quot; The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the three months ended September 30, 2015. Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the three months ended September 30, 2015 with no material effect on previous-period or current-period earnings. See &quot;Note 2&#x2014;Acquisitions&quot; for more information regarding adjustments to provisional amounts that occurred during the three months ended September 30, 2015.</div></div></div></div></div> 400325 -54599 402014 -58399 61533 27528 26024 31741 466850 90000 10000 29925 29925 87557 59269 239 215 242 175 248 230 23 4 29 277 230 -2050899 -310825 -5812183 -690194 17486856 1601175 1948791 2513975 2548329 8443060 431526 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 1:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"> Nature of Operations and Summary of Significant Accounting Policies</div></td> </tr> </table> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (&#x201c;The Joint&#x201d;) and its wholly owned subsidiary The Joint Corporate Unit No. 1, LLC (collectively, the &#x201c;Company&#x201d;). These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary consolidated financial statements and the notes thereto as set forth in The Joint Corp.&#x2019;s Form 10-K, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&#x2019;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended September 30, 2015 and 2014 is unaudited.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the &#x201c;Company&#x201d;), which was dormant for all periods presented.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;Net loss and comprehensive loss are the same for the three and nine months ended September 30, 2015 and 2014.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Nature of Operations</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Joint Corp., a Delaware corporation, was formed on March 10, 2010. Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.</div> <!-- Field: Page; Sequence: 7 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0">The following table summarizes the number of clinics in operation under franchise agreements or that are company-owned or managed for the three and nine months ended September 30, 2015 and 2014:</div> <div style=" font-size: 10pt; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Franchised clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">239</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">215</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">242</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">175</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">13</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">36</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">57</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(23</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Company-owned or managed clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">23</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">4</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Clinic licenses sold but not yet developed</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">180</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">180</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0; color: Red"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Variable Interest Entities</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a&nbsp;variable interest entity&nbsp;(&#x201c;VIE&#x201d;) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs. Such PCs are VIEs. In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice.&nbsp; The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the PCs. As such, the activity of the PCs is not included in the Company&#x2019;s consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its IPO in short-term bank deposits. The Company had no cash equivalents as of September 30, 2015 and December 31, 2014.</div> <!-- Field: Page; Sequence: 8 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Restricted cash relates to cash franchisees and corporate clinics contribute to the Company&#x2019;s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">From time to time the Company grants credit in the normal course of business to franchisees related to the collection of royalties and other operating revenues. The Company periodically performs credit analysis and monitors the financial condition of the franchisees to reduce credit risk.&nbsp;&nbsp;As of December 31, 2014, six franchisees represented 56% of outstanding accounts receivable. The Company did not have any customers that represented greater than 10% of its accounts receivable or revenues during the three and nine months ended September 30, 2015 and 2014.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accounts Receivable</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees and marketing and advertising expenses. The Company considers a reserve for doubtful accounts based on the creditworthiness of the franchisee. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management&#x2019;s best estimate of uncollectible amounts and is determined based on specific identification and historical performance that the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of September 30, 2015 and December 31, 2014, the Company had an allowance for doubtful accounts of $85,376 and $81,032, respectively.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred Franchise Costs</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.</div> <div style=" font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Software Developed</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company capitalizes most software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally 5 years.</div> <!-- Field: Page; Sequence: 9 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Intangible assets consist primarily of re-acquired franchise rights and customer relationships.&nbsp;&nbsp;The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from six to seven years. The fair value of customer relationships is amortized over their estimated useful life of&nbsp;2&nbsp;years.</div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Goodwill</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note 2.&nbsp;&nbsp;Under ASC 350-10, goodwill and intangible assets deemed to have indefinite lives are no longer amortized but are subject to annual impairment tests. As required, the Company performs an annual impairment test of goodwill as of the first day of the fourth quarter or more frequently if events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. No impairments of long-lived assets were recorded for the periods ended September 30, 2015 and 2014.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Advertising Fund</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee was increased to 2%&nbsp;in January 2015. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense properly eliminating intercompany transactions. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company&#x2019;s consolidated balance sheets.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Co-Op Marketing Funds</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops&#x2019; officers. The marketing funds are included in restricted cash on the Company&#x2019;s consolidated balance sheets.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred Rent</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which may include rent holidays and rent escalation clauses.&nbsp; It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.&nbsp; The Company records tenant improvement allowances as deferred rent liabilities and amortizes the allowance over the term of the lease, as a reduction to rent expense.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Franchise Fees.</div> The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of ten years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.&nbsp;&nbsp;The Company&#x2019;s services under the franchise agreement include: training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.</div> <!-- Field: Page; Sequence: 10 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During the three and nine months ended September 30, 2015, the Company terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, the Company recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Regional Developer Fees</div>. During 2011, the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from $7,250 to 25% of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from $14,500 to $19,950 which are collected upon the sale of franchises within their region and a royalty of 3% of sales generated by franchised clinics in their region. Regional developer fees are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. When the Company anticipates that the number of franchised clinics to be opened will exceed the contracted minimum, the license fee on a per-clinic basis is determined by dividing the total fee collected from the regional developer by the number of clinics expected to be opened within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the fee per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. The franchisor&#x2019;s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer&#x2019;s license.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Revenues and Management Fees from Company Clinics.&nbsp;&nbsp;</div>The Company earns revenues from clinics that it owns and operates or manages throughout the United States.&nbsp; In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.&nbsp; Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.&nbsp;&nbsp;In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor&#x2019;s PC.&nbsp; Under the management agreement, the Company provides administrative and business management services to the doctor&#x2019;s PC in return for a monthly management fee.&nbsp; When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.</div> <div style=" font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Royalties.</div> The Company collects royalties, as stipulated in the franchise agreement, equal to 7% of gross sales, and a marketing and advertising fee currently equal to 2% of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly two working days after each sales period has ended.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">IT Related Income and Software Fees.</div>&nbsp;&nbsp;The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic&#x2019;s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue&nbsp;upon receipt of equipment by the franchisee.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Advertising Costs</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company incurs advertising costs in addition to those included in the advertising fund. The Company&#x2019;s policy is to expense all operating advertising costs as incurred. Advertising expenses were $377,122 and $853,110 for the three and nine months ended September 30, 2015, respectively. Advertising expenses were $53,691 and $93,730 for the three and nine months ended September 30, 2014, respectively.&nbsp;</div> <!-- Field: Page; Sequence: 11 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for income taxes in accordance with the ASC 740 that requires the recognition of deferred income taxes for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">At September 30, 2015 and December 31, 2014, the Company maintained a liability for income taxes for uncertain tax positions of approximately $142,000 and $122,000, respectively, of which $36,000 and $30,000, respectively, represent penalties and interest and are recorded in the&nbsp;&nbsp;&#x201c;other liabilities&#x201d; section of the accompanying condensed consolidated balance sheets. Interest and penalties associated with tax positions are recorded in the period assessed as general and administrative expenses. The Company&#x2019;s tax returns for tax years subject to examination by tax authorities include 2011 through the current period for state and 2012-through the current period for federal reporting purposes.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Loss per Common Share</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-size: 10pt">&nbsp;</div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Three Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Nine Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(1,656,722</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(202,373</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(5,416,317</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(464,019</td> <td style="width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average common shares outstanding - basic</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,844,964</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,828,122</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,777,119</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,819,861</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.25pt">Weighted average common shares outstanding - diluted</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,844,964</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,828,122</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,777,119</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,819,861</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted loss per share</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.17</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.04</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.55</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.10</td> <td style="text-align: left">)</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left">Unvested restricted stock</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock options</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <!-- Field: Page; Sequence: 12 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Prior to the IPO the grant date fair value was determined by the Board of Directors. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs and the related deferred tax assets and liabilities as long-term or current, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets and purchase price allocations.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In August 2014, the FASB issued ASU No. 2014-15, &#x201c;Presentation of Financial Statements - Going Concern: Disclosures about an Entity&#x2019;s Ability to Continue as a Going Concern.&#x201d; The new standard requires management to perform interim and annual assessments of an entity&#x2019;s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. The new guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU No. 2014-15 on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In April 2015, the FASB issued&nbsp;ASU 2015-03, &#x201c;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&#x201d;&nbsp; The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.&nbsp; Debt disclosures will include the face amount of the debt liability and the effective interest rate.&nbsp; The update requires retrospective application and represents a change in accounting principle.&nbsp; The update is effective for fiscal years beginning after December&nbsp;15, 2015.&nbsp; Early adoption is permitted for financial statements that have not been previously issued.&nbsp; ASU 2015-03 is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In April 2015, FASB issued ASU No. 2015-05, &#x201c;Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.&#x201d; &nbsp;The guidance provides clarification on whether a cloud computing arrangement includes a software license.&nbsp;&nbsp;If a software license is included, the customer should account for the license consistent with its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a service contract.&nbsp;&nbsp;The update is effective for reporting periods beginning after December 15, 2015.&nbsp;&nbsp;The Company is currently evaluating the impact of the adoption of ASU No. 2015-05 on its consolidated financial statements.&nbsp;</div> <!-- Field: Page; Sequence: 13 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In September 2015, the FASB issued Accounting Standards Update (&quot;ASU&quot;) 2015-16, &quot;Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments.&quot; The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the three months ended September 30, 2015. Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the three months ended September 30, 2015 with no material effect on previous-period or current-period earnings. See &quot;Note 2&#x2014;Acquisitions&quot; for more information regarding adjustments to provisional amounts that occurred during the three months ended September 30, 2015.</div></div> 91623 51452 223419 148347 48254 50735 266592 299405 16111 -54599 17800 -58399 1198397 2368866 511921 900000 4652525 4652525 1461125 538323 0.001 0.001 50000 50000 0 0 0 0 0 0 151794 375925 21562 19301 17065000 11500 2500 2710000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: left"><div style="display: inline; font-weight: bold;">Note 4:</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"> Property and Equipment</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Property and equipment consists of the following:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September 30,<br /> 2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31,<br /> 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; text-align: left">Office and computer equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">470,251</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">209,575</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold improvements</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,330,927</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">665,961</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Software developed</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">688,471</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">564,560</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,489,649</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,440,096</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Accumulated depreciation</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(838,325</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(305,644</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,651,324</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,134,452</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Assets in progress</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">950,893</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,602,217</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,134,452</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.25in; margin: 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Depreciation expense was $257,197 and $532,682 for the three and nine months ended September 30, 2015, respectively. Depreciation expense was $52,823 and $141,707 for the three and nine months ended September 30, 2014, respectively.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Assets in progress relate to the ongoing development of company-owned or managed clinics, which are not yet placed in service.</div></div> 470251 209575 2330927 665961 688471 564560 3489649 1440096 3602217 1134452 2651324 1134452 950893 3602217 1134452 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div><div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September 30,<br /> 2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31,<br /> 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; text-align: left">Office and computer equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">470,251</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">209,575</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold improvements</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,330,927</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">665,961</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Software developed</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">688,471</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">564,560</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,489,649</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,440,096</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Accumulated depreciation</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(838,325</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(305,644</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,651,324</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,134,452</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Assets in progress</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">950,893</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,602,217</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,134,452</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> P3Y P7Y P5Y P6Y P7Y P2Y 4344 91831 100000 471000 293000 671000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Note 9: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Related Party Transactions</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company entered into consulting and legal agreements with certain common stockholders related to services performed for the operations and transaction related activities of the Company.&nbsp;&nbsp;Amounts paid to or for the benefit of these stockholders was approximately $100,000 and $471,000 for the three and nine months ended September 30, 2015, respectively. Amounts paid to or for the benefit of these stockholders was approximately $293,000 and $671,000 for the three and nine months ended September 30, 2014, respectively.</div></div> 110000 188431 224576 -10428498 -5012181 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred Franchise Costs</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.</div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0"><div style="display: inline; font-style: italic;">Franchise Fees.</div> The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which has an initial term of ten years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.&nbsp;&nbsp;The Company&#x2019;s services under the franchise agreement include: training of franchisee and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">During the three and nine months ended September 30, 2015, the Company terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, the Company recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.</div></div></div></div></div></div></div></div></div> 4138015 1816595 10072660 5061266 1150574 871462 3264278 2233053 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left">Unvested restricted stock</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">393,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">542,354</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock options</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">524,600</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">266,555</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Warrants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">90,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif;; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Three Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Nine Months Ended</div> <div style=" margin-top: 0; margin-bottom: 0">September 30,</div></td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> <td>&nbsp;</td> <td colspan="3">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net loss</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(1,656,722</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(202,373</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(5,416,317</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(464,019</td> <td style="width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average common shares outstanding - basic</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,844,964</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,828,122</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">9,777,119</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">4,819,861</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.25pt">Weighted average common shares outstanding - diluted</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,844,964</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,828,122</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">9,777,119</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,819,861</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted loss per share</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.17</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.04</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.55</td> <td style="text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">(0.10</td> <td style="text-align: left">)</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As reported</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">As revised</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Deferred franchise costs - current portion</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">668,700</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">622,800</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Goodwill</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">677,204</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">636,104</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred revenue - current portion</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,044,500</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">1,957,500</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Franchised clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">239</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">215</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">242</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">175</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">13</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">36</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">57</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(23</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">248</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months Ended<br /> &nbsp;September 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months Ended<br /> &nbsp;September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Company-owned or managed clinics:</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 10pt">Clinics open at beginning of period</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">23</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">4</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 8%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Opened during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Acquired during the period</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Closed during the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">29</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total clinics in operation at the end of the period</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">230</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Clinic licenses sold but not yet developed</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">180</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">180</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">248</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-size: 10pt; text-align: left">2015</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 16%; font-size: 10pt; text-align: right">431,526</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2016</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,548,329</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,513,975</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2018</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,948,791</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,601,175</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,443,060</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,486,856</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif;; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Gross Carrying</div> <div style=" margin-top: 0; margin-bottom: 0">Amount</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Accumulated</div> <div style=" margin-top: 0; margin-bottom: 0">Amortization</div></td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style=" margin-top: 0; margin-bottom: 0">Net Carrying</div> <div style=" margin-top: 0; margin-bottom: 0">Value</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortized intangible assets:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Reacquired franchise rights</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">1,296,248</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">108,916</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">1,187,332</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">387,793</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">101,652</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">286,141</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reacquired development rights</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">923,250</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">79,239</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">844,011</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"></td> <td>&nbsp;</td> <td style="text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="text-align: right; border-bottom: Black 2.25pt double">2,607,291</td> <td style="text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="text-align: right; border-bottom: Black 2.25pt double">289,807</td> <td style="text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right">2,317,484</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Unamortized intangible assets:</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; text-align: right"></td> <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Goodwill</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">2,948,363</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total intangible assets</td> <td style="font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">5,265,847</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: right">2015</td> <td style="width: 48%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 20%; font-size: 10pt; text-align: right">231,500</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right">2016</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">272,850</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt">2017</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130,000</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">634,350</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%; font-size: 10pt; text-align: left">Property and equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">297,630</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Intangible assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">153,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Goodwill</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">636,104</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total assets acquired</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,086,734</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Unfavorable leases</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(227,834</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net assets acquired</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">858,900</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-size: 10pt; text-align: left">Property and equipment</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">1,539,321</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Intangible assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,531,041</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Favorable leases</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">17,469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Goodwill</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,312,259</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total assets acquired</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,400,090</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Deferred membership revenue</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(117,301</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net assets acquired</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">5,282,789</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bargain purchase gain</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(384,214</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net purchase price</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left; border-bottom: Black 2.25pt double">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right; border-bottom: Black 2.25pt double">4,898,575</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left; border-bottom: Black 2.25pt double">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Fair<br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Remaining<br /> Contractual Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt">Outstanding at December 31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 9%; font-size: 10pt; text-align: right">314,775</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right">2.23</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right">0.92</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 9%; font-size: 10pt; text-align: right">9.2</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Granted at market price</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">211,660</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8.35</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Cancelled</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1,835</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3.49</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">524,600</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4.69</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2.21</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9.0</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Exercisable at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">111,502</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1.81</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">0.82</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8.4</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif;; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">45% </td> <td style="text-align: center">-</td> <td style="text-align: center"> 50%</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">43%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 46%</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center">None</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: center">None</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">5.5 </td> <td style="text-align: center"> -</td> <td style="text-align: center">7</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">5.5</td> <td style="text-align: center"> - </td> <td style="text-align: center"> 7.5</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">1.66%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 1.92%</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">0.07%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 2.05%</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Forfeiture rate</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 4%; text-align: right">&nbsp;</td> <td style="width: 4%; text-align: center">20%</td> <td style="width: 4%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 4%; text-align: right">&nbsp;</td> <td style="width: 4%; text-align: center">None</td> <td style="width: 4%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">Restricted Stock Awards</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Shares</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; font-size: 10pt">Outstanding at December 31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right">662,375</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Awards forfeited or exercised</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding&nbsp;&nbsp;at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">670,375</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 81%; text-align: left">2015</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">129,101</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">518,896</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">368,634</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">325,000</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">325,000</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right">650,853</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">2,317,484</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> 693953 324177 2450976 723955 5443432 1473025 13802282 4012328 646077 42047 0 0 0.45 0.5 0.43 0.46 0.0166 0.0192 0.0007 0.0205 8000 662375 670375 111502 1.81 -1835 3.49 211660 1336454 314775 524600 2.23 4.69 8.35 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div><div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Prior to the IPO the grant date fair value was determined by the Board of Directors. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.</div></div></div></div></div> 6.50 P5Y182D P7Y P5Y182D P7Y182D P8Y146D P9Y73D P9Y 0.92 2.21 3000000 450000 10857113 15627353 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Note 7: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity</div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Initial Public Offering</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company completed its initial public offering of 3,000,000 shares of common stock at a price to the public of $6.50 per share on November 14, 2014, whereupon it received aggregate net proceeds of approximately $17,065,000 after deducting underwriting discounts, commissions and other offering expenses. The Company&#x2019;s underwriters exercised their option to purchase 450,000 additional shares of common stock to cover over-allotments on November 18, 2014, pursuant to which it received aggregate net proceeds of approximately $2,710,000, after deducting underwriting discounts, commissions and expenses.&nbsp;&nbsp;Also, in conjunction with the IPO, the Company issued warrants to the underwriters for the purchase of 90,000 shares of common stock, which can be exercised between November 10, 2015 and November 10, 2018 at an exercise price of $8.125 per share.</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Options</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">In the nine months ended September 30, 2015, the Company granted 211,660 stock options to employees and certain non-employee members of its board of directors with exercise prices ranging from $6.31 - $9.62.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The fair value of the Company&#x2019;s common stock prior to its IPO was estimated by the Board of Directors at or about the time of grant for each share-based award. At each grant, the board considered a number of factors in establishing a value for the Company&#x2019;s common stock including its EBITDA, assessments of an amount its shareholders would accept in the private sale of the company, discussions with its investment bankers regarding pricing of the Company&#x2019;s common stock in an initial public offering and the probability of successfully completing an IPO. Although the methods for determining the fair value of the Company&#x2019;s common stock are not complex, the board&#x2019;s estimate of the fair value of the common stock did involve subjectivity, especially assessments of value in a private sale and estimates of value in the public stock market.</div> <!-- Field: Page; Sequence: 19 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Upon the completion of the Company&#x2019;s IPO, its stock trading price became the basis of fair value of its common stock used in determining the value of share based awards. To the extent the value of the Company&#x2019;s share based awards involves a measure of volatility, it will rely upon the volatilities from publicly traded companies with similar business models until its common stock has accumulated enough trading history for it to utilize its own historical volatility. The expected life of the options granted is based on the average of the vesting term and the contractual term of the option. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury 10-year yield curve in effect at the date of the grant.</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The Company has computed the fair value of all options granted during the nine months ended September 30, 2015 and 2014, using the following assumptions:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;"> <tr style="vertical-align: bottom"> <td>&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">45% </td> <td style="text-align: center">-</td> <td style="text-align: center"> 50%</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">43%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 46%</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center">None</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="text-align: center">None</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">5.5 </td> <td style="text-align: center"> -</td> <td style="text-align: center">7</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">5.5</td> <td style="text-align: center"> - </td> <td style="text-align: center"> 7.5</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">1.66%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 1.92%</td> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: center">0.07%</td> <td style="text-align: center"> -</td> <td style="text-align: center"> 2.05%</td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Forfeiture rate</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 4%; text-align: right">&nbsp;</td> <td style="width: 4%; text-align: center">20%</td> <td style="width: 4%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 4%; text-align: right">&nbsp;</td> <td style="width: 4%; text-align: center">None</td> <td style="width: 4%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">The information below summarizes the stock options:</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Fair<br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Remaining<br /> Contractual Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt">Outstanding at December 31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 9%; font-size: 10pt; text-align: right">314,775</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right">2.23</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right">0.92</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 9%; font-size: 10pt; text-align: right">9.2</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Granted at market price</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">211,660</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8.35</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Cancelled</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1,835</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3.49</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1.1pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">524,600</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4.69</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2.21</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9.0</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Exercisable at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">111,502</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1.81</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">0.82</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8.4</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The intrinsic value of the Company&#x2019;s stock options outstanding was $1,336,454 at September 30, 2015.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">For the three and nine months ended September 30, 2015, stock based compensation expense for stock options was $129,704, and $240,701, respectively.&nbsp;&nbsp;For the three and nine months ended September 30, 2014, stock based compensation expense for stock options was $7,440 and $15,538, respectively.&nbsp;&nbsp;Unrecognized stock-based compensation expense for stock options as of September 30, 2015 was $613,406, which is expected to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $23,031 to reflect accounting for certain performance based options. </div> <!-- Field: Page; Sequence: 20 --> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"> &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Stock</div></div></div> <div style=" font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The information below summaries the restricted stock activity:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid">Restricted Stock Awards</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Shares</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; font-size: 10pt">Outstanding at December 31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right">662,375</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Awards forfeited or exercised</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding&nbsp;&nbsp;at September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">670,375</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0">For the three and nine months ended September 30, 2015, stock based compensation expense for restricted stock was $226,875, and $405,376, respectively.&nbsp;&nbsp;For the three and nine months ended September 30, 2014, stock based compensation expense for restricted stock was $10,115, and $32,508, respectively.&nbsp;&nbsp; Unrecognized stock based compensation expense for restricted stock awards as of September 30, 2015 was $663,525 to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $122,841 to reflect accounting for certain performance based awards.</div></div> 48312 97900 134233 233563 197569 218400 598758 629225 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accounts Receivable</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees and marketing and advertising expenses. The Company considers a reserve for doubtful accounts based on the creditworthiness of the franchisee. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management&#x2019;s best estimate of uncollectible amounts and is determined based on specific identification and historical performance the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of September 30, 2015 and December 31, 2014, the Company had an allowance for doubtful accounts of $85,376 and $81,032, respectively.</div></div></div></div></div></div></div></div></div> 534000 534000 791638 791638 36000 30000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs and the related deferred tax assets and liabilities as long-term or current, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets and purchase price allocations.</div></div></div></div></div> 9844964 4828122 9777119 4819861 9844964 4828122 9777119 4819861 9844964 4828122 9777119 4819861 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares 0001612630 jynt:CompanyOwnedClinicMember 2012-07-01 2012-07-31 0001612630 2014-01-01 2014-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001612630 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0001612630 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001612630 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0001612630 jynt:TheJointRRCCorpMember 2014-01-01 2014-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2014-01-01 2014-09-30 0001612630 us-gaap:FranchisedUnitsMember 2014-01-01 2014-09-30 0001612630 us-gaap:MaximumMember 2014-01-01 2014-09-30 0001612630 us-gaap:MinimumMember 2014-01-01 2014-09-30 0001612630 jynt:ShareholderMember 2014-01-01 2014-09-30 0001612630 2014-01-01 2014-12-31 0001612630 jynt:TheJointRRCCorpMember 2014-01-01 2014-12-31 0001612630 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember jynt:SixFranchiseesMember 2014-01-01 2014-12-31 0001612630 2014-02-03 2014-12-31 0001612630 us-gaap:MaximumMember 2014-02-03 2014-12-31 0001612630 us-gaap:MinimumMember 2014-02-03 2014-12-31 0001612630 2014-07-01 2014-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0001612630 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0001612630 us-gaap:WarrantMember 2014-07-01 2014-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0001612630 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0001612630 jynt:TheJointRRCCorpMember 2014-07-01 2014-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2014-07-01 2014-09-30 0001612630 us-gaap:FranchisedUnitsMember 2014-07-01 2014-09-30 0001612630 jynt:ShareholderMember 2014-07-01 2014-09-30 0001612630 us-gaap:IPOMember 2014-11-14 2014-11-14 0001612630 jynt:TheJointRRCCorpMember us-gaap:CustomerRelationshipsMember 2014-12-31 2014-12-31 0001612630 jynt:TheJointRRCCorpMember us-gaap:FranchiseRightsMember 2014-12-31 2014-12-31 0001612630 2015-01-01 2015-01-02 0001612630 jynt:ClinicInTempeArizonaMember 2015-01-01 2015-01-02 0001612630 jynt:TheJointRRCCorpMember 2015-01-01 2015-01-02 0001612630 2015-01-01 2015-01-31 0001612630 jynt:ClinicInTempeArizonaMember 2015-01-01 2015-01-31 0001612630 2015-01-01 2015-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001612630 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001612630 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001612630 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001612630 jynt:DevelopedAndUndevelopedFranchisesReacquiredMember 2015-01-01 2015-09-30 0001612630 jynt:FranchisesInPhoenixAndTucsonArizonaMember 2015-01-01 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember 2015-01-01 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember us-gaap:CustomerRelationshipsMember 2015-01-01 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember us-gaap:FranchiseRightsMember 2015-01-01 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember us-gaap:FranchiseRightsMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember us-gaap:FranchiseRightsMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001612630 jynt:TheJointRRCCorpMember 2015-01-01 2015-09-30 0001612630 jynt:FranchisesMember jynt:RegionalDeveloperRightsInLosAngelesCountySanDiegoAndNewJerseyMember 2015-01-01 2015-09-30 0001612630 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-01-01 2015-09-30 0001612630 us-gaap:CustomerRelationshipsMember 2015-01-01 2015-09-30 0001612630 us-gaap:FranchiseRightsMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0001612630 us-gaap:FranchiseRightsMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0001612630 jynt:RegionalDeveloperRightsInLosAngelesCountySanDiegoAndNewJerseyMember 2015-01-01 2015-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2015-01-01 2015-09-30 0001612630 us-gaap:FranchisedUnitsMember 2015-01-01 2015-09-30 0001612630 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001612630 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001612630 jynt:ShareholderMember 2015-01-01 2015-09-30 0001612630 jynt:InterestBearingUnsecuredPromissoryNoteMember 2015-07-01 2015-07-31 0001612630 jynt:NoninterestBearingUnsecuredPromissoryNote1Member 2015-07-01 2015-07-31 0001612630 jynt:NoninterestBearingUnsecuredPromissoryNote2Member 2015-07-01 2015-07-31 0001612630 2015-07-01 2015-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001612630 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001612630 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001612630 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001612630 us-gaap:PerformanceSharesMember 2015-07-01 2015-09-30 0001612630 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001612630 jynt:TheJointRRCCorpMember 2015-07-01 2015-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2015-07-01 2015-09-30 0001612630 us-gaap:FranchisedUnitsMember 2015-07-01 2015-09-30 0001612630 jynt:ShareholderMember 2015-07-01 2015-09-30 0001612630 jynt:CompanyOwnedClinicMember 2012-07-31 0001612630 2013-12-31 0001612630 us-gaap:EntityOperatedUnitsMember 2013-12-31 0001612630 us-gaap:FranchisedUnitsMember 2013-12-31 0001612630 us-gaap:EntityOperatedUnitsMember 2014-06-30 0001612630 us-gaap:FranchisedUnitsMember 2014-06-30 0001612630 2014-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2014-09-30 0001612630 us-gaap:FranchisedUnitsMember 2014-09-30 0001612630 us-gaap:IPOMember 2014-11-14 0001612630 2014-12-31 0001612630 us-gaap:RestrictedStockMember 2014-12-31 0001612630 jynt:TheJointRRCCorpMember 2014-12-31 0001612630 jynt:TheJointRRCCorpMember jynt:LosAngelesCountyMember 2014-12-31 0001612630 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember jynt:SixFranchiseesMember 2014-12-31 0001612630 jynt:RegionalDeveloperRightsInLosAngelesCountySanDiegoAndNewJerseyMember 2014-12-31 0001612630 us-gaap:EntityOperatedUnitsMember 2014-12-31 0001612630 us-gaap:FranchisedUnitsMember 2014-12-31 0001612630 jynt:AssetsInProgressMember 2014-12-31 0001612630 us-gaap:LeaseholdImprovementsMember 2014-12-31 0001612630 us-gaap:OfficeEquipmentMember 2014-12-31 0001612630 jynt:PropertyPlantAndEquipmentExcludingAssetsInProgressMember 2014-12-31 0001612630 us-gaap:SoftwareDevelopmentMember 2014-12-31 0001612630 us-gaap:ScenarioPreviouslyReportedMember 2014-12-31 0001612630 jynt:TheJointRRCCorpMember 2015-01-02 0001612630 jynt:FranchiseFromRothPelanEnterprisesLLCMember 2015-02-17 0001612630 jynt:FranchiseFromTjscLlcMember 2015-03-03 0001612630 jynt:FranchisesFromTheJointSanGabrielValleyIncMember 2015-03-06 0001612630 jynt:FranchiseFromTheJointArrowheadRanchLLCMember 2015-03-23 0001612630 jynt:FranchiseFromTheJointChiropracticBellTowneLLCMember 2015-04-02 0001612630 jynt:FranchiseFromSanDiegoJointDevelopmentIncMember 2015-05-01 0001612630 jynt:FranchiseFromSanDiegoJointDevelopmentIncMember jynt:PayableNovember12015Member 2015-05-01 0001612630 jynt:FranchiseFromFirstLightJunctionMember 2015-05-18 0001612630 jynt:FranchiseFromFirstLightJunctionMember jynt:PayableFebruary182016Member 2015-05-18 0001612630 jynt:FranchiseFromFirstLightJunctionMember jynt:PayableOnNovember182016Member 2015-05-18 0001612630 jynt:FranchiseFromWHBFranchiseIncMember 2015-06-03 0001612630 jynt:FranchiseFromWHBFranchiseIncMember jynt:PayableOnDecember32015Member 2015-06-03 0001612630 jynt:FranchiseFromWHBFranchiseIncMember jynt:PayableOnOctober32015Member 2015-06-03 0001612630 jynt:FranchiseFromClearPathVenturesIncMember 2015-06-05 0001612630 jynt:FranchiseFromClearPathVenturesIncMember jynt:PayableOnDecember52015Member 2015-06-05 0001612630 jynt:FranchiseFromClearPathVenturesIncMember jynt:PayableOnOctober52015Member 2015-06-05 0001612630 us-gaap:EntityOperatedUnitsMember 2015-06-30 0001612630 us-gaap:FranchisedUnitsMember 2015-06-30 0001612630 jynt:FranchiseFromChiroNovoLlcMember 2015-07-02 0001612630 jynt:FranchiseFromChiroNovoLlcMember jynt:PayableNovember12015Member 2015-07-02 0001612630 2015-07-07 0001612630 jynt:InterestBearingUnsecuredPromissoryNoteMember 2015-07-31 0001612630 jynt:NoninterestBearingUnsecuredPromissoryNote1Member 2015-07-31 0001612630 jynt:NoninterestBearingUnsecuredPromissoryNote2Member 2015-07-31 0001612630 jynt:FranchiseFromChiroGroupMember 2015-08-10 0001612630 jynt:FranchiseFromChiroGroupMember jynt:PayableDecember102015Member 2015-08-10 0001612630 jynt:FranchiseFromTheJointChiropracticBellTowneLLCMember 2015-08-15 0001612630 2015-09-30 0001612630 us-gaap:RestrictedStockMember 2015-09-30 0001612630 jynt:ReacquisitionsOfFranchisesThroughoutArizonaAndCaliforniaAndAcquisitionOfClinicInTempeArizonaMember 2015-09-30 0001612630 jynt:TheJointRRCCorpMember 2015-09-30 0001612630 jynt:FranchiseFeesMember 2015-09-30 0001612630 jynt:FranchisesMember jynt:RegionalDeveloperRightsInLosAngelesCountySanDiegoAndNewJerseyMember 2015-09-30 0001612630 jynt:LicenseFeesMember 2015-09-30 0001612630 us-gaap:CustomerRelationshipsMember 2015-09-30 0001612630 jynt:DevelopmentRightsMember 2015-09-30 0001612630 us-gaap:FranchiseRightsMember 2015-09-30 0001612630 us-gaap:EntityOperatedUnitsMember 2015-09-30 0001612630 us-gaap:FranchisedUnitsMember 2015-09-30 0001612630 jynt:AssetsInProgressMember 2015-09-30 0001612630 us-gaap:LeaseholdImprovementsMember 2015-09-30 0001612630 us-gaap:OfficeEquipmentMember 2015-09-30 0001612630 jynt:PropertyPlantAndEquipmentExcludingAssetsInProgressMember 2015-09-30 0001612630 us-gaap:SoftwareDevelopmentMember 2015-09-30 0001612630 us-gaap:MaximumMember 2015-09-30 0001612630 us-gaap:MinimumMember 2015-09-30 0001612630 2015-11-09 EX-101.SCH 6 jynt-20150930.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Supplemental Disclosure of Non-cash Activity link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Acquisitions link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Notes Receivable link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 2 - Acquisitions (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 4 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 5 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 6 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 7 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 10 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Supplemental Disclosure of Non-cash Activity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Statement - Note 1 - Franchise Agreements (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Statement - Note 1 - Earnings (Loss) Per Common Share (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Statement - Note 1 - Potential Shares of Common Stock Excluded from Diluted Net Loss Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 2 - Acquisitions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Statement - Note 2 - Assets Acquired and Liabilities Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Statement - Note 2 - Balance Sheet Adjustments Related to the Purchase Price Allocation (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Statement - Note 2 - Supplemental Pro Forma Information (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 3 - Notes Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 4 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Statement - Note 4 - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 5 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Statement - Note 5 - Intangible Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Statement - Note 5 - Estimated Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 6 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Statement - Note 6 - Maturities of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 7 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Statement - Note 7 - Fair Value Assumptions of Options Granted (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Statement - Note 7 - Stock Options Activity (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Statement - Note 7 - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 8 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 9 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Statement - Note 10 - Summary of Future Minimum Rental Payments for Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 jynt-20150930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 jynt-20150930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 jynt-20150930_lab.xml XBRL LABEL FILE Document And Entity Information Customer Concentration Risk [Member] Employee Stock Option [Member] Note To Financial Statement Details Textual Restricted Stock [Member] statementsignificantaccountingpoliciespolicies Warrant [Member] statementnote1natureofoperationsandsummaryofsignificantaccountingpoliciestables Antidilutive Securities [Axis] statementnote2acquisitionstables statementnote4propertyandequipmenttables us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Other liabilities statementnote5intangibleassetstables Antidilutive Securities, Name [Domain] statementnote6notespayabletables Concentration Risk Benchmark [Axis] statementnote7equitytables statementnote10commitmentsandcontingenciestables statementnote1franchiseagreementsdetails Income taxes payable Concentration Risk Type [Axis] statementnote1earningslosspercommonsharedetails Concentration Risk Benchmark [Domain] statementnote1potentialsharesofcommonstockexcludedfromdilutednetlosspersharedetails us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense Deferred revenue Concentration Risk Type [Domain] statementnote2assetsacquiredandliabilitiesassumeddetails statementnote2balancesheetadjustmentsrelatedtothepurchasepriceallocationdetails statementnote2supplementalproformainformationdetails Accounts Receivable [Member] Performance Shares [Member] statementnote5intangibleassetsacquireddetails statementnote4propertyandequipmentdetails statementnote6maturitiesofnotespayabledetails Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] statementnote5estimatedamortizationexpensedetails us-gaap_NetIncomeLoss Net loss and comprehensive loss Net loss statementnote7stockoptionsactivitydetails statementnote7fairvalueassumptionsofoptionsgranteddetails us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and accrued expenses statementnote10summaryoffutureminimumrentalpaymentsforoperatingleasesdetails statementnote7restrictedstockactivitydetails Notes To Financial Statements [Abstract] Notes To Financial Statements us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Payroll liabilities us-gaap_AdvertisingExpense Advertising Expense All Countries [Domain] us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets Cash flows from investing activities: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use Franchise from Chiro Novo, LLC [Member] Information pertaining to the acquisitions from Chiro Novo, LLC. Prepaid expenses and other current assets Payable November 1, 2015 [Member] Information pertaining to the additional amount plus interest payable on November 1, 2015 from the acquisitions. Payable December 10, 2015 [Member] Information pertaining to the amount plus interest payable on December 10, 2015 from the acquisitions. Franchise from Chiro Group [Member] Information pertaining to the acquisitions from Chiro Group. us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value Cash and cash equivalents Cash at beginning of period Cash at end of period Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Cash Flow, Supplemental Disclosures [Text Block] Selling and marketing expenses us-gaap_PropertyPlantAndEquipmentOtherNet Property and Equipment, Net Provision for bad debts Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] us-gaap_TableTextBlock Notes Tables us-gaap_SellingGeneralAndAdministrativeExpense Total selling, general and administrative expenses Comprehensive Income, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Lease, Policy [Policy Text Block] Internal Use Software, Policy [Policy Text Block] Series A preferred stock, shares outstanding (in shares) us-gaap_Revenues Total revenues Common stock, shares outstandig (in shares) Stockholders' Equity Note Disclosure [Text Block] Income Tax, Policy [Policy Text Block] Proceeds received on sale of property and equipment jynt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFavorableLeases Favorable leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Favorable Leases Represents the favorable leases in a business combination. Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Advertising Costs, Policy [Policy Text Block] us-gaap_Assets Total assets us-gaap_DepositAssets Deposit Assets Cooperative Advertising Policy [Policy Text Block] Current liabilities: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights Franchise fees Property and equipment, net us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract Lessee Leasing Arrangements, Operating Leases, Term of Contract Goodwill Goodwill Royalty fees us-gaap_PropertyPlantAndEquipmentGross Property and Equipment, Gross us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation Loss per share: us-gaap_FiniteLivedIntangibleAssetsNet Total Net Carrying Value Intangible assets, net us-gaap_FiniteLivedIntangibleAssetsGross Gross Carrying Amount us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization Revenue Recognition, Services, Commissions [Policy Text Block] Revenue Recognition, Services, Franchise Fees [Policy Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Deferred income taxes us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Property, Plant and Equipment [Table Text Block] Changes in operating assets and liabilities, net of effects from acquisitions: Supplemental cash flow disclosures: us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Accumulated deficit us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears 2018 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears 2019 us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter Thereafter us-gaap_OperatingLeasesFutureMinimumPaymentsDue us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear 2015 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear 2015 Revenues and management fees from company clinics jynt_ExcessDeferredRegionalFeesRevenueRecognized Excess Deferred Regional Fees Revenue Recognized Represents the amount of excess deferred regional developer fees revenue recognized during the period. us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears 2016 IT related income and software fees jynt_CashAdvanceToAcquireIntangibleAssets Cash Advance to Acquire Intangible Assets Represents the amount of cash consideration recorded as a cash advance, as of the balance sheet date, related to the acquisition of intangible assets. us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears 2017 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2017 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2016 Long-term Debt, Maturities, Repayments of Principal in Year Two Advertising fund revenue us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period jynt_ShareBasedCompensationArrangementsBySharebasedPaymentAwardOptionsGrantsInPeriodExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Exercise Price Represents the per share amount at which grantees can acquire shares of common stock by exercise of options. us-gaap_TreasuryStockValue Treasury stock (534,000 shares as of September 30, 2015 and December 31, 2014, at cost) jynt_NetFranchiseFeesRecognizedUponTerminationOfFranchiseAgreements Net franchise fees recognized upon termination of franchise agreements The element that represents net franchise fees recognized upon termination of franchise agreements. jynt_NumberOfFranchiseLicensesTerminated Number of Franchise Licenses Terminated Represents the number of franchise licenses terminated during the period. jynt_RevenueRecognizedInConjunctionWithFranchiseLicenseTerminations Revenue Recognized in Conjunction with Franchise License Terminations Represents the amount of revenue recognized during the period in conjunction with the termination of franchise licenses. us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition jynt_RecognitionOfPreviouslyDeferredCostsInConjunctionWithFranchiseLicenseTerminations Recognition of Previously Deferred Costs in Conjunction with Franchise License Terminations Represents the amount of previously deferred costs recognized during the period in conjunction with the termination of franchise licenses. jynt_BusinessCombinationMeasurementPeriodAdjustmentsPropertyAndEquipmentIncreaseDecrease Business Combination, Measurement Period Adjustments, Property and Equipment, Increase (Decrease) Represents the increase (decrease) to property and equipment attributable to the effect of certain measurement period adjustments (with the resulting offset to goodwill). jynt_BusinessCombinationMeasurementPeriodAdjustmentsIntangibleAssetsIncreaseDecrease Business Combination, Measurement Period Adjustments, Intangible Assets, Increase (Decrease) Represents the increase (decrease) to intangible assets attributable to the effect of certain measurement period adjustments (with the resulting offset to goodwill). Deposits and other assets jynt_BusinessCombinationMeasurementPeriodAdjustmentsDeferredRevenueIncreaseDecrease Business Combination, Measurement Period Adjustments, Deferred Revenue, Increase (Decrease) Represents the increase (decrease) to deferred revenue attributable to the effect of certain measurement period adjustments (with the resulting offset to goodwill). Franchise from The Joint Chiropractic Bell Towne LLC [Member] Represents information about acquiring franchise from The Joint Chiropractic Bell Towne LLC. Franchise from San Diego Joint Development Inc. [Member] Represents information about acquiring franchise from San Diego Joint Development Inc. Franchise from Clear Path Ventures Inc. [Member] Represents information about acquiring franchise from Clear Path Ventures Inc. us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities Restricted cash Payable on October 3, 2015 [Member] Represents information about an amount that will be paid on October 3, 2015. Franchise from First Light Junction [Member] Represents information about acquiring franchise from First Light Junction. Franchise from WHB Franchise Inc. [Member] Represents information about acquiring franchise from WHB Franchise Inc. Payable on October 5, 2015 [Member] Represents information pertaining to an amount that will be payable on October 5, 2015. Payable on December 5, 2015 [Member] Represents information pertaining to an amount that will be paid on December 5, 2015. Payable on December 3, 2015 [Member] Represents information about an amount that will be paid on December 3, 2015. Consolidation, Variable Interest Entity, Policy [Policy Text Block] jynt_AdditionalLeasesAssumed Additional Leases Assumed Represents the number of additional leases assumed during the period by the Company for clinic locations. us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition Common stock, $0.001 par value; 20,000,000 shares authorized, 10,402,047 shares issued and 9,868,047 shares outstanding as of September 30, 2015 and 10,196,502 shares issued and 9,662,502 outstanding as of December 31, 2014 Total intangible assets Amortized intangible assets: Nature of Operations Policy [Policy Text Block] Disclosure of accounting policy for nature of operations. Common stock, shares issued (in shares) us-gaap_IncreaseDecreaseInIncomeTaxesReceivable Income taxes receivable Common stock, shares authorized (in shares) us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear 2015 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Thereafter Common stock, par value (in dollars per share) us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2019 Other revenues us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Regional Developer Rights in Los Angeles County, San Diego, and New Jersey [Member] Represents information about regional developer rights in Los Angeles County, California, in San Diego, California, and in New Jersey. Revenues: jynt_NumberOfReacquiredDevelopedFranchisesOperatedAsCompanyOwnedOrManagedClinics Number of Reacquired Developed Franchises Operated as Company-owned or Managed Clinics The number of the reacquired developed franchises that the Company is operating as company-owned or managed clinics. jynt_NumberOfReacquiredUndevelopedFranchisesThatHaveBeenTerminatedAndMayBeRelocated Number of Reacquired Undeveloped Franchises that Have Been Terminated and May Be Relocated Represents the number of the reacquired undeveloped franchises that have been terminated and the Company may relocate them. jynt_BusinessCombinationConsiderationTransferredNetOfDeferredRevenueAndDeferredFranchiseCosts Business Combination, Consideration Transferred, Net of Deferred Revenue and Deferred Franchise Costs Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, net of the deferred revenue and deferred franchise costs related to the acquisition. us-gaap_GoodwillAcquiredDuringPeriod Goodwill, Acquired During Period Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member] Represents information pertaining to the 2015 reacquisitions by the Company of franchises throughout Arizona and California, as well as the acquisition of a clinic in Tempe, Arizona. jynt_NumberOfDevelopedFranchisesReacquiredDuringPeriod Number of Developed Franchises Reacquired During Period Represents the aggregate number of developed franchises reacquired by the Company during the period. jynt_NumberOfUndevelopedFranchisesReacquiredDuringThePeriod Number of Undeveloped Franchises Reacquired During the Period Represents the aggregate number of undeveloped franchises reacquired by the Company during the period. Developed and Undeveloped Franchises Reacquired [Member] Represents information pertaining to the re-acquisition of developed and undeveloped franchises. jynt_ClinicsAcquiredDuringThePeriod Acquired during the period Represents the number of clinics acquired during the period. Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of September 30, 2015, and December 31, 2014 Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_NotesReceivableNet Financing Receivable, Net Business Combination Disclosure [Text Block] Non-interest Bearing Unsecured Promissory Note 1 [Member] Represents non-interest bearing unsecured promissory note 1. Non-interest Bearing Unsecured Promissory Note 2 [Member] Represents non-interest bearing unsecured promissory note 2. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_IncreaseDecreaseInDepositOtherAssets Deposits and other assets Interest Bearing Unsecured Promissory Note [Member] Represents an interest bearing unsecured promissory note. jynt_NotesReceivableIssuedForPaymentOfTransferFees Notes receivable issued for payment of transfer fees Amount of notes receivable issued for payment of transfer fees. jynt_RegionalDevelopersLicenseFee Regional Developers License Fee Minimum amount of license fees that must be paid by regional developers. Treasury stock, shares (in shares) jynt_RegionalDevelopersFranchiseFeesCollectedUponSaleOfFranchise Regional Developers, Franchise Fees Collected Upon Sale of Franchise Amount of franchise fees collected upon sale of franchise. Franchise cost of revenues Consolidation, Policy [Policy Text Block] us-gaap_CostOfRevenue Cost of revenues Franchise Rights [Member] Deferred rent Intangible Assets Disclosure [Text Block] us-gaap_AllowanceForDoubtfulAccountsReceivable Allowance for Doubtful Accounts Receivable Customer Relationships [Member] us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life us-gaap_NonoperatingIncomeExpense Total other income (expense) Other income (expense), net us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Schedule of Franchisor Disclosure [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2016 us-gaap_OperatingIncomeLoss Loss from operations us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2017 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2018 Finite-Lived Intangible Assets by Major Class [Axis] us-gaap_NumberOfStores Clinics open at beginning of period Clinics in operation at the end of the period Total clinics in operation at the end of the period Finite-Lived Intangible Assets, Major Class Name [Domain] Property, Plant and Equipment Disclosure [Text Block] Franchisor Disclosure [Axis] Franchisor Disclosure [Domain] Franchised Units [Member] Entity Operated Units [Member] Computer Software, Intangible Asset [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Amendment Flag Income Tax Disclosure [Text Block] Minimum [Member] Maximum [Member] Range [Axis] Range [Domain] Document Fiscal Year Focus Customer [Axis] Document Fiscal Period Focus Customer [Domain] Regional developer fees Amount of regional development fees revenue recognized. us-gaap_ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering us-gaap_ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised Document Period End Date Current Fiscal Year End Date Award Type [Axis] Cost of revenues: Office Equipment [Member] Entity Current Reporting Status Entity Voluntary Filers Entity Filer Category us-gaap_LongTermDebt Total Software Development [Member] Document Type jynt_RegionalDeveloperFeesRecognizedUponAcquisitionOfDevelopmentRights Regional developer fees recognized upon acquisition of development rights The element that represents regional developer fees recognized upon acquisition of development rights. us-gaap_DeferredRevenue Deferred Revenue Equity Award [Domain] Entity Well-known Seasoned Issuer us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Granted at market price (in dollars per share) Note receivable - current portion us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Outstanding at December 31, 2014 (in shares) Outstanding at September 30, 2015 (in shares) Cancelled (in dollars per share) Accounts receivable, net Co-op funds liability Aggregate carrying amount of Co-op funds liability (due within one year or within the normal operating cycle if longer). Statement [Table] Receivable [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding at December 31, 2014 (in dollars per share) Outstanding at September 30, 2015 (in dollars per share) Deferred franchise costs, net of current portion Represents the deferred noncurrent net amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through a franchise arrangement having an indefinite period of benefit. Receivable Type [Axis] Deferred franchise costs - current portion Deferred franchise costs - current portion Represents the deferred current net amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through a franchise arrangement having an indefinite period of benefit. IT cost of revenues Restricted cash us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Outstanding at December 31, 2014 (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding at December 31, 2014 Current assets: us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable at September 30, 2015 (in shares) us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net decrease in cash us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable at September 30, 2015 (in dollars per share) Income Statement [Abstract] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Exercisable at September 30, 2015 us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net cash used in financing activities us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net cash used in investing activities us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net cash used in operating activities Geographical [Axis] us-gaap_PaymentOfFinancingAndStockIssuanceCosts Deferred offering costs Revenues, net Cancelled (in shares) us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Net loss us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Loans, Notes, Trade and Other Receivables Disclosure [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding at December 31, 2014 (in shares) Outstanding at September 30, 2015 (in shares) Business Acquisition, Pro Forma Information [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Restricted stock awards granted (in shares) us-gaap_StockholdersEquity Total stockholders' equity Risk-free rate us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Series A preferred stock, shares issued (in shares) Series A preferred stock, shares authorized (in shares) Expected volatility Series A preferred stock, par value (in dollars per share) Expected term (years) us-gaap_FinitelivedIntangibleAssetsAcquired1 Finite-lived Intangible Assets Acquired Expected dividends us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration Transferred, Liabilities Incurred Net purchase price Business Combination, Consideration Transferred Payable on November 18, 2016 [Member] Represents the payable on November 18, 2016. Additional paid-in capital Payable February 18, 2016 [Member] Represents the payable on February 18, 2016. Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Stockholders' equity: jynt_BusinessCombinationMeasurementPeriodAjustmentGoodwillIncreaseDecrease Business Combination, Measurement Period Ajustment, Goodwill, Increase (Decrease) Represents the adjustment to goodwill during the measurement period for the business combination. Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment jynt_BusinessCombinationMeasurementPeriodAdjustmentsFavorLeasesIncreaseDecrease Business Combination, Measurement Period Adjustments, Favor Leases, Increase (Decrease) Represents the increase (decrease) to favorable leases attributable to the effect of certain measurement period adjustments (with the resulting offset to goodwill). us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Total assets acquired Entity Registrant Name Entity Central Index Key Commitments and Contingencies Disclosure [Text Block] jynt_NumberOfFranchiseesInLitigation Number of Franchisees, in Litigation Represents the number of franchisees entering litigation with the company. us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue Deferred membership revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Entity Common Stock, Shares Outstanding (in shares) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Net assets acquired Commitments and contingencies us-gaap_Liabilities Total liabilities Note receivable, net of current portion and reserve Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Deferred tax asset - current portion Trading Symbol Scenario [Axis] Scenario, Unspecified [Domain] us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued us-gaap_AssetsCurrent Total current assets Scenario, Previously Reported [Member] Bargain purchase gain Bargain purchase gain Business Combination, Bargain Purchase, Gain Recognized, Amount us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income tax (expense) benefit Income taxes receivable us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Notes payable, net of current portion Depreciation and amortization us-gaap_Depreciation Depreciation Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Type [Axis] us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Cash paid for acquisitions Payments to Acquire Businesses, Net of Cash Acquired Payments received on notes receivable Deferred rent - current portion Property, Plant and Equipment, Type [Domain] Deferred revenue - current portion Deferred revenue - current portion Leasehold Improvements [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] us-gaap_LiabilityForUncertainTaxPositionsCurrent Liability for Uncertain Tax Positions, Current Disposal Group Name [Domain] Disposal Group Name [Axis] Statement of Financial Position [Abstract] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Stock based compensation expense Other current liabilities us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life Statement of Cash Flows [Abstract] Cash flows from operating activities: us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Notes payable - current portion jynt_NumberOfMonthlyPayments Number of Monthly Payments Represents information about the number of monthly payments under the lease agreement. Weighted average shares (in shares) jynt_OperatingLeaseMonthlyRentExpense Operating Lease, Monthly Rent Expense Represents the monthly rent expense for the operating lease. Shareholder [Member] Information related to a shareholder in the company. Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Cash paid for income taxes Intangible Assets, Finite-Lived, Policy [Policy Text Block] Cash paid for interest Unvested restricted stock (in shares) us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Weighted average common shares outstanding - diluted (in shares) us-gaap_SharePrice Share Price Payroll liabilities Basic and diluted loss per share (in dollars per share) Basic and diluted loss per share (in dollars per share) us-gaap_IncomeTaxExpenseBenefit Income tax (expense) benefit Income Tax Expense (Benefit) Cash flows from financing activities: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Weighted average common shares outstanding - basic (in shares) Accounts payable and accrued expenses Revenue Recognition, Policy [Policy Text Block] Trade and Other Accounts Receivable, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Class of Stock [Axis] Accounting Policies [Abstract] Cash and Cash Equivalents, Policy [Policy Text Block] Basis of Accounting, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Franchise from The Joint Arrowhead Ranch LLC [Member] Represents information about acquiring franchise from The Joint Arrowhead Ranch LLC. us-gaap_RepaymentsOfNotesPayable Repayments on note payable Franchise from TJSC LLC [Member] Represents information about acquiring franchise from TJSC, LLC. Franchises from The Joint San Gabriel Valley Inc [Member] Represents information about acquiring franchises from The Joint San Gabriel Valley Inc. jynt_NumberOfAcquiredFranchisesToDevelop Number of Acquired Franchises to Develop Represents the number of franchises to develop. Franchise from Roth Pelan Enterprises LLC [Member] Represents information about acquiring franchise from Roth & Pelan Enterprises, LLC. Development Rights [Member] Rights, generally of limited duration, that the entity has obtained through an arrangement related to the regional developer. Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Forfeiture rate Represents the forfeiture rate in determine the fair value for the share-based compensation. jynt_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageFairValue Exercisable at September 30, 2015 (in dollars per share) The weighted-average fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Related Party Transactions Disclosure [Text Block] Other income (expense): Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] General and administrative expenses Statement [Line Items] Sale of Stock [Axis] Related Party [Axis] Sale of Stock [Domain] Related Party [Domain] IPO [Member] jynt_FranchiseMonthlyMarketingFeeGrossSalesPercentage Franchise Monthly Marketing Fee Gross Sales Percentage Represents the percentage of gross sales a franchise pays for monthly marketing fees as stipulated in the typical franchise agreement. Six Franchisees [Member] Information related to six franchisees. us-gaap_LeaseAndRentalExpense Operating Leases, Rent Expense jynt_NumberOfFranchises Number of Franchises Represents the number of franchises. jynt_IntangibleAssetsReclassifiedFromDeposits Intangible Assets Reclassified from Deposits Represents amounts reclassified from a deposit to intangible assets. Schedule of Intangible Assets and Goodwill [Table Text Block] License Fees [Member] Represents information pertaining to license fees. Franchise Fees [Member] Represents information pertaining to franchise fees collected upon the execution of franchise agreements. jynt_DeferredFranchiseCostsNettedAgainstAggregatePurchasePrice Deferred Franchise Costs Netted Against Aggregate Purchase Price Represents the deferred franchise costs netted against the aggregate purchase price of acquisitions. jynt_AdvancesForReacquisitionAndTerminationOfRegionalDeveloperRights Reacquisition and termination of regional developer rights Represents an advance for the reacquisition and termination of regional developer rights. jynt_IncreaseDecreaseInCoOpFundsLiability Co-op funds liability Represents the increase (decrease) in co-op funds liability during the period. jynt_IncreaseDecreaseInDeferredFranchiseCosts Deferred franchise costs Represents the increase (decrease) during the reporting period in deferred franchise costs. Debt Disclosure [Text Block] Royalties, Policy [Policy Text Block] Disclosure of accounting policy for the royalties from franchises. IT Related Income And Software Fees, Policy [Policy Text Block] Disclosure of accounting policy for income and software fees related to information technology. Regional Developer Fees, Policy [Policy Text Block] Disclosure of accounting policy for regional developer fees. Revenues and Management Fees, Policy [Policy Text Block] Disclosure of accounting policy for the revenues and management fees from the Company clinics. Advertising Fund, Policy [Policy Text Block] Disclosure of accounting policy for the advertising fund. jynt_FranchiseRoyaltyGrossSalesPercentage Franchise Royalty Gross Sales Percentage Represents the percentage of gross sales collected as royalties from franchises typically collected bi-monthly two working days after each sales period has ended as stipulated in the franchise agreement. jynt_MarketingAndAdvertisingFeeGrossSalesPercentage Marketing and Advertising Fee Gross Sales Percentage Represents the percentage of gross sales collected as marketing and advertising fee. jynt_RegionalDevelopersRoyaltySalesGeneratedByFranchisesPercentage Regional Developers Royalty Sales Generated by Franchises Percentage Represents the percentage of sales generated by franchised clinics in their region regional developers receive as royalties. Other liabilities jynt_RegionalDevelopersLicenseFeeCurrentFranchiseFeePercentage Regional Developers License Fee Current Franchise Fee Percentage The percentage of the then current franchise fee regional developers pay as a license fee. jynt_InitialFranchiseAgreementTerm Initial Franchise Agreement Term Represents the initial amount of time for the franchise agreement. The Joint RRC Corp [Member] Entity acquired by the company. Franchises in Phoenix and Tucson, Arizona [Member] Represents information about the acquisition of the operating franchises in Phoenix and Tucson, Arizona from Roth & Pelan. Los Angeles County [Member] Represents information pertaining to Los Angeles County, California. jynt_NetPurchasePriceNetDeferredRevenueAdjustment Net Purchase Price, Net Deferred Revenue Adjustment Represents the amount of a net deferred revenue adjustment to the net purchase price. Deferred revenue, net of current portion jynt_DeferredFranchiseCosts Deferred Franchise Costs Represents the deferred costs incurred and are directly related to generating franchise revenues. Equity Component [Domain] jynt_NumberOfFranchisesToBeOperatedAsCompanyOwnedFromFranchiseeAcquistion Number of Franchises to Be Operated as Company-owned from Franchisee Acquistion Represents the number of franchises that will be operated as company owned from the franchises that were acquired from a franchisee. Equity Components [Axis] jynt_NumberOfFranchisesAcquiredFromFranchisee Number of Franchises Acquired from Franchisee Represents the number of franchises acquired from a franchisee. us-gaap_GainLossOnSaleOfPropertyPlantEquipment Gain on sale of property and equipment jynt_NumberOfAdditionalUndevelopedFranchisesAcquired Number of Additional Undeveloped Franchises Acquired The element that represents the number of additional undeveloped franchises acquired. jynt_NumberOfFranchisesToBeClosed Number Of Franchises To Be Closed Represents the number of franchises to be closed. jynt_ClinicsClosedDuringThePeriod Closed during the period Represents the number of clinics closed during the period. Concentration Risk, Credit Risk, Policy [Policy Text Block] Opened during the period Represents the number of number of clinics opened during the period. Clinic licenses sold but not yet developed The number of clinics that have been sold as franchises, but are not yet operational. Assets in Progress [Member] Represents information pertaining to assets in progress. us-gaap_PolicyTextBlockAbstract Accounting Policies jynt_NotesReceivablePrincipalAndInterestTerm Notes Receivable, Principal and Interest, Term Represents the term over which principal and interest are to be paid. Company-owned Clinic [Member] Represents the sale of the Company-owned clinic. Property, Plant and Equipment Excluding Assets in Progress [Member] Represents information pertaining to property, plant and equipment, excluding assets in progress. us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs Clinic in Tempe, Arizona [Member] Represents information about the clinic in Tempe, Arizona. jynt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnfavorableLeases Unfavorable leases Represents the unfavorable leases in a business combination. jynt_NotesReceivableInterestRate Notes Receivable, Interest Rate Represents the per annum interest rate stated in notes receivable. Deferred rent, net of current portion jynt_NotesReceivableContractualTerm Notes Receivable, Contractual Term The contractual term stated in note receivable. Franchises [Member] Represents information about the Company's franchises. EX-101.PRE 10 jynt-20150930_pre.xml XBRL PRESENTATION FILE XML 11 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Estimated Amortization Expense (Details)
Sep. 30, 2015
USD ($)
2015 $ 129,101
2016 518,896
2017 368,634
2018 325,000
2019 325,000
Thereafter 650,853
Total $ 2,317,484
XML 12 R48.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 10 - Commitments and Contingencies (Details Textual)
3 Months Ended 9 Months Ended 11 Months Ended
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Jul. 07, 2015
Minimum [Member]            
Operating Lease, Monthly Rent Expense     $ 1,432   $ 10,500  
Lessee Leasing Arrangements, Operating Leases, Term of Contract     1 year 180 days      
Maximum [Member]            
Operating Lease, Monthly Rent Expense     $ 13,213   $ 22,000  
Lessee Leasing Arrangements, Operating Leases, Term of Contract     10 years 120 days      
Number of Monthly Payments         66  
Additional Leases Assumed     46      
Operating Leases, Rent Expense $ 402,061 $ 33,860 $ 756,678 $ 100,942    
Number of Franchisees, in Litigation           13
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`*1K<$```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8< M4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SG MVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0// M>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C M@KN_V/P"4$L#!!0````(`*1K<$=AI.76UP$``"`>```:````>&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/%V%;L;B`#-^/[<2*L\HFVZ8W@.RQ ML6(#8J9J??>A7E1NDCG*PM+9@`#IFW?U@(;'+M6K'_'8Y$/?I?8PI-F?T[%+ MJ^G^NFIS'E8AI$T;3TVZZX?834]W_7AJ\G0Y[L/0;-Z:?0Q:UXLP7L^IGAX_ MSIZ];-?5^+*5:O:S&?3W$T+3(_/0_S.\OUN=]C$YW[S MZQ2[_$5%^+=`%J`$20UDK#E)"&N.U@*X%H[7`L`6CM@"R!:.V0+0%H[:`M@6CML" MX!:.W`+H%H[=`O`6CMX*]%:.W@KT5M*W-OK8YNBM0&_EZ*U`;^7HK4!OY>BM M0&_EZ*U`;^7HK4!OY>BM0&_EZ&U`;^/H;4!OX^AM0&\C[96@S1*.W@;T-H[> M!O0VCMX&]#:.W@;T-H[>!O0VCMX&]#:.W@[T=H[>#O1VCMX.]':.W@[T=M)> M-]KLYNCM0&_GZ.U`;^?H[4!OY^CM0&_GZ.U`;^?H/;_2.[7-&+>O>3QT^W3K MFO^&PZ(KO%,^'^/M4RY38<.5UGE:*8;+\>:OCLO4OR'AT\_@IW=02P,$%``` M``@`I&MP1YBKU[%R`P``$@T``!````!D;V-0&ULO5=;4^(P M%/XK&9[T00N(-P8[PP+..N.%$=9]CND!LK9)-R=EQ%^_)RD@**W4A_7%)/V^ MU6;6INT@0#&#A.,Q011]G6B3<$M;,PWT M9"(%]+7($E`V:-;K9P&\6E`11$?I6F@M[#@MW32-I>!6:A7>26$TZHEE@U>DQ/)RE7BR#?W4KU M@K_2L>YS"YNL[0^Y]!DW$)'2+>GK0X_YN2`_8\?MS;B:0K2)_?QQ%8LG,.@\ M;32/Z_2W#L'J/)<-/))J.N328-B9V_8\JLVYD5S9&D/Y1MMF+5>;G_IUG*(UX6]M7G`&8+$3K`_]D"F=DZ1_9_`W.Z4[. M**-^=1(MCUE?HH@U9@:8GK![K8YVVR7V@1K$!PT9+^8TB=,5 M?S.)TF.+D2=..BV0/8(`.>?/,12C6X1>7G\+QETR24?JG"KFG!+GAKQ64TFR M61?Q0Q=LP\_6!@WYHMR:L%Z9_&OG=R"?LU]:K2QO0FSK[@7--+ASWQ./,QR)+TBRGG.".KQ0OU M:%[876'EO'1RG/MY0%LI\N'NZ)ZV_[39IW^*YD[KO/K]UBJ9!YXSRI*$FX7+ MSG7F[ZT[N54'G]Z6'UZ2P?8OH/`?4$L#!!0````(`*1K<$<)%%E`'%B M$A)#(&XA\;:PYD.)IZ[_GBSK6L:X[,:MKOT^?ATGI7!,6`_/WCKPJ"#<['5M M`A-NGFT0'2,DB`UH'D:QPL3DRGK-,89^31P76[X&,BZ*&=&`7'+DY`#,74_, MJE(*)CQPM+[#2]'CW<[7"28%@1HT&`R$CBC)JE>S-;8Q)1GT51D=USS@PDJU M4B#OVJ'L,A4[(W@=CG*0??OT]T\/*4.RKG(?5%_5-,VHF:2Z.#`E[XNGEW0V MN3(!N1$054$Q;!W,LU/GM\G]P_(QJ\8%G>:4YG2VI!,VOF7%].,PV9F_P;#N MAOBWCD\&TW9180U7[C9I9%IN^DP@"4%XY5!9&UL[5I;<]HX%'[OK]!X9_9M M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/`0LZ?O. M14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%: M;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YO MI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V? MC,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$ MUFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7< MK_WUE[O)I#-ZG7TZSFN4?VFK`:?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMA MAR=N.Q-R.AQG0GS/]O:1I24RS^_Y"NM./&K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 M`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S- MD77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L M+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;& MO%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_G MM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C M[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@ M!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)I MF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^ MYRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9 M$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4 M)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6 MVZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F M.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#" MQ([A[8N_`5!+`P04````"`"D:W!'G=');T<"``#@"0``#0```'AL+W-T>6QE M@8Y4T,*Z7J3Y[79!5FJ)F+ M&G.]4@C)D-)367I-+3'*&Q/$J+?P_=!CB'"81+QE2Z8:D(F6JQA>C1!P\7"2HD4/H@M`:+<,2P M\[A#E*22&+!`C-#>P0L#V+,;_!CA0MK<+L-^GKD_99)E&D-_>%Z>+IW8[6"V M1RC=W9X&DJA&2F')EWH"!GO5UWIS7'#L1%J_(]ZE1'VPN-X*L(/.FPJ98SEF M#N`&2B**"Z4#)"DK,RI1&^E"*<&TD1-4"HZHH=Q$#(:FS3"E#^9->2QVN+L" M.!]SQCX$1L7&U(48S.D:V*)ZVVR.>YO6/XL7=,680$>CNJ;]9TI*SK`3ZZ"E M&&;'Z(,#]$F$-JR@$I(\:W]S$3(-8`G!&DM%LFWDIT3U"G=JN,%>5QQ2>.Z6 MW[JF*;^^=*PK`?=D_MNC.D/"G[_/__.JY$BAI/]#>>D91^M@NF? M+OD%4$L#!!0````(`*1K<$>!5+[UJP0``($0```/````>&PO=V]R:V)O;VLN M>&ULE9=-<^,H$$#_"J73S&'6EH2=Q#6>*D\2[Z8JR;AB5_9,)&RS0:`%E*]? MOPVR)RU'9).3)5D\T?!HFN]V\JC-_9W6]^2IDLI.S#39.E=/!@-;;'G%[!^Z MY@K^6VM3,0>W9C/0Z[4H^)DNFHHK-\B&P_'`<,F9()D MF*;^V0CI;T;#43+PL'VH"T,*7?(6MMH*^_?NCX24?,T:Z5;0V?UWITF:T2P; MMPS_VJW@CQ8#_0/""B<>^(K=39-A0ECC]%Q(Q\T9<_Q/HYM:J`VP$K(6QKJE M#S>\60DE*O'B^PUW=JL?_])&O&CEF%P61DL96OD_0B/X@OW]!/KH1-%YT;&[ M&S\3TV0\!."#L.).2.&>ITFXEMQ',C@()0S_ZQ5187#V4TQFJB3GR@&%7*AV M\F!H?!_@Y8LR?-A,!%R8BS)MAPJ#3K4JN;*\)'!EM10EC$I)?C+)5,$)`F4( ME'T6E"-0CD#YAT%+!S\0,@)1!**?!8T0:(1`H[>@95/7TG\;)IZ<"5M(;1O# MB5Z3:ZV^(=`8@<9O0=?:<9*2;^2:N1W@5\U-NSP)0Z`C!#J*@#(`S8I_&W`G M`%#S8]3\.-(\]_V`"TMN>,'%`_,"OB).$.(D@J"`6!C('`;T8]Y$Z$WM!PH+ M.,0&#B.H$:`N8(#5QB\$,K,6K,>4CL<](@?*^'=,"_9\$%"*!4Y[#`Z$(R#X M*-PS;HJ537N<#4V/0PB%KCA9L2?>Z3U6->UQ-0!.`'#CLS58NF!^3%>&*0OY M"Z.PK&F/K:UD0V"=ZJH2SD^'#;,#R\`)C,*ZICV^+L5&"=A1F$\T1:$;:*\V M9`%KJ1#=`+&P:=.8O8?RDR\K/]_V*R9AA]//2IP-? MDCCT#*.PR=F'3>X+,.ODY/]7NI>!W&\#?0+1F'+L_&(5MSV,Y/99=QVR/)"J( M$*.P[7G,]GZ4]P*CL.UYS':/.K=.5&$'G%4:2NB7PWHVQ[;G,=M[TN=.=UP_ M8MMIS':/NO))!M9-N_KV8(S"MM.8[3@3[U??BC^YIH/"MM/WDOJ<"4-NF6S" ML#=5?5@&4FP[C=GN44NGBWO(H&UJF/D34[<$HIUB.V;[4:A@K#.B:$MM3PTT MC,*VTYCMA]54;[ZBV'8:LSU65]$CC,*VTVANC^R#%%3O MK^!H/4W\^1>.NHV4I_#LE[K4+)P26_+^X/SC/U!+`P04````"`"D:W!']H"L MLFP"``#B"```&````'AL+W=OQ>;#*9B]UK:FDUH^("K;-OOX#6<>`X-PKX?>?'40Z8 M#XR_B8I2Z;VW32=V?B5E_QP$HJQH2\03ZVFGGEP8;XE477X-1,\I.1M3VP0X M#-.@)77G%[D9>^%%SFZRJ3OZPCUQ:UO"_QUHPX:=C_S'P&M]K:0>"(H\F'WG MNJ6=J%GG<7K9^7OT?$2IEAC%[YH.8M'V].1/C+WISL_SS@_U'&A#2ZE#$'6[ MTR-M&AU)D?].03^8VKAL/Z)_-^FJZ9^(H$?6_*G/LE*S#7WO3"_DULA7-OR@ M4PZ)#EBR1IBK5]Z$9.W#XGLM>1_O=6?NP_@DP9,--N#)@&<#3K\T1),AF@TH M-IF.,S-Y?2.2%#EG@\?'C]$3_7*D']8M2.0GU3"N*_%Z$>7#782;% M8:G`1H%F1:!BSP`,`0[8L>//@*.KB&!`!&80+>R1L<=6!JXB@0$Q"(@=>VH! M1D5G%/'XBE*$TRB$,0F(21S,QL*XBBT,2$%`ZM@S"^`JT$H*&Y"P@`:OK"\$USIR2QG;*PS2K"PQ!!<\ MVXL,N36/0[2RKR"XXI%;T-C>NSYIDE&S1H'+'KE5C>T-#-)L+$JP.%):RJ_F MJ!5>R6Z=',^.>70^SO?FT`L^Y$7>DRO]1?BU[H1W8E(=;.9HNC`FJ9I*^*02 MKM0/Q]QIZ$7JYD:U^7@$CQW)^L&PO=V]R:W-H965T&ULC9E-;^,V$(;_ MBN'[KCC#[\`Q4*LHVD.!Q1[:LQ(KL;&6Y4I*O/WWI63'E6>&B[W$EOP.^7)( M/APIJW/;?>MW=3TLOC>'8_^XW`W#Z:$H^N==W53]Y_94'],O+VW75$.Z[%Z+ M_M35U78*:@X%*N6*IMH?E^O5=.]+MUZU;\-A?ZR_=(O^K6FJ[M]-?6C/CTM8 M?MSXNG_=#>.-8KTJ;G';?5,?^WU[7'3UR^/R%W@HS229%'_MZW,_^[X8S3^U M[;?QXH_MXU*-'NI#_3R,353IX[TNZ\-A;"GU_,^UT?_['`/GWS]:_VT:;K+_ M5/5UV1[^WF^'77*KEHMM_5*]'8:O[?GW^CH&.S;XW![ZZ>_B^:T?VN8C9+EH MJN^7S_UQ^CQ??@GJ&B8'X#4`;P%@?AB@KP&:!!079].X?JV&:KWJVO.BNTS& MJ1KG'!YTRMSS>'-,5!I3GWX;%>O5^QK#JG@?V[E*-G,)7B3WBE)0Q)ND2/W? M3*!H`F?Q;HK72H[78KR>Q>M+/)!!7"3'2>(G2;2("C09"M>A\M'YH&5#1C1D MN"&2LXV9=60F"81@J.^2RQ"-]4YV8T4WEKLAP]Y8UHU3-LRZN;CA,J],5%9V MXT0WCKLQQ(UCW1@3@Z)SQ64ZV@!&=N-%-YZ[L<2-Y[D!2S-81.@+N"&P(P=(D"4K4VGJ8$>'>E8Q2 M0.;**.H*^?B=0@1/37$A@#;&8L:3C&?@?#:4SZ#Y^),G-G5EHC)>;@%EWB+GK:&\18&W)DT]@YLD M1`\F5SB@3%SDQ#64N"@0UT;OF25!%YS+K4?,%*Z,5U M;I_)E$5.64N9AA(]@TGKFCKR;-8,>&]#YA$&9H*[FXVK):&M MW+*6^8J\.+:,CKSN-2%X>CJ4=[IK@E+5ZC+YT3*O->>UI6S4',-I#2FDPE(0 M^I@P"IF]IF5>:\YK1^FHA;K7N52,4TN"+L;L":)E7FO.:\?>%'`,`[CT].18 MF@1E.JY-6G,95YG7%QRSCM:C@L:R'/T\KK6,:SW'M;M6:9D69+YJSE='^:HM MRQO=HC^4W/N0F:HY4QUEJN:P3`6I8FF59!`S]926F:HY4QUEJA8J5U3I8#;T MP4Q2@D$5LRM/IJKF)'24JII3]5.B@:./W^5/".\]R6S5G*V.LE5SMGY*4YZ/_>*I'8:VF5XVO[3M4*=6U>>TEW=U MM;U='.J78?SJT_?N\E+]W_S_F,PW$^ M$/K&*HRY\]XV'=NY%>?]%@!VK'"+V(;TN!,K9T);Q,607@#K*48G96H;X$,8 M@Q;5G5OD:NZ%%CFY\J;N\`MUV+5M$?V[QPT9=J[GWB=>ZTO%Y00H-O2@U*B%+]J/+!%WY'P!T+>Y.#':>="R8`;?.0R!!+-#9>X M:60DD?G/%/1_3FE<]N_1OZGM"OP#8K@DS>_ZQ"M!"UWGA,_HVO!7,GS'TQXB M&?!(&J9^G>.5<=+>+:[3HO>QK3O5#N-*"B>;W>!/!G\V>.%#0S`9`LT`1C*U MKZ^(HR*G9'#H>!@]DF?N;0/QYHYR4KXHL2*%4-D98A,ADACB)XR/%*L&&(K M0VPRQ!I#_*G_QS/5BB6QLB0F2Z*Q),9N?3@^&LXGA"NBU$J4FD2I1I0:B3P8 M0A^&&GII$WI9'$'?3I19B3*3*-.(,B-1EL:I"631Q;'_(8\LV;8J!PVB%.IE M#IH?;!":A_9<-Q*!10GNT07_1/12=\PY$"ZJN:K'9T(X%C'A1GP@E;AEYT&# MSUQV$]&GX[TS#CCI[]?H?)<7_P!02P,$%`````@`I&MP1\A1%ERH!0``B1H` M`!@```!X;"]W;W)KAN.7X!)$[WS)E+GS/2]%16/^MM MGC>C7\7^4#^,MTUSO)],ZO4V+[+Z6WG,#^F?Y[(JLB9=5B^3^ECEV>8<5.PG MJ)2;%-GN,)Y-S_>^5[-I^=KL=X?\>S6J7XLBJ_Z=Y_OR]#"&\?N-'[N7;=/> MF,RFDVO<9E?DAWI7'D95_OPP?H3[E58MY(SX:Y>?ZM[O4=OYI[+\V5[\L7D8 MJ[8/^3Y?-VV*+'V]Y8M\OV\SI9;_N23]:+,-[/]^S_[;F6[J_E-6YXMR__=N MTVQ3;]5XM,F?L]=]\Z,\_9Y?.-@VX;K`:SMR@+X$Z(\`\VF`N028K[9@+P&6M##IN)]';IDUV6Q: ME:=1U4WW,6M7%=S;-#?K]F8[%6G4ZO1?BYA-WV8!II.W-L\%,N]#L(/@+63) M(1]))JG]:R=0ZL0<63AI8,$109,^_&^2U:=);KJIQ;'2O7C7Q1LYWHCQIA>O MNWA+QKJ#',X0WPTD6&6](>/!<<&#<71>.$RC,^@#&1F.0]1:V8'AL2(]R^DY M0L_VVC%GB--!*4786=8=HRV#+7DV"`[11L*.ITM#%6TOWPT[)[)SG)TG[!SO M#\2@(\$M>"I+)XZG0NU"<&1`5Y^FNF'E15:>LR)K8^Y95]J5H>@.]7Q%!J5) M+5GR9-%:$\C,KG@R5`;,0%$)(K7`J9&%,0]\PJ*WCL`6'(80#%N.'&9C\);N M-0YS&-.JE;E%D5MDW"+IS3SRWFA(NXAPXS"PJ3.4&X?Y&!T=@A6':>_5T$9K M%5R2),79,4U2?"&!0Z()"P%FP;#=)L!2_3-`"XF``Q.T\0/\!B07.#^D_("U M9""52K"4(0="`&>CI1P%H%(>G:.3*""M7<4!/0-9; MT'R@#!THS;=3].#I.A=PUCK#AXGC(*8Y1KJ-)6!2ZG[UN.4H>P+@IH#V:0Z& M+X:@@59@`19]9&5*@($V2>XI08Y+(.N&YE`V!Y-4@1$4[(,U MFL\AQZ$*:!U0BH*#\#J"'M!0D*T!`L!EJ[EP(L(!HJXBL!EYR" M5T-%678+P.U"I'8!N'2;5!@4[=)"`()*Z"4/01R#P&* MF@CD^F&OU>:Y;:K*#0.X@0%$+@8*2 M.P"@S#2?,&LL72M+*9T/S"J+Z=)A<<`^H&P?D-N'5$`H0<$_**7IXET(.)FA ME`\5GS\IWR<490>!W$&`HA8"N9+?)1CY<24AO M@AVRNRC;".0V`A3U$=:"/-.".]?"&3\8 M$QW=T@(P'1Z2ZE+AD3)Z[X$=],6,$(.C-">]Y^Q%7KVF@Z9M>[ MU[2I_VG6QJ-MGFVN%_O\N6E_^O2[ZMZ4=!=->7Q_\7-]^S3[#U!+`P04```` M"`"D:W!']-6L?4X%``"9&@``&````'AL+W=O&3O.BD5:J*KVH=+I'MKG+&07=(30)'M[_?9-`LN" MY^^J+T#">/*?B>?G2;QXKYOO[:XLN\G/ZG!L'Z>[KCL]S.?M9E=61?NE/I7' M_I^7NJF*KC]L7N?MJ2F+[3BH.LS)&#^OBOUQNER,Y[XVRT7]UAWVQ_)K,VG? MJJIH_EF5A_K]<6JG'R>^[5]WW7!BOES,K^.V^ZH\MOOZ.&G*E\?IDWU8BQ], M1HL_]^5[>_-[,HA_KNOOP\'OV\>I&324AW+3#2Z*_NM'N2X/A\%3?^6_+TX_ MKSD,O/W]X?W7,=Q>_G/1ENOZ\-=^V^UZM68ZV98OQ=NA^U:__U9>8G"#PTU] M:,?/R>:M[>KJ8\AT4A4_S]_[X_C]?OXGF,LP/(`N`^@ZX'H=/(`O`_AS@(R1 MGI6-9VPPGAT3U,;7]?X/%;U:T-G6VN%O/>^_42A"ZQ(C4\NL!:6P3&5V`8!-^,]Y<@$@X$.I`;!WQQ M(%$6SC;'T28;;69.K&>;1=$`0_%B;(X5.:C(@9`<=N"A`P]"\E%(_D:IC#;" M$L6]]BJ:0E!UKRH*1H5RDI`]40"(SRD,=YN=CLC$DJS.3U\I)LX/<)9,$,38DR4@Q\9R2,FQD@4M1SM+RL', MLZSE&([EL,X.!Z$8;FO@+:D'(]0"AI):243I\>)-%B/4:H8*&4G-'XQ0"QA* MB67!8HA:35%6,6F*LK?BXI"TV@!0'>>:&\".R5">RA'&JM4P9(4RS=6>9)9M+`GQUQ$G%!&& M*VFX6HIFR(HT76)[1@"N7G)5:G=V%WHXXU+]$V'`DD:BQ(LS`;Z2#W$!K(&=2)ZEVFA,6-*$ MC=N`%6G`9EE.63RM@9T-P;I$CTJ8L.24(J\4.5#3CO04TG;.NQ3R"?.:0-=+ M<==+NJ/U?:L9PX@TL)VP\XD5A#"O"?$Z[GV!D5//2`#68G/*4QG"N";0_Y(J MM*`R-+,L>8RL-:%.F1T[28C"P";0").J-41B8X(/*E4YD&^%4RL;8VCS+;0O M_4.*^XPARZ"%C9>8%0/*BG?D5+J!NQ1F&6.601.K.AK6G)U9DSG=50-W24&) M1W?0QG+$KGP*F^CS%J&32SJJMAP%#PY`',R*46:\:@ M90U:R_%JS9J@9)V/JP.8V9Q-8BUB#%H&H.48M*Q!.\MZ12:$6!-HCIWM:R`U MF3!L.0,5F^`C8SXRX*-J'H&1XC4#AKK^\9Y2B<9H9(!&CM'($'C&Z+GX_U\3 M"(:B@$Y6XC5?4">+](AN9?\S28(Q*P"S$F-6X)L"RB3+E"QH*A0HT4(*IJT` MVDI,6]&T)9/E/@L:8"1*EUQ*G:AN]=_]W(P(@4@4F)$BD9D'W:\J@%7 MJFSG-V_\J[)Y'7="VLFF?CMVY[?JU[/7W98G&G8,HO,K^[`^[YE\NEDN3L5K M^4?1O.Z/[>2Y[KJZ&G<47NJZ*WN)YDN?LUU9;*\'A_*E&WYF_>_FO'-R/NCJ MT\=&T'4W:ODO4$L#!!0````(`*1K<$&PO=V]R M:W-H965T&UL;5/;;N,@$/T5Q`<4QW%ZB1Q+3:NJ^[!2U8?= M9V*/;51@7,!Q^_<%[+A6ZQ=@AG/.G.&2#VC>;`O@R(>2VAYHZURW9\R6+2AN MK[`#[7=J-(H['YJ&VR>%AA=#;*\4-Y]' MD#@$J^B:5U(L")G,Z\2"K05J(F!^D#O-_MC%A`1\$_`8!=K$KR?$-]" M\*Y/W,(#RO^B(:IA5T0+%':.)*RMP[5A4*)XA_C+'2KI.WZXZW"[HUY/#VW6!;%4@6PAL)X&['RVN M8';)CR)L<:8*3!.?CB4E]MJ-AS=GY]=YG\8[^887><<;^,M-([0E)W3^9N/= MU(@.O)7D:D=)Z__/'$BH75C>^+49G]08..PN'V3^I<474$L#!!0````(`*1K M<$>Z8F)KH0$``+$#```8````>&PO=V]R:W-H965T&UL;5-= M;]L@%/TKB!]0;))T5>18:CI-V\.DJ@_;,[&O;53@>H#C[M\/L.-:F5^`>SGG MW"\H1K3OK@/PY$,KXTZT\[X_,N:J#K1P#]B#"3<-6BU\,&W+7&]!U(FD%>-9 M]LBTD(:61?*]VK+`P2MIX-42-V@M[-\S*!Q/-*1T0"_)(PNM69Q-POB._1^%&?:!93``65CPHB;%=X`:6B4`C\ M9];\#!F)Z_--_5NJ-F1_$0Y>4/V6M>]"LADE-31B4/X-Q^\PEW"(@A4JEU92 M#)CVJ5)^SC=/&4S;9O`9P*_([`I4$KSJ_"B+"R.Q$ZM[46<8'[D MH1%5=,:Z0XHNW$5$65S+_)`7[!J%9LQYC>$39D&PH+Z$X%LASOP_.M^F[S8S MW*WHCU/T_=.VP'Y38+\2V,TE\KL2MS"[NR!LU5,-MDU/QY$*!^.GYBW>Y74^ M\S233WA9]**%G\*VTCAR01\FFV;3('H(J60/!TJZ\'\60T'CX_%+.-OI24V& MQ_[V099?6OX#4$L#!!0````(`*1K<$=\E:43HP$``+$#```8````>&PO=V]R M:W-H965T&UL;5/;;J,P$/T5RQ]0$X=DJX@@-5VM=A]6JOK0 M/CLP@%5?6-N$]N_K"U#4Y<7VC,\Y<\:78M3FS78`#KU+H>P9=\[U)T)LU8%D M]D[WH/Q.HXUDSH>F);8WP.I(DH+0+#L2R;C"91%S3Z8L].`$5_!DD!VD9.;C M`D*/9[S#<^*9MYT+"5(69.'57(*R7"MDH#GCA]WID@=$!+QP&.UJC8+WJ]9O M(?A3GW$6+("`R@4%YJ<;/((00<@7_C=I?I4,Q/5Z5O\5N_7NK\S"HQ:OO':= M-YMA5$/#!N&>]?@;IA8.0;#2PL8158-U6LX4C"1[3S-7<1[33C[3M@ET(M"% M<)]%XZE0M/F3.5861H_(I*/M6;C!W8GZ@ZA",O3M+5J_%Q!E<2MWA[P@MR`T M82YK#$V8!4&\^E*";I6XT/_H=)N^WW2X7]&/J7I^ORV0;PKD*X']U.+A6XM; MF..W(F1UIA),&Y^.194>E$N'MV27U_E`XYU\P\EVY;64356U#Y6B/+3/K#VV48!Q`:_3OR]@KV.E?@%F..?, M&2[Y@/;-M0">O&MEW)FVWG>)5-ZV."%3F;>9748)Q$ M0RS49_JT.5UV$9$`OR0,;K$FT?L5\2T&/ZHSS:(%4%#ZJ"#"=(-G4"H*A<)_ M)LV/DI&X7-_5OZ5N@_NKL?!O,9I144(M>^5<
    /[6XAOGRJ0A;G*D&VZ2GXTB)O?'CX&PO M=V]R:W-H965T]"PE2E63A-5R"LEPK9*`]X8?\>"X"(@)>.$QVM4;! M^T7KMQ#\:4XX"Q9`0.V"`O/3%1Y!B"#D"_^;-;]*!N)Z?5/_%;OU[B_,PJ,6 MK[QQO3>;8=1`RT;AGO7T&^86]D&PUL+&$=6C=5K>*!A)]IYFKN(\I9U],=.V M"70FT(5PGT7CJ5"T^9,Y5I5&3\BDHQU8N,'\2/U!U"$9^O86K=\+B*J\5ODA M*\DU",V8\QI#$V9!$*^^E*!;)<[T/SK=IN\V'>Y6]$.J7MQO"Q2;`L5*8#>W MF']K<0OSW259G:D$T\6G8U&M1^72X2W9Y74^T'@G7_"J'%@'?YGIN++HHIV_ MV7@WK=8.O)7L;H]1[__/$@AH75C^\&N3GE0*G!YN'V3YI=4G4$L#!!0````( M`*1K<$&PO=V]R:W-H965TVRC!<8%'&__OH`=K[7U M"S##.6?.<"E&M&^N`_#D72OCSK3SOC\QYJH.M'`/V(,).PU:+7P(;#@E33P8HD;M!;V[P44CF>ZH_?$JVP['Q.L+-C" MJZ4&XR0:8J$YTZ?=Z9)'1`+\DC"ZU9I$[U?$MQC\J,\TBQ9`0>6C@@C3#9Y! MJ2@4"O^9-3]*1N)Z?5?_EKH-[J_"P3.JW[+V73";45)#(P;E7W'\#G,+ARA8 MH7)I)-7@/.H[A1(MWJ=9FC2/TT[.9]HV@<\$OA`>LV1\*I1L?A5>E(7%D=CI M:'L1;W!WXN$@JIB,?0>++NQ%1%GW9)?7^90ND7W`RZ(7+?P4MI7&D2OZ<+/I;AI$#\%*]G"@I`O_9PD4-#XN MOX2UG9[4%'CL[Q]D^:7E/U!+`P04````"`"D:W!'!/CG+*(!``"Q`P``&0`` M`'AL+W=O M=P?&7-F"%NX&.S#AID:KA0^F;9CK+(@JD;1B/,OV3`MI:)$GWXLM M+'&]UL+^.X'"X4@W].IXE4WKHX,5.9MYE=1@G$1#+-1'^K`YG'81D0!O$@:W M.).8^QGQ(QI/U9%F,0504/JH(,)V@4=0*@J%P'\GS:^0D;@\7]5_IVI#]F?A MX!'5NZQ\&Y+-**F@%KWRKSC\@:F$VRA8HG)I)67O/.HKA1(M/L==FK0/X\TV MFVCK!#X1^$RX3P0V!DII_A)>%+G%@=BQM9V($]P<>&A$&9VQ[I"B"W<14>27 M8K/?Y^P2A2;,:8GA(V9&L*`^A^!K(4[\!YVOT[>K&6X7]/T8?7>_+K!;%=@M M!+93B7??2ES#?`_"%CW58)OT=!PIL3=^;-[LG5_G`T\S^8(7>2<:>!:VD<:1 M,_HPV32;&M%#2"6[N:6D#?]G-A34/A[OPMF.3VHT/';7#S+_TN(_4$L#!!0` M```(`*1K<$=M1*QXHP$``+$#```9````>&PO=V]R:W-H965T0/"%[VDG3EM91-%;4/E:(\M,^L/;91@'$`K]._+Q>O M8Z5^`68XY\P-BA'-F^T`'/E04MM3UCG7'RFU50>*VSOL0?N;!HWBSINFI;8W MP.M(4I*R/#]0Q87.RB+Z7DQ9X."DT/!BB!V4XN;O&22.IVR3W1ROHNU<<-"R MH#.O%@JT%:B)@>:4/6Z.YUU`1,!O`:-=G$G(_8+X%HR?]2G+0PH@H7)!@?OM M"D\@91#R@=\GS<^0@;@\W]2?8[4^^PNW\(3RCZA=YY/-,U)#PP?I7G'\`5,) M^R!8H;1Q)=5@':H;)2.*?Z1=Z+B/Z6:?3[1U`IL(;"8\1`)-@6*:W[GC96%P M)":UMN=A@ILC\XVH@C/4[5.T_BX@RN):;@[?"GH-0A/FO,2PA)D1U*O/(=A: MB#/[C\[6Z=O5#+<+^B%%WSVL"^Q6!78+@6T2N,^_E+B&^5HD7?14@6GCT[&D MPD&[U+S9.[_.1Q9G\@DOBYZW\(N;5FA++NC\9.-L&D0'/I7\;I^1SO^?V9#0 MN'"\]V>3GE0R'/:W#S+_TO(?4$L#!!0````(`*1K<$=@,"L)HP$``+$#```9 M````>&PO=V]R:W-H965T$F\\JYW(4&JDJR\ADM0EFN%#+0G_'@XGHN`B(`_ M'":[6:/@_:+U6PA^-2> M_859>-+B+V]<[\UFFLE&X5SW]A+F%VR!8:V'CB.K1.BT7"D:2?:29JSA/ M:2=?:/L$.A/H2GC(HO%4*-I\9HY5I=$3,NEH!Q9N\'"D_B#JD`Q]>XO6[P5$ M55ZKPSTMR34(S9CS%D,39D40K[Z6H'LESO0;G>[3\UV'^89^EZH7#_L"Q:Y` ML1'(YQ;S+RWN88HO16]7YOTI%+@]+!\D/675O\!4$L# M!!0````(`*1K<$>1TY]TI`$``+$#```9````>&PO=V]R:W-H965THI;;4CK1:.8P4I1#JU:$'_+C>1L0$?#*8;2+-0K>+UJ_A^!/?<)9L``"*A<4 MF)^N\`A"!"%?^&/2_"H9B,OU3?U7[-:[OS`+CUJ\\=IUWFR&40T-&X1[T>-O MF%K8!<%*"QM'5`W6:7FC8"399YJYBO.8=G;Y1%LGT(E`9\)]%HVG0M'F$W.L M+(P>D4E'V[-P@_F1^H.H0C+T[2U:OQ<097$M\\.N(-<@-&'.2PQ-F!E!O/I< M@JZ5.-,?=+I.WZPZW"SH^U1]>[\NL%T5V"X$-E.+^V\MKF$.WXJ0Q9E*,&U\ M.A95>E`N'=Z9EBN++MKYFXUWTVCMP%O)[G88=?[_ MS(&`QH7EP:]->E(I<+J_?9#YEY;_`5!+`P04````"`"D:W!'_I9N:*4!``"Q M`P``&0```'AL+W=O\2=<_V!$%MU()F]T3THO]-H(YGSH6F)[0VP.I*D(#3+;HED7.&RB+D7 M4Q9Z<((K>#'(#E(R\^\$0H]'O,'7Q"MO.Q<2I"S(S*NY!&6Y5LA`<\3WF\,I M#X@(>.,PVL4:!>]GK=]#\%P?<18L@(#*!07FIPL\@!!!R!?^F#2_2P;BO=G9N%!B[^\=ITWFV%40\,&X5[U^`13"[L@6&EAXXBJP3HMKQ2,)/M, M,U=Q'M/.+I]HZP0Z$>A,V&?1>"H4;?YFCI6%T2,RZ6A[%FYP&PO=V]R:W-H965T M[%2E4O=J_=Q$E0 M`6>QTW3??FT@-+*/;PJ8,S,F_LZH4UQ5]ZY/4IKDLZE;O4E/QIP?LTSO3K(1 M^D&=96O?'%37"&,?NV.FSYT4^SZHJ3/*\T76B*I-RZ)?>^G*0EU,7;7RI4OT MI6E$]V\K:W7=I"R]+;Q6QY-Q"UE99%/]* M7O7=?>(V_Z;4NWOXN=^DN=N#K.7.N!3"7C[DLZQKE\E6_CLF_:KI`N_O;]F_ M]Y]KM_\FM'Q6]9]J;TYVMWF:[.5!7&KSJJX_Y/@-J[:_7XH[3NG*(N/DJU8D7VX1*-F>Z^A03,I,IM]*D&HQ):"<,+A'.Z0WX4O MQAU&$LQ@@ME=`CXFX-XG(LT,%YG#(G.08.X509H%+K*`118@P=(K@C0K7&0) MBRQ!@K57!&C6.2ZR@D56((&/'=)$#GX-BZQ!`O_@D29R\,[=R$$Y2.$?/11% MSIY%G,I`"O_TH2AR_`S:]8D12.$#`$2VT4?J8%\S#E($K0>)(A`P;'\6>IMR M'P,HBG&`.P`+[4UYP`$2Q3C`38"%#J<\X`")8AS@/L!"DU,><`!$+,8!;@4L M]#FQ@`,DBG&`NP$+K4XLX`")(AP0[@<46IV8SP$413@@W`\HM#HQGP,HBG!` MN!\0L#KS.4`BBG!`N!\0L#KY'$!1A`/"_8"`UX'Q"P.@4<`!&/<8#[`0&K\X`#)(IQ@/L!`:OS@`,DBG#` M<3_@P.K%F=QE+]$=ZQ:G;PI8T>R M?J@Z*&6DW4O^8+U\LI/O]%#+@W&W2WO?#;/@\^3;:3O-U^1]02P,$%``` M``@`I&MP1QQ8YZ"\`0``>P0``!D```!X;"]W;W)K&UL;53=;J0@%'X5X@,4AQEM.W%,.MUL=B\V:7K17C-Z5%)^7,"Q^_8%=*QQ MN1$X?#_GX(%B5/K#=``6?0HNS2GIK.V/&)NJ`T'-G>I!NIU&:4&M6^H6FUX# MK0-)<$S2-,>",IF418B]Z+)0@^5,PHM&9A""ZG]GX&H\);OD%GAE;6=]`)<% M7G@U$R`-4Q)I:$[)T^YXSCTB`-X8C&8U1S[WBU(??O&[/B6I3P$X5-8K4#=< MX1DX]T+.^.^L^6WIB>OY3?UGJ-9E?Z$&GA5_9[7M7+)I@FIHZ,#MJQI_P5Q" MY@4KQ4WXHFHP5HD;)4&"?DXCDV$^C^X.Q)W$)4/^KI=BL;M>4197$MRV!?XZH5FS'F-(0&S6Q#8J2\6)&9Q M)O_129R^CV:X7]'S.<-#7.`0%3BL!/:S0+8I,8;)XR99U"2+"-QO3&*8A[A) M'C7)(P*/&Y,()DLW)GC5'0)T&RZ!094:I)W:8(DN]^R)A.[ZAI=%3UOX0W7+ MI$$795V/ABYKE++@4DGO7,&=>PF6!8?&^NF]F^OIF_(+4$L# M!!0````(`*1K<$=_Z).+P@$``+P$```9````>&PO=V]R:W-H965T(#%(<9M9DX)IUNFN[%)DTO=J\9/2HIB`LX=M]^ M`1W'6'HC.%53$"GF>R0@OH4/>V.Y\PA/.`W@U&O^LAEOTCYX08_JU,4NPC`H31. M@=KF"L_`N1.RQG]GS;NE(Z[[-_47OUJ;_D(U/$O^AU6FM6'C"%50TX&;=SF^ MPKR$Q`F6DFO_1>6@C10W2H0$_9Q:UOEVG&8>XYD6)I"90#8$/!GYF#^HH46N MY(C4M+4]=7]P=R1V(TI7=.NV$;6=7XZH1FS'F-(1YS1V"KOEB0 MD,69?*&3,'T?3+A?T?=SPF\$#D&!PTH@G00.A[!`$A1(`@GVFST*8;XQ28,F M:4`@V9B$,&G8)`N:9`&!;&,2PCQN3/#J>`E0C;]%&I5RZ,QTCI;J M=WB1][2!7U0UK-/H(HT]Y/Z8UE(:L%'B![NKK7U*E@&'VKAN9OMJNEW3P,C^ M]E8L#U;Q'U!+`P04````"`"D:W!';2`4H:0!``"Q`P``&0```'AL+W=OWQ)0P1YL3WC<\Z<\:48M7FS'8!#'U(H>\2=<_V!$%MU()F] MT3THO]-H(YGSH6F)[0VP.I*D(#3+]D0RKG!9Q-R+*0L].,$5O!AD!RF9^7\" MH<+[S>&4!T0$_.4PVL4:!>]GK=]" M\+L^XBQ8``&5"PK,3Q=X`"&"D"_\/FE^E0S$Y?JJ_A2[]>[/S,*#%O]X[3IO M-L.HAH8-PKWJ\1FF%G9!L-+"QA%5@W5:7BD82?:19J[B/*:=_&ZBK1/H1*`S MX3:+QE.A:/.1.5861H_(I*/M6;C!S8'Z@ZA",O3M+5J_%Q!E<2GI[JX@ER`T M84Y+#(V8S8P@7GTN0==*G.@/.EVG;U<=;A?T?:+G^;I`OBJ0+P2V26"??6MQ M#?.]2;(X4PFFC4_'HDH/RJ7#F[/SZ[RG\4Z^X&71LQ;^,--R9=%9.W^S\6X: MK1UX*]G-#J/._Y\Y$-"XL/SEUR8]J10XW5\_R/Q+RT]02P,$%`````@`I&MP M1]B?!UBM`0``%@0``!D```!X;"]W;W)K&UL=53= M;ML@%'X5Y`QC&Q4X+N"X>_L!=EPK8S+V`7O0?J=!H[CS2]-2VQO@=20I25F> M'ZCB0F=E$6LOIBQP<%)H>#'$#DIQ\^<,$L=3MLENA5?1=BX4:%G0A5<+!=H* MU,1`<\H>-\?S/B`BX)>`T:[F)&2_(+Z%Q8_ZE.4A`DBH7%#@?KC"$T@9A+SQ M^ZSY:1F(Z_E-_5OLUJ>_<`M/*'^+VG4^;)Z1&AH^2/>*XW>86X@)*Y0V_I)J ML`[5C9(1Q3^F4>@XCM/.UWRFI0EL)K`[`IV,8LQG[GA9&!R)F3YMS\,);H[, M?X@J%$/?/J+U>P%1%M>2'5A!KT%HQIS7&!8QFP5!O?IBP5(69_8/G:7IVV3" M[8I^F.B[75I@EQ38K02V=T%)=GL`CBP?_"2^+GK?PDYM6:$LNZ/SUB1>@073@H^0//DOG'^FR MD-"X,/WBYV:ZM]/"87][A@C>6[I0$``+$# M```9````>&PO=V]R:W-H965T0/*`YQ MTC9R+#5=5>W#2E4?=I^)/;91@7$!Q]V_+V#'M;I^`68XY\P9+OF`YMVV`(Y\ M*JGM,6F=ZPZ4VK(%Q>T-=J#]3HU&<>=#TU#;&>!5)"E)69KNJ>)")T4>;)J2"FO?2O>'P#%,+NR!8HK1Q)&5O':HK)2&*?XZS MT'$>QIU].M'6"6PBL)FPNX_&QT+1YB_N>)$;'(@9C[;CX08W!^8/H@S)T+>W M:/U>0!3YI6#[VYQ>@M"$.2TQ+&(V,X)Z];D$6RMQ8O_1V3I]N^IPNZ#O1WJ6 MK0MDJP+90F`[M7CWH\4US/V/(G1QI@I,$Y^.)27VVHV'-V?GU_G`XIU\PXN\ MXPW\YJ81VI(S.G^S\6YJ1`?>2GJS2TCK_\\<2*A=6-[ZM1F?U!@X[*X?9/ZE MQ1=02P,$%`````@`I&MP1R,?:#F\`0``>P0``!D```!X;"]W;W)K&UL=53=;J0@%'X5X@,4969L,W%,.MUL=B\V:7K17C-Z5%)^ M7,"Q^_8%=*QQZ8W`X?LY!P\4H]+OI@.PZ$-P:4Y)9VU_Q-A4'0AJ[E0/TNTT M2@MJW5*WV/0::!U(@F.2ICD6E,FD+$+L69>%&BQG$IXU,H,05/\[`U?C*.'53(`T3$FDH3DEC]GQG'M$`+PR&,UJCGSN%Z7>_>)W?4I2 MGP)PJ*Q7H&ZXPA-P[H6<\=]9\\O2$]?SF_K/4*W+_D(-/"G^QFK;N633!-70 MT(';%S7^@KF$@Q>L%#?ABZK!6"5NE`0)^C&-3(9QG'8>TID6)Y"90#8$/!F% M-']02\M"JQ'IZ6A[ZO]@=B3N("H?]'6[%(W;\XBRN);D/BWPU0O-F/,:0P(F M6Q#8J2\6)&9Q)O_129R^BV:X6]'SB;[?QP7V48']2F`WEYAM2HQAOLGR$#4Y M1`1V&Y,8YIM*\JA)'A$X;$QBF'QC@E?=(4"WX1(85*E!VJD-ENARSQY)Z*XO M>%GTM(4_5+=,&G11UO5HZ+)&*0LNE?3.%=RYEV!9<&BLG]Z[N9XNQ[2PJK]= M]>6]*3\!4$L#!!0````(`*1K<$<_))A%H@$``+$#```9````>&PO=V]R:W-H M965T0/*`YQFV[D6&JZJMJ'E:H^=)^) M/;91@7$!Q]V_+V#'M;)^`68XY\P-\@'-AVT!'/E24MM#TCK7[2FU90N*VQOL M0/N;&HWBSINFH;8SP*M(4I*R-+VCB@N=%'GTO9HBQ]Y)H>'5$-LKQ1-.ZX*!%3F=>)11H*U`3`_4A>=CLCUE`1,"[@,$NSB3D?D+\",9+ M=4C2D`)(*%U0X'X[PR-(&81\X,])\R=D("[/%_6G6*W/_L0M/*+\*RK7^F33 MA%10\UZZ-QR>82KA-@B6*&U<2=E;A^I"28CB7^,N=-R'\>8^G6CK!#81V!6! MCH%BFK^YXT5N<"!F;&W'PP0W>^8;409GJ-NG:/U=0!3YN6"[74[/06C"')<8 M%C&;&4&]^AR"K84XLO_H;)V^7)%WO($_W#1"6W)"YR<;9U,C.O"I MI#>W"6G]_YD-";4+QYT_F_%)C8;#[O)!YE]:?`-02P,$%`````@`I&MP1Z'& MG+J?`@``:@D``!D```!X;"]W;W)K&ULC9;;;J,P M$(9?!?$`Q2=.$4%J$JUV+U:J>K%[[29.@@HX:SM-]^W7!D*I&595I&";^>>; M<3)C%S>I7O59"!.\-W6KU^'9F,LJBO3^+!JN'^1%M/;-4:J&&SM5ITA?E."' M3M34$4$HB1I>M6%9=&M/JBSDU=15*YY4H*]-P]7?C:CE;1WB\+[P7)W.QBU$ M91&-ND/5B%97L@V4.*[#1[S:X<29=!:_*G'3DW'@@G^1\M5-?AS6(7(QB%KL MC7/![>--;$5=.T^6_&=P^L%TPNGX[OU;EZX-_X5KL97U[^I@SC9:%`8'<>37 MVCS+VW+2(K/<102#$ALSDY#-@.[?(Z&>3'>`DAX.@ M8)YTHJ=#G@M9,-`!`QQX>6QZF[:S23N;/$UBA&!.#')B@$-A!PGH(/E"H,DD M4-8'BAE:"C0%.2G`81XGG7%P3'-*%G8^`T$9`(H]4`:!,&(+H!P$Y0`H\4#Y M#$0H)B1>^#.ZG@-5'0)0J5]V:)Y4RI(ETD)]8X"4^20\)^&4HH7=PV"=/V(" MH'(?168HEL3$?KR>`'B+R4(\<,ECH.;S66^CLWA2QFB\4`H8;@X8Z`XY]E%L MGGJ:D:6JPW!_P$"#R+WZW@U&TTX4HW2Q$V&XDV"@E>34SRKY&BJ:G$B-4*?N M:-?!7EY;T[?T<76\/CP2=Z)YZQN\VO:7@`\W97'A)_&3JU/5ZN!%&GM>=B?> M44HC;)CHP>[(V5Y\QDDMCL8-4SM6_56@GQAYN=]LQNM5^0]02P,$%`````@` MI&MP1_Z\P(W_`P``9A0``!D```!X;"]W;W)K&UL MC9C;DII,%(5?A?(!`KT;:+`3BKTKEXL\UHZU2`=H`CLG;A],0Z5X] MX<8#?OO0[EX+[=5-E3^JLY2U\RO/BNIA<:[KR])UJ_U9YDGU25UDT7QR5&6> MU,W;\N16EU(FARXHSUSRO-#-D[18K%?=M:_E>J6N=986\FOI5-<\3\K?3S)3 MMX<%6[Q?^):>SG5[P5VOW#'ND.:RJ%)5.*4\/BP>V7+'@Q;IB/]3>:ON7CMM M\Z]*_6C??#D\++RV!YG)?=VF2)JG-[F16=9F:BK_')+^K=D&WK]^S[[MEMNT M_YI4@OG((_)-:N_J=MG.:RAZW"OLJI[=/;7JE;Y>\C"R9-? M_7-:=,^W_I/(&\)P``T!-`:,=7``'P+X&$#LPP!_"/#G!@1#0#`W(!P"PKD! M8@@06H#;?[O=;)Z3.EFO2G5SRGY#79)VW[*E:*:_;R^VPV[F4C6?M<1Z];:F MV%^Y;VVB@7FZ9VA@@BFS,9F(ILB+B;`IL4.%PI%QFX6,JR&TFB<""836*6*B M*?.,F%A;SHP\VQEY=B;#/0\OFL,1\KL$?$C`<`(?)O!!`FUXNYXI.L;O&,M@ M`E@B`"6X5@(Q/BX2PB(A2!#@!`(F$"!!J(T=,0(7B6"1""2(<((8)HAG=(F8 M&!=IG1H9@V>F8)ZN>N]N6XA>TW[@>;KR_X5-&[(X%0,-6?8Y@_;PR&C&5X<@ M1I8Z6)$,2))Q2PJL289$:;0*(&NK6)@,J,X<1<"C2/\!2L"C MC-UK,MRV);`[$7`G"O560F/6%'N><5L$7"0FW+0E['8$C(R,'[W"_'8"#EHR M.1[%PN;AA(V1@#&2X3:144J0<4^94,*DINU@DR7@GV08"H!LFX-CD^7`9+FF MNQ<(673'L4%R8)!Z'602=K68_D#`ZR(ZZ(:H,G.%(*1 M]D?E><+U&R;@86R,P<0:/V:Z96P!%W-AW1C8*#GP0*Y+E)M_L9A/ID1G'4\ M(GND]HA$N[YARV<&KK^PY;8_4OF;?KVZ)"?Y7U*>TJ)R7E5=J[P[6CDJ5^]3T_U9)H?Q32:/=?M2-*_+_ABL?U.KR_NIWGBTN/X#4$L#!!0````(`*1K M<$<+$3>5EP,``&(2```9````>&PO=V]R:W-H965T6=Q2S+)%/M^6]'^NE3&C[>W]FWC=PZ_%=:L9AG?]*#.-?1 MFKIV8$=ZS<0O?OO..@VN)-SSK&I^M?VU$CR_F^A:3C_::UHTUUO[CVMU9KB! MU1E8O4'O!S>P.P/[T\`9-7`Z`V>N![,U6!\ M:PC9J!#2(XPZ@#X*"XLBLA1SX"!6$;X-8I@D2:9)MI,DNU&2@58;S;C]8&^W M&7=,G,!!"1R$@(`I:S%%@W%:&7!:8P1#7)!3!./`K*H8XKFX(!<5Y"*"@)/( M59V`J8L1R`+(42$V@"0JQ/5P,0M4S`(1`R*-%HJ/;W"]JS0N?.HZ6,RH!@E$J`8)1*H&*>:P$;8'%>$!B=EC,7R1&[C.P MMF8BJ?GB/29?=$:"4,`ZVX&&H8+L(D3*NXSP@-&ME&"]%!;;#C28(BA(Y5$%(32PVH[S#!7AO9U@S1T6 M7`0$PXUG8#9$[=RP'H;=>"50HA4B5-\R3C/$-)>(\G M6).'A9>H_5DM#3/:/,*CO$G3-%LL')"9W3C/,#/X?H%@&P9ELM5&;GD>3`T" M4KKL'*9D@FDH"]\Y$&SKH$PXTL]567,V#W.8DCE,VSE,NPFF88+PG0C!MB(^ M#`;9'_@F#&9\@]`&8SQ\WN:L/#5'%Y6VY]="M/[[T?YXY+DY1`#C$5G%!!G? MD%72'GY\TH?!A9[83UJ>TJ+27KFH/\J;S^HCYX+5L9M/=64Y,WKH'S)V%/+6 MJ^_+]@BD?1#\&ULC57!CILP$/T5Q+T+-@9"1)`V M)%5[J+3:0WMVB!/0`J:V$[9_7]L0PAHWW0NVA_=FYHU'GK2G[(V7A`CGO:E; MOG%+(;JUY_&B)`WF3[0CK?QSHJS!0A[9V>,=(_BH24WM0=^/O`97K9NEVO;" MLI1>1%VUY(4Y_-(TF/W9DIKV&Q>X-\-K=2Z%,GA9ZDV\8]60EE>T=1@Y;=QG ML-Y'"J$!/RO2\]G>4;D?*'U3A^_'C>NK%$A-"J$\8+E<24[J6CF2@7^//N\A M%7&^OWG_JM7*[`^8DYS6OZJC*&6RONLLP`EJ7=5CD;,=HZ! M&K."'R&[)01,"$\F,&4!;5ELX8)N!,B7B%5@Y/!?)_N'3CZD&5B+%"(RL`B-+DYHW&,T")4.K^$]F0^56E&\486=% MA:$AS1[1T.7-7JV&L+.>%]PIZ*45@YC).HVD9ZA>/<.^!>L<6.P[.<*&B7-W MGZ4=/I,?F)VKECL'*N1;JU_+$Z6"R-RE&M&PO=V]R:W-H M965T..%.* M^-\U)JQ9N;Y[#7R4IT+J`,A2T/,.)<65*%GE<'Q)&#.:. M]KYG[%,O?AQ6KJ(Z%'V9L:S:L3$[ MB=?1[`38$6!/Z,^Q$X*.$-P(X4-"V!'"N2=$'2$:G0!,[FWEMDBB+.6L<;BY M[1KIC\I?1NIN1F3I)0LBF(*+%NHPZR$&MIAD!-E.(7Z/`,I` M[P+:7*SAA#XZ8#-%),'(PU.1W4.1.YN!M5C!@!]TQ?J/0&@5""T"X:C:!E.U MF-!@7H,@>!T59`J+0CA1V\Y3VSU5NTLNLB8769*+[`*Q52">49UX:A2&L>>- MJC.%P3B.!G9,=>:I[9ZJW26WL":WL"07VP42JT`RHSK)Q.BKYTV*,U4:_^6W MLX1V#X5,2F#P$%',3VT+$$[.SI4TI#[:=YDWJ!^R47SM+S>^);Y57R95,]G^P`>&9-8.?=>U,=:J+[9+P@^2CU=J#DWK<0L)*NO MC;'OSMD_4$L#!!0````(`*1K<$=]`JB&PO=V]R:W-H M965T$W5:8(BQ6"?NO3EG"J:U;&L?M7;+&L6OXM\7U\OMTUS MN(JB^GF;%6G]I3QD^_:7E[(JTJ:]K5ZC^E!EZ:8W*O)(QG$2%>ENOURO^N^^ M5^M5^=;DNWWVO5K4;T615O_>9'EYO%Z*Y<<7/W:OVZ;[(EJOHK/=9E=D^WI7 M[A=5]G*]_%-QET.69X]-YV+M/UX MSVZS/.\\M9'_&9S^'[,SO+S^\/ZM'VZ;_E-:9[=E_O=NTVS;;./E8I.]I&]Y M\Z,\/F3#&$SG\+G,Z_[_XOFM;LKBPV2Y*-+?I\_=OO\\GGYQ\6"&#>1@(,\& M4DP:J,%`S370@X&>:V`&`S/7(!D,DKD&=C"PI_ M39MTO:K*XZ(Z;=E#VC%#7/EV?SUW7W;;J5WYNOVM0ZQ7[VME["IZ[QP-F)M+ MC!PP;HRY!9@X'F.^(C]^C+GC&.E)K&\(0_SPQ!/$XA1DE8F(0%21CLP$$'#CA(R"@Q:% M3,O=YY#[SR&/DY!QT<5Z(X'>6#..2]PE&^<390.F26)8DDB6Z#Z3F>S8QLOT+Q,+B))$X M.1K+\%C..Q,<%Y8HR25*^IC&2M@<6JV5":TX%B&)1"A0'"06%XE:"$NS!:`X MM+.P=DB@'2[4XV*^*M0?T%01*-2'*,Q8!1CK1,`%IJ)"W4%"4Y5L#P@IC-2! MGD<%>G_`61<:,::B0FT[2Q?T[<)8'Y!#A9FH4.?.%A&`0GV3PBQ4H%%PH50Q MNQ1JSZD8*E[B)T5#81HJ1$,JAHH7\*DG)X69J!`3-0W%BVL[=N\#BZ`Q8S4G MHPPQ26,R:DY&Z6A#H7GY]#8Q]'#A?H33"#=."9-;HSH;TY0D"R6$=\K3O0Z` MLGWL<4F@']58!310`=I^WVE>N?]P1GM-2R$""AFW13X@+#IP'(!J/`EVH[FP M..-\<%6PL&B@&<[01)J8 MB[]UDNG.Y[AQ2E@*#3K/QS2U^ROM'K=[>O%4]DT M9=&_BW@IRR9K?<9?VN2W6;HYW^392]-=VO:Z.KV9.MTTY>'C1=OY;=_Z/U!+ M`P04````"`"D:W!'N^^9B*A*I2;3:?5BIVH?=9YHX"2K@+)"F M^^_77$K!,Q%Y*9><\3DV]J=.?-7E6W52JG8^\JRHEHM379^?7+?:G52>5(_Z MK`KSRT&7>5*;Q_+H5N=2)?NV*,]<8"QP\R0M%JNX??=2KF)]J;.T4"^E4UWR M/"G_K56FK\L%7WR^^)4>3W7SPEW%[E"W3W-55*DNG%(=EHMG_K0%OY&TBM^I MNE:C>Z<)_ZKU6_/P8[]3>'X_G/T M;^UT3?S7I%(;G?U)]_7)I&4+9Z\.R26K?^GK=]7/H4VXTUG5_G5VEZK6^6?) MPLF3C^Z:%NWUVOTB65]&%T!?`$/!X$,7B+Y`W%O@]07>5X'7+DTWE78AMDF= MK.)27YVR^WKGI-DD_,DS2[UK7C8K:Q:A,K\UBE7\OA*1'[OOS4"]9CW60*N1 M,)5LL(0/"M<$&%(`E6(-J-PVF%5L"45$9Q#D2HA1O>A6(K@Q@$<.X.$!HL`* MV6F*5A/V(<-`,-K')WU\PB>T?/R1C]=]#U\P=L,G('T"Y.-YEDV`;`(1<.;1 M-B%I$Q+3D99/B*?#9!"*&T:2-)*$4609263T`!#*6T81:13AA1NM?&<4(2/I MR^C6!VK011U>AJ.`U%\X%C0-CG8=UKQE8@.(`?V9GFA=-,-'(XQ1QIA_*0EV\V M)(N8'6I>.`U%\XEC0*']O^:84#Y(<]302LT+IZ%HF'&"9HS;H3#/'GCH!2C3 MK&X:B08?Q^3S&-B1,/H>.`^%G7USAW`:BH8DQY3D3-A>!":%](#?P"2G.\I3/ZZ:1:$0#1C0^ MY8#)2Y_R.X334#2B`2,:G?(U^.B3V*>\#S4O[$*YHZXD5^6Q;>\J9ZM:F3SLT>0YF29W>,C4 MH6YN0W-?=FU?]U#K\V<7.[32J_]02P,$%`````@`I&MP1YX9A;G<`0``0`4` M`!D```!X;"]W;W)K&ULA93;CILP$(9?!?$`:S#' M1@2IV5757E1:[45[[<`0K+4Q:SMA^_:U#:$T$.4F/OWS?S-#[&(0\EVU`-K[ MY*Q3>[_5NM\AI*H6.%%/HH?.G#1" M95F(LV:T@U?IJ3/G1/XY`!/#W@_]Z\8;/;7:;J"R0'-<33ETBHK.D]#L_:_A M[I!;A1/\HC"HQ=RSN1^%>+>+'_7>#VP*P*#2UH&8X0+/P)@U,N"/R?,?T@8N MYU?W;ZY:D_V1*'@6[#>M=6N2#7ROAH:82DBL8268=59:\&N( M[W'R.8ZT<^,PGN3!%+8=@*<`/`?@,?$1Y-)\(9J4A12#)\?6]L1^P7"'32,J MNVGK-BDJ&ULC55=DYL@%/TKCN]=!1%-QCBS^>BT#YW9 MV8?VF1@2G16Q0.+VWQ?0&!>=;5\$+N?<>\\%KEG'Q9LL*57>.ZL;N?%+I=IU M$,BBI(S()][21N^ZHW5M'.G`OP>?CY"&.)W?O7^U M:G7V1R+ICM>_JI,J=;*A[YWHF5QK]"#$3H2@UVXKMR>* MY)G@G2?ZTVZ)N51@'>NS*8S1'(6NFM1[!I%GMQR%.`MNQM&`V4XQT&)2^!&R MGT/`B`AT`F,6<"F++9S1G0"[.2*-G!S^Z>3PJ9,/:4:+Q8HF_&@H5N(4J\Z%_:MZ^$^SUIRH3^(N%2-](Y&PO=V]R:W-H965T[#YM,YF'WN6(5,D"9M@ZS?[\M("I<)O@@ M;3GGGMO;'MJH8?Q=9)1*XZLL*K$Q,RGKM66)-*,E$2^LII5Z45?N2&N94GXOQTM6+,QD7D;>,LO MF=0#5AQ9`^^4E[02.:L,3L\;5FY/)(DCSAJ#=\M=$[VKT-I3 M:Y/J0;T4JFI"O=.(./J,73N(K$\=J,?L'C&XQ>#0&S"6BC^(8$ADAR4`X0M)K1F;$T6E"1'K1P?R#0UUN$`25_K`2!@AD= MV)4(LN6,KQ'L2[3`F`D$PC.[!,'61`N\F:"I.4@D#.C`_L8+3#R'DV='/B>-YKV`8!Y(5Z-MXSU<$J6E%_:^XDP M4G:M9'=^#*/#'6B+]2D[&M^A==+=9.YAXJ@F%_J;\$M>">/(I#K#VU/XS)BD M*DO[16V#3-W>ADY!SU(W?=7FW7VFZTA6WZYGPQTQ_@]02P,$%`````@`I&MP M1Y\4H)3T`0``-04``!D```!X;"]W;W)K&ULC53; MCILP$/T5Q`>LP4!((X*TN53M0Z75/K3/#@P7K8VI;<+V[VL;0K*`MGWQ97S. MS)GQV$G/Q9NL`)3SSF@C]VZE5+M#2&85,"*?>`N-/BFX8$3IK2B1;`60W)(8 M1=CS-HB1NG'3Q-I>1)KP3M&Z@1?AR(XQ(OX<@/)^[_KNS?!:EY4R!I0F:.+E M-8-&UKQQ!!1[]]G?G0.#L("?-?3R8>T8[1?.W\SF>[YW/2,!*&3*>"!ZNL(1 M*#6.=.#?H\][2$-\7-^\?[79:O47(N'(Z:\Z5Y46Z[E.#@7IJ'KE_3<84XB, MPXQ3:4A[EN[-P/)QMOI*T3\$C`$V&*LTX(1D)P)X2?$L*1 M$/YOA&@D1+,(:,C=5NY$%$D3P7M'#+?=$M-4_B[2=Y,9H[D*736ISPPB3:YI MB,,$78VC$7-XQ&"+V>*/D-,2XD\(I`5,*O":B@->T&3\Z=. M/L@,5HL5//"#L5C1K%@#IK&8>%`1Q?Z7>);/$A;A+9ZGM((*\&9>_?,2YH=^ M[,6SW-!#4S`0I7V.TLEXUZ@AHB^%9#QO%V]LG-?V4 MZ5]02P,$%`````@`I&MP1_.0]=-S`@``N@@``!D```!X;"]W;W)K&ULC99-CYLP$(;_"N+>Q=]`1)"ZJ:KV4&FUA_;L)$Z"%G"* MGOK.L;Q;>&U.IZL7TC*(KG'[:M&M:;2;=2IPSK^C%<;S+RD5_RLU-5, MQI&'WVK]YB??]^L8>095JYWU*:2[O*N-JFN?R3WY]YCTWS-]X'1\R_ZUM^OP MM]*HC:Y_57M[J-=%66W=@]4?.06NK7%+TY-K0R7U(W">U.E@_3-VX&X[686+U M^?:E&PO=V]R M:W-H965T,#C(KBH;$F8P_9O=AD,A>[ MU]32:D;%!3K.OOT"6NL@GT+?6(DQMSZ:NF5KN^2\6SD.*TK< M(/9$.MR*/R="&\3%D)X=UE&,CHK4U`YPW=!I4-7:6:KF7FB6D@NOJQ:_4(M= MF@;1?SFN2;^V/?LZ\5J=2RXGG"QU)MZQ:G#+*M):%)_6]K.WVB<2H0"_*]RS M6=^2V0^$O,G!S^/:=F4$7.."2P4DFG>\P74MA83QWU'S9BF)\_Y5?:]6*](? M$,,;4O^ICKP485W;.N(3NM3\E?0_\+@$*`4+4C/UM8H+XZ2Y4FRK01]#6[6J M[8<_L3O2S`0P$L!$F'S,!'\D^#="\"4A&`G!=QW@2(#?=0A'0J@1G*%8JM1; MQ%&64M);=#@>'9*GT%N%8C,+.2GW3I29B7\2D:7O6>##U'F70B,FGV.`PL3@ M,V2[A'@3PA$!IA3`E"('"[IFL%DB8E_+\%!D]UAD;Q!)S"OQC?7T9WQ_K&=H M%@B,`L%"`.C5S@=,JS"1PB1>X+JN5I"'L$]QH#$.-*PGTGS@S"<8(L,`P#L^ MH=$G-/C$9H'(*!`M!/PPU()&BZ`>C/V[%8F-1K$A::*=HGA1>>A&\)Y/8O1) MECZ!ML-YLO#QPL!+M$.]6<+TH[)$@#B)76VG=U\)#4MR9A=/@^E9O1',*LBE MY<,ZIMGI&7H&\N+2YG-OM?$,\UMOM1M>F9M\EG;HC'\A>JY:9AT(%]>ENO!. MA'`L@KM/XHR6XF&=!C4^<=F-1)\.;\TPX*2[OIS3\YW]!U!+`P04````"`"D M:W!'*-0JM(T"``#P"0``&0```'AL+W=O`4G&3[][6!I&P\EM@7 M?&'FG+GXR"XNJGOK#U+JX+VIVWX='K0^KJ*HWQQD(_H'=92M^;-372.T67;[ MJ#]V4FP'IZ:.2!RSJ!%5&Y;%L/?F$=W?1UFKRSJ$\+KQ M4NT/VFY$91'=_+95(]N^4FW0R=TZ_`*K1S*8#!:_*GGI9_/`!O^JU)M=_-BN MP]C&(&NYT19"F.$LGV1=6R3#_&<"_<]I'>?S*_JW(5T3_JOHY9.J?U=;?3#1 MQF&PE3MQJO6+NGR74PZI!=RHNA^^P>;4:]5<7<*@$>_C6+7#>!G_4#:YX0YD MAC]X"EGJ*" M1W:PH'^3T9R*<`8S?7ZDPL4'F/HR#P0N/_B$_@`7("Q1(%`GX9PD)(T]5+@$ M88D&P15A9KAR#Q,N0EBB0G!ER"F-P==%7(;@ZA"I7^8>&!9G)/=QX8H%OJ2` M'#F<.8]])PO7-F#B=BKHJILDD%%./9<0+F^"R?N.BKCJ)CGE"?.<=H++FV#R MYO=9F7?C@V1<:'6\OJ]NC[SR'U!+`P04````"`"D:W!'0E[%ONH!``!Q M!0``&0```'AL+W=OL M@%_,Q#'I;+-I+YIL]J*]9A1'LR`N,./VWQ?0L4;)W@@'WO,^!_DH1B'?54NI M#CXYZ]4I;+4>CE&DJI9RHI[$0'LSTPC)B3:AO$9JD)34+HFS"`&019QT?5@6 M;NQ5EH6X:=;U]%4&ZL8YD7_/E(GQ%,+P,?#675MM!Z*RB):\NN.T5YWH`TF; M4_@-'L_8*IS@=T='M>H'MO:+$.\V^%F?0F!+H(Q6VCH0T]SI,V7,&AGPQ^SY M'VD3U_V'^XM;K:G^0A1]%NQ/5^O6%`O"H*8-N3'])L8?=%Y":@TKP93[!M5- M:<$?*6'`R>?4=KUKQVDF!7.:/P'-"6A)0%/A$\B5^9UH4A92C(&E$*,#YD?E'A!B0^4;T![49SA+$[\ MH-0+2GT@O`'M13%*`0!^4.8%93[0]B3L15^!#IQ*=AP\ATG2P%. M8S\'>SG8PX$;#MZ=.13#/,';+8I6UVD@5_J+R&O7J^`BM+F9[FXU0FAJ/,&3 MV8W6O']+P&BC;3&PO=V]R:W-H965T+57'=G97E^JK7*UYGV3(MON7K;%5]\Y9OEFE9O=V\ M]XKU)DNGC=%RT9-19'O+=+[J#OK-9S\V@W[^42[FJ^S'IE-\+)?IYK^;;)%O MK[NBN__@Y_Q]5M8?]`;]WL%N.E]FJV*>KSJ;[.VZ^Y>XFKBXEC2*O^?9MCCZ MOU,/_B7/?]5OQM/K;E2/(5MDKV7M(JU>/K/;;+&H/561_VV=_HE9&Q[_O_<^ M;"ZW&OY+6F2W^>*?^;2<5:.-NIUI]I9^+,J?^?8A:Z_!U`Y?\T71_.V\?A1E MOMR;=#O+]/?N=;YJ7K>[;^*H->,-9&L@#P92G#50K8$*-="M@0XU,*V!"36P MK8$--7"M@0LUB%N#.-0@:0V24(,ZY[O,1<$FAV2+8)-]ND5POL4^X2(XXV*? M9^VIU=P<:V2CD4E\JKFE&FW4J>:.T^A3S3VG,:>:(:>QIYH1IW&GF@=. MXUW7F-,DIYI'1F.C4\UW3B-.-4^U",!R]'DYUFU6A,$TZ3\%$<'\51#\XKU8DC:9$X*S$?)V;B@/E( M>`_)UP7TG)"1V@B.M%[VV14P^KJ"GEO1<7H!40(MM.+K(GIN10%5)`"Y@D,W M]L,P(@>0$`!PP1#NE]*SH(BK,QD"B`O*N'8*^``("XYAZR_`YJ+A`I(%Q904 MU%,K"EB3!$!9,"S[!?4D'`GC0!A`LF!0]@OJB16!E4D`X`5#O$-M"[`L* M`W@U03P.C*45W0:`W@U`;R.#.45)-H`7DT`KR-. M%(,M@P&\FH#V.C*45W,F0^@DB^,5;`T-X-4$\#HT%_%J`*^&XQ6LA@;P:@)X M'1K*JY!PXVT`KX;C%=S66,"K#>!U:"]JKQ;@:@-P'=K@]FH!KC8`UZ&EN*(P M`%<;@.N0$Z&-MP6XV@!A04<"!UXYB'04K`=Z- MHU!+)V.2I][1P^UU^IX]IYOW^:KHO.1EF2^;)]UO>5YFE<_H6Y6/699.#V\6 MV5M9_ULG:K/[V&PO=V]R:W-H965T&8QZ84>N]H.4'\YY:78Q=B4`A]HX!FJ7,SP"YX[("G].G/\E M7>+2OK`_^6YM]0>JX5'ROZPQG2T6QU$#+3UQ\R;'9YA:\!76DFO_C>J3-E)< M4N)(T*^PLMZO8]C)BBEM/8%,"61.(*'P(.3+_$T-K4HEQTB%T0[4G6"R)780 MM0NZOFV)VNXY1%6>J^PA*]'9$4V8_1)#/(8\W,\89/EG$;(J0CQ![PFR0("3 M_$IE"2H"*$URC->%TE6A=$UH0WD]ND67K3$%KX0]51];KZ""-O5[^@K12&K"4^,YR M=O81SPZ'UCBSL+8*]SHX1@Z75SK_*JIO4$L#!!0````(`*5K<$>?$I$`4@,` M`+0.```9````>&PO=V]R:W-H965TBHU(!Q@6,V;]?!M#@3$\2'^1VND]W3_>!F5UT M]5(?E6J"MR(OZ_GDV#2GAS"LMT=5I/54GU39/MGKJDB;]K(ZA/6I4NFN,RKR MD!(BPR+-RLEBUMU[JA8S?6[RK%1/55"?BR*M_BU5KB_S"4RN-WYEAV-C;H2+ M67BSVV6%*NM,ET&E]O/)-WC84&D@'>)WIB[UZ#PPP3]K_6(N?NSF$V)B4+G: M-L9%VAY>U4KEN?'4,O\=G+YS&L/Q^=7[IDNW#?\YK=5*YW^R77-LHR638*?V MZ3EO?NG+=S7D((S#K<[K[C_8GNM&%U>325"D;_TQ*[OCI7\2D\$,-Z"#`;T9 M`/_0@`T&[*L&?##@7S40@X%X-X@^-)"#@;08PKY87:G7:9,N9I6^!%7?'Z?4 MM"$\R'8QM^:F6;NVS'7[S"`6L]<%3\0L?#6.!LQRC*$#1MYC5BZ&WB/6+B)F M]Y#'3YUL/G02MIG>TJ5HNG1DSX94(MP!0QTPQ$%LU:O'E!V&=QA&NA].Q%$B MCA`E%A$?$24=1DX%3B)0$N&0B%&4/8D8D40=!B(BA3<=B3))A`DL)NG4C0M_ MV2*4)T)XK"9:1DY&-`(_48P2Q0B1U<_+V$DH\=,D*$V"T'"+)AG1Q/U03(%Z M&L'H+*8#Q"%B)/:X\$@)(+$*>\0!Z5D&'B)\B,&=8@8>&0!\C,&=8R16YL2: M3"4DXY^'%9]I<(>:"=\ZX1,+V,@Z8HS,+$TBNW'6""[BG-AE<%&4D\@>WPW& M*@3S-1&N$X`)161'A(%\/+A.`"84OM7$%0`0"0!B+X6K`901;\/C(@"("@#8 M3(G#!)3&W$-%<1V@B`X(WRL6UP&*Z8#=HA3KM'>KYB'#UQ^U1%.3CP46*(B(%U"ZD^[4A)1/4J1!S,K=P]R'A M"D9=!1-@?\91[JXM@)2>%Q_%E8XB2@?U[UFZK^HM&GZQ[QME%=_`=02P,$%`````@`I6MP1R4` M'X%8`@``V0@``!D```!X;"]W;W)K&ULC59=DYHP M%/TK##]@(41`'61&[73:A\[L[$/['#$*LX'0),KVWS<)R&JXNKY`$LXY.319[QDV)50U^%)T]U3<2_#66\6_G(OPR\5<=2F8$@SX*1 MMZ]JVLB*-YZ@AY6_1LLMP@9B$;\KVLFKMF?,[SA_-YV?^Y4?&@^4T4(9":)? M9[JEC!DE/?/?0?1S3D.\;E_4O]MPM?T=D73+V9]JKTKM-O2]/3V0$U-OO/M! MAQAB(UAP)NW3*TY2\?I"\;V:?/3OJK'OKO^2H($&$Z*!$(T$E#XDX(&`'4+0 M.[-Q?2.*Y)G@G2?ZS6B)V7.TQ'KE"C-H%DK')/4W@\BST$VREBCN$9,!@$ON)CR\?A'!:8@0*SB4",4F<5 M(,S<"03"+&`C,6@DG@I$H6,$PB#'R&/,C9$$-)(``LZV;2`,=HQ`F!EL)`6- MI-.]17<.QQP4F#^QMP`FBIU(($P"&UF`1A9/[.T4@Y%[6R"=%#9B,AATZ<,G M=A<$N0<>!-TY\>A.!D)3">RN"PAR#_T7H%LS8*Y:H^B9E8%`KI>'F%LK<%)# MTZP6XXD5".3>01#DKDMP53%J*HZVDDJOX*=&]5EY'!VK]3HR%<<9WY@J;BO1 MITR>M>1(?Q%QK!KI[;C2]&PO=V]R M:W-H965T7-]&_R#/GRGMKFTYN_+-2EX

    MJ?0GGI.3L,06T34D+2L&5UYU?EL/;45Z6XJJ;N M^%/OR6O;LO[/EC?BMO'!OR_\J$]G91;"J@SGN$/=\D[6HO-Z?MSXC_"P@]1` M!L3/FM_D8NP9\<]"O)C)M\/&)T8#;_A>F11,/U[YCC>-R:29?T])WSE-X')\ MS_YE*%?+?V:2[T3SJSZHLU9+?._`C^S:J!_B]I5/-20FX5XTI1'L/ M\;V6O8W/NAN>M_%-3J8P/(!.`70.@.S#@&@*B-X#AJT+1V5#79^98E79BYO7 MC\VX,--S>(CTSNW-HMDH79/4[PRB*E^K)(K+\-4DFC#;)88.&/@7L7,1M$AG M3*@5S#(H)F-+W006!8(H<(8(+31:Q$=3H8E5Z(CI!DP\8"*(LRS!>6*4)T9X M4HLG7O`48RT!C7"6!&5)_H,EP5CLSKD@$A04EY*B4E)$2F9)P3"YI03#K'0X M0X5D;@*(+"&9TV$*D*8$Y\E1GMSEB8G%DSO;F@?1RO^H0%D*A,5JWK9PJOD$ M^1J-<3/,``A"1&T'($X]41"O=`=6G`80(KL_$VA94D+CE!#;<%S<1Y\JH*[S M"!21Y+@?=6J/@[2P!;FH]6\:<(L"Q*-BVZ/`-2D`2,C*-PNX2P%B4[%M(.#Z M%`0YK!#A1@6(4[E$F`OE:Q7A-@2(?\2V#Z&@W.()%V=GR_O3<*>0WEY<.S4> MDO/J?&]YI,/9^PZOR@L[\>^L/]6=])Z%TB?X<`8?A5!<:R&!+OJL;U;SI.%' M98:9'O?C76.<*'&Y7YWF^UOU%U!+`P04````"`"E:W!'C(+EW,4!``!#!``` M&0```'AL+W=OMD5.0A]JJ+ M7`V6=Q)>-3*#$$S_.P%7XS%*HEO@K6M:ZP.XR/&<5W4"I.F41!KJ8_28'$[4 M(P+@=P>C6@'-/Y(3_7CD_)7WBEH>^9O,#D0=Q"E#_JZ MG47C]CRBR"\%S;[G^.*)KIC3$D,")ID1V+'/$F1+XD16Z93&VP3IIL=T09!. M!"F]\SAA9,!D`;/;D71/MW6R39ULK4.3.YULI?,MCK^HAFZJT+5*EMZIT'4U M^WA=#5[&ULC53+ MCILP%/T5Q+YCGDD4$:0A2=4N*HUFT:X=N#PT?E#;A.G?US:$4(*FL\'V]3GG MGFNNG?1/]POF;67PO#JYG+`"!7!D%K(Q87;LAYW8&VGKA&`D!!-ARK-."$=">"=$'Q*BD1!] M-D,\$N)%!C34;D_NA!5.$\%[1PQ_N\6FJ?Q]K/]-;H+F5^A3DWK/(-+DFL9Q MD*"K$1HQV1P36,QN`3D]0OP)@;2!R46PYB(+'NB+!,='Q"Y<>/BOR/E#D7]L MAJN'%<[XX7A8"Q?9@&$6L[68C1_M%M4\@K[XF]"+_45)GQ$[KX@%NRC>1HO2 MT*PG*(C*WD;IY+QC:JAGBDX7_CDP/;6(9_[^Z*_$3_J!&.[S73Y-6ES!#RRJ MADGGPI7N9-N+)><*M'WO27=PK9^P:4&@5&:ZU7,QW.IAH7A[>Z.FAS+]"U!+ M`P04````"`"E:W!'7"<$4?+%4[XX5"L>%T@6A6(5@0VLVI;3&,P6UM*3W^S@BQA MP9=P`3LM8='67\#.2]CF$6:30Y-K18&7YD$+)V-=(VU&HW7L&2^!OI8S^\'? M'?T5^TGU&-L2[O)ITN(2?F!>UHUP+DRJQV"N<\&8!!6]]Z0>0:6ZX+@@4$@] MW:HYMXW!+B1K;VUN[+7I7U!+`P04````"`"E:W!'5*3,VJ,"``"G"0``&0`` M`'AL+W=O)M?OVFP2D")\[W)@?SCG?7_R2["+DASIRKKVOJJS5 MPC]J?9H'@=H>><74@SCQVGS9"UDQ;9;R$*B3Y&SG2%49$(3BH&)%[>>9VWN1 M>2;.NBQJ_B(]=:XJ)O\N>2DN"Q_[UXW7XG#4=B/(LZ#C[8J*UZH0M2?Y?N$_ MXODS)A;B$+\+?E&]N6>=?Q?BPRY^[A8^LC[PDF^UE6!F^.0K7I96R5C^TXI^ MV[3$_ORJOG'A&O??F>(K4;X5.WTTWB+?V_$].Y?Z55Q^\#8&:@6WHE3NU]N> ME1;5E>)[%?MJQJ)VXZ7Y$D4H@3Y=D)$#2V:V1 M%81)!ZY.T'F:H+,98T*$;C'/8PRE*1QT")8G[`F$K9$[68M`@6@D0..!E^L& M4SM,TA0O"@<5W@`@1'L!W_A"05\HX,O@F*PA#(&-Q*"1>)PQ',(""2B03,A8 M,DY&2'IFFI2-4<1<`7=2-@.=F4U(&82Y$W$*&DD!@6@02]J+)7*8.(9MV,X/ M-1H$6*'#-H)&9J)[9N[T,PR8B8<-#8\J$R&"AIE=`;@PG(U.`P!+C-%DV%4` M'$8HC>Z<;PSVP4=,@`@'+?NY!?43.?H7!+T[HN+RX.Y_Y6W%N=:- MW1-CL+_$\Q4&]M=X_M2\(+[E\^S$#OP7DX>B5MZ[T.9FOHP;2` MHWDU=8N2[[6=)F8NFW=$L]#B='T6=6^S_!]02P,$%`````@`I6MP1T_:"KCK M`0``4P4``!D```!X;"]W;W)K&UL=939;IPP%(9? M!?$`\0)F&3%(G415>U$IRD5[[0$SH!A,;,^0OGUMPQ#$N#=>__-_QVLQ"?FN M6L9T\-GS01W#5NOQ`("J6M93]21&-IB91LB>:M.5%Z!&R6CM@GH.,(0)Z&DW MA&7AQEYE68BKYMW`7F6@KGU/Y=\3XV(ZABB\#[QUEU;;`5`68(VKNYX-JA-# M(%ES#+^APRFS"B?XW;%);=J!S?TLQ+OM_*R/(;0I,,XJ;1VHJ6[LF7%NC0SX M8_'\0MK`;?ON_MVMUF1_IHH]"_ZGJW5KDH5A4+.&7KE^$],/MBR!6,-*<.7* MH+HJ+?I[2!CT]'.NN\'5TSR3P27,'X"7`+P&X#GQ&>32?*&:EH444R#GK1VI M/4%TP&8C*CMHUVU25&;.*LKB5I(D*\#-&BV:TU:#G0;G7QI@_%<(]D*P,QB< M03P;0$1VE*TH=:(X0@0G?E#D!44^4+(#>40DSB*<^TFQEQ3[2.F.Y!$1%.4I M\9.(ET1\I/T1/8I0'F=ICORDQ$M*?*1\1WH4H00B]+\UI5Y2NKE1T7S6!.Y` MZ0,HB^,()M`/RGP@\SGL+Q5*XRS)R/Y:@F%_:+RT@TJ.`MMWIY[/8T0 MFAE3^&1VNS4_W-KAK-&VF9JVG!_]W-%BO']AZS]:_@-02P,$%`````@`I6MP M1T)PR9JD:0``0*T!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.U]V6X;69;@ M\\Q7!!+.*1D(,0B102G*)$,504I68Q[R(_IE M@.J?RR^9L]XEX@87V5D+T*CNM$A&W.7<<\^^_+ZJ-M&7U7)=_?-W-YO-[;,? M?JAF-]DJK3K%;;:&7Q9%N4HW\+&\_J&Z+;-T7MUDV6:U_"'I=D<_K-)\_5VT M7>=_WF;GQ7:]^>?OAJ/I=W_X?97_X?>;/[PH9MM5MMY$9^MY]'*]R3LU MCYD7Z^@TJF[2,JM^_\/F#[__`=_A]Z;1VV*]N:G@G7DVK_]ZF=UVHGXWCI)N M;UC_\5UQUXFZT_"/LH0/V75>;_.MV6)@'J55S,8^=^R MM,3-1R_236-]IZ>]Y+3?:UG>U>TO/C';+D\_;PN M[M?19996Q3J;1Z^K:IN5;6LM5BM`JLM-,?L<1Y>$6='[[:;:I&LZCI-\+0CW MM#Z$P=2/#[<-@/>ZI_^[]86+K,R+>>MA*;+^S__Q/T(8:89Q#_X5?-F`4_U) MF3?X[/_NU[\Y@U?G_/HRO:[_NDB756/EYP6@][H"J,-?5;',Y["]>?0\7:;K M60;P!3I012>*(;*>3^MT.\_AP:=PNS]=OHA.GC2!G_"6MB*.U_YZ+,;M-\'F5?;O%(*X)@L;D!2C#SX-V@9,4&<&WW M,Q1X)IFY5T#TFV`:QNK>:!`#JYS M/"3>3G"A/Q;%_#Y?-FCW"Z"#5;YQ`;@+<.'?%,67>7J5+_--GC7QW.#G;?I` M&(43IK-9NW`"Y9K[!&\M(/0/)"YAEMIX%'B;>>E,LY\#(?T=W??/00-U+ MX`0`MK,(D$%V53%/?M+M=+L]`&@9`=7>9O\4#;MQM]L5KAREV\U-4>;_D!>8B7[4T)+:EM7K MQH-N$G<'8_W56>8TGHPF[F_.NEN736_"L+WI*!YVD^"PHU%"OS7'V[O=LSFP M8\`K+2%L%D&TO>M-J#GGSJ\6;DXL4?[G)-CG(8Q7*.T^B M'UHTFO8[83"/Q-,Y4.:T!)H#H*21&N!K'ZF!K;L$WKW#"/Y]S1#%8;*W?R&/ MA8?_]E$P"+ZZ?]_!U\Q>=V[5OV+FY9V3!=$4M;",B39(9RC\*!-MB'X?X1H,2)C/2T<0[/T_(ZA9MZNRUG-RD?AM#;QTA_JZ_]EW('$N<1X6`U=PM#?P M`D(7OPXNR=#E`+2J?$9#S?/E%N_%-F@(!A)4XAVB18?]I6(G-O"E2("Q"W0=5:ZQ'`M_@W M&3E.MA51K*?`:(N['"AV=/5PV`(N\(4*+R=@3G25HL1U%;*5!*D<+>QZ36QT M>XLW?`:B5$7B),)0GB9B7>(Q-14HV,/"(_Z-,3=9"1&0@MOM6BAV#_B348NGL+[\/!MT(C1JJ;ECEDHJ"0!L/'4 M\!H!+O+VY`(V4.LF!7T+)(^U>ZAD.:#5.-*M40NSQ2*;;007G6/984AH-UZU MF51V:K8[#66B,N_3<*7X4+YQL'H!M=WEF5S/3N`R=$8>\'WP1]B7;M`>\\A!--]Y[`` M&`%5VWT.!B,*0.@2'PYBWH?L5O[LD^H:V*(4=,,MJ!AQ@6^Y%VETDJ/XD MH"RM36M09`ZVA/C,-!C;UBN$+(U@&&UP.,MLX:IFSBO[] M8_9E$SU?`NW\/SL7.O<6NM:%RND^/(M>K]&(M0;ZB#?T/M_<@';F7W*/TU31 M?$NH!Y)8!">;12O6CC+4CH*&ION,AT/,?=*+A_UIW$]Z[;.!Z,IBP'`^];L2G%MY?" M#P6*YO`5P6!%FZAN\EO`C-GG])KH=$Z7))W?D=6#QH;!^]T>?IU]F1%O(BQZ M,HA'PR0>)D.](CP_O'T-K/H:9D+Q?\O,]\EX,(C[PRX^N_;,R8`S"&@4ZF$Y MG<@:J)8/9#7"7S?YBE8#?\.5)$Z>TGE6!/Q96I9Y:-,X\W2,AC0XJS(C M@5%/;LM\ID#TL?^$_##)TT[;72D?S?0>=9=NTK:C[)$)LG:42]C7^M"#Q"\" MJ[6G^C>#_Q#@?Q8VXM*<*"F7"+44UDUN)X+)L#M&]*8[R9M[[%G!+#?Y[`;F M*K,Z*>A$+QYQD+#D)="=?(&7TZX4Q8&Y>L[@;C2(82?H*.R!.O8NW0BE=XQ< MN,G+[6J%405HD\Y!H5CD,PSH$'$75WX!JE_(B?$>U/BUV"AB1T=4\%TPIAGX MA3BS3[-Q2-$ MF!G5>N:JUL$W83J8(?JI@-.F:)I.=/+K+W\QW_WZRW\]I8T@4MS?P#6&O=QC ME$>UO:KR>8Z;\T<`1@A`^;2&F_"NZ$1P6=Z\.8].A`2`=(LPFIQ*>9@8?=V8"(NM$(8T9_]BK!?0>S]!*-OEXRKA7^[ M9HXV(X26Q.A\)?)\I6O+YH1?+6/IR_I2&_FD29'T1V@;`SPP<,AAW_EZ#K>; M#)VH_'^Y98YGU6.=7*=;;`&J#UE:\MIR)^C.+!L>+(OM-:`W7^ZY1ABQIP\7 M=/SJ`=(&'3I`;Q23R.;FD=J/Q!7%M,^:WSZ4$=P6ABIVC0"=V4-5XF]#5@S[ M!'C-$;SK#5L3`/0!'#F#KRN'4!,ZJ6?#[(;0U!%W@>YL[K.L9," M?ESAP]DR)PD@4WIEX=ZA"V1-NV3&W6/Z)9PDH3U=908I`'TRYGZ'R`<&13IA MEE;;'\C:(!8M4_+,S.20B&$CN!&;V93Q-@5I"]WG.'87Z!6&S##6`>Y<;2M8 M&IJ=MS`"!3[AQ/=K8ZQ,S45._A\KFA)0W.6AT)9[&3/U/L7HD=HC!Y%D" MM56B)IF&FLTBC4"DE(G%SV]T@GEP6M2-0("0(6J7%[%7C=PT_MD*4'"6\OUW M=X1!):'1E]%\DK^'\S@HO66T`-7HPM86Q"1KE0&M;"(T`]@P9A!]^>4KSC\ MHO#\2B1]!EO`%UT_:?0.1_"^>>6<&._B&8]#M-#^=2Y;Q*CJ%B-2E/2G48(O M#)*H-Q[BW<`].?J4/-CK1[U1U!]%PS%(>\+4FX^=)!'Z,TZ2/OU[#A>Y_;F3 M'OYGC/_!C^>A(Q'57*Q:S@C)8`*K[YI_#P+=>=O)?0-`PG8'\/^M$!S(`SN@ ME\#/-%`KW$X)N`+;H\`UQ;'Q/Q*(=MS;XS$#6_[EN54GAMM8H+`*5`%EB`$Q,EMOJJ`@T7'V!R,=OC8:=P'C`J\%UER@N81/QU([4/Z1LL)I M51O"XY/T*8]:@**-L\QAV3,Q&QB;M)V`B-L*_?2.N(!"(%P8>0T>^QU0,=AV ML8+#!]0@^0[-%TC!3JYXQN)JF5\S/J$Z<545Y17]L$K_A+2:=H4,GJ=7R*EA M`3F9^"?1==!X4_S(8N^7MU%E0&16'.\^$NLVO`RTPO7<&&"31ET3Z8L8(,1,%W\.(B M(^Z+-,-*1,00+\X!J2^WL"/XBP`#1V'4-^"?O/'8VS#B<$8`1S$1#MH)OC%+ M=A@OZ;HX/B^O"4'9&SEI4C(?+[U!3B+$ZX MBX9E+A\03CE9*)8,![1LTQ)Q)`(#'`H^/L_8(D8JCQ#6)CJF@N'[KZF,3]:[ M"F`>N\\\.$\@<<&QC4Z>KQLJ[%ZMIQ.9G`?ZXZ7->?``@P/E&/%(8+Z!RPLT M8YG#TSAOM2FW?(IJGQ2W`)P37&C@HC#I"@5SLP5DXB(O`88M,PY+N,H:J1>= M^CJ`"6S)N@"OYYL"EH0'I2HZ(Q(;TV>`>T!-_PR/\[P,2PL'7'F^V=KWU,RQ M$:=DI494?.]*HCO$LE:OFMB4)[M5W/'>.,,X$0'AQ'#^C. MY)T9)>V\.'U_6QM/KY==#%%F=W!97-N"+^;E;#,1SP/%A&I4-D>ZN38K M#D'T\=6[JR+8F-41X5=KGB$N/L5`&Z1QN6T388CC(^31JC">?%]FJSV"XMP#@F2[R$C`#W:%QGS&Z@ M"T]SZ\70;=>*XN2]DDWGE(I]9-QF`"&X?B7&N_M&0L(`JS3ZK2%BLKPL\21(( M>0>B?VR7O,XE'B@Z7.8YA@2A3`(403@ITR;,D26V9_0.W8INENBP;D@O@P&5 MWO?#W.TGJ%0@4-FJW(E,_)-E$.<4 M5M":'VIOW,R8XRIK$%,W;L-'Q>9;#AU+7<.:*%IRM^:HLJW%L:PK-3[YW(W? M-!ZGRO$G&2<\6FC$+I,*RT=_@!,=\U*C8Z)P!BDMB^3@N283(<"Z6O">`HF\P MZH9T5="_@12HQZ[,--C]B,E)9&.K)WZDB!Y&Y:)U=0L;0\"^&W6? MDGM+7A-:'ZZ9V,B)1B1C4A[A_)]8?\<`SNP^7%7>$\GJM7:\(R2H4 MM5NR4R*O/,6*X^%`"]9\CA?&\.5Q"[.Y2HPL^KP;SDQW3?W&#CSD$M)-(XM$ M3N3>R$`(GS+/2.XT`Y-@>&725XA@U-R-5YYOTUBO'87<WBZ5SJ-^@O$E-QS[XHU$X\=LL5%9-?LB M'R0E.U^H%DV(M@:>RU%\<1W1<"T2&(CBB6C"%2(^I>SAQP0RGXU1<[X/H4 M'C8I?3;(8+CG]O8:'2A\U-GZ!F^NL8^M29:*`^1NY(A`/"'//84%LH>7 M(W1,1N="2#QISP[J6YNO4&R.(\(@O'+3'J;8)"U(S=8F+'<']KQ6--A6_EE9 M(DF>>:6/$=%'=LT3>-MML"<_*E9%#=Z^T M$2;I1I@I9RXY>!/)*2HR==;VL;'X\.9KQRA[@/=:N56B4V@=!?N'G(K9IC69 M$`&K!<\IO/QEVI-&JB*BJ?H,:EA@8*A2MQN(A_$QVTKT=@Z*[$2?R+IY=GD> M]8?=4W0MF]AR M-!8P`:H09.K/2R*S&V/C4H>'+XX:%1E)=_!MA)C=@=5S0&1`&YDQ6"Y`V0=! M$70.EE%`]L9TLP7.F[$'8A$A_K`/=I:7P,N11J)I3`*%20Z])_F=7E[FGS.R MN:44!JS*=_-(47539_D6(S&N,@R'1ZJ`P;X4($(/@T0&<#Q]0[D,*G2WI2CHH8@P4/DM\,<C9@&K/N!=GS% M@9QW6:F!0KK295%\KASJA"*;O5!KQ$UU;;#>Y\0DB7,+IZHJE0]@-VQB*6GF MYNYM@`C#`%?TKG``4K%#J/X>!8@:-G)T4!#&>%LEGHQF=2,H;!SN;U[=9*Q< MU3-Z<4XUA/U@S&/ME@+8AN-;6&02]T;HQ%(8GP591-!0;49:@`YPSZR-\D'H M7B??(\1_2N%Z@62%F_./LLHD^K<2LV]("2M,C?Y@RZ%BW^^O9AIA@LO M5*>9F>0E!>0L1?+TL+(F,JCE!XU4Q&7G.>6$.[ZKNE>M'8N(:2C*L96)=`QS M,S7:2230S%$P<$L`.KP5<#M4#*C/]:V/PI@S/E"1-9<*:E8++B>B.&@COEN? M`?]LX]-LY(@M&F!"1P22UM+,*Q%G>?/FO>!H;J=&F,?MB*< MGW%5FBB0R@9(Y*5KWPO%V6ER4,.,*"8KR3"!Y3S:X=#"GN;1DV3*%9C8=#KF M#[9L11T$]%AOV+?O]"?3>#RD=\06X;[A);Z@Q`AP6CZ8B].)3$;\"X-^>-21 M5ZODK;7.O#*U2G0WYXHL'Q1A.XB6'P0M7]L")$9K9V1R926V\K@WB31NGW_/ MQ!1D#`/LC"LJGX33;:_=&(_`$!6_Q9R1!W%J&@LB^J*MP[LQMV<).`LX;!C2 M3_KC<=Q+$CE5.*Y>K_O(2,VZ(7W'K##/:-KC2:?]>-Q_Y)R#^IQRAA\IY=VS M#ZC=LIZGV^8>1F5S/.BJ#Y#TO$JL`):BDBDO4("`/1#D+LG6'&;$,>,<$B&Y M/^&*`O1N(.Q$#79:/41%"L88=S(FM#;HFC49S[C;:G`2&U.6;E2'4?Y`R_)3 M-CTAJU:IPLA&CJAAZF,V-^UG-8EZA<^C$$/J[DSCW/$:.=LU0?^H3&?,)O&3<:6T+",M'>40WX6G-LOZ)N1!LC;_-@+?L"BBO+*`S3@9DE%I'\$D*UN#;&VH[&B&P3A=BB MP=;7H+7":/K>BW3T5VBVJ21`B$S(V9?49%V*M`VO$<&TH?&Q[X/>9+,;CH3# M:'UK%-.Y:CH$%0\3PN!L6NS*2O4<'!&R?TQ:%EL+,9(PM5OV%KU$#U.U,2`G M*%%8GA^R,.Q^SQ#-;XIBS@&C'/L$[65VA*H M33KL89EWO$PK;X%>?5%_])/>(+&2!3`PS4EV11"ROR!E>-(?.6)(-_2L)3]P M9$Z$3"/ZU=A4O'$7C4)%??_DOH!LFYD;]9FY:5>CPZQK::W=N9UFU M*@(^J$)KE#AU-DVQF^"`NEU-201G*C.@6)I%!Y_)JNS:2^N7#FF0O6U&S0-$ MZ1F5@VZ$EE7EQ>+XDL;"-JOD=,_3$M_G6"TMAS25L;0B.=6[XH)8I@C63*H( MWHB?Q#BRKS!*Z"Z?F^1KS%)Q*X:D M0"J)3QB:B24!PE%+(C'9;D^BDUX\&H[B<8*)'/`QZ29Q?]SG#\-XT!O%_=Z8 M/PY&@[C;F\*'1E&R=L"?D@`VP]*P@T$\'0VB03Q))B0&@X:"`C$,"=_UL'AL M+WK)$$913R$*EWO+^/R,B]LK>"@%!?]WU'JT'-NA*]I;R`U`T^THD+J=[D#_ M&@[U+Q#SGQZ2%&8PRBS=(C7MW.JZ%%QN#)ZZ-'-9S/*`XV8S-.&PM\F`UV(F MJ[2-J>\IT'R3G^I!')@3%L*X3QKC6T?ZJ`\:2;\_C8;`8OK#0>.S?^##9!"/ M@+$Y5LE8IC$^76;\IOU03OT+U MS>056X[#.#5J7CSD5*#XSBN5+.82IT8AJ;7`28U.JVICTK.G]&;=$6M!S2?* M43I_WA;X'5L\V<]HL\-;1_/HDA/O\WR9`E@O9S<%)3G?2HIU3A6G5L4\6Y(= M!3EDR;'1RYE-*FD"1&:((Y5-J+[/K66WJY3,EM<`-UT#'D*Q5O<-F8YQXMC' M\=9S()O04F0%M[0MQL:>+A#EC6""1KP88ZOAQ%&RBJUT3TP+\]4>\FPY-R*I M)*H37-`]3$GA1:DZ`L:R&\!'=<#?^]D;P@&?%[!Y"MBEV)("C=A:1$]5#P=J M'$[(-,!-P$[]*HSXVIVJ0DW+J]A]/827B(\4:=F#-:"*F&!]4'OBPSK1)PZR M?BDG5$G@:7:;EJDKV!TCR',0(/J&40+F$/-0C8=0,0@1Y=J2BJV)P@E0HO#6 MSQ;-Q-KL'`0KIR)".%&;+$,]3EV1H#(K[E()#0Q@IH@*K8O@A92*BPPU>[-8 MM.]CC)LC6[JXTKXIKR;![IA0J?=\&B@-273[6LM,[2`]L1^V*"%/&-,DJD[( M@1M'6I9GEC8L2:[G;]X6=:KT4:WJ(:V_8=T0![S&-XH4';7S[7BZ-GE M)RH9@;^>8MR1QZ5Q#_4UXCMZBU&2C;AP3CVM#<2QC\(A)@6(" MJPDH-,;2\0.:"JAL@%M1HCH"K&)CDSC(D2WIVICPX;XDZNQVB1XYBI3,ON25 MF[GA&2>OMSD;->%8/W4N.]&/9V<7)KX-9#`8OA+Y"U"3YUEG]Q&)IDC0&\^P MED[2@;K>6>F?^.09=)5,*+>R.B4R0'!P+W(^O"=R^(9<[*T$QF"]+:?3S./2 M?.LJ4R\MPY_!(Y'`:]@1)7UM_*Q$5S)E-B%`D75JW+Q=HE$\2;XXVU[#"1Z" MI6@Z__67OQQ4Y.HT^K%@-P3>V/4SKV!C>H4I=("ZE#3..ON97%W`J'/.A\C8 M=^B-TT&31>/X6WB*Q#>9ZCL<"DQQ3C;Z10K6R"VBI:1V*3-O*0S(&2]%G?D@ M/I%Q0>%O,LG#.%%JS6$WDWRUI6!#SD13"N=68,H7-CF);J!$'8%$4&5>P"FQ M#H$P(<>Q^[+7R][+^LT2*#IA/&2L7*`!SYC9$%T`;T:Q-5`Y)9#0%I71&XT; M*=0>8T;\NREI[*H`S$4V1.G"Q].#[RC?`"#N2\>K6+\`^,MIMT_(;VQ=I]%K MM'&86V!^.+F$`RAN0?&=](>G_>Y34+UAX2#`/N@^ZC?H109'A@WJ"-KDN3.( MOKV=LXE34!RK<-/BZ-E&X'#JVG#I66O*I!1R31'+U MWM$)@K+,-F5A'-EN\+JD1O!Z*>Z&8Q3%!U<7A+WA&Y=EP5WWV`!IJXZ$;\NP M$[U,,5S*8'=.%@F0Q+5209"NB"7]+I/(P6SM>J<-Q;'8K`GFKHN%4PM-WI2Y M;X]*/:]=K!:N`DMAKJ(BSN\J5Z+"_9*#_$)K3&)5E2W;(;;TR)F5?\VE,93+ ME!4`*;9TA-BUB7C$#",<<&8&=`1JQ4)$`1/X(<$4L,-%X&LWMR06$[!$1DLY M0,$@(VKIBQ+>;+)ZG81-B4MD`WY]QFK'2MP2`E)KP-F=K4_HU\(@,J`*J$:9 M[T9RQY@M!/X`3/^F=!\QZ3BZ;\V]+;3?`O]21(TJ^L0`./D.IO[N*4^,/.Z[ MYYKF##NZT@B7Z.0CLX+N,,`':HC^EIUTN,!3:1KEM'OH?!4![?8[=QP!1=*7CH64\\`9L,Y MS[+@B"S(767*SB1TF-V'-D""##B8&*=A`$)AB<_)QALOD1^2W3ILI_"LKW@G M2!V`>X27HA%8M2+N9!2/^^B(;/23.$F2<3SIH]?V7;9IO/LDTL-JS[`DZ^2.K,<%ES^0 MH)B6)$-\:FSC;#3*ZM#$0TGB=Q(<69^$FT>?ZL&;`4@XVY%OB&>5F2]D-3-9 M-#.-[IW59]NWX!8=\#IU\+Q.WJ0;75/OU$"26'68BGM?J"&M2-4NLU40L_DJKCS+JL4TB8E1@(R M_6';?">U]-$Z$8Z-8#1S7)ATC=?F.M+D9<:1#^O"+*,P#C,+'K\$OUMTN*Q7 M->>:?>B--1DL4D1'4@B$7#KZ"T'!/P$/)I60S^I9X$S.'%\?_7U''HG66B>- MEM]`C4:C23P&&@%_)4D\<8D@?#4>QPF0P2>&(.YO(XZ$-NX.!M2JX@G0RNF0 MVU;L%IB&QS?(-)_L@0_)24-MA M;--U'7%2C:0VXI4*D!22FIRM*'J69"BI]%9KH,1$!&&(TLVFGD^NK972IKBH MU[[X5DV62*C:WVBI3A:*EI9+Q_57BDQ_'U_>=J51?X%:>Z$>$GO3(HDS-9WA MK,NE5*^WCG1CLS[.$\\L@-L1'=*`J"%[#^+)=!(/Q\.P]'VLS.VW[ZIE2<=A ML24S:6I7#VXQJDSRT[BF<`,O:BS M9(@B:*#F;`TQ.Q&/ZX!,C_)K-K=25NW`6]/R8+>A'LAT(?N309P`CS_>9N7IX5K0Z$E_ M!)QX.B:86.K5])4%-#K%UT.X=65%PISI9M>F37!O*UF$B&=MR MM`46V4"7A=6]B3BB@=N4)C+!@%Q#S9.W]BBIE@Y\A;KJBCF/4EUM3\2`\JI- M#Z-7=0U,^AH:B<[T06Q1;(?Q`(T\TZZ5\YPVATI/3[2E89N&.XR321*/)],H MV.,[.E'DY@%J./$DLB2UN5LQ][(^QEK%$6IS#Z:%U0TF^S3G/CPVGO;C1^O. MZ%!B%AZL%K1;F4:,M"%R^PA;8;ND[+6;;&PXA@["+EX"I]OXKE9(QUZOW:Z0 MD^TMI-"L>X M)K_D:&N<)-40N,^D`M&&>]Y;(SWRR'S)GA:WP9CE?(9O"@BW&(#\'^J8Q6.P MG)4*9L\Y2@G1EK+L_DREAO]XDR_]^L=70*JS.S5!4^:;2[[MCC2T!Q7DM`+A M`>'.Z;5XTO*@HEJMO-%AA#>FH#[>""W^PFNJO,%Q12Y"X$]:,KS;BC>*4%&P.07'GUDPB\I)3NM(?2NR?G.4;8V1B!9?$!6AZOF+!_)+[%YZO:Q++;'->ME> MZ^%X4=1^_'0]U/M/V_DU3Z.5T)F&.'*(1"^8N&\_<_"X[H$2].#2?(PEKH@< M^C'"[(IM-&`N#6V,N7*I6$5FH*]E?N"]<%(_SX6RB`+\'C42KIFF=K5`B9"C MK$7D<546L.>,W0*46-L,Q2:7`3F:/WGD)1VP193S2V$!=0;-.YY@8^K0UMWG MQ@D)9\T&UOYC3BOK^0X93MNSR]A82]EJDXR?;`^B3'?8N]=/NP=@'4U'!]O5 M&T+]W[]E'":"V3;V!-Y'3??2MDO::G6& MG].O[<;FQ8@XIQ(FI;[S<>""1M<12.1K/G10:FFS2LB!3VDEF9AD+-0A>G"K MIJ!#H#T:K=S#48*:%-8-[\;)"*W:>%>&<6\\]7)8D[@[`OUD*BF8D]X@[H^F M_&$4]_L3&$Y26I-X`@-.*#.3O%7[SCI$ANE(W>K+5$JA5GR,J.-RN:TVVM$, M;[AVVPDT-\5R&2+N-_N:.D(`UR\\&!L<+O^V*#-4A&(VW[ABC%E8Z)]J`U`C8_+BC56@9,+=!S8-OGV,+=2ZV MSPI#D&9<`]-)W(=K2Z4B3B;#03P=3)XVBEL%^`Z31P_,7[6O@\CQ8=M*@/A,XLE(^AZ< M].*D.XU'D^2@C?E[.JMTMP-/.C816J8DB5_*UE%O'*^IL^PJLA5!]B^#E7VE MBJ;I1ZVXEFOB$27`-5BH.!F\5>MY+1C'BC557;0@'YXSO`W(\2OJVUI_T@+0 MUN:UA%3[!9`"&M!=FS%S;66X9"*:X[B-O*- MG:(*!]AAF\YWY.ZSW6KJ#[XI4C1"T&.Q]+/%5;^GF>U[U3>(O.L_:RQ'ZCJ@ MN^>G[9*<(XDOXE/_A+3F7.0CK\?9:FBXXQ@Q1Q'[AL(K*M]8=W*D&!Q'D3;; M-5678*Z/W42*DLH6:WX>;N>*['^V-LTF&GU/]14P@6@EV0R+S<,IQ'D M"\WHDBJ[MC&S5^W&%!?@)C>`L@^G:&KDH6(G"-VFN?6E,N.&]2K'Z33N!(!= MTZ<\ASI.I2`U&9.N,[+A(^HYQ0D3$-J2(:E]G*Z=M0.U4JBN3\WF$;HF;]GH MH$V(^4!*!@'H%*XGJ.?(T`9,AKTJ%UJZ0XX60<#XQ-YS>6"OB*OK;QJ,044:]E!W`F$#/3$M?7M`.H'!I\DX&H$F-1WU0DTS M1I-)/!CWHB&H5<-1-^K'@PF(,(,I8,1@@`ZG$4;:ASO9G$Q`X>HGJ&&=]+M# M>`W]1J#2#7OP]0"&Z/4'\6"8:/5ZM]_)=-B-)U-D:$]@UE$WB9/>F/QI^I+7 M`$DM46B>>)(,QR!1*B[U$Y2YOE%US?9)AZ!1)GVIC#;HQ>/N^!M5UPQ`QW>0 M:$ZTVY2&ZP7M#,^)G2+LZH.A)/F3=&`IMLU^2,HVG,U!WTRU'S)HG::?LV&N)U;],,;,ANRZ8 MB+_G!B7Z*]JW.9#)R-1UGF]J6WQ;HL[,=W('NF6SOA=@$$YK.= M`F8]6UY1@=X#9M4(-C=NIPT0^#(^_U-65ME#@Q?.I,NH$VO!2N!PTN<:@;:" MX+#+$8CWJ=^])^51TOF=M@T,-&KU0D_V!W,%HIGJ`6,4[P47M-N(]]*M'QSM M%0!?K>+T5T1JN81@9ZR6]BIKB;M[9-@6GM81@5GL@*>H=&W_F M!$LTC]H8"YKPXB!^.C@;,118O.`,JJU.VC4'8*:?T>I((K"3^1LHD!R++>"+ MN(:-JW+'VBD3]\_4`:K8?9K-^!(M);-*V?,4"("@ZTA-6V^)0Y+/V'&7^XYX MSE^>!^2SUJZ9/Y9H_#G7P@+<_<.3D,Y<0P3:KLW#/Y.9XR!:"=3^AN$Q4EW3-_VT;\UP<2;=-<6 MG8BGZ0#$QU%?(IZ:5A4*5P+9=3(8^V#UY+(>B*Z]J0AFNJ!O(PQ^9*,:E;P) M.T8?)P!V3/VS>?NP1J%R++XBCNP08%Q9&Q2%UP`'K]*2J7\?5R MX>B9/PVF$[[*KDHVL(U#V)\F1]C"G$L25HOAJM<9NJ8KZ;O>,!VP'9M!<[O<.F-@=VNR#L`J+7RM=*`L MKL72A:_7SV=L@Y)RQF+I?2:Y95X-%)!4TW7M0*6E>$YJL;-=J91)]AT)_5BI MBX<23]^F((^`FKD/2T;=WQA)R'#X#;'DXT^7YP=@P^`(;.!"WFW8`&*"I9:[ ML"'\OA@O98B1 M@8JR1#E@"6K3Z_7L^"N\X[:AN('&'S*)3C7F^V]ZX9+]-Z[W6Q\JUDIKG&G] M>,[*LKB_P>I/'_")QY'7'6?CIBVXEM8*]"[J=H^>:*G_)MD3\RT%\)DV1E9[ MI.&1+-RDRX7Q`[9!78A;>S>PU_>B]QPBOOR]":6D8>S`GS_^RW.;[Q_OIS_#Q].? MOR+JO)]M"F*9Q^&-=2JX-&<8TH!::$X=98;_D"2'K5?M2'.^Q(2QBQ0F_!D. M!/.-#D"=Q[`N`N+@KX@Y`#-%'G-V3WI)@%VU(L_019[^^(!7_5V^]X(P=HK# M_=\8=U"MJ(G!)/PBE2P.,C1TCV8V?IC((!QT)'M',1C% MT^%O?XT;-Y%.X\>RV-[^1I>OU_VM;U_K1>H9A>QR=4@S0YJ'^,S4@ MPH"/A@,K/[L@<@&#J]LZ]^%5>LQ+`__ M]Z01XV-A9X%UMJP*K6O2Z(V-_8SJ M!82H#/&]=N82[/%`[*3.,$!A"]-=Z*@Q3#/0H:\RYXBT\Z^%I1N$6/]V0FB] M-N\[Y9@FG5XRM#C=D49D[Z7KS>OUD1$%IA,\0@&>2WJ]>#3JUOIJ82TLN+'% M@_;[U9Q'#)G57S0]D#*,`*)7V@YJKNV@M`"6NZM:A0.XL_T>AME-.Z.D)?^] MED[AH+')X<'YL845ZOTV(;BU3Q7"&\,<3&,'JM%42,NK)08L.T%B6G81QA$0UT*WR8!QU>R-.R/;03?=(H,`6>%?]<`!#%).QA M#E&FYFPSZMW(59)W(59!F0V(,:,U2<3#Z^$56^RK$@B2DZ M18W^D&'#,$U02-TJ$X63K1EA!<0@)V\P!I\BF8C':E$-:CETOY8GJ$&UW8V4 M2]"49FSJ9PL6,1U7*@\'YK6.UOZD\CA>;3H>[!"FUU!;%5`X%+4.<\>66#+3 MF9",[0NG@J4T]-GL7F)C9=2RZF-)IP=*5_>4BL%P*\/9MKSCNJ]<(B)0E";0 ML?(F=5KH-F\K%2JK@6M^7*R>R8^.G0:#-A/3J;[R[(@^N2\5:O;$0<#['G@E M>FT&??QK,/K>/J>-'RN0+]89_\?\2"=X0A$Z3Z-A!R.HQ_HO_/>#?Y"]SFB$ MX_Z&L+%7IE86RY,S`!R& M3YK>N2:<_ M!""IV(9-?,\YX!0^G?3B21_S!_J=P;2^BL"Q:1?8)Z#>CJ:\FAXLHZLSL$(8 M?+?70[6/$LT[DQYM89+`\@8"U@U@)/;_;2>'G@#G)LEP'%K<[X_BP7`0GI^S M@S>/B$GC>0.M%-UH,7]QO*!D&H^[@UALX8,N?.K50]P>M:C!XQ.H!%3I)W4XB3APK)BKLV[J0?MMGZDD"NCV(^D[6;*U$E^H88L"A MT&3A#=J&_(/M)LY%?GK67.\,Q8D+EG;VTMX1B-L4SYTQY$I M>!QE*!/2(67P!1-03HK)'-JSG\*,QEV:[S>]K`UX<593(E6!Q?$YA(6,_JKW M-;PN4*%[&NWUI(^6\0,N[=%3R7GNN;ZC/I4]_L>_JSTLZ3UXW&4543YH-9Q0 MXA;%ZG],OV2!G"W][:N"5@"U^_&C/`!=4BJ3Z!2V0G M@*EQD'XAR80GZX0-RE,XN@\RZD6*^:0?G=RD^BOM3QYE99X^VS&G)^5[:714 M6FNY4:/",KOV<^I(AU/`N9J:VDR\VEW2G=?Z%=1DX]3O(*7)*8^K`PBK:7H* M.I*=(6$J6/FR-`-?9>MLD3N5_[W%4;I.S2C==3+A!V/N\?%ML@R^Y3*3:=\N M<_0URZQGJ0:QI]=%<1X-R%IV;SV7?KC7V1H+?M1?V_GP49C;ZS[;/;76!`,< M?>2.JW+"Q_4U`(5VW9O@AGNF/D/$S0#NLB;`?'MT M+Q[T$P(6".-)K]\1?QM1YJ]*K!$I8=#%.F$]O@3CX2@>C1L2R[>:NJ(5VNM5V%4E/8@*PA52]LXBX+`?HLDQ&XK*,AY@XE4S9 M:0D?`8Y83HW\'#U*JQI/>YSA`THX*'T]^/6CS?&9@!(&=&)$74`PN0<$S^$H M>@.(<1)PC-?,M,.86?(O]6LC*N]#+-=DW%(Q6V=J,D&B?;G>(S:=WV'6LM.2 MSV,9&HIA$UZP3LO_P]F7"$` M*?'4&0PMXN6FXF>9$%R5Y'LA+QQ;)V.WB`D`8#O'0G[7R_P:+P_\8/*D)8/8 M#H%[IQZB)!??9>N4Q2&L[HA&0LQ"64M5V7D&&UA?`UC+8GV-U;H5CIHZ$VB? M0:__^LM?S#LD?6^(P&%S7=>KNEV3*X!ZAK*89FS+$MJ-A[I=TVJ<<7B)9G)\ M=6L*W!@H1^FR0E$F^XSK21MU\;$G-1F;(Z@OP\D,["YG)2!-.]*^G]3=#3__[V55%U*LA.SY7YYI]+>;W'J)_EW]WB)[F]0N'YHFP M9`N+!@LY&CJISI^#2T##='BHDHP"1*`3G0"5,=_![7[*AT%I\@5Z.[DH#.8. MY_,G()%WPU`ZN-@RA@O2$A8K_CO[0_.24<:UI[K17? MYD92@O*5<67*VK*Y%M`(C>470CVHF+($&01J\*)FQ6K>C0()?G!O8D.7P M'4)+;71L=E.S/%4F]*QMCP[1M>5'11P4&67FPCUPN"M8Y0U<\;^ M^V^P9(FIHJV%Y>SO_'7)9UAA$,I7%C%OVHK2C42*.&7:#]Y.BP4Z-&;M1%!] M>Y$M4RIZI\(SW9=[4K+)UEAHMK*$"G:!4J,USH1)6S5!"M\0L`"#270PA"-F MG!;= M7K:Q5XULX7TC1YV&/IVAG#<3C=+=$>J'H=&I*\BU!.&(]OLJFU/)-2Y%>V[" M36FY=T"50614PSF+Q]P7X*,7X]&HW4],W@0WF`6L+8@D)CVHCQ"&2W^BUCIZ M7WD/GH6J[S?#4UXY)\:[>.8$J=B_SFV?^#4>HU/D(_L.6S"#^M[\]'C.PY5^=VQBSJ&[<%9`%K1MIR\?U M)@D=DOZ[1S+Y&:XK7=W7FO[Q$D1C*M-Z,#]K&0,5O;,U.J8P77$VFA<#!EEPPW6$JI7.:."Z$"] M`2.J#=V5D_0ICUK<9Q3SS6'F(MNY;C:>@"TVU-G%"E$H8G,?)]G?[X!2PK:+ M%;`)UY>-5/+DBF[T8E(<<5> M9=H$CM@X&WTRO71%>9URW`7O@YDWR%D4OP$O+C+B\.0Z,%(7,=V+T62Z+BED7#$Z\?SJ+ M&LI<$"EX`WUS8;\/5/5.>U/E7(+/YLS@,ME-5IFH;=(>_0XL#NZE@L[[[Z1! MZ[.*W"&Q^XPQ^N$*HZ9;A]5-JADNV8Y&UFYFFR8<(3$$I6!S2@'6 MF!J#5<@1PHTIL.Q,X\R.K%9_#&([08G?!/WKXSF?:5<<\T+(R48UWVL0\`\1 MR\*6+R:9T[WE[U*)!'A+D=L4K;!=SQVKG3.!-@5%0[^@QEVQ!'Q`#F=TV//B M]/UM;3PXIW,I\RJ+(:;B#BZ+:UM0KA=24U[JM9-)SS1ZGA-&\D(M<5+S;@&? MB1.8%9-:I_.NS+S$U]%9O"&--V2``UE9'1L8W1]'YWS'^<,QYAIG*#;+V8%@ M6S4ONG>!KSG74JA+OL=M3WU4';#[W<6-"XBMTV7QD"XWVK1'4FH=,RFW%_+O MH$=_1-HSJR,&J09D(9@U(HA6;R<#/JLC28GIK)D.B,DQ2A0;%SFFLDS^;JW! M=CCZG@PH;D"PDK?2-+.I.=.DKI7QA6GSF4I#$NSX()]@R`'^L(YZW>^5H@4F MX?+8TJRIT53^ZZUO]19`9[H$V[3G&&P-O&Z'='9EW5W:1@K#'T@"=P^%BTMS MOJ)3>8(B+!@#'[C6-B%-V_4,IWB[DD(DED-.7"RV5QN,%S#'X:5(,7K=H[.( MKTT#&4VGK+N<3%DLT^O]H204[9U5>7("5MO.[L56Q[X:OG_*A5EJ0QU-*]^G M()&`\NVEO\ZQB/;&B9>1?GVL(_'J["!Y5>]>?47JJI-D&5Y\RK37$54-G"28 M8A9A1M2&E#\3+>$DT[D:GTNWT#G[645R[6\A'G5IW4%"H"U(4.6QA'D8S2CBGP'Z.%9M@ MS\MZJ%A3+.#R[A\XWIWM*I>BI,2.1;4ZY/Z^T*KQEE^>%]BFQOS@1(_0#_8F MN[4"C/G4J6G2K!*@^<^I:X85E5GN[!R5;ZT=;YH.:$W[O'+B_)V\'>MW-4FF M:,\3*UZJ@2]'=0DZSH]V3"\@W"XI3Y0HAV"MM9K)G11*F^*(,0QHW#A=$@<@ M&X'-<;!X#6(1HAF6IZFL2B/M3M::`]'2*(C,`J9D^Z&3DTS.MG?\R'&,G,7: MNCJ;F\H5WK'."\6/&(,0H%J:E[PF;=B'I1(D1)-;-%-#Q']B"P^&<&;WZ5)H M57U?L_0VWV#;>'3W_1'1+(?+33`R#?Z*LGY0TC2C!%939G-M%,&B$G4R)@QN M:XN$0Y09QTE96N1Z$TEP0UJ/VB9ZW]Q^J/E:TP0"_7:R$J743P`*;>9T#,Z: M!E`OC#77XY8&6)68]6H-HZ2M5;4Q\<$.?(58$$4@&UA.[,X(F`CO,L](73`# M;Z7/M>HK2#5KX0.-_JNEV/>,5<@+$^@(-5,\L049;$`>W,1KOBCNQCR2Y&`: M1H42>GK]+6^HC4DZN\G8..B.1./';"-4%0,3[DNVB%74:D^K>$@4U8S[G&.< M60UQJ:Q4LT449\+3551HYE5-M=:J0'*WTKFFP%<2M\6W$_4SF4YZ8W#8-U%6 MOZ8!*NO.''#C*;'=%[LHP,[%)N4C-N=#I8?M[36*IU)Z9GV#E,!89*F`4%Y) MO8HE2Q!T1'-*CZZTU`!&;)!:Z)2P$U:4*^5KR8M&&`ZKB"D`^B@OQ^#"F9,\T>]VZ'?M*G>$$J/I%;7Q2`3DD31*]3% M5D,TZ!G+2TX;S8@-$"7!/TU4D3S*7Z)8 MK>&]>0D"!Q)>DOJ-(F;QP0%FP$3F;EPE<"S+!30-%)7[M1!<6F$@X.RU73IP MD!=Y=5N`;(^G]@;VS\3$H-3AB-1XV;OSK"UCL862P'RZY')H_"2Q,KLL7#]V M]XOPNG&(!W>E8S"ZX-,HP,RZ7F;:ILDFZ1I!U81@2](Q%8'TJ=.R*#Y7#M5# MH=5>U+766\-38DW=B8H4!["M3X23PV[8XE;2S,W=V]`R7ZQE:A*-=[^8$RZ[68B M3!6RWKU%)D&\E`7((B@?JZ:PV9$6F?:CX]Q@H@O)]WAX3DOFH8\5529U^RJ1 M6MY,N";] MNFH"6-5P`J21X%0?8UD)X*31C<8U/K-V'A,X:5-=[<8]5Y*%CR?D'0"6G?[+ M&HB:YG?1'N`^N0AYC`$_X/0`D7/EU6^E"^LBM.\T87KF'H`M\)27%+2W%#G> M0_.:F&2SZE*6+.8Y)3HZ[NBZH[P=+8F+*0ZSS9(T-J>,(T=$VM0JHZ[AEC#W MC/-85?2IS_4;GRV9/(ZA2,8(]@'IL$?A62?R4H15F:IG$-LP6QN=QO9K+SQ- M3L(Z57@.E221ZVA\-66JWM"V'[3G/.:N5H`5HK-Q'A5&K[HWVGW14'D*+$75 M=;O,9"2E:Y6OC)S6E1&2@)UB9;3D3HUK(W,!DL<)?XY1QMI'R2WK-+!SS"C49CZXR+6VET'+W^:"AT+D'CBH?41]PHGSPFAPL#6Y!R>KN1]5BSM#4O MOT+WS0'@]-\(U&QY7#T1)Q^WQRG:_:X#>+>[LS7"QRP9DK!$7@-*V>5RD!(7 M86+6G.+7>>G:L$.1QQ3]%#*5B_E4,EYA.8]V!;9P=RP"-G6J6$S&_('T9\$@ M'P12ILLI*=&?3./QL,OYP:3`N&]H]D5&-D#35U:O>0"#!-M?&&Q_19AYS!4, M#M&"JTQ8WEK3X9'3A5,1=@TN5=OE+,Y5QFRLSU[O(_:N+S65M8^FJHM4Z#G# M/#J]_L<"N3E<6A]NIUIPSJCRE6!NC.C16K*W^0+L3`S!QBS(<0Y%Y8LA?[ZG->.=.Q@S=IB.Q;<%S.+4:K<5.G:4;M2JH'$++\F0/7[6H]3DW&D'' M>HEQV2V;]C.=Q>"!SZ/H3JV,9YIDAI?1V:Y)X$.KG"2F7V6F?E9A"MKC)^,V M;EE&6CKF&GP7GMHLZYN0!Z4H@.&5CB<*!7,.1S`^[_0NS9?LDBA0YJ?D8K-/ MK];7SZ;[N"O\EKXJ2%OQTG4ETFD>`+=$:XFAJE'`4MV=K5?&E#3;/%AOHX#B MR@H,1OC`#N]:B*JTY7*0L:7KE@)IH$5@;,9"/#@@RJ.D]3FCL-1T+>'R:E%W M7]3N(!4HKQR52FZH[$MJJH&(C@FO$=FU26.Q'\>SR68W'-)-]0JL-5KFJFG. M7-"ZJF_:;XO@XDBN5;\/3]5FOP!6JTGMEKU%+]'K76T,R`E*%%_N!Y5AC6*" M:'Z#Y50HS8$#\\1M2`!JG7@Y5V']EM4*YS5+^/4& MB94P>UI!RQ=%R2**E.%)?^2(H]W0LY;\P)$Y(8R-G`VGTB!M\]=?_L)AC@X5 MPZU.[>SK*HJD(QKC+H/JM`:)8.+C<7L:A0GH!@[ M,;:IVH@]J[WS"/G-[><=M4;]T2(/L;3/&"4"4GE%MZ49(G459 M+%?IU1AU>#HYW?.T!)7C44KRJ^&0=3'A95JB3Z^*+N#@J*SL5TN:E#&-S.^< M*Q?2J!&6_IAQO,8MU4OAJH8WXLTUX3M7#UPHW!0XU]1K(5OW4G7[5&O$.UFL MSIA^B>E&ZB`PL7Q)\QVTHFM8$4J`7/8*/5*8$E]@$P`.%9CC:(@R_AIL;PP` MC[`B:?<*3H<2^LB)EB>U M+T6@)X4)6:YJ8]*SI_1F/8;$GBPC$(="_GE;X'=N:,\EQ MJ\.XE97DM3O5[9H.$'&_>`@O87#U6N4B]UC?])X@W(8(](FS?%YJUZ)CK"SU M=R6Q(;M-R]05>H]1-4.0D"MJH`E1P#[8KCRK2.E)>W(%YXM'J8Q:+' M#F.2';G;1;OV37FUEW8G'L1>HS4/*8GC,"#AL1U4+/;#S"6D%&-&;2NQ1KA) MS!43;7Z(:V5S@POF;=D'2FK5LQ6RB#0L/Q6O1./11<.(VY32N+F3P#2Q&VTD M94QWA(^1IN?'O>$I:87E1I&D[-XK?%@6ZV*KT;#'N420Y[>/A?SE;?K@J/>O MSBZ?:_O&L\M/5'(+?SWM3C')54R&[,C@P$G)4#[7!#@3_*BW,S5U*S:.6D,99.Q`'%DRQ86^*ZM,C3"W1JDX%/8GN0<^K:F#;COB1: M^':)OGN*<#==LG4IKD'X>INS(1G0A;IF_7AV=F'BDD$JA>$KD4@!Y7D>+-U- MPCKRG,8S;!DA`<9O>SSQ.0@VIA'FHMQ8B1<0,MR+G`_OB4)+0M%!K83+W"9; MUK"9L*W%7ZI,XT$8_@P>R0A9%]P;.-_X)0U<69TYF0!%UJE)7W:)1MDG$4A: M,1^`I>CT^/67OW@5.6'25V;@2[OWT^C'@AU(2`G6SYQ24$(KZ;#:=S.Q24KN4F;<4!N2, MEZ)A0]@PC/I<"/Q-S9DP3I#)`&'KUIQ9;2F4FQ._E7*ZE3#SA4W9I1LHL9<@ MM%29ERA`+,GI!WKTONSULO>R?K,$BDXP(QF(J>BY[3+-_=I'L34*.J4H-Z9, M>N-&"A?!<#?_;DK!&]51YB*^HM3BX^G!=Y1O`#"-I>/1KU\`_.6TVR?D-_;% MT^@U6GW,+3`_G%S"`12W^2R:](>G_>[39]$E%>=>/.@^ZC?H109']KK"ZLXS MR1(TB+Z]G;-965!\CL_F^FPCX2-U[>;TK#4?4[$939S.U:_FUK<@;)!TF;F) M[C$AC2VQNU9B\*;#0AM8?M98S.WD9#%@_MWAW;O(3J36%;H6R$?\.6MSJ?!B MT=13C3I!4);9IBQ,$(F;="0IBO`C-4;]GG4!VQN^<5D6.0:/B='7UD`+ MWY8A5M'&2$^#W3G9:%880#YO=WE2M1X7XIO.-"DE]3K/&V95/)EAXYLW*UN32& M88QF)VE[P3 M*V&5K@U+(QH0)TAIZ(126^)QLO/$2^7[9T55LZEH$ MW0E2!^`>X:5H!#7N"6?J$#*2[5)+/INQ;[FS".N4,(`Q/M%L@I!BJ0M@C`M@ MLI(>NS8FA^O",B;;54:/Z52->\8(H=]DXK?LP,A9]!UGJ?WZRW^>.8ELW]'] MH^`)M^ZX-><>>I6PPU19*U)Z&/S#O;=`S`P68*:X0'()D1%E;U.'C^A$:K9T M>$?%^_G'AF-"XM9)Q1-;$6>DV=9AY)HZUNO[W]5Z_[M:[S]0M=X#B_5VI5AO M-UBLU[U,H4`*ZSO6:(-O>+G^.Q#@'S,08!<2G0&%-_N]-/N-7GK>?M:2C)VA MB7F_+0W_!_'PLTB@1$N#PMIXYBN;:6B;8-%I?]S.*HP+D'Y8T;^_I5O5=/F[ MQ*`L"XQ_*LO,Z<#'KMBF#O#HXVJVLSQSG'+T]QWQVM;B5*CD:3 M>-S%[H8C;+,,?YDR!?`5W(L$4!O^ZF/SX($=6YT`H3&3N`N7;$BC]N+I<$Q_ M[P+A!VOP>FVU&,ER-WP(P?K&<5V=2:O.QT*TI0`5;&`ZCD?`/9HU.S3#QP!) M`[\=Y]$D^$DGL)D MK>OLQ8?M"+7M4GQCZ6HZG=`]S-7A(GPVG++H`E8$O?:=<> M_XI0D5)D%1-.>C!NO]MKW<4H-3O(5XMX>C!!$%:^=UXV2$=QE/?QCWQE-/)L`^L`#^ MJ;"T26\0]T=3_@#R0'\"PXF(`'0"!IP@IPO2810>6VJ^M5'DG;7F'GUF/L0\ M`OJ>_#U`(;H]0?Q8)@HP71+7TV'7;@V**H_@5E'(.DE(+4\<5X*'N$0G2.-&D9M MI^>2\N9;"&-#:QY[E*T%)W\L$8'/U:W!91,\8)YQ//PS!6^7N0(H9A,1S%J"_!W%Z@UJ)X$VPF0PGYBG/ZU>D5]^'D,A]+KHB2> M1`DPB1Y0:F!44_I;\"K27=,W_:I M83'RGG37%AT^@/V0^W#-F0\TXS2(B`.:3P;CG?S<+9L5JJ,D#9Z]DWDI(8Z/ MQ1#I_]Q+IL"0>]S_>=B;`/:/N/MS'\CAJ#_@WL]PGXB14^=G_?#1]GT>X;T9 M*B1<:`;ORPBM/&2)N4@?:/V'W)6W7%I?NA*\,6$XY$[[2C@DV`>;-PC['P/- M'G89#CU.!3%;`YB`<-X4T&AC8]C82^Z[<UL\&L`F\<+HWD5#5F?1H"Y,$ MEMWVB$EJ*A.PXK_A)L M?BVG."$"(X,O&+/9CIDY1[C_H$8@A?4#`C];UM$00!6=-S98BP./KK/U3J.Y MQZN8%[T%EK7:KJB8#9#%"XW*1T'^O4EN?<,:U%?2Y@'2YF0DM#D>(M=-IDR= MX6.O3R(\\:D>\>3QM,><"BX#R`QH`'=X%WN[ ME,JIK@\`8/`.>_I@#2RTF$R< M^<@(0]M'#(?I(X`NL^`$$4E8SN#%(-AV]-?:?'6R,!7Y*\T[;D8GYP?XV@?IIF[O2ETBDC7A^^CCH"= M1?A"\!(.V\^Y]!V0]!\)P*7"V.[R7TNABX/KS<.*2)-!.TD%$M6UU!F++M1( MA6T+./?7J(7CD`ATM3[+"(UWOZUKLTYKZK/U/-&N\6NR\^>?TG5' M.=BP01.SVXYA-RWTS7UFT/(,L$HS2=LSE_D7>[`.C8O^;ZC/B/NS42.;G71: M*:45V*RU^Y#&/$`U\+OTNH%-PU&GV_V^_JWR36>Y%GL_L.;:ML8]'08^<0[% MFWS16,N(8_'V+:;^>S_\6K,R4K,HU[FI]/<)L^\N4]^MWECAV_3+H^$R;ME= M;QTVP3]F9?@\T(3?`*7K%V4>2M539U*E:#%L;$)S[[:<5&2T#UY+67L M[!1G6N@,Z%ZY:E"U;AB6@7L=O5'W]D=3OVU/!3HIR7%>+Z[6&-,,B6K*WPPBKMOB>&N*<^[-4\^F6RRC^D7 M8/TFFTQ.HI%KN7:"X/&5YU)A)HYLL2M8H%NTQ,3OPTTOM\T[8(26P!VT4DB[ M?C,7-;R5_NX/OZF_TA:$TX!W:RQ.FM(1NE%I&RS."Q$@#L]5MMC_*Y$@E\[#7 MU?FNJF,<_8@?K6`0BQ.M<>GA+O]4Y`#?#Q_.,=[EUA5N`7&BL_5UMB19>8L% MTXY13:RN3RAI]:3C5G&PB"T>JF780]6J]N]T;.W46':O^T@Y>\=@AR%!,#;" M)C!C=!I#()-0>>?&1"^H4@7G[G_5=(8D@X!`A.?Q\^ZSZ9!8\!]I>.;2[>LYL]V9L!>+QA$$[DMC#"#BOE6(#5IU MHY@3D]8T9NA\*%6US._XJK\1^3*&M\92N=Q>V#;6Y$=>>QO_;#_:-M]*>\EI MD"YS0,MUSA]=G$/.N8]L[Z([\-L^H\3?X8KW&!K^SE;\][&\(TGXWV"1A]U/ M=U0M91V\:99:O=A#('8Z).PP^RF-4^9^WV#N6Z%1VPD\IO%)MH4H20?-TK)Z MRBGZ%\S*?8X9;=9"(R70'Y`=`)RQV,GA'H'#CM+)1@Q$(LS;(T]-6+7UOI!!$`X/-K%@UTJ2RN6 M>"')P97T3:R4:A<"T5%K[+6N\?7A@[0-T2,7Q/[- MFZD^`'[7'Q^$;-`^QQ7)I6T9`RF\@9EYV-.IX0P,S=!#"1"[+H"[YY"E+4T4WF!C0"E8;"AE<07"^0,#^/C?`V?:Z8RK?M%Q2?F9W/!&) M*/O<"5MT.>R>BY_I[WP&]$M8SV3_,]W=KHNSVW+OFM^F\$RR;STXSNB`9W:/ M\RJ[ZF"LZ\YG;-,>--E^*#8WH%8MN69A5H(4CU3OS9OS'2&K6-1M76W*+?.! M5UC=)7S#'-NMT@'?J"P79^\"<1!:H0,<'L4H&TC^?TRORCQ; M(@E:`MT'C;?=DU-;C1GGK"R+^QLL7_ M9=9C!C/L3(9T*2ALK..R8R5&[U"DHDI;$@G_K>=JGE$R_!98A#P=<2;Z>%_L M6>NKO*PP3RKTS'1H<"X]`),"W0P/M;SK'GW3_^RW/' MKM>&"C#>^]FFH+R(XY#AX/%MHL(.!M^@C9S&P^=;3['L?"0_B)4C!+K'Y!D2B;>B#7@-Q"EAYS64(/0=(+%$Y M,6DV]$2SIQ"-,7;2$)V".>/[(DQE@UI?4$,J7XC5J32]L MB\VT8552(;0]/_%=H7%;G,X7^Q.@-PJO(07AN3%$%[9#F1,F7%^(!(Q'R7`8 MM+-=CE10YH,`8 M`QHTI/S&T'<1N94?OL(6)E(%P\G"IVPN_E/SLEMY:R"?OJ%;!(/G!\%(]V!F M?4.8--;Y)$@U_+3[IL(\&C7FI63\QCS=X,*#_H;QGC51SG^#_&'J?RL(3.6! MP&(#"K5?0*`Q5?`E@PD^:VZD`3^E`C(_M,0`[\T;WQ'A>]"[\V*Y1.":^GM' M#U-_?AK.KI&OHW$_>(AM50H.6Z-3L*`='OY#1V\\D$1_./!;7MZ_B/UE$W;% M>!_T\C=81/V%B5[9P:C=R8>7H\ET0_?CX$AX+^ET;U1]L,#"OBR`"7DHG*;P M1Z@\3GZ-,;U+]DUXLBEMGIT+%RFZSRBJ,YVUQ->W3TTL$-V*<&KM@7,M,VG< M.O$OY_O@F@\I'K$W+7EW7C+;^<=AW*N5E(A-PN$'=G*&4ZHPF)DS[&MM$U#V MJ!6I8,&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"%`,4````"`"D:W!'F*O7L7(#```2#0``$``````````````` M@`$2!0``9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`*1K<$<)%%E97)PC$`8``)PG```3``````````````"``1\*``!X;"]T M:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`I&MP1YW1R6]'`@``X`D```T` M`````````````(`!8!```'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L!`A0#%`````@`I&MP1_:`K+)L`@``X@@``!@``````````````(`!JA<` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`I&MP M1\A1%ERH!0``B1H``!@``````````````(`!`2(``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`I&MP1[IB8FNA`0``L0,``!@` M`````````````(`!/2\``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`I&MP1\'ULY6C`0``L0,``!D``````````````(`!R#0` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MI&MP1VU$K'BC`0``L0,``!D``````````````(`!5CH``'AL+W=O&PO=V]R:W-H965T1TY]TI`$``+$#```9``````````````"``0H^``!X;"]W M;W)K&UL4$L!`A0#%`````@`I&MP1_Z6;FBE`0`` ML0,``!D``````````````(`!Y3\``'AL+W=O&PO=V]R:W-H965T@O`$``'L$```9``````````````"``0Y%``!X;"]W;W)K&UL4$L!`A0#%`````@`I&MP1W_HDXO"`0``O`0``!D````````` M`````(`!`4<``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`I&MP1Z"-Y;NE`0``L0,``!D``````````````(`!N4P``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`I&MP M1Z'&G+J?`@``:@D``!D``````````````(`!85(``'AL+W=O&PO=V]R:W-H965T5EP,``&(2```9``````````````"``6U9``!X;"]W;W)K M&UL4$L!`A0#%`````@`I&MP1P5/IEQA`@``U@<` M`!D``````````````(`!.UT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`I&MP1[OOG*=C`P``5@\``!D````````````` M`(`!AV<``'AL+W=O&PO=V]R:W-H965T M7P7(_*P(``!\&```9```` M``````````"``31M``!X;"]W;W)K&UL4$L!`A0# M%`````@`I&MP1SI)?+:5`@``+PH``!D``````````````(`!EF\``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`I&MP1T;* M^]!8`@``R@<``!D``````````````(`!-W<``'AL+W=O0``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`I&MP1PW=2_63!0``5B,``!D` M`````````````(`!JWX``'AL+W=O&PO M=V]R:W-H965T?$I$`4@,` M`+0.```9``````````````"``62&``!X;"]W;W)K&UL4$L!`A0#%`````@`I6MP1R4`'X%8`@``V0@``!D``````````````(`! M[8D``'AL+W=O&PO=V]R:W-H965T,@N7&UL4$L!`A0#%``` M``@`I6MP1X'/6DCP`0``-`4``!D``````````````(`!4I$``'AL+W=O&PO=V]R:W-H965T5``!X M;"]W;W)K&UL4$L!`A0#%`````@`I6MP1T_:"KCK M`0``4P4``!D``````````````(`!@9@``'AL+W=O&PO00! #```` ` end XML 14 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 8 - Income Taxes (Details Textual) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Income Tax Expense (Benefit) $ 6,148 $ (163,051) $ 6,148 $ (284,574)

    XML 15 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Supplemental Pro Forma Information (Details) - The Joint RRC Corp [Member] - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Revenues, net $ 4,159,975 $ 2,668,562 $ 11,030,264 $ 7,465,179
    Net loss $ (2,064,297) $ (814,369) $ (6,338,663) $ (2,811,855)
    XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Supplemental Disclosure of Non-cash Activity (Details Textual) - USD ($)
    9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Dec. 31, 2014
    Franchise Fees [Member]      
    Deferred Revenue $ 976,500    
    License Fees [Member]      
    Deferred Revenue 914,000    
    Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment 1,539,321    
    Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill 1,531,041    
    Goodwill, Acquired During Period 2,312,259    
    Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Favorable Leases 17,469    
    Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue 117,301    
    Payments to Acquire Businesses, Net of Cash Acquired 4,652,525  
    Business Combination, Consideration Transferred, Liabilities Incurred 744,350    
    Deferred Franchise Costs Netted Against Aggregate Purchase Price 478,200    
    Deposit Assets     $ 507,500
    Intangible Assets Reclassified from Deposits $ 507,500    
    XML 18 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Equity (Details Textual) - USD ($)
    3 Months Ended 9 Months Ended
    Nov. 14, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    IPO [Member]          
    Stock Issued During Period, Shares, New Issues 3,000,000        
    Share Price $ 6.50        
    Proceeds from Issuance Initial Public Offering $ 17,065,000        
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 450,000        
    Proceeds from Stock Options Exercised $ 2,710,000        
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights 90,000        
    Class of Warrant or Right, Exercise Price of Warrants or Rights $ 8.125        
    Minimum [Member]          
    Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Exercise Price       $ 6.31  
    Maximum [Member]          
    Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Exercise Price       $ 9.62  
    Employee Stock Option [Member]          
    Allocated Share-based Compensation Expense   $ 129,704 $ 7,440 $ 240,701 $ 15,538
    Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition       2 years 255 days  
    Performance Shares [Member]          
    Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition   23,031      
    Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition   122,841      
    Restricted Stock [Member]          
    Allocated Share-based Compensation Expense   226,875 $ 10,115 $ 405,376 $ 32,508
    Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition       2 years 255 days  
    Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options   663,525   $ 663,525  
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       211,660  
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value   1,336,454   $ 1,336,454  
    Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options   $ 613,406   $ 613,406  
    XML 19 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 5 - Intangible Assets (Details Textual) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Dec. 31, 2014
    Regional Developer Rights in Los Angeles County, San Diego, and New Jersey [Member] | Franchises [Member]          
    Deferred Revenue $ 914,000   $ 914,000    
    Excess Deferred Regional Fees Revenue Recognized     254,250    
    Regional Developer Rights in Los Angeles County, San Diego, and New Jersey [Member]          
    Finite-lived Intangible Assets Acquired     1,583,000    
    Cash Advance to Acquire Intangible Assets         $ 507,500
    Amortization of Intangible Assets $ 164,193 $ 0 $ 289,807 $ 0  
    XML 20 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 9 - Related Party Transactions (Details Textual) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Shareholder [Member]        
    Related Party Transaction, Amounts of Transaction $ 100,000 $ 293,000 $ 471,000 $ 671,000
    XML 21 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 3 - Notes Receivable
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Loans, Notes, Trade and Other Receivables Disclosure [Text Block]
    Note 3:
    Notes Receivable
     
    Effective July 2012, the Company sold a company-owned clinic, including the license agreement, equipment, and customer base, in exchange for a $90,000 unsecured promissory note. The note bears interest at 6% per annum for fifty-four months and requires monthly principal and interest payments over forty-two months, beginning August 2013 and maturing January 2017.
     
    Effective July 2015, the Company entered into two license transfer agreements, in exchange for $10,000 and $29,925 in separate unsecured promissory notes.  The non-interest bearing notes require monthly principal payments over 24 months, beginning on September 1, 2015 and maturing on August 1, 2017. Effective July 2015, the Company entered into a license transfer agreement, in exchange for $29,925 in an unsecured promissory note.  The note bearings interest at 4.0% per annum, and requires monthly principal payments over 12 months, beginning on August 1, 2015 and maturing on July 1, 2016.
     
    The outstanding balance of the notes as of September 30, 2015 and December 31, 2014 were $87,557 and $59,269, respectively.
    XML 22 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Fair Value Assumptions of Options Granted (Details)
    9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Minimum [Member]    
    Expected volatility 45.00% 43.00%
    Expected term (years) 5 years 182 days 5 years 182 days
    Risk-free rate 1.66% 0.07%
    Maximum [Member]    
    Expected volatility 50.00% 46.00%
    Expected term (years) 7 years 7 years 182 days
    Risk-free rate 1.92% 2.05%
    Expected dividends 0.00% 0.00%
    Risk-free rate
    Forfeiture rate 20.00% 0.00%
    XML 23 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Potential Shares of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Restricted Stock [Member]        
    Unvested restricted stock (in shares) 393,339 542,354 393,339 542,354
    Employee Stock Option [Member]        
    Unvested restricted stock (in shares) 524,600 266,555 524,600 266,555
    Warrant [Member]        
    Unvested restricted stock (in shares) 90,000 90,000
    XML 24 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Earnings (Loss) Per Common Share (Details) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Net loss $ (1,656,722) $ (202,373) $ (5,416,317) $ (464,019)
    Weighted average common shares outstanding - basic (in shares) 9,844,964 4,828,122 9,777,119 4,819,861
    Weighted average common shares outstanding - diluted (in shares) 9,844,964 4,828,122 9,777,119 4,819,861
    Basic and diluted loss per share (in dollars per share) $ (0.17) $ (0.04) $ (0.55) $ (0.10)
    XML 25 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Stock Options Activity (Details) - $ / shares
    9 Months Ended 12 Months Ended
    Sep. 30, 2015
    Dec. 31, 2014
    Outstanding at December 31, 2014 (in shares) 314,775  
    Outstanding at December 31, 2014 (in dollars per share) $ 2.23  
    Outstanding at December 31, 2014 (in dollars per share) $ 2.21 $ 0.92
    Outstanding at December 31, 2014 9 years 9 years 73 days
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 211,660  
    Granted at market price (in dollars per share) $ 8.35  
    Cancelled (in shares) (1,835)  
    Cancelled (in dollars per share) $ 3.49  
    Outstanding at September 30, 2015 (in shares) 524,600 314,775
    Outstanding at September 30, 2015 (in dollars per share) $ 4.69 $ 2.23
    Exercisable at September 30, 2015 (in shares) 111,502  
    Exercisable at September 30, 2015 (in dollars per share) $ 1.81  
    Exercisable at September 30, 2015 (in dollars per share) $ 0.82  
    Exercisable at September 30, 2015 8 years 146 days  
    XML 26 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Acquisitions (Details Textual)
    1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
    Jan. 02, 2015
    USD ($)
    Dec. 31, 2014
    USD ($)
    Jan. 31, 2015
    USD ($)
    Sep. 30, 2015
    USD ($)
    Sep. 30, 2014
    USD ($)
    Sep. 30, 2015
    USD ($)
    Sep. 30, 2014
    USD ($)
    Dec. 31, 2014
    USD ($)
    Clinic in Tempe, Arizona [Member]                
    Business Combination, Consideration Transferred $ 0   $ 25,000          
    Business Combination, Bargain Purchase, Gain Recognized, Amount     $ 384,214          
    The Joint RRC Corp [Member] | Los Angeles County [Member]                
    Number of Franchises Acquired from Franchisee   4           4
    The Joint RRC Corp [Member] | Franchise Rights [Member]                
    Finite-lived Intangible Assets Acquired   $ 81,000            
    Finite-Lived Intangible Asset, Useful Life   7 years            
    The Joint RRC Corp [Member] | Customer Relationships [Member]                
    Finite-lived Intangible Assets Acquired   $ 72,000            
    Finite-Lived Intangible Asset, Useful Life   2 years            
    The Joint RRC Corp [Member]                
    Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual               $ 0
    Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual               $ 0
    Number of Franchises Acquired from Franchisee   6           6
    Payments to Acquire Businesses, Gross               $ 900,000
    Number of Franchises to Be Operated as Company-owned from Franchisee Acquistion   4           4
    Number Of Franchises To Be Closed   2   2   2   2
    Number of Additional Undeveloped Franchises Acquired 3              
    Net Purchase Price, Net Deferred Revenue Adjustment $ 41,100              
    Developed and Undeveloped Franchises Reacquired [Member]                
    Business Combination, Consideration Transferred           $ 5,396,875    
    Payments to Acquire Businesses, Gross           4,652,525    
    Business Combination, Consideration Transferred, Net of Deferred Revenue and Deferred Franchise Costs           4,898,575    
    Business Combination, Consideration Transferred, Liabilities Incurred           $ 744,350    
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member] | Franchise Rights [Member] | Minimum [Member]                
    Finite-Lived Intangible Asset, Useful Life           6 years    
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member] | Franchise Rights [Member] | Maximum [Member]                
    Finite-Lived Intangible Asset, Useful Life           7 years    
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member] | Franchise Rights [Member]                
    Finite-lived Intangible Assets Acquired           $ 1,215,248    
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member] | Customer Relationships [Member]                
    Finite-lived Intangible Assets Acquired           $ 315,793    
    Finite-Lived Intangible Asset, Useful Life           2 years    
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member]                
    Business Combination, Consideration Transferred           $ 4,898,575    
    Business Combination, Bargain Purchase, Gain Recognized, Amount           384,214    
    Business Combination, Acquisition Related Costs           361,997    
    Franchise Fees [Member]                
    Deferred Revenue       $ 976,500   976,500    
    Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual       1,198,397   2,368,866    
    Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual       $ (854,948)   $ (1,209,682)    
    Business Combination, Consideration Transferred, Net of Deferred Revenue and Deferred Franchise Costs $ 858,900              
    Number of Developed Franchises Reacquired During Period           23    
    Number of Undeveloped Franchises Reacquired During the Period           34    
    Business Combination, Consideration Transferred, Liabilities Incurred           $ 744,350    
    Number of Reacquired Developed Franchises Operated as Company-owned or Managed Clinics       21   21    
    Number of Reacquired Undeveloped Franchises that Have Been Terminated and May Be Relocated       34   34    
    Deferred Franchise Costs       $ 478,200   $ 478,200    
    Business Combination, Bargain Purchase, Gain Recognized, Amount       $ 384,214 384,214  
    Business Combination, Measurement Period Adjustments, Property and Equipment, Increase (Decrease)           47,859    
    Business Combination, Measurement Period Adjustments, Intangible Assets, Increase (Decrease)           72,400    
    Business Combination, Measurement Period Adjustments, Favor Leases, Increase (Decrease)           17,469    
    Business Combination, Measurement Period Adjustments, Deferred Revenue, Increase (Decrease)           7,032    
    Business Combination, Measurement Period Ajustment, Goodwill, Increase (Decrease)           $ 130,696    
    XML 27 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Assets Acquired and Liabilities Assumed (Details) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2015
    Dec. 31, 2014
    The Joint RRC Corp [Member]      
    Property and equipment     $ 297,630
    Intangible assets     153,000
    Goodwill     636,104
    Total assets acquired     1,086,734
    Unfavorable leases     (227,834)
    Net assets acquired     858,900
    Reacquisitions of Franchises Throughout Arizona and California and Acquisition of Clinic in Tempe, Arizona [Member]      
    Property and equipment $ 1,539,321 $ 1,539,321  
    Intangible assets 1,531,041 1,531,041  
    Goodwill 2,312,259 2,312,259  
    Total assets acquired 5,400,090 5,400,090  
    Net assets acquired 5,282,789 5,282,789  
    Favorable leases (17,469) (17,469)  
    Deferred membership revenue (117,301) (117,301)  
    Bargain purchase gain   (384,214)  
    Net purchase price   4,898,575  
    Property and equipment 1,539,321 1,539,321  
    Intangible assets 1,531,041 1,531,041  
    Goodwill 2,948,363 2,948,363 $ 636,104
    Favorable leases (17,469) (17,469)  
    Deferred membership revenue (117,301) (117,301)  
    Bargain purchase gain $ (384,214) $ (384,214)  
    XML 28 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Acquisitions
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Business Combination Disclosure [Text Block]
    Note 2:
    Acquisitions
     
    Franchises acquired during 2014
     
    During 2014, the Company acquired substantially all the assets and certain liabilities of six franchises including franchises that manage four clinics operating in Los Angeles County, for a purchase price of $900,000 which was paid in cash. The Company is operating four of the acquired franchises as managed company clinics and has terminated the two remaining franchises. On January 1, 2015, the Company acquired an additional three undeveloped franchises.  This resulted in a net deferred revenue adjustment of $41,100 to the net purchase price.  No additional consideration was paid on January 1, 2015. The remaining $858,900 was accounted for as the total consideration paid for the acquired franchises.
     
    The purchase price allocation for these acquisitions is complete. The following summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date:
     
    Property and equipment   $ 297,630  
    Intangible assets     153,000  
    Goodwill     636,104  
    Total assets acquired     1,086,734  
    Unfavorable leases     (227,834 )
    Net assets acquired   $ 858,900  
     
    Intangible assets consist of reacquired franchise rights of $81,000 and customer relationships of $72,000 and will be amortized over their estimated useful lives of seven years and two years, respectively.
     
    Unfavorable leases consist of leases with rents that are in excess of market value. This liability will be amortized over the lives of the associated leases.
     
    Goodwill recorded in connection with this acquisition was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible.
     
    The Company has retrospectively adjusted the condensed consolidated balance sheet as of December 31, 2014 related to adjustments to the purchase price allocation of the above acquisition.  The impacts are adjustments to deferred franchise costs, goodwill and deferred revenue, with no changes to total net assets.  There were no impacts on the consolidated statements of operations or cash flows for any prior periods as a result of these adjustments.  The balance sheet impacts are as follows:
     
        December 31, 2014
        As reported   As revised
             
    Deferred franchise costs - current portion   $ 668,700     $ 622,800  
    Goodwill   $ 677,204     $ 636,104  
    Deferred revenue - current portion   $ 2,044,500     $ 1,957,500  
     
     
    Franchises acquired during 2015
     
    During the nine months ended September 30, 2015, the Company continued to execute its growth strategy and entered into a series of unrelated transactions with existing franchisees to re-acquire an aggregate of 23 developed and 34 undeveloped franchises throughout Arizona, California, and New York for an aggregate purchase price of $5,396,875, subject to certain adjustments, consisting of cash of $4,652,525 and notes payable of $744,350. Of the 23 developed franchises, the Company is operating 21 as company-owned or managed clinics and has closed the remaining two clinics. The 34 undeveloped franchises have been terminated and the Company may relocate them. At the time these transactions were consummated, the Company carried
    a deferred revenue balance of $976,500, representing franchise fees collected upon the execution of the franchise agreements, and deferred franchise costs of $478,200, related to undeveloped franchises.  In accordance with ASC 952-605, the Company accounted for the franchise rights associated with the undeveloped franchise as a cancellation, and the respective deferred revenue and deferred franchise costs were netted against the aggregate purchase price.  The remaining $4,898,575 was accounted for as consideration paid for the acquired franchises.
      
    Additionally, in January 2015, in connection with the default by a franchisee under its franchise agreement, the Company assumed substantially all of the assets of a clinic in Tempe, Arizona in exchange for $25,000.  The Company has accounted for this as a business combination.  The Company completed its valuation of the fair value of the assets acquired, including intangible assets, in September 2015. Because the net assets acquired exceeded the consideration paid, the Company recognized a bargain purchase gain of $384,214 during the three months ended September 30, 2015.
     
    The Company incurred $361,997 of transaction costs related to these acquisitions for the nine months ended September 30, 2015.
     
    Purchase Price Allocation
     
    The purchase price allocations for these acquisitions are preliminary and subject to further adjustment upon finalization of the opening balance sheet. The following summarizes the aggregate fair values of the assets acquired and liabilities assumed during 2015 as of the acquisition date:
     
    Property and equipment   $ 1,539,321  
    Intangible assets     1,531,041  
    Favorable leases     17,469  
    Goodwill     2,312,259  
    Total assets acquired     5,400,090  
    Deferred membership revenue     (117,301 )
    Net assets acquired   $ 5,282,789  
    Bargain purchase gain     (384,214 )
    Net purchase price   $ 4,898,575  
     
    Intangible assets in the table above consist of reacquired franchise rights of $1,215,248 and customer relationships of $315,793, and will be amortized over their estimated useful lives ranging from six to seven years and two years, respectively.
     
    The estimates of the fair value of the assets or rights acquired and liabilities assumed at the date of the applicable acquisition are subject to adjustment during the measurement period (up to one year from the particular acquisition date). The primary areas of the accounting for the acquisitions that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired, residual goodwill and any related tax impact. The fair value of these net assets acquired are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. While the Company believes that such preliminary estimates provide a reasonable basis for estimating the fair value of assets acquired and liabilities assumed, it evaluates any necessary information prior to finalization of the fair value. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the revised estimated values of those assets or liabilities as of that date. The effect of measurement period adjustments to the estimated fair value is reflected as if the adjustments had been completed on the acquisition date. The impact of all changes that do not qualify as measurement period adjustments are included in current period earnings. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could be subject to a possible impairment of the intangible assets or goodwill, or require acceleration of the amortization expense of intangible assets in subsequent periods. During the three months ended September 30, 2015, the Company made certain measurement period adjustments related to several acquisitions consummated in period. Property and equipment was increased by $47,859, intangible assets increased by $72,400, favorable leases increased by $17,469 and deferred membership revenue decreased by $7,032 with the resulting offset to goodwill of $130,696.
     
    Goodwill recorded in connection with these acquisitions was attributable to the workforce of the clinics and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is tax-deductible. 
     
    Pro Forma Results of Operations (Unaudited)
     
    The following table summarizes selected unaudited pro forma condensed consolidated statements of operations data for the three and nine months ended September 30, 2015 and 2014 as if the acquisitions had been completed on January 1, 2014.
     
        Pro Forma for the Three Months Ended   Pro Forma for the Nine Months Ended
        September 30, 2015   September 30, 2014   September 30, 2015   September 30, 2014
    Revenues, net   $ 4,159,975     $ 2,668,562     $ 11,030,264     $ 7,465,179  
    Net loss   $ (2,064,297 )   $ (814,369 )   $ (6,338,663 )   $ (2,811,855 )
     
    This selected unaudited pro forma consolidated financial data is included only for the purpose of illustration and does not necessarily indicate what the operating results would have been if the acquisitions had been completed on that date. Moreover, this information does not indicate what the Company’s future operating results will be. The information for 2014 and 2015 prior to the acquisitions is included based on prior accounting records maintained by the acquired companies. In some cases, accounting policies differed materially from accounting policies adopted by the Company following the acquisitions. For 2015, this information includes actual data recorded in its financial statements for the period subsequent to the date of the acquisition. The Company’s consolidated statement of operations for the three months ended September 30, 2015 includes net revenue and net loss of $1,198,397 and $(854,948), respectively, attributable to the 2015 acquisitions. The Company’s consolidated statement of operations for the nine months ended September 30, 2015 includes net revenue and net loss of $2,368,866 and $(1,209,682), respectively, attributable to the acquisitions. As the 2014 acquisition occurred on the last day of the period, there were no net revenues or income attributable to the acquisitions.
     
    The pro forma amounts included in the table above reflect the application of accounting policies and adjustment of the results of the clinics to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied from January 1, 2014, together with the consequential tax impacts.
    XML 29 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Balance Sheet Adjustments Related to the Purchase Price Allocation (Details)
    Dec. 31, 2014
    USD ($)
    Scenario, Previously Reported [Member]  
    Deferred franchise costs - current portion $ 668,700
    Goodwill 677,204
    Deferred revenue - current portion 2,044,500
    Deferred franchise costs - current portion 622,800
    Goodwill 636,104
    Deferred revenue - current portion $ 1,957,500
    XML 30 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 6 - Notes Payable (Details Textual)
    Sep. 30, 2015
    USD ($)
    Aug. 15, 2015
    USD ($)
    Aug. 10, 2015
    USD ($)
    Jul. 02, 2015
    USD ($)
    Jun. 05, 2015
    USD ($)
    Jun. 03, 2015
    USD ($)
    May. 18, 2015
    USD ($)
    May. 01, 2015
    USD ($)
    Apr. 02, 2015
    USD ($)
    Mar. 23, 2015
    USD ($)
    Mar. 06, 2015
    USD ($)
    Mar. 03, 2015
    USD ($)
    Feb. 17, 2015
    USD ($)
    Franchise from Roth Pelan Enterprises LLC [Member]                          
    Debt Instrument, Face Amount                         $ 155,000
    Number of Franchises                         2
    Number of Acquired Franchises to Develop                         1
    Debt Instrument, Interest Rate, Stated Percentage                         1.50%
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year                         $ 25,000
    Franchise from TJSC LLC [Member]                          
    Debt Instrument, Face Amount                       $ 60,000  
    Number of Franchises                       4  
    Number of Acquired Franchises to Develop                       1  
    Debt Instrument, Interest Rate, Stated Percentage                       4.50%  
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year                       $ 30,000  
    Franchises from The Joint San Gabriel Valley Inc [Member]                          
    Debt Instrument, Face Amount                     $ 30,000    
    Number of Franchises                     2    
    Number of Acquired Franchises to Develop                     7    
    Debt Instrument, Interest Rate, Stated Percentage                     1.50%    
    Franchise from The Joint Arrowhead Ranch LLC [Member]                          
    Debt Instrument, Face Amount                   $ 10,000      
    Debt Instrument, Interest Rate, Stated Percentage                   1.50%      
    Franchise from The Joint Chiropractic Bell Towne LLC [Member]                          
    Debt Instrument, Face Amount                 $ 58,500        
    Debt Instrument, Interest Rate, Stated Percentage                 1.50%        
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year   $ 25,000                      
    Franchise from San Diego Joint Development Inc. [Member] | Payable November 1, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year               $ 15,500          
    Franchise from San Diego Joint Development Inc. [Member]                          
    Debt Instrument, Face Amount               $ 80,900          
    Number of Franchises               2          
    Number of Acquired Franchises to Develop               6          
    Debt Instrument, Interest Rate, Stated Percentage               4.25%          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year               $ 25,000          
    Long-term Debt, Maturities, Repayments of Principal in Year Two               $ 40,450          
    Franchise from First Light Junction [Member] | Payable February 18, 2016 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal in Year Two             $ 25,000            
    Franchise from First Light Junction [Member] | Payable on November 18, 2016 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal in Year Two             25,000            
    Franchise from First Light Junction [Member]                          
    Debt Instrument, Face Amount             $ 75,000            
    Number of Franchises             3            
    Number of Acquired Franchises to Develop             2            
    Debt Instrument, Interest Rate, Stated Percentage             4.00%            
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year             $ 25,000            
    Franchise from WHB Franchise Inc. [Member] | Payable on October 3, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year           $ 25,000              
    Franchise from WHB Franchise Inc. [Member] | Payable on December 3, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year           25,000              
    Franchise from WHB Franchise Inc. [Member]                          
    Debt Instrument, Face Amount           $ 100,000              
    Number of Franchises           2              
    Number of Acquired Franchises to Develop           4              
    Debt Instrument, Interest Rate, Stated Percentage           5.25%              
    Long-term Debt, Maturities, Repayments of Principal in Year Two           $ 50,000              
    Franchise from Clear Path Ventures Inc. [Member] | Payable on October 5, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year         $ 25,000                
    Franchise from Clear Path Ventures Inc. [Member] | Payable on December 5, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year         12,500                
    Franchise from Clear Path Ventures Inc. [Member]                          
    Debt Instrument, Face Amount         $ 75,000                
    Number of Franchises         3                
    Number of Acquired Franchises to Develop         3                
    Debt Instrument, Interest Rate, Stated Percentage         4.25%                
    Long-term Debt, Maturities, Repayments of Principal in Year Two         $ 37,500                
    Franchise from Chiro Novo, LLC [Member] | Payable November 1, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year       $ 15,000                  
    Franchise from Chiro Novo, LLC [Member]                          
    Debt Instrument, Face Amount       $ 53,000                  
    Number of Franchises       1                  
    Debt Instrument, Interest Rate, Stated Percentage       4.00%                  
    Franchise from Chiro Group [Member] | Payable December 10, 2015 [Member]                          
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year     $ 25,000                    
    Franchise from Chiro Group [Member]                          
    Debt Instrument, Face Amount     $ 46,950                    
    Number of Franchises     3                    
    Debt Instrument, Interest Rate, Stated Percentage     4.25%                    
    Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year $ 231,500                        
    Long-term Debt, Maturities, Repayments of Principal in Year Two $ 272,850                        
    XML 31 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
    Sep. 30, 2015
    Dec. 31, 2014
    Current assets:    
    Cash and cash equivalents $ 9,522,013 $ 20,796,783
    Restricted cash 188,431 224,576
    Accounts receivable, net 605,876 704,905
    Income taxes receivable 449,803 395,814
    Note receivable - current portion 61,533 27,528
    Deferred franchise costs - current portion 548,400 622,800
    Deferred tax asset - current portion 61,000 208,800
    Prepaid expenses and other current assets 151,794 375,925
    Total current assets 11,588,850 23,357,131
    Property and equipment, net 3,602,217 1,134,452
    Note receivable, net of current portion and reserve 26,024 31,741
    Deferred franchise costs, net of current portion 1,799,000 2,574,450
    Intangible assets, net 2,317,484 153,000
    Goodwill 2,948,363 636,104
    Deposits and other assets 203,244 585,150
    Total assets 22,485,182 28,472,028
    Current liabilities:    
    Accounts payable and accrued expenses 1,436,350 1,271,405
    Co-op funds liability 159,770 186,604
    Payroll liabilities 1,397,215 $ 617,944
    Notes payable - current portion 466,850
    Deferred rent - current portion 101,498 $ 93,398
    Deferred revenue - current portion 2,275,035 1,957,500
    Other current liabilities 48,254 50,735
    Total current liabilities 5,884,972 $ 4,177,586
    Notes payable, net of current portion 167,500
    Deferred rent, net of current portion 488,746 $ 451,766
    Deferred revenue, net of current portion 4,820,259 7,915,918
    Other liabilities 266,592 299,405
    Total liabilities $ 11,628,069 $ 12,844,675
    Commitments and contingencies
    Stockholders' equity:    
    Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of September 30, 2015, and December 31, 2014 $ 0 $ 0
    Common stock, $0.001 par value; 20,000,000 shares authorized, 10,402,047 shares issued and 9,868,047 shares outstanding as of September 30, 2015 and 10,196,502 shares issued and 9,662,502 outstanding as of December 31, 2014 10,402 10,197
    Additional paid-in capital 22,066,847 21,420,975
    Treasury stock (534,000 shares as of September 30, 2015 and December 31, 2014, at cost) (791,638) (791,638)
    Accumulated deficit (10,428,498) (5,012,181)
    Total stockholders' equity 10,857,113 15,627,353
    Total liabilities and stockholders' equity $ 22,485,182 $ 28,472,028
    ZIP 32 0001171843-15-006357-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-15-006357-xbrl.zip M4$L#!!0````(`(5K<$<"M`@\O>T``/S9"0`1`!P`:GEN="TR,#$U,#DS,"YX M;6Q55`D``SH@2E8Z($I6=7@+``$$)0X```0Y`0``[%U9<^,XDG[?B/T/6.WV M1'>$99,4*4JN*D_X*->XQ]?(KNGIIPJ:A"1448"&H&QK?OTFP%,2(5&7K;(9 MT8=%@IGY9282"3!!?/SK\\!'CSC@A-%/-7U?JR%,7>81VOM4^WI7/[X[O;BH M_?7HX__4ZU\PQ8$38@\]C-%]?T0]')RQ`4;_.NE M.M3%M:CEHD-/'QL%`0!1/1??%0^: MDP]ZF!0_`S<*FN-GMU_<7MPI>(#01\S#XD>B>P5H"&>FH=OSU!:U2![X/J;A M1.NPC[\S0L-]EPT$`TMK-[2DM4_HCSFTQ>T'AZ3$">4O0UR+WG.,.T9=?A#Q)"?$,J=I+!*`R4FFT?P-VDH;CA3;E> MW*YY$-W,-R5+=*'G&?L^-61KO=UN'\B[:5->U`ZHZ@?_NKJ\<_MXX-1GZ'.R MS%-'__U?"'T47`^YO-7!722E..P'N/NI)IRWGOCH_C/W:O%MX26?:IP,ACZN M'41TH%L>'@\P]>#?\-QW>LAE-,3/84>0\KXE)M'T^,]V73@^\3[5W+INUHZZ MCL_QQX,9.AGY4QDMPG/"7.?P&QY?GO>+P, M$U"?!AVGJ1O-!$XAS1F6;#!@]"YD[H^[OA-@?C,*18<3(_D$?_(M&9NU=@UY MV"4#Z`&?:A?7YXD,<'U$2=13$F&$QS[^`>X6`]&EX[@^5\KG;T^\W%]3VP#(9Y?I,DIQG^D_F0&3E!)-92 M&K9K1]Z5;#40#CH=G\>#"/[X1DCV(,Y>(@"EGT7*[_(=$!!9T#()305/T]%Y'HLG7@T0-4WT<\)-UQ M?)%`^@6]'FG[AD7H#'9G,/Q`'_CP9=C=]W&2BJ"^PQ&&O.O!)[P/8Y5#D9-3 M31=4`XP#%$5,QS\(XI`I:/[`,JV!I&WB(=9%'`>/!`(P_-W%0;3T0T1@!:O` M5'\?"1D@_PO[_CA'J8LQ>@*)"'4#,91Y*&3(^"73#Z'H=X>.(*N02T41G00+ MQSV0#G(ICD)!/B,+*$10AW3,%>M03WWB]A$DG8*1/_+@$A"&'#0,B&S@.KR/ M&(U$9I1#=/:B%2S'%P,+`EWA$&`<<^0,Q&H2E^3P\Q"F@M"N"QU#"B%8[\F_ M$BD#[+(>!3/R64T',`[1$8XT"K]\R512Y1@-`S%$@<*P3Z(Q#)XC,%`$;DQ; M)';<<86IA'"Q9!EP0(F?P2S"+CG]1&*3$-(*7D8M.3C2-/_[#,9H?YBOJ[(] M;!-_9PG%G$$V-QJ?C*`-J`5`/<3)P2E`(9Y8N(0?]T*OX,C@R=X>A' M)[(7I!7)E7-HZ?8)QZ>,+TZI*U>4#^*W2[^%?*@<>Y'W"]PH,'',Q1M=54J=ILM5N6;;VJKJ\@ M&$+GS!8GCCT1\,5O/L7A(@Z=9SCZ_WJYN]54I;9'MM8PU$I90^+557'N/+(@ MF@-M6@WJ*8QM-MNKZ6&.N*OKX`+FW+1''GP,TT`<;EP1MM(?#'->1%I'YM6U M<2N'S'`,_>XS1(*AN+AIC:@CA]VR5G2-,G(OJY6$^!?&O"?B^QO6@ZTINTA# M:[:;RRABD:CSH7>2#,N[$&DPZ1(G=:WC>$``Q5["9>+#<)*NF,@.*=I&G;)H M_7.!%DQMU4"Q*:%?637*P7IB'8;?=+-1^KX?L%&OST;A<4#^`W,+$.`4IC4P M[:!$_,B1NNF>RAG$!;W'@R&.'U@TNALM_6U:Y2OM+K*+&;T^4MH%)E"_BS>\ MGJ$I;J4K#L%L-.AE?.=]9<.H[H+/(@0O7"B_H)>/'M(=]#&!AOC6^<^@9P3T&6*[QT^\X MX'B\2*U-39GJ6YJ=+9&6@9O73C3=3K1[-@I@*@06C\)L8<"WIY+OI)^RX(QP MUV) M:(N#B*%I"D3VEFVT[OBA1J2_AM=M:(C)=7Q%Y]E4Q]_\P*'H&QN,5%L=-@Q5 M3]AVM-KL@&$HW'^A&8`N?>T!0V4"?6K@+I1U94A;'3%4T4AO;A/25N<=A@)2 M8ZN0MCAFZ.V&`I)E;]E*VYV7J/J3N2O=J=S(LOV0MMT)B:K#;-L,&YZ**#K) M0C/<,=\[&877+/P3AQ&3J.QD^35YHZ$<(EK:I#957->1SUPLGS+[-%O+R\=N MAJ+8@2?KJ$FE\[*:$XNYS89RW=QJVW:J/17/U>2*5V?GR64JY6HUFYJYA%PE MZA+*N9EE*95EVBTC7<)=^/Z_N,$:5FPHW]E:9LM<(%A9C:UAS8;RG5G3,%HO M)-\WL0%`OH.\(_9)'??B`KC;4>#V'8YO`^+B%7S9U-?QY1(R+<;%J+NZQYO*JA7=;K>U M1?*GO-<2<['C6\I7YH9EFW![>3$_R_*^K,(F>F=UCD4QE*RVR=["E4IJINN7 M`A"AAY,-3).)XKZ(ZUJNDGA(>_!(PSN\< MD!Y2+0@AH=-;6%^AJYU%=,FF:KZA[6O)4)<-1'G='>N&3TZ`A?6B@L\U]E;8(#4,Z]7>BI?: M$[!R!?V*VP`N[E'L0"CR(%EZG?@0$DXT6;B<5>JG?^5+T.-2:XZZBIG[$L:C#%D7FHK0[(%ALET/@_N*7*.-VTX?V$$6O",@F@-`CT2#WO["%24%*(G MY>D!'@9`6U:]HR[$SB(A-7SI%DH]]`BQ#@23CY MB-!C_CIH"I-A"&)([<[3)*@M5DKF#Z,AHRD-L&\*5FR"D'L"DAB'URJ*CR/F M"B$P'T"G*NLNZ.RD:"&,@DVV[:^*;E7 MKXR?([MZZX#>TM/\MZPP&Y%_*=TWE%6U==UN:>LA("&!]"ZY?PP3E"BCQ<%@ MJ9V7(BNS:D>WNO9G*LXV%U?67\LO=>Q#4H_.()V3\P07KK!()WMR M6RQ,&@91^@Z!S^T#ZSVQ#5:#)%W.(0AUR=#QT4-R4*>7;.%-TE+YY9=\TAUOVMV#&8(O/FZ%TCW`R9Z[``71AQ,$G7@"(AJ* M;)>E=A56!B&P%S.6VXTSOM.Y?LP6P?0"8G%,(DPW"TCBXK43/"?7;B7]8_D= M,"?:&)Q'!/<*J1.1P?=&?O*!.D'U'(OM?#X2'_J0<[L!X>)+=U+<1[$]K@M35?8DK20JZ\%L`V@D]R4+'="16%N3:DLT M13-;(OG]L\QTR$D2';!"``3`:)$+RWEQ79I=W$D,WY6ML+`GCB;=X)SQEG". MHDW4=W@8RA4^U(@_^=!Q MD]\QRP<6@#KJ8O;O##GP3?[Z@)Z(%_8/D:UIP^YZ)!`TW->')3@`=-`0_52S:\MPRV,1 M^1H./J!8K8D`)[X#*9D4`\EMYK$O"P^ZBASGLW`<(R]`S?<"]/U:=)GX M`6R`;`]2/.J)T90%,+#U'GXU-'//:+3V#,OZK2C&Q(.LU?QE9@XT&UPR;8I? MN9E27&0CLAPJLLX'2',IC9/'H2R94ELQ%D&?E:#TH*PFH8B02Q!M+2*:Y0]& MH_TZ,KX%WU=:;,W!9JS9>09@=5D>S4D=.'8U*'7EU6/;VA'F)'';U")CL M-'Z3,?#7.4E!.6%^>P-:J%==?<(GUAX8*Z?8^3QO8JU#&?RB/;-KA+Z5%UE!56NULE77 M+K6J?/S-:F/]DJLWI8X=#H!5[=5NO]:9XSK5&[;*%._4%%5%XJN;X%5[PXZE M_55-UDL7.\S9=%S%XG<4""I35-UB-VWQ4X^/J\T*URIVVMW9^ZL*]?H25&JI MU/)SJ&5'9P7&OF'%IKEGH3CUZX4F`CG&*P]]$0WDL=&#C[<^T"[#+9?VV,MN MS=H:JLHF*Y>C5S:I^LD[M,EK]Y-JJO"393F56BJU5&IY"U.%B;<"/G$Q%5_? MY\SWT,,H1)2%:(S#]+OY;Z%H2&]594.EM]"^0WU4_O&"_E%RS^XV_XZ/9BIY MPE+^3"838[9^SID5!R@1:BD=-.=/5]KW?/2=.6)XF9+RTZ*74_& M+8(M.EPMATYU&AQZYH>4^)]J83#"M8-)`2=.;(;?TV^+%)]MJ MQK>3^%`:64'+B<`F3P"^[V-Y`$ZG3B&TQ3GBQZXK#BSFDM0EP9[9-Q M]G=ZEO(UH_+,2R!F0C@VS$D*.3)],#U$\<'\#BNS[&H3R8S9/6=OPSPEV?<4##3\;P M8\BXXW^!+&S(@80_$LL%H@VP)&`A+XL=4CGQ/N4;L4TYRK$FE2"\HR648/ZI MM[2S;2OBU6ROS]A>MU[&]IN&?%$*[RS<9D.184C0FG M;ZF/2FP6*RF/?54-O:XW%.A"NH:AUH6YEBXX!U.=L^#6&0OKWW3O86#F,*:( M\7N-],-N-IJV\HQ8E.-?+8M9MNLL\H3?[X/3N+5@T*SX0UZKJM3+&R3!-Z4H>% M_5L,6OHL)!@&@O;EY>FBO*MIJ,YC30Y"+B'Z!H`VX)]R0.^_<_?2+XB=T\"L M70'67`R,2V1QRGSGT"_.0T"P_T]Q5OH8''DAVH;*C/:+HA71L9P9`>09P3TF M$<"G6"GX?45>T68Q1-?@;+XJQ6;I?_O&W MD_1W&2-:*H#F2P.TR@$\]2&!N77"_C_!3<6`4P9ELZE`V5@/93H`?J7IJG/V M:+J=M0CQ9J?MC;+XRDE<@/5LMG4'.W'[,[E)[586X*RW5F29*BC&-);2$A6@ M21^YC%\C)(M"N%A^N_3)ZDU5A]*U*?GGR+`!B+ M*K>*>@/HUU:+:%NZ2JG33J%@.D\\/BN168<4&/)?F.V*;T5%N6J'\!\GXQ,, M3PV.3WZK@-C"SFO67),75/LE\AHC9U)627BT2+)=^PXV=I/O3#=%Q5YP&;RM,-57*H'I>+17T]=-_2U<`O MF/4"9]@7%4"R_27CQ[2'?G>#X8QI;-W!#M4"N M#G&9>"NCB'/\C:&P5.GC1E!$B[_8.^;Y==])@T8(BJ<+&[>9:G*A]L+E811H M17[2VA_'[PF*7PT88C#.,,^9(BF7`)K3L66*;X%DN6GT[!R[&/=-`EUK,XL\JAG2#-[EQ,KABE\QT=XE=CB.?;X# M#O_Y>2C6+LITMV\=!\8S&52NP&D&H\&B8&*K"VATS4H+:!8)MT4/U890TAZE\A:TWC'01;`D<<4E<5`1W&^!' MPD;<'R=E7*>,AS`?.F7T>SPY_8.$_>GUOUPE7?$[^O++IA-SDTF`5B-SN(V+ M_>(J*;\N:RM#2:/5MJV744DO>K\?QV!9PU!8:EH.:UI)8D**>20*6W,'W'B$ M#WUG?(@(A2$ZV:K5=0;$AXLA&<",D^(G!!F60Q6?N*XH?JK-W^(FZC))=QQ? M)#"\@IV1MF]8!,A/G3%41E1Y$ZZ%P,"-S@9*W`:E?H.$X^0+F?=1-'0C<`]] M3^[?CK,UA+FHK2:\#[F4@X*$EI?2&@9BXCE`(4.8]B"G0P(&1#@O*9<5%6HL MX**%PSEDX&+O>$Q`,.5#Z'1=`@QZN4ELS(OO(Y%U!"`4X0FSO0)!X*8S!A'C MK2BH"Y-LZ%<]P:$+]D+_9^\9EB:D,*Q?DFWJ\"],:D;0-T'8;M(/Q<-[H-`` M06[3SUV'YF/@+5XOR!]1L;N@&^P*"`_"FY.<^ZA2H*!&]*ZJ?)K7S_^V];7/;1M(H M^OU6W?^`X\>IDU2!"E[YXIQ-E2S;.=KKV"K)V:W]E(+(H80-"'`!4K+VU]_N MG@$P(#$@P'=2R)-G(Y+`3'=/3T]/OYJ.#BH1HO+6'.@#H-0SK,.CYL6,6D^Q M(:K3\VG$D4N\@"V`EJ/NQP(\S0N);:(7+YB]X/,VD1[?3F"Y0WXYT.Y?\H%& M;`RE#@F"&,8A9V8C>?AB+ILT<0QDBF--@?F@T\4$`VHL;#`YH_P(PP' M2SZ!)Y/Y/:Q(./.](`">"@(`Q<=/6L+B)V`P'$FXDP%TQ7)DZZL+4G)\<4B? MCJ/$!\:&(8#F]RPG+78'$3U!BNR74@:V1/HL^\Z&<[J9P].E^U."8F%?PT$W M(XYB9:R6+P,'+Z)B^"DJ@,#L98K[%+`A5)(9"+1I%`LO6")')(6>@>9';R^@L20RKE@\\^"[JO4D:0A0 M,DZZ$*1K%D]`P/H2EZ(LD[9J=HVK8M_[2`BY,KH"&Z``@)_C%5`*&(#LR7PZ M#>A;>';*+1X7VC>)(6)0E0&^9(DMJRGH)2HDQ)Y.0'?#0\0G>-30"AX%&0P\ M&>.&'S[B]0"GHZT)\M['=]/M`T!@4":(H.G4B[-=AN3'@063T4H\$2-S_HLC M//1F*(J)`7625_CF/)0D5B;<8)L)>X8WB<('_GBY:"L1([H0%8)T,9L`;^%/ M\U`0L&2GE7`EKE3Z9!13:M;_?`>58?!+D@M&3NAJEO`I#!4.$1\HF##<4O"T MKL'9CA5D!.#(+E$\(]XE-N20Z>+TD'_V4=D`'6+HI;+P/W/0@$BIR'!C\*H0 MP7GI&I3I8B"<&V,)V$R>';66$>76H@2!N;!W7)P\^E,8!)_`6X'/0$^Y`U1I M[/'*$R$A5&<%8?*V#DDF(C&X%A]504 M=VW37D5Q@F!M0)T<4&Q=Y6:IV-/2I#5AN^*V`1GE&Q9C MI"":.C:T*:H"H=$`5`.%2M@J\;OE%W)#I%-R'>*CF/4HK9G_C9; M\_<9F[\YZ]#U+F<>LH%S*TYZ`1.Q"!=2S9%B]1%Q3Y(-%LR+P^SN+<;+;%5H MEO%G>&'DL_-+)SR6-1['A^)H_O`8S?EE\`_85'!GI;`N&1+M&J_B$9S_"?V$ M%LR8%>Z/R]/DEV8]!W'!*$J6T.SRCC]F9M"B:28:C]&"[&E/7NPS;LR=D(9! M=V&<^)D%`<8`:5-O^!=AQXV%8T854K01)IW.0T1P&ON8)HV&BR%.$`L[&%EH M$O@E8)TGO#JE3\JTN)Q0F'_!+(VD#[DQ8"54*0GB$3>=C(1W+K.A+%A7,FNQ MH!/:,NAC1C^85-%H(%B-FSUT-F8%V%.'[12O"S95,YM3OPDI'*LXL3)%` MVQ&:"!/*HWCBE+P7H6'R,!G'"<-:.30:F4"!=T):6$")>]'ED<:,R4!G-F;! M'-Z]'_B<6\DP-P^"A;=Q->%$XA;7(E89#R2+[Z2<$H4`C<`!9!C^C(9KE"T+ MILH2T_'-5;(=@TV3PU$^54G+\K=UBEKM*7J^IVC**@6&+1P0@L$3X>WST=P* MPA5@F\X#LET+G7A1,Q-L_19V&3)@8E7 M2'X7@MV8C60MCI3[522;,)>()3"!+"OI@(I"/S,R%R0@>9]3`34&C$DT:1GE M5KDC497`0[?X0BXV[OU..OKL.=*>H_@O!&KDO<"38Q#\W%O(C>.\_#JY-=$3 M/]J*G*D4%Y)N>*%'[O$1$?EZ^>S%6*AC MS'S4%91E6"KN*(YT0[&5J2&P+P0^6P)S'XA7F^>*B"LOW(=#.U$-^97\'-_KQ.USN?5'-;#>1B-V!PI;>0=V&9=TFV`Z)'2 MLUY(9'>@"(\KH>?@HEM[!VZ;GL-*CG^OF$6,BW$E_V3HNF&C2W3U/;!/GA__ MPPLV-?W;`X4]I81\QD5_F7P[PXM3<9YT'CQO^BY-L(:Q\"6L.C02RF3>!<35=;25=>X8S*"-K+1CG$ZZ:?F!3T,Q\VC_P M=\!H(\&*3")0,O]+W]_$:%B9O=P$('/@MX^@'$Z7:H(67#+*5Z3Z`\IG/GX7 MM;HNDX21D,/@1[A'KQ+&MJ&VSMI]VRH2:RLDV!=ATQ2*0Q%6&1=O&RY<@7=. MV"S`Z\;ST9CN37WJR=1\TZL4($HIZ7;[3D]"IGS:-6%;O=E5R@3FGCF6,>BY MC6%+"^`FWR+%&^6ZR"U+9J!-P#+>S>"2@^99D"P\JH/=<2,65SZDR/\ZGJ0_ MZ2#.F96;$WE!/SSH5R:A6!4GC=5W3)E$>\5^6Z2G*86F>M8;E[)C4>>W\$HU\V,OA)W*01.]4U&NW& M;%GJB-O9=+)9TP^'<_1[2?08(CW0FID&7',/`'KG1&1K9NLLF"GG8=&G5G1W M3&F_4F1]1,X##%G'W(,H320L`<)+.(`Q6@[E-1,#)-HS>I[>VKV>#N<"F4[? M]EU;-TTC"ZR=/<:,NVI"X`ENPQ1V0^V.36I6_?Z";K4Y9,W"N=M`57FK[SF.<3!$S>TCJCR93->U^P?CWNJ- MNG#77WT9KC`@=?L%$\TQ;=+&:*I[,!FN73".'],&;8RF4F-B6:VQA9SZC->E3%'^(YO>S\3Q8=D:L49#*<91@]Y=9<#4(VP%[91$T MQU$F7O5-P[8V!%NRGG\=7XBR)G/Q&`?O1BSHC'SA802#X*N=]!O-M/[E_(!UA'!EKLX\%KNC>7:X,G=(=?G==]Q3I MOF>YOA;=EPL$GP6_[U.VKT7WY7KN9\'O^Y3O__0P/'BVFM;+%X7UZ MI-ZS2%\@M43;Y8+;@K:EE7S.2^#69D#U1?&4&7"?,E;-@,H+834#+AM3:D:; MNDJ#FF4Y?=?LR];`,EN)8N;5L:2NTCAF]9V>95C].C-O$%WOJ&MIFVZ_WR]D M-[/=NPNFVP83OB M48^X'%UXT/A,VH>8@WP#8ALK(>'YL+T8S3P^\BBB,1,LC.K-1U0<9>R'7CBD M:LQI]RM,I9YR0J05:T>B6$84)B";1I[R3:`AQF12ER(->Q1=:#_FD9G#7[(? M\R]'O_Q$H8M8K.3Y,<(:R+Q0!Q:.AM/8BU\6QHRP(@M5=]&^1!>:J6N?/U]I M/XKL;HIJY*4GY)F7PD1A7@H@+9"C":[)8S0/1EB.(F8>!:D.\WI,/!-^D1:( MYUV.UNHYTDJV821JT,2,*K]K<*9@^"<6>0D7IRF&PGZ*X@DP3>?_R\I-IV&U M&`^+962"*)G'"V6X\_+:WG"((:0C_$,<4UA'!D"=4AF`Z[1"KA^*3/Z\O`!0"R9LB2!`D(M$@Y=>SY89AYP#L_JW?)'AU[RJ(V#Z#G)`G)]K!WC3T3E@"0%,BT#5#Y6 M^G+ZDBIFF"9%-464:I]E!/&Q&GHXHLJ]3U11/JN;DL<]IY.GTU$5EQ?FQ1PV M/\RK,F1@+U96&D7#.:]@0T@@0,VAIU(Q@B\V*JFP?JQR/05L06E;;LYV$T>X MR[SKG';K:&\=:V>UTV8\[H`%P13C[,.'O[V!6?%S,O6&Z6:^PO,?8MSZ_P+'98\]L>__`("<#1[?*?U#&/ZG1^S&D$2 MI]-0$.70"])C[#Z:S:*)].2HY'SD7XK?TY&6U0%-H-GA@P+(*3&JA@,\@1SA MW][TWE0,+1^]0ZH2]8LF2);.]C[P8.5A3HT$",T,3$*RV,NVRC<*V_^=1^M_ MQ/UR=BA^P7R$*@Q_GL6GQ1KV#NBV+"7/#2'GW!`Z_Q5JLC-A2ICB`72$<(3G M1A2_T^*'^Q\MP]$MNZ];KOO3FQ)2B3/",7XH(A*P\:Q0<%*'0VZF)KD8Q_QA M-547WU!,_';UJ];"N]2^B%YV=-,=Z(->!9.LFK\1#L>!M:5WNWW=[5JO"FO3 MU`W80E:W0L2=(=H]W>FZNMD;[`+K347//Q_A3E$F;TKA^`)7:;@")\N8U*5T M4_*6D_1'2S>Z("\'O88S_71PR/NFH]O="EXX4KB[N@VG4[=KGQSDEMX'R=-W M*XZ8>I#+>^UGNB967)>;77U7WIN3]&W8@M)&WQK>ROCS3A>$`1>=`J1WKUE M5'.-JGALM+ZWS),@DGH:)=\RO\)E[/\W"KW+<'2%S0:C./0]*N,H=7WC326N M0<.83)EX817]7%==IZ%K#LK.]]746$G%]U[\X/GAC6@[^!O\G3=NJ1<\9F)M M/A5%UZ.$H;'3=WZ)4]Z)XEB6;:JA),J ME*LR>F]WS%U%?F4MA",GO[H/I]%3J6A-R7\E6H#S*RAL_(3WH3%7RUG#VJJ< M[:O+'!B52Z1$87?(5XK3M(7<".0C]J\1GW*I*N0M3+3R['$J*DP-BB4NCH,R M.SA^U1JZ6XC!/@X"'/%)JRXCTA_TW;WSDE1C_%K4#]RP5)PZK[_G.(7:[9N! MN6^4]R-JE/MLS\3[D,76K1$-E`SZ5K=W%/%`BF#=SBR:OM/D+U*',WU7$O_# M_ZGVZL"@I=&M^0BE7B;778R*S?U,=2BX'$S\)9HQS7JW%$0F;.=J2"0RJQ]6 M8;@FL/*-OP)BV>"??TZ-_OQSO3#MLM#FC4*W5U8A;0+=(8+(/?/"F<^CC(.`U_CER4D45ROZ MBP6YZ-6B<8Y)XG_/6XTE(JR9:@/G7U+;4!Z/#+C-XZR?:!X/"S-\CA+M,GQ@ MV.SK"F\Q+[KHD3@55QWJG,D*T[\=&(8.>IN(JG[VL"FFS^/`O>2QV/#3EVVB%QQ/MY8C\X`3;2!?N0S41K7\8CE;&'6="R)IW?X"<16LP+-GL8L5/2#32+ MXT8*O'5,W002BJ:/^$:1XJ5S?8ED4(?RB9TO0[2$>!I[G9+I;=_MZP-<0"]) M@]L9#V3V>#/1631;FH`&3\,;2U;O8D\;;.\[&HFWL!T\7MD-R2(HD@B:B*,( M^1Y9.&`SQLD_CK`^&9(_F4]@`NH'2F'HGA]K3]@F*/,_>3>)Z'X,VW^W`6W28+IJTORBI>%N;+2G\T^>')>U5H=^E_5Z(/UC:[&51_2J?QEJ>I2(V23V.61O:MS4' M+(%,&7@WZ.E=V]@VI&H:E*F1&\9IE0!<#\J\+IR0%RO(L-%J;TJX)L-)(8:N MC8K&CF';UJ+6WNE+`"]%25^D<=*_1='HV0^"IB10CUA[C%:]W?9,L:63U@SFC"8OAG8`GQC_Z4_Y4S\J>0F40*R]XO$8T M)KB#`$`;@!]K#*">D&ULGK#Q/-`"_XE;%1*T0E&RN\CR?X[XI\6>6&=JPUD^ M`>55$M]0Y8J8*BV0^12K#/BAQKYCD0%>WR'^"^0<&6O0JN,GF5GFI6)E\F40 MQIT(&[G"`WS>LR5Z>GD!F@Y1>*6E0D(F50J9(15E\Q49)6>SV+^?\*R9UHTG<(: MH:O41U/Q);;'XV-FD#ZDL&,G/>][![Z;`]0`3]/EJN$Y.H1%,[6#HU$]9K,X MRJ6`L%6SK!A(6>&2>R_`9@M:\LA86@[C`QN*U%IN>7:X+!.+(14R$4NJMJJF M>^4>]I#,'0H3/.Q3P&:(RD?,%F?*3/&Y!*:VAWJ^R,A"BQ9[G?-G&&D`8_C` M.-1TC0HS94<%#T!!S0OA[12R*%RNK5(L("251(GBQ>HJN%9`)O@K+32"^T1X M'@2]D@+N2EH5EZY`N438J9/6@'P(`W)=Y7S#NW.=1/T&%SQ5:8T54]9/X+\H MIO`OB9EM7)A.G/3V?DA_2372X/!L?KT[!\R?X/!80GR7W%8&\$8S?GB7.BVZ_ME/J@T&*TCC84]5QQ7Z;U&U^'`Q#K;O166DZVZ``\9UI:EM[? M)RT/8M;GD^H>'"DD6A- M#XS366=+-QQ'=W<>,7"R!#+U@=O;`X&:^A'2)_Y7IZ-]\EDP>J?=>`]PG[YC M_YFS<(AP.%JGDSZ]8"J8PK.=^YAY?W7NV3B*X7$O>/9>DF+$?K[7)9'%YZN-X?!'H;CTDU[.V'J%U M5T2@4UPQ5B&=1%2%5%67N!@6C6DZ/IP29+)EW]EP/F-4H1S.J.?9(T"+-<@? M1,PA7JW(K(_V72UA,0]5U^9A9OC%3")OR*V:9%!EW_UD5HC6YJ;5F'7$XE%( M]L-#S!ZPW#D,9]E:'H^-$]N.(D1;KMR`!)WCTXLVS7N-"^(Z%>+J+1,MMR)DOL.+R`-J62S] M0@P]YF8)XWX>%(X>0?$@#UA6T_C1>V+:/6.A'(V?U@Y/`9QX+VC]IP;8^,/D M0KOD-;0Q5TM8JXO<@09SI"'&1\.0"XSIQV M<%R(0:^+9Z.>MP$HL*DV9N0VI&+[Z&.="I,^WR:2VR)_Q0/.8H(]"DZ&Q5L\ M,4H/%#X^?^8U:9")76D#U^ITC:7L!SGJOPBS<$]+?DKA MJ%/D17!'Q!!G#;CG6L^X(7T_8C%@+<^\3SCRJO:IT=DAI#X[> M'_1UM^>6)SYLD.ZP]Y-DWV?*999V@BTF_#S%A)\@I7Y=6G(/O5/WP'"2N"GH$""\^N?%H3=]:+D942$RC M+?I$%W>(+QQN]R+=%<5MFN^J&B?-`.$]/C!LH.#=S#,_%(D?NI3;Y2^&F1#5 M\^.<)_J\9T-OGK`LJ6@QDP1C&=@H]^PN,'R1]G%6X@+QYB4P\FU'GU!LV7VX MJX)Z/LKU#IY%M4+QV$K56+0;4M0NL\B!5Z#?5^:C9=RRR$3HW@>M)O!188NY M_BXIM.-YC$UVY#1%TF^P>TS@_[<@M^#XIP.U$$>P(LLM/[3[G0[RGW; MQA8XG7"#K>2KK70QG'F^VLI\/=G\YMH#W;;,,W>RO.*,-5AA4S><52M\+,NZ M95_#IXW23$YB@;'^_^!$5K?AIFW3$+>:-F3IMFG!KEK%+:>3B+AE:?%*>II8ONLS7_2$;JV8X9*:`UO1TB0CT81SR#96:1E'GY&XR_37 MXTM.+!]C6_>1M4:7I935M_1>?]5IM1D2)RB]I)5^7V8#/00GG;#D$M;B5G+5 MEEQ%6]])"2Y%;'TA:WG'PJTV")EW\.#$V&9<52/K9\/$K=O=)V[MT'R[G+?M MD M3=V+\0NI)RC+;0^C&_\T1QN M^(4T6^Y8%NY.[[M(/Q7>H\7U2LJ]V`C\O8H!EYO?R\B1\Y[?T`,YQ?I+%E5WSFR!>TG,]\))_8 M\[@>N:M_&D=#!NLOP)BQX6/H_V>.:>>@J0:LX'"_9X'/GM+JK48 MP:A/_HA1_J^71"'Q(E#$Y^X_\6#*937V@?JG9!,?*`SB<803),R4MQB)5%-.DY':?Z*XR>0UU[CN;!B(>_R15?>:`3Y09* M(EMV<48)4^"1S@X`X91\'[#Q&(4(5IQ8%A?3YI-)24UG:L8A5\XABA*3T M^J,WXG%\>:"*"&E;)`6'B^]58B)8GRPMGH"/2)S\9XZQEB]4R;<:=%Y<`[>4 MJ`N1YB3P1T$0HH\9MLEUNC@SE"6<[HDV\H%&DJPL[O9_ST%?W'P9:$) M3)$*29T.)R8"88=#%J0!.BF7M\=Z*4TD)_K662+U9:*P10?XTZ>8H#BLL42&S'(8^N&;>6Q;YQ1>2SP M&$!!W+.#D/1%(&MWT+TH4WBK\B#<8\V#V*FV7K.6S%+8R_%7D]FJIKS#<*6# M9GB`)-"HFR-<.OD!`"3^FM=+^?&/T`/E#%;J)]5E\IQO/GG8%6=R*?@J86FX M>DHAU!XU4IM4QYRR+`W\[&67"GYX4$Z#.C!Q^12A-Z@XD*24R%NV7"LIUK1W M#GV173_(:W54%P+/X=:^45\;3%BYQ;XV.O]"!_K&_GC[Y6::NS]7%/38N(;, MNM4["K4[WXWHTKII2[+AW=A#OF M8*6#:!4DS5$Z-DI8.A;><;O6JZ>$:<*MW]"M[BK1>?ZD0)N)JYN]50$DZU-B M/R$BI4"A'SZ($E5`Z(*`'O77F7`J..#0V?=/1[971U:>! M2U>WX=CL=NVSP,;2^R#J^NZJLV^]()PMAS$?U)%(G MB^3O(H-,?6N-Y-#Z/8H9QC3H/(E:]MAE@"T#([P,19?N>#Z;QZ6`\B@*X:62 M9D#R<%L3-SJYN;MR"1.9MIEWF3\NN=2Y31<;5:*S@9R-]R_%(@&\$`<9@Z]# MT-PG#(N!H/8KC3.%)1ZBB9E[LM##``2(>7X[&9G+'O9&T7263YGZ8B3[WP)6 M%V@+R+PW"_07Z":IZQMC13V]_[+N./G#Z/Q5#:/12 M?P*W;!8(OQU,F]E6ZR%JP2G;U_O=KD#4U"UCH'?[5BU4BUA>)BG^3L%K'`U% MYKOP*`=>@A+A)64*R>TO%4N7P":O*."#VV=(S(/5+RQ[R MQ=@TX=V70Y)2/W&IZ`A'"TUH"LP"X+'I@%.F3^6=Q M$W*1A:(MCT12%W;Y/S\W:WG_Z__[_VC:_ZEXYR:.R%![G8ODCR+LX6O\&3;K MU_$E/U/8'3`"DWJ=?P"A<.$SA-SII.9GTZ*3D)6-88P%ETG(02ELSCVYGVUG9F`Q3W3L%&>[$W4-'$ M!$4/]+PSHTR#W:?D%@LT0U`,#TF9VZSLU#4J3/[81Z7GDLY[,?SH,AQ]SJ,H M+WG(ZF76?BTCC;^#O6;UE#+>-/K=GNU44F]#]/9//L%.2O+=,ED5_SK.J[%^ MRXIQBD)L,&]>C!,^2$-]'5^1[GD=4NTV\<+*M5!SLNL8AC&HEGY'NQ97/!I6 M^B%-G18[3;E,:EHY1H4\[-F&N1M2K43E&*EXI,RN5)K.=`'S'"W^\%>\PWU[ M],(L''2=;=!54M&U3?W""JY#FSMP$7CB#)SYFAM1U MCDPE@6#S#VQK1YM?B<-1D&WK1V1/>2D?]+KVCD3!<=/XJ,5&A7WI"';%E9<\ M$L[)(S[QY`7H8+F<77EQ_.*'#_\@WTM#8=#KVX"W"NV!:\$(=HYV+1BV`K;8 MC%5@*S50R^@-NO#((>"V*^$&+C-[2KAMU^SV7.,PY%YQ9)AJ?=&R>_;`9O-.`&ZGK&75"2:BPQ2.0.7C1 M`A_H@C$GR2R>\^B4M!2;:(GDA5H4^P]8]P2C]^:Q/Q/Q35)T&A;\P'XQLPAK M1%!7,)83_&*A80QU7Z,80'C=GT4`$@;A3:,LH1TFYJ6C0.B.?%%R@^;E]1GR M>#V$W)_-\_>P%=;P$0N[^.$32V8\?$N$_A2Z.?#X/9R%QVEA8'WP(G=76XCA M*O3.D6,C^:A4C.+)@\?G4B`8]C,>GC1DVI0DH2!4C:K`^S<1?I-4C M58%`-*K:`U']'3:B<9&0US=?J2[&8Q3/.MB^#"`,_\*H)J3PTA38KVUIS431 MEN4<,R(8G(;BV[)4Y5W_O?+D+IZ_=8[L6R!Q[&.XL13 M.,GSS4EG^2LZOR7,24#S&D-TSM)GN;TH'9=1/(VP>6D6Y(H2B\**LYCBTG#M M+YX(??W=B_]B=&Y]FH>\<-K23&EE-A@P/>Z>H@#..`Q'C=D#'^DJZGR=+HP' M9P]I8SE4%.:_T"65\OD5`/FIDI$6O5IL!XDO9Q8R+0]9U3Y$PSDOK41J#2S2 M$,_I,(>88LC3>2?9O#RHF%+O$OA\5$==O7-K^03F#V@#$3T'T?#>?3@-*;O""G-N2-6[_R:!O=?=Q]V]0?"431_!HDVYV M-']?3"^32!OE.Q+TRS`*.R1?L%7@$ZCX[U0[H3PM88]8U"GE>V`0KY?+A47S MN)@!AG>/O,WQJ&D?[6 MR\O691WSEIKN+G3UELIZ(XN&$\N=5//NUEB0+;4K M%+IJ\V06N=4>$T$40BV6O:*B[C!OU"YX+E/K4M;+ZF&O(_303%*^YTP' MVRPO[#G0NJAF:>UVZB70YMOO8!O%/8V-Z M.Q7U\3HZ]H)FCJ!]'?\33DHOG'V-;Y$('[^S>`B'#O52SGY,Q*^)67JG,#NF M\^?=_#[Q1S[<;>_@6O!U?#>#&2DPX_KFZZKXB>Y`<37JP/)TOM_'@=])'CU` MYLVO_0NSX)5!O;V;QG+WY M>8-9LWNL-*LJ'G[=64NR>)O=4?O=?=U1MU^;ETXUTWBGE9X>E7])).5N19FH MS0Z>D^M.OSU;[M?,+_8Y[Y[[RBH9IZZWM"X[2=K4AUN_Q, M#E[P)LD94-1RSSKDO#4-.H+AT'UK65PAO0=](*0F]I_8?4RU`NRL5D!:OL3' M:B;17U3*`H`:9K4K<+O*L%R4[8GW;/:,A0F6%!O:(67*@^Q&32_P3EL`,^A@^S1TX2LX_4,"TGU6@0)"K8L$3- M0K.AMZ;NV!91TK1UR[0W*<,LVG,=8RT.:DQ+[2C2!@N-BE[G#F$L/__6,;!, MF\F+K?3`%L9(<`;/.14[BGB)J(64O-L^%-NO!4Z\"=H,57^M4QI\PX+?VZCR MVL-*!6(!0GO6MUM0WKH@IBUUWH5 MYALM\)8;FM9<4DMWG;YN6ZMJ4A[+2FZY0SLLZJK*HJ>YJ*"]K"[D?"R+NJ7M MV3^_E32Q/I_>&ZQJA'XL*[G][=E0,)W&HG8-4S?/=7LNM16X2!L+?,-2B-X8 M5,&FF*O'?`4MQ?NZX]APP3(.CN'AQ<0VNGWO9-#5K:^WI;AO/),DB7JZT^_J M?7>59KL][+;9^SM]IJ*;H&4>;S?!XS;6?O9G_@.9WK9DIMVUA66M%NGR3SF%<;O139ST63I)]2Q^@7-@T%&'=&B%2-W,,8'_EO,L4AS11*>[$$^ M?`SAI3;H:7M1$>5#]BS1))F7FHT9B.XL6(`Z)DM34^04UAM%YJ9/8T/&NF2"[3EJ.+T1..%>1%>(946C?U MI2_7'1_-:;%&;.Q1%6'>NY6J`L(ZZE@)?8*"!OWW(M+#QY6([_VT0+U(T$$3 M,[Q]YX7:!Y\]1+J6)^MSAAD&GC]!#Z8A#%R)A/] MH,LY$W/-:"M,8*TID$_4B-`+9*?TN[+%A)GP8`%:IO$FHK`W$G6>I$VT)]Y? MY'5"EO9FQ)7(U^@.*H=+Y!1&(;:3Y1C=/$8L]+_K*807VD?DV0P8OGBBP72V M0?A`Z2R\:KL74E^&)W\T]P*=Y"A%MG2>,<&!NLTOQFE2KX.LE'C*+A/OA;(2 M0F\.:X!M22E`%6098\6@6YZJ(8K"H\JAT\N9",<X-@*Q!WNY>@+Q.DOF:5.PI`30-QX`[=Z\"0#[OFL#5H)XZ],L$7:?K&M:F MP'V=SS(1N@[Y!NK@M'ZW7TT]:>Y-H%Q-1\M00]GM6M5DK`/EVI635`&/@OM* MP2I+KUH)RNIJ2`-ESA?R6ODZEH,"2M\C7!C@Y+RF9BT\K6[#.B]6O\T.;T<\ MZA&/S!Y5V(G:Y[17Y::YX#6,&_O%17XUS'CJ6W> M9.TP,M&][F"E1&I*^<6S(<3`)G[YN?63OZZH8`W^U;A8B-T>!^V(1SWB*10+ M*>Q(LKSP+:GAGMR;.*T=6;DSX?UIT251,$0^4)Y,6E[+7^$#P2%D^Y64[,O; MS'&[DDA#BUZ\8)9VXXO(\B1W,^6-#XM&K$(!+F%=SZ#S0B]X27P^GJ@8ME`% M#*V#OIQ.N5!1!`::#UDZ8`R<4!K.KLS22_SO"P001G,@@MO]@=I:2A>ZK.17 M#$/Y3^B]7##:^2/)9X-%T6!EX<2)D]3EDX__$#-TZ>`/(?#$#VF5KY))T*B7 M=9:4LEQ/[216GJDK#M\;%N,7W@,SET_?DL9D2P.\?WG/8)&Q]@MELUT*&M]F M).;);65O?GN9,GKI2JSETC/BW=^]?T=Q^E!"K]SYWS_E[+4J@ M,S3HN=T*0DKT6:*DZ-:*K:\VO-;V6CVF'?&H1SRR:^T-".JA/Q5NOL)>W)W" M5_Q%F$7+>L1+';I3!^-,O$K'(9`0AZ*V!!HV);C@7BQLH?X8 MH8(1/8>BG";/8=877N">V#]`P&I?H@MLL/OY\Y7VH^P^XYY4V3.\5%9M],M/ M6>*]!\]8A'=AJGNT]+MY]&^Z\BR7_;QN8]BVB0G"1@ MX+[!)OQ6#^?D*.T@/XOAW..A:X(>&*RH/46SPI=BC"B6AKEGHCXU7&-BC(\) M&9P#)+8QGBE']"FE^<)P^1,_RF?M/ZX_%LY9#,L4T3XC'EB9:0X$`#R/0./) M4:9'7&@Y#6"DVO#S?0P&@U.>UB28?).^]'[B8\: M/>.M/M)&`/90E&CB51!]$?!%$_"HJ0AH(AVD6#<<#E'Q&CSVO^$^#VA'$W\H MAR?2B?GC/9\QN@_2J%&,+;I/HOB>?IC@C534=4=[/LL*IB,`:?TAW&#7LSH2=624&XT5RD8 MCY;$LG,<>&0.@'+"9H_1-C2MH]O%5R)$C+B:@O&XZBG3&CB":A^*&$-,EG^8 M!^DF28,F*7KTT8\C\066'.1\)+88Y\C"(PF+GS#>$G>,J`Y,<;0\E(P)^0F< M].!1-RBQ,CQL,_">J=P\O#AF2<*K0*01D=R(&VLW5XEDLM-XU+8(WV3)*ID2 M85&VI+.D@7@RL5)"R_@L%OTGFR<2RI\)T@)%%@^WI?IO MHI#D\@[SQ*9=+7G2S2M!>)E0Z+DN/YT%&B(L/I]%W,E&J5&YM-STRJO=,2CL M56KXHO8N#-Q/[#(O%+V>PNZT/0/:$8][Q"-3V$L+S6_/<'9,3KT[C#V7RC>3 M2`?1!&+*3QZI,JE\35?J2QQU5(Y_J M^$BGTN+)F5?/'^-J2"5049E(F*A$RAL,4"G_-&ID.H>#'W'+LSNRA!Q$J9`9 MPPM4Q0+>Q4EQ*ODXBA>Z*41U3ZA"VZ##G4WJ0V;Q.$IF7\>B<7WI^=.KVQG0 M<)2=&7N.Z_0+\9S2K(T`F=:+CJ)I!&WW*[ MYI9(5+OWH>&J0W![]L"TZRW:!W8_V[A69&]G,:[UBD^ITKWEY%ZC)+F7OE,6 MHJ+YE3GO,&BIA,]'H/<7BR6YKCIA>KT#E8I==I<[*BPD7"]#(I%9_;`*PS6! MU;Y0K?P;7BN_`F;^L5B`8#%#?"<6N-UFL&8U&LU>6:W$$0M`\,>49?K6=%TL M\4CM!;+N`GAKA*M=+(?!I#W_1&Z6*/V\6$Y]H?@WO?PBC\?#1H&916BFF1?N#QI52@_#^23MZS/EWE0`0E3-XWTE.,6F<''/Q\#4 MW@B3AP'XG.R>2&N+&2H^2(!\R#0?+GM]<=EZI5C\\]''_@^("\8Q8:Y>]"ST ME7P\I&CE41=0A:T"JCZH MF?;*;=(U=KQ+QMB(8(O;Y-O?[Z[X5M"J^-YIP/>V4<7WP8M4FK6*[\O?]T)> M598/T3U_GNNNY#E[USQ7)9FSL@82QR6HVY7RG##4YSYV+$SPFWZY3UP.7^`)=7,_HEO M@&,]"5YJ<'_?T`?'I;'XWZOTE:Q\DM@W'_AKQ'4KU14':-5TKW`Q8N_N]%B] M3_+MFAT5EP6E[BTLL;LTA)_W'BPH7E*>QUO'T!UW:6XL*G;/\GVZ0(+S/3-H MS_17;IK>S@TPE++39-O@-JO8-I_\&!;V,P7Q_%W4J5JU5QH?*SF+]2MVRS6G MC=@P&+_0;-/HBATCL;NT8;+%5&RS!5;/#3H"A:HMNO!N"?H%QEU9JM+L'V^I MRET7\`-5I\Z=Y=CNUV0#JMAW__R_[_-^Y/KJ$\I=_X0Z[);[.IQ%I%`VVV]Y MMJ5\*KEE9BO%J;3%0^DX]3C:&^Y)GDD\\52].ZX"V``@!F'"?P`1L*MCC3VR MCA9'1'0.NT6`C.DNR9;SK6F5:&[*7>+*N\3NU7BUB/CY:FYDS:YQV;=WO$O0 M%K1PR:>K/6H'42WKOM%8[THM\:989FT+S&RN9N;%&\4YLU=JJBCM9%?@,*>K M#]S=R^$E44I,]AL6/MZ1]#2-+;)7,^7`-,ZI6%I(05)9%Q5 MZ`:'?\*[RZ:]=WO'INTB1W$T*[O(2?V::K>1<_K'VD?.:H(O]I$S5K4S.:\^ M5>>:LCDX=0'!R_8Q$8E;V) MJ*7NINSU:GH==6U'MU<*J.-K=%2>$*`(T%Z.XKX.DUD\1[W[DS=DEQ/,D"TM M[6QUS-Z?[T71M\O\TD$UJC(C)E:6PX!.BN*4@CCA9KNJ`XI6W043&&;11!1,5(*]6K+%)(E:)2N<]+UE&+2M7>-4K]C&@U0(A/H:H24_.=T!^Z&"*4E M`VZ]&>-==/+2FP?2O"QUS5"`0(5N%2);)<`.=+/E1CT9PLY1(+P/]\^M]FQ31,2UE,PW1Z_>(]HQ*.#8$NJ[3[F,`]O>"G!? MHG"X/O5Z2NHY_7[/Z58!F,^\"8RK:=A7TM!QS5YW0QB7Z\S(I/MSX4%0NKV0 M5U#,VESD$JI.RPI3:3\8]+INV<96%*79'@*?>0#@.RS_X1R;@;/^_O_"F(]C:FEZ^%06_A.[,XEM4(T&7^!PE MES!3P)(K-'*\I)KV93CZPI[_SN*$O:P\A`RE;643:FT@+7O*BDB6U7,-VU5" MM$(<50-60U"JO0\#MU>U+[8!V)]W:<'-.]@*7NQ'O!N-^'`3LR>?NGW?,HQ= M9*-5*V_UE/O$,AQG4WPV$_I])1,X?C+U1S41WH!:";J_0>%J>M"$XM>]4[D#I&'5MJRN7<%P7 MG"8%'+N&S-Y[B3^$-S[XP9SJ[&[$]2K)U8$+2X<;MQ*<-7GS M:\>X,"5,5L"U(1*->'^@('\Y$K)=5J+T13)6L5["3 ML24D-NBGV0.M$$1_VQ#@512R_QPE">7E7463"59]0>Y1Q0$O_GU:A>QI`U&O M(4)XR!&FW8O)':2?CD,WX6Z(F/"<^&W6\)Q:CHR6<4^H; M]K"1QDP*[9FESLB\"^.%E@J86A`]`$3P/J\G1:V4L)]C-`-\?>I@/<+1L#], M$09>BYX7UA3W2Z`LB`1=+DTOOL$43/I3BZ949G]/_2%K\6YE6M+:#+HFN`N3 M4/A\GEBX.E,0@>%P:-](B'P!(7*+0D3G7^C:';#)>#&G<%7.8@[(BJP1ZFXJAY>7A*9B_:.49.&G^3:FX+51= M7ZZY+MK`8G+S[Q&U*/^(++ M2?#GBJS3=73#'&P1U4V%B91]OB597]+^9T7"L_K%G'0[F;+%I<5EM[CL\JS' M/_\I[%M::M]26[4ZU(UX>#34'NA]Q]$'W8J[PJDPCJ/WK;YN5NDFIX+*0._U M>KI9=4:="BJP*B8P6=<\FMV\=-A6PO&1VX^C<6XO3MA05(%[=S1D;D^`%I<3 MQ&4?M_!%D$KM1/F7^(CD-KF3O3MJO-YHO^\H*>S7HN5"!;KNK7S%XHQO=3B$_3ZK6 MN%RV5%V#5U?>EL>!D[5M]NC-M&<6 M8QLS#,8&F4'-";3FK= M?W=FB_*+)J3V+2N-1VV2+E$1-)YOC9KQW`M1VH14WCEF%T';Z9/U>W94OE=& MJ<8](<0,J@#D%;/5#TJ\*(8EEH=OW\?:SP35<\!7:T M]T/]&H&^9X/HJJ#LLT'T]:[HOD.+Z[4Y^2-\8@EJ3XM9;.IU4C?VJBVEMM0; MK'30DA9K*I.8/;!UVZX7\KEU.,^`?JYCZ;9;(;M:^K7\=R;\MS/S6#W`:@:< M;$UM7'L5ZRZ=Y>A=H\*$LC.(CIKNU6VL%=(DY9/#L`G^U!5RZC]3P]K MI<[.0;X-EAIAOGJVK0A">H74:!EDGPQ2T]72Y&]UA:F%HE$+%:8FTR!Z8>R6 M!5BJ7ZI-NDE%>66Q3],>]"RY/\S*^3<&=W7]SZZR(F+7[`WDVJ1K0GO'XB=_ MR-)Z7VQT%4VP:0!5P?L2"9O'Y;,7CQ)JPRO_?A4ELR_1[%\,X!M&#R%P'794 M\*/1IR@67^%S9IUJ8'_2)%GA[PQ`5.>_3N6^+UFMLY[1?_/KC?4O.#D_+%-B M/ZB=&%EO,^,5$7:9I);Q6DB:C\1?^CI[9/&W1R_DW%92W+@1254%^GJFNJQT MURZTZ3D8ZOM:@7QOJZE=04E#67"U:]J.T=T')244BE13-RKX(V'C>?#9'[/E M#9S6K)?^5#7/21NEW=Y>747Q=(W^"%ES!=X784D8N#;*U]Z_KDR'`U M3^!ZQF(Z.G$A'_UI&3$&)!GW3XP2H:XBQBWS\F^2K^.\?<:W1[AX/CQ&\]EE M[/\W"KW+<'0%:N$X`I4,/TA#?1U?!0#I\#K\QH#]Q0O;8K`_;['+!_W^.XPU MF4^*M.YA[Z$NT+K;TGJ;M/:^+],:^;IK'VB3GRZM:TJ,KK-#B0$T&LXG<]+V ME76T"VK+%HX&U5%LJSL?F49_8';KT$"%T7%0I'+-U711WS<-L^M:IT\7J3%I M75Y15IKO#2Q[<)0DJ4!'W=#$Z@_Z(CO23:_EV.9RS^%_/B3[Q(;V/$ M;&6#]ZYK]%V['F(K`-L$PULV\3!P,X8#P4^&7H"#KK6$ZN8!U@`VZKJ8E@*X M"<8;+:>M0M*VW$(_H_5@VABO:+[6XMG*HV<+>`%,F^+%@T7704PI6.QNOVL[ MFR!&0&V,V7.T%E[JWCAFOS^HJ2LH0:J-U6\QQL`?1EU2-^2Q!EW+Z=>B`2%P M"'37U(64YXG=[_4&]^:3CTN/`B^ M:X@'I=+9=QS#W`C7H/R.\9^Y'[-1B=_H&,S.RM9^MI(I^F:)?E>-^\E1:ZV- MY-K*LZ=G'81FIVOL:\JNW0K=SG1+=+N6^-OF_J[Z2FBZ)9KF05;@B#J9*Q5S MT^W;FXJ+E('0?9J44J9^KT1U;^/NH&?V9$`+TS8#J5'G0T?=S]CM.@-W.R`U M:N7I5/1;=_JVU=\:F>KWYW34JJQK`*4$27<$WY"?U/;QK]XN,OS!Q4[`: M\93:F^+8[E;!:L17%=>1?M3Y*U.1K>.<% M[.OX)D99.WNY";QP]A'$&^GW&W895;L_3+,`:SUHMH-!&;TED%57%>U[\B[T M@[^]F<5S]N;G!5A8R&(O0,U@-(%S(YG%'I:($.:Z#;=N5WD4."#A#+EA\0I` M-H2ZT0H[]V"W6CC:_6ITS#M?I]N2GQSHE=7RYTU1X/$`SPS[I0 M1]'HV0\"941OL^N@&@.KJXX5M+NFW$8YA:DNI(>_!U2@W5?RFV6;Q8-F3;PK M8JY=)==8J#UU[?4G7QWP[:I]KALN>,J:=S-OQO`0N!NRT(O]B)8[_7`3LR<_ MFB?!RRV;1O&,C58N5D]IC^WV>E9]D-/[PP=J7,LC@S>36XXZ0%3)1V50*.`- ME^W?XB>>U]"D!W:W9QL88(AY$R?67[H=\?6,>&2]Q-/]5CAG,OT/S)%&A`%YX9`_KQ?N/TIW;/ M9L^,A>FC_$O`:`BW)0__Z\?#^03+H0^Q-_8])@MH4:C!_=EC`7&<%2%\COW9#.8<1<^A]OP(?W$(V6BI[?DN_RXY]%8=9<43 M\#JCZ]?Q9U@.LF'RU_XO"S"=YX_-KASH<%9J%=(-N18@6X&]_KT#85_P!9&24>,'2RPLYE4V5$,=HE9!VQ*,>\\8V(C&=TAUR$Z7'^SB*Y0,9CS^&J@K:85&UB3708N!HYZ>P M?/JB*N`/X"J9*$ M4(')`1M,H40L<.9E[$FEN6?RD0_*DT004N>6WZ,JOHA%3%5\(Z[:3>E:FF@, M2VT6RVMJ*-9)X\"CZD!ZQ3H'U<)1%PZC"4-+]B<0#%?`KGXXAP7_"JAS1_![ M!M1@_+EOWG>6?/P^BSV@DQ]Z\?1BN@.FDT;6?6G.T,W6S`=94O;J,FC6!&229X[(=8BGL242ENE7Z@ MTSNYWB;4"Y^3?N9]UYAPP(%2XDVGZ%6CTNTF(J=K-CSPEWX'G3; ML;^)IM'K.@-;*=VZIAQ%J)A]?1#KG5<`HC6HJ,"Q.Q`;*2`#99P`Z&NVX9H[ MA++^2390>CP[<`Z4*)5UH=S`'`0+[+AN:P[:V\E;>@XBIP@'LO\_\+ADI_MT'L-QRA)N M%9$GXV1=@>-[EAZ^L0CO([#2 M`!)MS,3)'XNH9AA?A#7SW[#+#<."6A?:AY1$"+8"Z1BA2\C+@VXO;K'!Y]%O M!M`A9L)T`DC+Z.K:\Z,_?-3(*\5\,N'`BPH\Z">/,!NA$C+T(L+5!@>-$4^6#M5E4E#!IVW7,_5HA`VGS\&>:S!GI_`W138[2_4P8$O0K(S9O;0PHO$S??H M$$UP5#1I3M%S^1T.JY#SQOU+^AH94>>P,V+B8LG320^PX6.(I8RU"8O]W`.= MSE4TJTY`%O%.]#S4&XAW59DB6<:LD<=JV7 MHUP`.H!%1-M"2G*BTB,V*M,>4#J1?QPHZ!H_<(KZCU$T0M3N&9(CY6E.MGG` M#<,:W33FA/4Y,OOE3&5(_@""@G]KTK=.\?J()2X$GWF90'Q9/BT+&V?A2K=\ MS30="\O^$@!O38L^Z+@&*'Y\."Y>=&YX1_G]UN[F#]M&V;/Y(0%R\@=0($-4C?"^U:!E""/4DB/)%1FI/B4:!G"2+":2`<%^1AT!YXU"O'O1#W MFNW6P@[/<1O\DM"4,8-3*.2+BY_QHI_(H1B+4@?/E5S'K,1H1;3'&,2/!,Z]F2DT-QQ5)95`W8)$\9](;UDC0%==R,9Q!GUC MR>B[,.5:4*V.W%572[(';M\LN\!70D5F,!"]]-_K\%+H'S?>"SY.8=9#6'JY MTO.&B2FVN@I2UQDX;@&#-<#;#8J-6%F=/^BXAFON#44%JS5?,W7EJL[`Z?:= M.@@U9\(J\!NMA[H44-_M6UL''E>K(*->ZB^!Q$1K94-M!%`CHKIJBZ=C#JQ! M;P5=RX%:A4UZR=U*JJ'I*O.D.J;M#*S*G;H`RL:0-Z.^VI+KV*[M5F[)QI"3 MRD?ENWE0Q:9'@-*>;UJN.U@!^R(PVP"_.C%1Z2)IN!75W1,V)*@Z[;G7&U@] MLXJ@:J"VB4ZS\U.=:=OOF^Y@-^BLUM'6X'1UVKX]Z%5# MPQH86T>"=FHJHSYG5_T-MXC:AVBY3N5*E,.S+2R:[0REL]8%L=^U=X3&U]1F MO$61I0YPLUVK^@Q0PK1%9)HMBS+\S.VZ3J4FM#8N-S&;PNTW7="TZFTXVN(Y MK3Q6.I:%PJT*L3KP[0;'9M)->=8XKF57"K=M8)BW=;GRDL=/4S"[0_.F^\XLFK[3Y"_29NOTG>CIVS.,Z7?NSM?X/S2_ MLELE#%KJ10CB*F(N=T1]SKH_UPU?9.0@(4].I"684X(> MC8>8"8;>S)-F2F(/`'Y*K`YU$//65O(!480V=)Y^C1!-%UC1>94W7[KQ0 MHT)K/+OS:XRI*]FO7A!H(&S(.R.\+]QY$8VUO%2&KGV,_?REWZ,PCO*/7[PD M\>;YA//Q.`K^RJ>`62^#>R1`G5F_@$3Z5Q3_)5)@'ZL(08F]\#RO'H>?V'>> MFT..%FKK;M[GG+??+N49/=PU#>_:2W!]%GE@:Q1L]D:_+ MFRT[&:50S8*3&5-_?/(U9L$*:9A)ZCI;\HT],HPHA35*O&'F<'P[,)W44RA\ M@Q1[(8A0C$3AOF">?,V&<]FI5T+(G/M*4Z.OR].%!Z[5Z1H+W"WB#J3DGU%> M:39ETA*$X=1-0#AIY'1-(1OE43A)N@PAGCFTC#)OI*[392+C4H9LAG-Y#YX? M)CP"P7L`G!\H=F@A'SV6'?[$!WP@$5<"D@4Q*9V'LYZ4ZU[">ZCHE5)9*Y5( MJZ1*.GT19@&%!&1YY-(,>\;![V_AYJI;KL&]IS&U@4!84@Y%Y(HKZR4E>&5K MG@HF>'AY^2_@P!&Y2)0\-&C-X)52RO`\'RUF?<79JVA!'E2NL[$"[PR-M[V?H]5)1!"Y'.0,5 M*AR,<%PB)$FF&&TX4PJZPZB9@`H39Y&VO\]'ILQ*DB!-TT`G/0OKHQR\+1O=//`<_L6;QXZ M_P(4!Q;[XXK+P*KK`+]22&]P-;J$E)*J7=:4NJ`S:P+O[,9B5O;;EL<$[(%( MX=_>8/%.]03R:@U)1P1UDU,RG?-]`.HGSJQ1^`T/@Z*S9OET*+M,+*KPITA$ M>PZ2HE6KKHZOBKI2>[%MD#;KO-,2 M6!`%^TALC7DQAINM,GLT%3YEE^WXX?Y'RP!-U>Z#MNK^M"2@RHPEF5GG,BO! MM%3,Z9UBX1H)O');TCIODZZY_NOU)V_Q.U'\MK6C_IF9K\J`RDRE/R@LI;?Y M72G/E^$WI17XBJ'-'YJ1*7M-`=#;FN];"P/D*V;JUJ"K6TY_0TB:HW1TE##Z M^L#LMG30S7Y/MVUK9Y0XCO,Q[5W"D^K2YB7'*EEM6)/>P#[/8\,T3+WKKF*X M$T7.ZG=UTS%/\4!T;1`J.X-&PJJ)N,GJ_ZP++1PGQ0 MR,^2L+T!R/M!2]=MT[7O.+IAKA)36X;\.#2!79P<"E.&=6&Y0*U1-(?;>"V% M;6FU:H]LZ5VC!^I]TZ.G]@2[/7N/@8+]@=XW>J=)O_5H(SC'-GNZTW=.46E1 M2><_0J^Y16QK(O^4K"TM[MO#O62`':@?JD-]#\#M_0A7+4FAVT3+S2WNKT!I MM_2!T]?M[BJ[T)&J[9M:'[A*Q8L!86C7\KF^@BXUO)[2'*]QF[3H-T9_M?:_ MINV^Z<`Y]5S=ZKIZWUEUE5D;]/JR(OVF&$Y?$FE6+](K#1RH#O3Z11,2YY:- MZL6Y;3_.3`[,R(J,8:3I6[/KZ.;`YO61Q)TSBRUM6CI8KJM$\:VQ"`J.TJ9, M10C6FJ?8N2`EV__J=+1//@M&[[0;[P%8Y4Z4]P/2];1.1T'B*3S;N8^9]U?G MGHI\O].\X-E[28J)--V21!K3$IL31\U#BQ=8:@&VGQ$X-3B*%:]>W(]9?PHE MD;."7_-8SV2M2,_M!76>7.CC1G<),7=?Z<0LBRT\+D=N M5^W(M0:Z::RR_AW>C=M,"TR71>6H/[BFXII]O3]8%4=P[+=L%=E5&L3!R6YW M^WK7/DF+I8K6JIB>L;<)=M..\SDMZ7:_;P2_I\M]RA8B5U1VJRT%\HG;"U()NS0[M_;8; M1COB48]X9,U15U?%6+N+R%%53U_.W!6IME*746J(T5$&^)/I9E@:,UR:WU[H M3B`"#Y*2SN^5IPYPUGO"UZ/$GR0@=5P(M&!,"R>;7SK&U\VFB# ME\G@)?S][YHHV!%R,Q5/EB\"7TX/,FAEL18I#O">U,4U8>-YH`7^&,?)J6;E M?_))ZS+DECNDKCJ:JD^R+VSV\3M63H<%2]W2ZY325I=9M4!5<(KU@U>#L`V@ M5U?:5E=8-5T;KB];AODZW)307;NO[E3I6EVW7ZQ$MQJ$):"I14#]`O/J6N_J M`I].L2!9/F438*K+N2I[ZZXHYPHSAE[P1\+NHO'LV8O9FNI=KU7OVA&/>L0C M4^_2_:9]2"L,;46_6[>\V<[4NV(!JBF1`+6M292@340004Y,&<(O7*-)F/3* MB/]`#5IRS5#J:(JMU6*?S;`O5S;P'/NUW,/4L!K^,)&[A5&WEW"4=G1*@4R= MKL!7W@-+^['E[US`DPF5-Z/6*7F3&`#%GU#'8Z`BO)KP1G4Y8M1+C'L=J312 M.L*%]I5J;X78R0<8A/LG'ZG@DS?$KF.+Q:MH?)UWX`E%%QI8"OZ!R*1C_ZL1 M*)S#K(5=3,AX@4Z`R(3UDE3U!ER`C`\QEFR:AS,_X+704FKZU*`&9H>?J,,= M-N4)F.@M`]".1/<#(W<=:0F`$=[?[8'\(4#[$W$BV+6/B(1:1X=3MJY<9;A`'.][Q) MW*-8HI$_HWY MJ5L`7FB_>T0R7H>-^@%FUXJ4[\NY)SW%D=*%M9(4?0!=PPY%*+XTE$QI0T2\ M`>!RE>K_>MKG");:U0ZL]9=K*D6%YC/RU64XNB5.%]5K-V@F#*I53UVYW3$L MHRL5#"Z=?5T`:VN>/779Z9[;[?;ZNP"P22/AGKK"MVWWN\:.X*M=:K>G;$OR MJVD8`\=J#N`&O8-1G7;L5IUN1SSJ$8],G+.W)ZE=`V%]X#Z=<"UJF@\ MQO*A&!3&,G4,])!I%/.:MOBS,)KR-SO1,S6AA&^XVCO*%&8L@5IHL$MSI%;) MB?>2-2*D-H*/U(WQ)>U2C&UODZ$7"*TO\.;413`/![R>Y?5"D\(0HB,A'RE! M-7@>,#&F+RJ>)T7%IK.HV/!&K/$DM:L2\*KRN%Q72S32P6"."2AJ3Z()M-00 MN%#+-)P5&QF'HP6#`!90SY99\J^;?%-J59'0-I1\`J-BS#*N_!6BO1&?9-5BMIV0UM]]W!KUR M8HH)FP.TFN]Z2KYSS%[/[7>;`_3R*8K_2)LZ4R]4QK*[!'7IA@8XSD&QJ$TI8V>0NO+?0\L=J>)X?M>6*? M2L\38D0M9[X*L,M"`!NU/-GN36:'$WXCB'I+V+4B;460-)?35MT?SUXZXV@>IQE<_(Y$ M<2$)_PZPGL:`B#\55OULQ*GWPLW6=(^`\6"LV7,DAM(!`"`DF8LOYP^`&5+/ M%C>Z&6_G\'K`=4=7"!_DAY7OJV3(N=%19YO&W M)N=PGMTXT`>6B\\D;.J1J4#)^PD-M;P[BRCC:ZJ-"&#WC=_\#NU[DL MV+;2Z]&U'5MN,"C/I(;A=V(PO/?%/]_/$U`&D^0R#^LD&]"G-!3T$PB/.R^DMFA_CT`Z M?,B=_=?A,#42J8C357L`'<-1K61=O'9&&;-?CS*?_#B9?485^N_"Y\X)\N<= M]FC#6>]`?H-HC>C=&^\%-]`G=A^CNF/V4(W8YAUR/B/__O^^QSG5W955+#W51B[9(:;CUJ7`4PS(TW>_P' M3("Q,G5(TE.:2>V>>Z0D674P*5L16SVK?S#A>TM9"2,6?QU_\M$%AP.6XF=U MS%Z]);^-9H\W#+2HCZB_@DZ:L.3SYZN5JV[M0+:6XK<':MFUQ<6W?R?#S\'J M/:'N9;V^8G,HZO0[9DWQ`=HY:3I7CS[&;6)WT>%[%@3?T*A3AZDJ]MW),=6> MM,0SVH9;I%BU#I1I0#CO:A*KG1CNNN?;X4B\J799I2FJ_:4GQXL;:I"K=/"O MPUD$C]FU&+!KM'2M2=?4NE.3L.?%L!LK^36YUJU'7*5QIR5N%>O6I*XZO-DZ MM4.I!_>5FM1%Q1).[RC3P;=YT*LC5,R3XUA0VHT&-/TMCN;3.A1-N=0TZI%4 MR::G)P16V0R4X426;>YA2Y+C0:S26O%9RKN7V2VWX\@SK@-3%C\D`:$Z-"I3 MGK^PV967/-[$T9,_8J/W+W\D;'0=?O(Q\0IC*]&'PZ.W``8_G,-W7_.$P*\W7XQ!,*=[K.7>7^[O1, MMVOT^RN1K@GH;I%NM-!=I5"`A>ZZEK57G+.XZ)TNM-KAT7$,H]_MKT:Z)J"[ M1;K10KOJ'6V:CKU#G$%!CB;L,_:[WRBGTU`'FW:`5;N]!6;-YVT$4I,D26.@ MIJIE6';/W@9$39C;&"AUW(X+V]TV>ULB4FW6,P9JP>K`S^:@)D3/E\-AA`GN MX0/P9@A_BJQPGN^R0?IFK^LX7:--WWP=:8<8KQ/.M)R;M"([O:9,Q.M0^]VC M:#N'1]M]NKQ[K_E),FV? MLS3#+![."S%V#[->*$=.)`[R3+L)+@$OV\:'AD?XZSY/I7-UDUBGN&,BO16!K#*(*,89=0))L7 MCY:?(3SFE`V9!OGRB+5^L6Z&#^]@@3B>RDG%+F@(^-.;$2YB?3A.CQX,'84B M?S2D"K94(F+,-7(O0)AFHIX&#USD%3A&6?!:4H3@D=I=8'>%&9`U@+DQ[Y33 MGY-GPF:/T0@>BNEA(,F(8J+881KP3?_WR'S\-?;F`EL&9!6F;E4T:>NWP%.]IO1#O8 MCD,6P\1Y#"(L[WTTQUHRVD?:@/G@@U\2[9(GY.`&$8HP;H^+`;VGO"@67_"DVS#$(LL8M6:)!'QL.-<.A2!\W+@A@7@.*<, M.7`D>F!+1B&C2B2X9$#,H)K&#C86%(N?X-5@V>">(3]Z^-8"Y(<@FT*$,$7=/4:\8C9ZGD M=QX-B[R%X6!ZGJ$`RY*^,\N*A"_)GB'/RPI>%J60#X_D6]H;1=.43Q>8NK8T M6F.OG\0)>SF-_4"*:)<$0`Z,$.08K5*4`FF%0=CIUY/I/!<'V0\_W@&[15-_ MJ/5M%]3:G]YI=[`Z`8"8+M:B**'XXVL`@5B*BF,5-OI")/Q\2CLJV^PC?-U/ M7U\JY.3EQ_R(/YLFW+_@23[EP.1EN-(H[^21P1%#NT"4P1IE^?6D<^##0R^. M":]<>>#E6L4I5IS.#Y,9\T;XU#W#M_+)/5)-J(B6'/E/I)'W/1VK:<$$7G!V MR!9F7YB52D%EQQYNU"Q[`',T%A,-%LD;LUD_&B>!"^IC)8FD38)SH`O<261\QV-Y&'6!,@U;%\H M1%0H)Y(4Q7`KE&`M%1H)QI,495&JY/_O1+X^X?)^8L"W5`0565&["J+YB"@^ MIT>DZ@=%A:)8X#D[Y,0YG&#YD1AKP@G)%:+.C:<5LC[-,2DB0V8O0R`@+@.Y9.H_8=B1,Q5THJW6M++"MD@^9.IYI#"HA MH97(AO(BWAOK%LB>#72++>XP=5KA7G(7=RD6\JRJ4GU%WO9WX@Z0:']PMOF1 M:/R?>31#;2;_\!-?+50^\R]3WS7RPSTL&->J?_S&]1C#+5%B%D3.[\S#`QJ7 MMW-#;*E=CA!=:<%IJM(S%HX>R@84-=YCR3+AY:.(&J5/?L(+2/)37QQ<=(]` M>H*`0LV#I^I1'=(<-+%C4E5G<2?A]]S@P3D]G3F;B9>G3"_3BQG3P_EDCH6: MGA:OV+E>L`P^5:),B]9G)'WT1OP$3NN#CM(J]U)E>[I9\3N"3*5"15=^?I?( M#%CP(2L=D5^^0'@)O8O7?_7)%)QO8EX#TX*DJ)H(1L%B".4+=(B\@Z>*QJ$7A!7QK@@P4LQ897T-F'_\`"4$:<5`>,G M*4-B"G`YQ\@$GGB@>S:%C9\]890K1"F/Y&I61TP&5!+2./T&=$&4[T"P.Y@J MWTU4L\'*#W'G%RG\))%V'>[1281[)$1;`#_!8_;@Q?R"6G.714-1L[?QTFRG MI%93Q\."VP*>3QUGW+6QE0*G1E\9VN@8AFU))964$*P-:",765\9P-YQ'7

    =1],U+*<.O#D`VP!Y M-8DKZ@F;/;M#PQO0_#(KE2YY$=Z_P(=IE'@!19$F67L6?$:8KD=Y M``A%DPH=Z"L6^[FB6C^K0DG=OI+\@X4HNR5TFY/#%>00)SNOZD`YGRWQLM;!ME6;C]C:U2NWGX\WH(K1;7!5DN-/0F-"J@E,!62 MHEI%W50XK$50E8!P]B0>ZM%3(1,VHN=*,;`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`Q?^5CI2]+Z5/EP70X*5Z**2(3@[%3@F!+>]C^%*/^1$=)EI.0M^!,)T^G M&\\#GF_!89-#Y/(,E=EC',T?'M,TLE$TG//84)$Y-UH#>HP\3/EB%VTDSN:( MNLEV&Q*[H.1N\Z!2QI:74?9P33E0#-'^%LF)*X2(G"XE)%CI,;7B"-)W=0:E M4OD96\/BSA-)'"CTEL7'N79;N01L$TFY)0$Z3,.7TV4CP8RYWMZ0B\Q[-GO& M0''58DHJ!&5D450Y"_P)AOFS],S.M]/1T_>@<@C9-V:/<'SCZ8)VTRV)GQJ2 M9K^8JE-TMBE@&S$*AJX$:"=/&V_G*\&_CKF,2[P)RPM34'0ZOA%BPL*J*/WT M:&ZZ#;7=`XC8$-X'`Z.?E`M]%QEUOF-AE)%4-,5/F'2 M/Z3^`VG3>QU+DP1<[N0*417^ODTS4OB%ZCL)H#W@F?*L>)7 MJ5%A7KP[E4R+.5)!-!1#+"CLJ*C@GD>]B,:_G(!N,?2XSB]C!+^5CN[C_?!A MSK.K[OE%ZQ,;X251HR9D>.W"D,,T.?P)"[K.$ZZ+:=Y\]ACQ\J,+TH4SS?_J M=+1//@M&[[0;P/@7$$__F;-P"(S3TSH=^5&)OZ;P:.<>KM]_=>X9K#H\[07/ MWDM2M'!V2RRM+?.S!-K/")L$3F/)0=0&'3%ZIF4G&VY"]CUX M)>%7??*)TSJDI`]SYH`KTP@[>*:\(#5HU$CHBVS`8I-3S'\2G+3AT?!N,\&I M$!O90.F"-#5PWT,NGB"8HD3/QA3FM.PU0!`@7_NU-3^T6*)E2Q@JKE;'X%TU0.X7B?>`- M_^*P:*1+"U9'!ON=\]5'Y"L$Y#[6?B;0@ MFSEI/DG'$Q=<[XYE,>W]+"8*RM>'LO/Z4&Y7>3VA`]/!\`^@F88C/*NC&$[* MA_L?+]N*Q15PF,M@-#OOU>.HO.`-1^ZO&CE74BQ[<&AHSXN>*T5$2\]&]'2L0T-[ M5O0T>WODSVV=%/]\]&=LO>M8V9%@I2OX%8Z"8E&/6N?`1LRP90ZHN^SV0<$Z M"1)U6Q*M()'=DF@5B=S>CL':N_:]OGB]'(JHHE<@8']J`::EYI+RY MK2.BC=3;U./=6$=[=>$2;4!)RT/'SD-[5[G;*+U:RG.[,5KANBD/M:'TAV:B MH]-6VZB]O?G=5O%6ZQ9MEZ==GN,+%VN7Y:AWS3%?6-IHO@.'NJPJ$=`*]5>8;S*EI(CUULIAW"U^[3IM*[6B7:=V M/[7K=+3[J;WDG)N.U9*J)55+JO:2LY1L1M<8+?"'V.\Q02O92+N?SZACX0N; M94U1SC#"S.RO.FO;_;$ZM[VE4S2'O$TU8T,9[%$>]'YJ MA6SL#WW1CM[+47U*Z;XP7/Y$H0_X/ZX_YA^Q`[@OM9^&>:6^K@0`/(]`8T_/ MLBZO%UI.`QBI-OQ\W#&,JSUZ">I&CZEY->_2-7STL!<:BWU8DF'R3OO1^XF/ M&CVS&&<9`=C#F6@Q._.?B-_R":@IUR0"FD@M3K%5\V3JB=?@L?^=:`S0CB:@ M-$U93%V8PR%OT?7C/9\QN@?NX`9A;`-^GT3Q/?TP\?Z-W=4(*VP'R:=/*2=: M?I',Q![;&NC""9#G:Z:Y1"- MM%^U:DGP=]'L570JX]W.R/(-S`%03MCL,=I.']PCW,E7H*QCQ_.$]^F#OWAS M8)G>O&9#DG<;3-OR";)2VSZVW,>/B!N.TFW&N;+P2,+B)W@5V^K".-&3/^*M M_@+V`+N-"3D*W/3@A8#L2*P.;_`7>,\)M@.'%\>,N@"B*R/OS$CMZ6ZN8*O> MS0$C^(N6&Q@LZR&?,(&X7D`8=R8EOU/#7F#?O+]\#K+4!N_9G_'Q.7C+%!2X M)=0`'N3&]V$PIT:JU/Y=I];+811V.(51T*2SB#U5H%I*\8N<6ZBIH@P^`!R\ M(,5P<\4LX!1Y]*<<6!R3"`++@X^/&&`[\4-JO"X\/\O;S1,[>+48$N.#E,26 MR,-'77[F17H"A2>.+9IF4X-D:?)<9`]^25;WWEYKE^ZF?WNU`#B$HG+E)8^T MX/3'1]B33UZ`5-N2GG(J(D_>*LA1L#'CA+;@(Y`:3LG`!]H@)R:S>,YW^'0> MPZ&,612T?6`/PQ$&8P+W3;!7;L;46-Y(=+8$Z1-@JU>N%`R1Z"PG^H6V``>H M1G,/&\'#Z_XL`I!PZTZCQ.?"#"?6>2]FD$N@/_P''N?S\MV5;PB$W)_-\_>$ M2/)QG^')RC>FV(7W7D#'?O+(T$9"O5-A%N[M16D4O"PV=^6_+0O-"1PE>)R@ M%.>CTI&2-F;-^MOF#=9]DH9()H!FS+N[HJ(2)G.4OM@X?9%6.!%'`Q[`?NLS M4&Y\>@T7,756Q]&0L1&-BX2\OOF*DR6/43SKH+`#",._0/`1A9>F&(%46EHS M/&U@.$6ST@^@X_!O3;VLJ35GZ8JVL_V3;CM[?`+O%E@D]H?()BCR7IF8D[`G M/B8E@)$XHL]90U^6=GCGFA/+PD%(J_;OYZCH1>I3^0OI%B!V?O?BOQAM[T_S MD'>07II):$(X8"H5GJ(`1`%JXUGWZJNH\W6Z,!YL43JXD?#+M**LJ:CVP4^&<+/!1N@?HB$=!$+ZPR(-YZ3,91!36^-T MWDDV+]U!1F01QU[7)WF+.*S2$H58ATKJ4W[%3[];/_EKESMZWZIAC1W]B>[( M_H1O1_JO=&8]`./"$264`Z%&AWBGQUO1/$[HAI8UH([SVPTMQ].(%I-HC/T?P0"R=Y3%[8N&<+1RA!?5!6!.*$6-@!^D^E/_%]9RELUG7$O_[`@6F,5P(R1#@ M=G_`MT#=0>5B5-!8N"D#+4]%A$?^*+\ED4X'2QM-&"$&5RIY?+@Z`K6I>7H( M3/%#JJ243()J9$IA.85WS6[J6Y%`K^K:=)FNR6VV)J],[ER6<&7&S9HWX3^. MYHQ;\>1-A18U4"90/<^_!ST?+2Y\`C%X5+\H5/0ZH*FI6$73"5B8A^BK2? M%*YNL%%]]LQ&`@$D,I>IZ<6(FT'0SLLMK4`^N"0^L2!#!E\>P97`XUK7,`(J M:./Y#-40;F?ET.6#^(EDGRJJ9O=D%H>5GN!P@&P[]2VU<4/D2XI&3YXJ@(\_$\X'`& MN++S8`02=3QF6#(6+>'B6LA/->:![,0[7&8V3E%)D27]+D4HE9D9S=+K;]V; MW.)-%Q=86H%RIH/QW_9=W>YU:="W?5,W;`NMITC4F0^K_M(JA$W%\0<&/(&[ M)%?4KZ+DU1FQ,C+D4G6(9)`$\S":3'RRBPL-!*W?4X\L6RAN_@W"@/9R=O=) MO(!Q)U(^:NI%$2)XA/X8O@MS/DX5%.Y3&T8/9*S74ZM3HCVP4!AVYE,AA;&Z MJJBIZHD;YR:;@3Q-.ST]#\KU-S'JVW!8XG*@Z79*POYL''0BPU^`L`:&AQL#L3*=QY,I&0?F22KW$SB!<"4Z`:G*Y-#3Z&`E/U]V9,P3 MAA(\`)9.;LFH%5P1U7-R MB=9G@C9,]>(%24:>E/:9+!@%]H_4:[YH`[0TD]3 M!H1!%O@/5YZ&GF'L@"YD(;\^(TMRD3D=45T((!JA$PMN\?@;[A6-EWT'6[R@TK&NV@\>T:B?B@$=YZE5"Q M342D1TH($>4ZX3I`(GP;28'=A;)`&@&%1?AT>\EL0,C^L<_(*IL-3&;3^Y?, M/HQJ;Y8OR'GW_J6@*8^%$)/\YVA6R=ZYX+I;MFU3!1_V"WI^0II^1L$'\)Z, M6$$ED3;^A?:52PO-FTZ#]+:"+J.8><-'QN-%Y)%H?)V'C:267%@*_H'(I&/` MCG!UDQP)X0J)[WJ!OBA'$!8NE1$7(.-#C%=,V-Q^P`5^2DT_67!>X<$5L%DJ MZKP1IY]/0\VX90>6`,W@8CJ.W!#/C(1K5F(,835#=Y@T![!8@M?KXBT:I&-4 MX*94C\R8(;L#SJV[PO'IG:).$J1!$9E^",R&4]6O59QTMK\.;W M/;I("8^@,&`7XH>24BM[0:"(G2(,^J"Q:4]>,&A,D2?0&+:OZW)>#+Z;$@'`0.\)Y* M<\^I9N5_ELF#5ZO3_19%(SPLSE>32S%,=V;&UWDP#.E!(NP(-RY&6*8;I,B7 M^6Y'Y438:=/0Z`5)D&V:U!:=[XL$=)P$>%PXQ[]$H(I8I;O]#PISO+R[TFS7 MZ)@&'&TI/EP_6IQ5BA)'[QC29HQN`2;NVCQ,%VX[L"-C:3=A\A;=N>;W_Z9` MPP@F0%L[13+[,2EPLRR@*8WG+IIK,^/:(@5?\SAZ#YAVC"*$3F@*LQQK*D!E%?PW]&"Z!J'UA'!0L),H;LL0]DWV; M7@[\OQ@%6`%TZ#X4;LWE548?QQ0)`V)Q#K33[D$U>B9]8^C%\0M^3P^7:A7' M91`XJ'3Y#%S6^>SC!7S[JL`IF%7DPYI[K'BL(6Z_3D"$$?N6[A_Y7D$MGZ$, MDGB,AY[!'LD21,Y<*HD2:^A@`V/9(AIYF7L25;=,[S9$`T0 MHB^11)"$)S\LOO?,8I;?5M([,`^(.)"+_GQV[Z7D%L:HKM>\>2E/(<&L0#]Y M9-PI*9%GC$%OR'YI8-K/6;B:VM4.'"TE'XS)(7W_PH\9;O?AVY("3C!:.1MI MS)CVS"_3,2/_,6Q1ZX><0K`+_^[!^1N_$,,7MW?"'@`Z'J%(%J-L6(S]2P.2 MR/^$RCO=RB6C:+P0[1CQ'5_(&"@$.G.-(?.`IP:!D6R6Q:F+ND3FW4J6*9TZ MP8BBF?TD-4YS2P403%BV\DRX8>XF#Q-O*`QCEP*R'/%"J'1.GX*)I099ZF57 M+-!JLUOQV0B?TKC4W5@2CD'6W,%M-[]=BP-1%CC%@%VN+\C[`CW+_*+AHR]C M*,RK"V)H(:PGC97!L!ZZ?Q-*)B M$=S(R20;-J(D;Q&4AR`74^/`XJ3'M/=>C3J0Q4'<;L\??I*Z0,"]`)Q%@9L] M$9?$3\$TM)__G`;\R[VY>0!>H3FWV&9YI"^?([6?H)$5#?&?1$$\6 M0'*D2ZYU5#_PL-+IH^LP#Q-0` MZ>0PXK?^-,N:DX[K#>WNK\[PX2K7+6MKB0G"NCW^J%%U=N_Z6J;D\*$'/!,L<#629_XR/B;^1;LUET@KI<_2WH4S%ZF(M.#YYYG$V3R+O>K7)>RHHB+26,'-2_GX2S@4+[VEKO. M1\);SF?([K%Y38=:.$3#X3P6#G4I3)%L6")0L=H%5M3MZH&1'J7O"T>T%]1L/XS.`][*L[:P$C,3" M?BS'_Y;P,Z^Q419F+`(X.@ZE4/L-E4X/F0* M!YYF,M07FM@/L,1F<8D+QLXRY84"KKP).0?"!]S`B`;9]2@:CD<34+)AA.9Z MGY>F$@/@I+D=X('A6--'2G#AC3GO*9E.2^G9(!)_,DJ[AYH=V6 MD"@%G<[_(G5,1W<-(L];K`RE7)-9T+?2)(H&"H[P6I>6N%A2<+)"9L)V5;6^ MJ;Z31Z/YB9Q])E+D2_(TBNR74@:V1/KL@L)8#<7"OB9''M=92U@M7P8.'D)5 MR##)M3<149%EZ_-T9K[Q81S!SR+>6P8"23STIP(,P=BU8>'1C6B@9R/%G!QG M6220!0/H(@H_"?/%0BH>IA:#2I8=D=2R`]_.-T+FL2@AN6")')$4>K0P#&?9 MBF=H+(F,M$98U7I*E1V0=*`5RN&=C!7*[:$LD[9J'N59P;[WD1!R970%-D`! M0.[<:BC36F0>:;^!".-%:XP7F++:@IZB0J)+!*%JU&\-)<:6L&C M7I8!F<60\"3]K`11EN%YS_`6GF#LLQ=GNPS)CP,+)J.5>/*3-)05%BY3Y-)Z M9"'GX7DH2:Q,N*%=:\C-Z:"@/>C"WE2@(6++32KCR MFW2/BN+**U2%5%AB&2C614B'= MHK*`X/Q.AC)=#%1,B$Z_1:U%F&.X>1?-)S'Y1")Z`B.#?,P1OL-`#2\KAU1- M`JH=4;Q+T)KE%LDL$JU\L"+YA8AK+3CEYDI^?_X]OY]_HE1YE.$I^:]2&]@* M#5\65\R+PVSGB?&RDPJ%LC]#=A&W]ZFP%&:6@D1;*/+U!P;HP;6+"B06[/:X M$:.L=F))A<[E:?(MH^<@+JA$I`?E]15CEBM!1<$L3`\>75$95^4F=#6DG8`3 M/[,@H.3^J3?\B[#CJL*8>10<)(4+86PE14((HV0L3D&2SVCU#%@'"P',TB=E M6BR[Z>=3)'W(1<%*J#PY5*CH7\BC"19I1"HOIQ-E7&14*F,76"U^,!96*RNA M6307EM:93(^W9Z&.9->:D?1\%"^H=!C:D/#RF5[!&)5=-#+U;!3A^T49=!L/`VKN8\'')]2QEYLO!.RBE1R*/B^/$Z$U%N M=&HO*"HEBB,6Z]Q`>NX^_7KOLCIU@*@-[8*,2<%9`B)CYD_GJ5=$;77&&A\! M+DB/+J$/,:9ZDC*ABXNJ.DB+M']N)\"(HG0D:W&D7'>7K;>T[\I,=GETN&22 MH[H>N(J[)4NR6?TJHT MGXS[_)!#4HEN,NAV*W/',U,2U'[R9+)837XQA*-PGBCMW&L$"O(ABH5EI MB2"0JQ\TYG<7B50J&6.WG-<_/SWO@]&8ZT;]YW[?6=N8DI4162(47'B2B MS)`HJG*_F,38F;CUB5C$ M<99Z&8X*`8-D!5]N8I"6F!"39!'*7&3)DW%=AHZ5F(2)$*P%4CGY6X MA&[J[.%^%I],&O?T;EHF=<2#*/%39B91@)'J-I1GAN_"4[-@$8G,WIU$LB8D MU3W!H-@HR5RA]/23YP>\`$:$EBK,;LOQ%.%75,%'^X<7S$55("G(-"[&V!,J M(F(_&]Z?HT,#M+[RU$Y;D+$ONS=R*A1>)H^\QRSD1S1-$ M^)V7!LFDZC2\1OK'''9'['.+0Z&VZ8P-'WD'F0G+PY)$>#*G#H8B/4L02:U:P@]-E_#4:JL>%HT@)$J'63: MS_%DTQVX>$%"MDY<7;BL:7>/P#;GFX'X'G3H(:^"2!$,'.GD413ERFI]+@;) MH)F0WA(')U\`-NIXZ!5_*`1S2&,FA9+_DA&<\RAHAWY`\]6"Z`$@PLLXJ+"B M=@F<\],(/3,\EFN$H^'&+<+`]Q=Q?YSJ>,DL&OZERSF%XAL>%0Y_"G?]_O(F M:G%P96/?4C;-0$XO\O")&M]J0Q8$4[3UA`]_>V.\H<^8Z)9^%I#H8Q_?Y+ M:E.06OVNZ'8NO4&/CTJP7]$^N"`S-(%W;NJHW2H9L`=$BA`;G='XHL&+`Q MY^\O0L=>L6/$..8/-3?%XFN*V=_6>[^_\#X%*M$`/YIZU^WJ/B[NF-V==OLO58".%U'-\S!MM'?EJ3ZYZ,_8[L\?01$I5BM]79. MVQU/WN+7XG>4^.U-2\'/_Q1&/2TUZJE->1WRQ@^/=3D&>M]Q]$%WU57J1+G- MT?M6'^.>SA.]@=[#L*Z5)^F)H@>K9P*#=LWC%!7E:D(E4!^Y11ZC>E(+?,*& M<^[>>G>LZ]">22U^KQ&_O>D4*OA*37SYE_B(Y..ZDYUQ*RBQONFPZ.M2V`$5 M-[:=C)[S0>>@,+M?_EM);X.E:EH@=X+"W2\CK MONNU^+7X'3-^^]$Y2X'BH=`8[CM:#$).LB#P72S%*D>SPKML7*STK#=RIQ\0 M$6,MO\P1(N*N"F\[%41,8RN(+&[G]!L,-^=?TN.)Q]%^46*-DOE4]9$D8FHW2L4(E]8'B1JLP- MDV<\\/K@2U,_4UN!F=])'3;O#KPPV93B(W%?K2P%`N)O;W@D9YVDA6VG(J2/ MUTC04.^O)0+7"8R]V#R8?L64]6-E+XK1LN5)"?>Q]C.!MASX_GI(4YI&4(\R MZZA+)\ZO]GX6I6ZH^GFA7"O5X+Q0;E?Y`!Y@.?:]4I7(5,L_PB>6\,)QQ0S- M%7`*6A[8&MVW:#N.+=0'Q6-'4=2[?=5?*OI6G+ MIZ^,3_=CD:L'99/0G^UJLYLM<]VUM1R]:ZRRO.P6ME.@D]7MZNY*4UM+IY:? MCHF?]JYDEZW$/[T86Y&K7$?I$U55 MD:UCK8J\`,R1U40CM;OSGDI*8M$[%B;>MEO!'Z'[KK32*2]$QLMKBJ9V2R5. MAQ*-LN*F_)6L7UO:4FZDC3T_UIZ\8,ZRBHC/7CQ*>SUK6`&1MQWQ%AOH95T, MDX4QZ=D.O5D<7K:><<_?G`J:_V<>4<,_ZHA"?9A$*4@<5SE:H2Z:&`E?(,MC MYV[X&&'G$-'F+&T#-8E&+*#FQ62NQ+IMH/<,J:,++UJ\1!`Q@ZZEA3*]))E/ MIGE9QXDWHJYI0+<4!ER$**3E$:/0Q'K1%ZI>%P:FHGD,Z/B"VSXK^TJ_";H$_IA=:#>Q'\5I>>'K MFZ\YX;5%PC][B_TKB>81]IL`R#_XP(O8@O="NZ)VAGG58HEJP-(`#_<5)[`] MJ+L%EJT>X3;A;"U>>TJK*"]V;\P:)A48GA?L!YJ`I'[1L`*T7&D3N49TULKY M!0MLHK#J!%0CG\T>HU/J\7Q0X?P'[_SR,>WPNDVA?"J!%M.83;VXT$2I205E MG_JH8Q\FK-%+E6.%S.]["F+H$#X?HE\WJR!9Z^2$,EU@?>NCE)>^E MIF*PKR;>7TSJRDNU9J7=R8N=B[J66;WQ1-1M7:].-,TAU]H-(^P[J%T.9W,J M"9O,@UDJ&'A=^+1]&5:*SX`%T0U#%NK9R@)$C51:UI802NNQ\PK_T?Q^-IX' MV5&K\].IPP_-@GBA"RPG)#Q6<1[IV!0)!PW\IZS&/C#8?Z4V<4&$^87P^T@4 M>(2E_T:E$')IIHZ.R*O)+U?(3#@G*="R(+BKWZJK2 MT/HR)B73P%$':^W':0."AR@:42ET4>(9&X)3\^P[]R+51?]T>?=>\T$8`(=>WOVA?8DN MZ->.,="UV[0S!N_0RMM/BS9Z5S!K!+(T:T^1"50OQ!Z8R/XSJ7N$W)Y!:KH! MCXA6YFG7AK2[.(T1B*X35*4-[TCAS[)N MTSR.#Z04GR=DSQHEOJ'"M_2,:`>'MX>_>^$<6UKP"O7]HOKFPSM"LTM5X?2\ M@;,'<1'KPW%Z])ZHG;H_2VJ>-9D`])-A$%$?A"($V($`FS:\4,LYT9/0X_3G MY.&:(#P4T\-`$DGO+48X^P1Z[G#_`"W6V M&;:S(@A%A?X;7O<_.^,^922ZRU>QH_T6\=YH>`S!Q!_RI<2&\7.LOZ]]I$V8 M#XY5\"_%P02;!/>S3Z-3E7*D/RA6F8": MX"J)-HC9'5;:%]C5!%6YM/%#K*&LH%L4*A:@:2%1*%Z75"5!?-H!:R.8"Y-< M"BW*$4%7?G>CMF74'H5Z@V8=,)"W8.:NU$42EB5]!UM!,'IC2?Y('5:+D@CU MEGQ;>R-Q4T:UNLC4M272T:LOFT@!4-8"T;)N00CDX`B![G8,NR@)LE8:'>T: M2^MG(B'[X<<[8+EHZ@^UONUV;..G=]H=K%``(*8+MBA./C!@TFL`@=B*>BL6 M-KMD)D6>F$]'O*&,V/`C?-U/7Q<&!7&<4+MKJ6,./9MW6+FGVR`"D]^2"MU# M^$X8D9$D[6@5A7FCYB%<,`BO7(DHJO.%Z;"W*/.D7CGYY!11SY5KN6DUD4;> M^W2\RG>C,>H.Q=D79DWO&/EF+=BB+E:0-V:S.$K[P&"/F2"][?!S6^K(.B0+ M4MK<;?%&K)AH28R,`5W8CKP/RCT#]@V7Y4@^EA`HKCS\1R_&:WX/?G1/,%64EQ.2Y-(FP1GP)?D%E\T$K:-1@D' M,Z5B*I1;_Q1%<2N8A&!2:"9`Z@7-)%7X_WTJB.;< M'S&G1RYSPT!1LJ+KKVA6EQ1K3?J"!!AB]"(R,L`+IGZ3QBZY%`38VZ0W%]*R5!E8R0 M6A()S4$E*+02^5"<8VLZ!K)G`QVC,I>IRC%I'ZMCL@2@K8J(/+NE5'^11<"= MN!^M1/OQ&]=K#+=$ MJ5D0/[_S9GZXU)T;[LRXS)TE%_E4I6G,V4PX27[)7O26#><3]--1 M+[3"U3O7$Y;!I^;->:\W0=)';\1/9)2N`2.-21B[D43"`H!$Y/<&F4J2+IB> MYR7R`Q9\R$I'Y!>R>Y;J8=R+)AKSY8UBR1OE8Y-XT0Y5G/2DH`G$EUZB#G^\ M1Q:WKQ=B4<(Q.8_*E-8>/G4!CE"E+*([G:U4G=@)F1._T&=$.4]4"P.Y@J MWTU?@(J:E1_HSB^7^6HFTJ[#/4I-07URY?#3//<)U]UET9"W&6^^-"K#[O_Y M&?!^\+SINZ_Q@P=;GD"[RHX3^'`9CN0KU-=Q9H_)S3&Y\06>OLL]+KF8NL'. MZCY+OH'H?1]$P[]^_7__'TW[/]GLR,.BD34>T_#4+1O_[YUY,GKS MZ\#L6K:$<#YE`UB<'!9G-2R6"A;7=%QK4UB`&&9]NM@J6"S+=LS!%@ACUB>, MHP+&=/JVTZL+S.?<474E.DK*@/FK2=/#Z92DB%Q?4/8--9'[]D9$OO,"E@CW)K9SVHQ_35=)6G,`D"Z*](79 MUX&OC%LE@+H*@+3OR;O0#_[V9A;/V9N?UZ1,?:8SE3O;LKO]?K>[$\HLL9@$ MD&KC5E+FA@>49NI?^("J'@:UI+9T,J77(U8&C-E5;9S@:DM M22C7A*<4B>1;=,DOWJD=@"6_Q5@ZIQIZ.@#_3-^1+AZ7W_VD`S>[OT=^.+N] MO;J*XNGO=!]0X^K:2EP'!OZSA*L2[$V17.87)9(?8`\$(/!&0.T_X.HC/GU* MPYY@DPB;QF@E`1R5O/C5Z;H6_-\.*`";]^OXRDL>Q2^CS42-8RH7L0D.2U!M M$Y]*T62Z*EE91QKD$-W$>`K.7FX"O(.&HX_P[72RJ$@VIJ_95=+7=$!+JZ2O M$J;MX=)(N'65]V37[MOR17EM5-(&YB0(;[SX:TP6@]$_,";R!LXQRE=H?O=P M#86R@?::SO?[./`[/(/@S:_&A6'(@KH63-O!8^4=Q344,F-`#R>5\]AC% MY*Q>9QWD[5J$UUTX-"KGW@S.&G3N[PO.:^X:6(>6`R6,*^#C?`-;H:,\-DW7[`V<`H2K`-@"Q*O)Z2B-T';/'11T MEN801T/&1LFG.)I<10&&R9*'`/TB"<:=^T^\+.9F6I?:DF>Z74N&OQ8X6\*A MF;:E-H\,[.+!OB$.Z87S&L.XO>!F?A_XPZ^8,;,HM006IMDQ'?G/N_E]XH]\ M+WY!0\/7,>TPNF]=WWQ==8_J]M68]HRNNW#:UH1;C2X'<6<*OW+OF*:KPF0% M2%O$I1D+J@WV.T`%>>8K3W;Z^)W%0S\IOPUNF_O4QK:>N:CJK0!W";MR(N2^ MS\RW6=\(E@SZ5L]^\VNMY)ZQ-_$#^'+F8U8%1D<#Z%ZHJ"`6U"U*K"J*((?P M&"4A//2=LD!Q=0D9&+0T-B'+B+> M:,*TBFKU?+]HH@S3+1MMFFE8F068QNW5%C%MW?-C++>[5+X[*^S]"FL/9Q&\ MMKE$BZT4)=X+3VZ-N"37;LZ"E90QTM[=*0)]IG=W/S$O8(\AZ MS)*(HR>IB,%9U;"S=!M.Y8&UJH]66^VOVW7UPR!]8MD;H,<)5^=9=F M4&5!$4W)LXGN5M3OE7K7UH7\AA-*+-7OZTYOK5:CN\2O7:1"">FNH[O=5=50 M=X_?04['LY?JMN[T!WK76=6BH3W_3-UQ#-T8=-L34!*`ET.1$$B%$:8Q&_IY M8=A6Q-9CK1_[L$:VM>JJL2T$5ZYQN[M7>.Z9MJ,[KM6>>_*YQRMF\FSWAY@E#6TCKURH#EQ#[P_L8\.O7:0F M_1W.],ZWO.K6A>5N+*RW,6@IQ?E`5!8P8-NREV\\DWS%[!J6;IFK3*S;0ZY= MI,:+5/>4W\[Z\GB:\XCQ.$J@2V-I-@"_22#/!\F(D'5.P7X7;RVWIYN# M'CEYW[HV:/!]*R_93/59\*>0&DA$E85:L'IZ6OTP>+G0U).ZEMZW;#ZGZ9AZ MS^BM-Z>S,.>>R+GW`+%EQ5C4:DKK#J4EF87+)"U-+[H2=*)GK.R,A7RHY.]( M&P*O^L.L^#=Z6]*2T51CFPI:B=IS-0KP-`DPK1F:NIQA*V8ROY8\YJOQ5"9$6[9M#*S>\2WEFH@J8\:QD$UW3RS;9$%3[^Z'7%*MQE)9 MKJ7;[SN](]R8:V&I3&1SNX[;-8YO+97/?/PNJAOR@^LZO!''UBHBV(8R@0XS M_;K.X/C6>A=44&?J.8YA#+I;IL)B)9:Z"87*X\2&VRE\J`'F4IF89D#6R"%4 MG@6FB2A86P62ES*J(.?!6$J=B=AU3=MR:I`A16YC6AQZ>U44?*K+$ENC11.^ M:(ZIDOD'KM$?V,>ZZ"I$)R]OI4$5FIGM07@]NF;3=O:UQH@DD)FFBWQ*:=6-R0]V2YT,HC_@DV M;X)UU?_;8/+D$9N49AVS`AQ;2WM;*J`;Y]VOZ4A=,N;MT4"ZL^E^][!/3TCM M1T2K'<^/.9F'C_`HKVF?VJ`]Z@U"UKCH-/<-RX)IN.E2DE.[G8AVL<)L,,,W(;1?C4UH[V$ MOVYUKLJ4V\-AU2Y(:7KMOK':UYEU?O*W-'OVU9]*I9FRK^QQJ59;:\MM.H,ENU%7\UTE/;6](A%Z1S M2'SV9]-KG'ZXV_%VE,FXY4E69)KN"J5V0;9R]NYC0>0-G*>1TJ?ZT0!-XP#^ MH+B6SQC64J?YXJT7/O"`TM_]T)_,)TMQI(XS>//KC?VO&K#F<^\<6.][.;"N M`<#VC@'83T#/&?OL/['1=3@#R'U@`*X1O7_Y'6-JK@(O20B=*^%03,W*"R^4 MH&D"FNZIH9FU[KS%K2I"ENNPH&L#NMVS0U?)Q,Y),O$\`5G*XEN,X,)>*X_^ M=#DLW7%=0,[:$+DG/X$9/D7Q!Y#5,WCJ,HW[VJPE4$6/5=LI)H`H0=@$V$8] M?TQE#M3`[-OF.M#>\NB[&P_6XQNP;^)1AZK+"3W[=2Q]5Z>E^)^*\8!YY%]X M0B#VPD,?,HM7)6WT+'7&TD(_XP8(;9<22V?7CBBA3&]UJ"72H2FQW,9]9Y10 M)FU8`_LX*&'NAQ+J;M_='?-$LG&[K+Z[AT26':4B4+>IP3M-NA'4_$L3]-2( MH)I,4?FZ(/]]3L4[OCTR[8H7XM`H=I/"LV<1]7>:!S,,_L>XNX`]>('F/<1, MA)X_^[-';0C*`P9Y#Z/)!#9>@MW>^$Y)LFARRCJ@6AV)!LK&.(HGNL@)0 M_^`J"TTSD[9Q.@!^?/)G/LMZ30F`+\K64VP@#1MNXMPP3SK7/0O9V)^)41)6 MA!>+OWC3:1Q]IS2%X$5["SM6ATW+:\&`4*S*R^.7V"3KMVA6'UVF_V^(ZNR#8'9,B:K M<^G59Z]E.6ZONS5,4.2QT4MS"SNN(9IF7US$XB?6#AGMVP8/6#?VBC<,$O7V8=RTX[8CGAT MJG&MUTJR=,46U*0]J%('%O\^A[1-63%^`(T,M%2&2BTG"FA5T?SA4?-Y4VUM MG-H;M3%C"6I1#T`O^"$-4H[3'Z(7+T!=5M>\$3D4*;]V/*?,4!I%LGH'RKE<*=%7'0!WXA(!BS+QDX2N M#$U+-;2'0#OB<8]84X`=]&0`C8UA?KJ6>5E`4B8SI;UD?=TW2>#2?CO>Q4\G%^$IC_Q9Q^7CX5ON3G5Q"\:/-I%*9V%U3$^73\ M9#B:@Z%$TM<]'#*._`0G8^,[0EO)IQWQN$?R$H25JQ[VPX)T&Y*!I38W0JZ1[1 M-!IFP_+B,V/X;U;QYKI471?E3%+!B2584HF:2=L4+9PCF=\G,R_$D4"DHL(= M,-+5*>"6SY"9O`%942&G`O+9RQ0#"V&T:#B0GF,5S^O0S M$&V4%?+FQ6;@S;3^MV3K3^;3:13/+@HL@^G+_@CW1*2-?:R80Z6'(@D2[B6( MQF,TA<-C#W,/?IOA#_Q@\V/@GDX,H"_RK,G= M!K8A\07L==0UDJ(S0.=:S#.+<>?"Q7;LS0/R4CQYL1_-807N`2.QP!F_^;&L MJ90P'VW+4H5(%)!"2'%,71MM!WUIJ[^U!I*+I]_C'P"G["Y>)`'O"N!*_A:[ M/]![KL$+VH,&6'Q#[&\B&BB&3T@G^'8DU,>C4[D*^E.ITE6N5?7J.FCP#JZ* MFC#M/HRP!&9M.)8#'JK@4,>Q],VN.]@`CB8.*\-6&OY-P^C!(\9&!*D=TF38 M2G.^:W1->&0E'&3:>DGMAINQB;*"ZJ^FZ1IN3PH(*\[;#*9&+*,NI=KOF4[7 MV@Y(C;A'72[5MKJ.U>MOC4SU&4D=R&=A@P/7K@?3W?"1C>8!^SJ^!%5KY`=S M%*EWH`S&%`S`*RRST2?0GGD0+QT37\>IC^F&Q12ZLU9Y-K/?EF<[RO)LO?W4 M)OM&^L7O7*WXB&H%`I)5*%NJWG;V!/F":M9Z]#B2TFVG7"KOU=0$+"O]=ZZ( MOMX5W6.90;=;N\;;'^$32_!2'&?Q03SV3KU.ZCIRM:74+DOX]>N7S+,'MF[; M%65M=@GG&=#/=2S==BMD5TN_EO_.A/\.7/+R#F6R%DWS(/W3KE?B6H[>-2H* MPNT,HN.EB=7MZJ[;1$,Z?YJT?'(`/CE`I1]ZY)]>C)ZMI;\WF$M^2M-]S0^ M'UK[1G-_@;EO<6Z=?Z%K=RSVQ]LQ\C=BU!46ITT,U>N:EPK&I86%%>$2G5DT MI6!1\3$=(8WL+S/M9T%,ZPRY;/Z6_>^OB[RECH+]4'==1\/!MH2]@S6K85@^ M`116.0%.`(5S7(5=[;`FF+9C[=M]4JI@8H-?[.RGYO+,XKB.+;5I#4/)8EJN M4?]HZEVWJ_>LBM*$J^:OJ"%^9,A:AJ7;O8IZMN>#JJL[9E>WJVJ`G@^R3M?1 M#;.>FZ0>JELWYF\L!P4(:U^QRTFWDRE;7%I<=HO++L]Z_/.?I"IBU@N,Z3VP MK)83&F$2+9K/,-<%55.M`\,G_O!HJ#W0^XZC#[H5=X5381Q'[UM]W:S234X% ME8'>Z_5TL^J,.A548%5,8+*J=GO'XCDOA>/C>,R&E**36FZU)#/=OCL:,K*RCUOX(DBE=J+\2WQ$[_K+OH*W,=E>_8O!&-[J=0GZ>5*UQN6RI MN@:OKKSGME1=AU=77;EW`/FNC6ROXT+4XM+BV M,>!JVY8I7>$95+@#C8LJMV==7^?>@3::FNR/`>BJ+(.C!=JL"*MN[A^N'R[< M*)Q7&1,RH?<$DU=:.XTAIR;O@^@1!:0G?+S%0&X[H,MATR MGCP\>XS+[*Y,#<].=&6MZHXVG,,/X4S#_97V=RBEKYC5VF>>_.HX.;,$'I5A MH=OMZ[VJ)+-=YO&?,MTL2^_OB6[[JBM`C_P61:-G/PBV*%3J")(ZRU1W:7H] MW:JZ2IU*WN062&%W=7.7I#A`&O@J<9[6J&X@QH]]&2W=H# MM[=;8JQYMV]\+5==\-,;=Q1+_2+7S_3=6?^&+67Z[O+^K>*B8[DN'D?=SAS6 MMH+G6I39^B5T!8:9$,N,'?W_@:#-J@K:+4U&=>G7=5&;VE733NG7IYV M2[N2FV-O/WQWN#J@BU+;2E?I*TAK4!&E3D&K1/7)E`0S*[+Y3\4JLDUR=%MR MR/636W(4:J56A$4=6NQMQ1:LE(`4U1*?J0S\L4(IJ`=,1:F/DZ%"6SVTR!,; M'XPM4QR]GE>P=2B%WU40)1N)OK6-*T7CO](PLLV+P89SU9.JVT*H_A9[G4O0 M-.&E78*M+T&%RM@NP?D*HB-3YRL/NB7KM!_F;;712LV[K8_2GN'MZ5?'TM@_ M#HS:Q4!W0T6X2[L8[^=*)G M=*U%L08;UGMH`['.%]$V$.O<$&T#L4X]J*/*R]'&PZSK&FDI5TFYMI_UNMS:Y?B[)>BC5$\^!(<=#<Y%B=]/JYW*]PHV.EX;^\'!>KP$+1D:X9H<>I^T5X43TW): MLK1D:"_6& M^!3%7[DE)'SXS#R0@^LW?K`&KZ0/XX:)6'VC=LI!=6[RHBK%G]`J9'O6:FK0^JRE$? M>LTVWUSUS^OC72A3'\#FZ@TJJM`=>J&VNKGJ"Y%C7K.N8>J5M=X/O6;U-YKS#ZI*\[CJT;W:.I$K2W3;ZA(^%X'1,5*N\6_1%F3W?Z M7;WO5FB)^W9+-+B84TO1P.YY-YX,V$HV%#@@(/_]?+^@^_7K)^ M8;/M,>H_O&#.J@BZ#XVK]"`7*\Y&<'REYZ7FT8%94A"NK@!;6X]>W['8>,H6 MEV/$96=WU;2*F?N#0J6]95Y:]6&<=JGEN"9J[#+[\CH6\W4-Y-8/:F."->CJ ME2]046)C%,1W*9AZEVW@G=.!1&KW]5-I\+>?2S'S^IL@U1- MELXA$4&$9I"5)]%:6G>E13&W)V[9+%H^<+ZH`\L&L='8`KH%>,^(B+V!7MGT MN:7A:AKV'4(^7C`RK])^EA:C]J"6WC5ZH`,W.!!J MC[V+T^_`U.H/]+Y1$:%P5+1J3`?!$39Y1BH*.QZ+BJ`2G'^$7B,CS38$\?$; M"EH\F^!9\NYVCWAE3L!.0=K'@:DB>^I,;!FSQ?/D-%N+(L7L;H4MX\ATVPUN MUDMY_$NGJ)H*-?Q;#0-+3IGC6U0;[9:%T)I=1`>54\K5K:ZK]YT-T\;W$OI3 M.TY'%>CSNS>;Q_[,9\G7\>ITVCI87!B%U M('6C%)57&9%MVH9N5.WKXX_'WF"[K]:F-^">,P_)[MJ.;C?V8QU%/'8]G4JE MD=VR8?00HL'R>@0ZC#_VV4@H=\*U"4K>9]^[]P.:`WZ;3]AH?87-;%.'ZZ4. M.[65CYL82]S-7C0O'&D,5HW)3:P*"G=ZNJ.IV\`I`9W==.H\/Z=J_:6`<9-GGR;:VEH MT3GL=]WH=_6>O<.6?0>_OBDBQ2YRU_#8>XIBTE$"RHUKI4$5S_QH63V]7\4R M.VM"+W3M3:C&36CEQ>#<;D(KKW[R MT>K:`]VV*L+HVKO0<>M&K@WZ455@_*%7;7N%8#ZMJP(=\?KU=*=[Q"6RME$1 MIKV_UJN]99L6;)"#-H@ZGKU^KI=95W<,0S<&1VR^VGK#81KK`QNS&'.=)E1R M`_/]M)@]L5#DR[>"0765->&0L(W&R2E'<)7=?;N>@]YJRU_?@B:_UL"%H+"^ MI??Z%4?)9J"?ANR15O.]%S]X?JA-Y_'P$51'#3\=V/QQ]'+'[L/.-4_1A+8? MN9,QTS3VAYL<8OL2.]M(0EM?--6>W='[@[[N5A7*W#T)MAUGL95("548QMVC M%[/WP(JCJV@R96%")17N9O#*URE55[@%_"3SD/;#"=Q^_LWCH)\4O;QJ>$:^`3I\\/RY\D1=/:VDDOKME$]!4166Z M[-LK`"7VAK.Y%VB?_?$2S?:A/Z69`2KOQ]?Y+)EY(:X&=D[]P(:BU*9)I38K MU$JUQV%W;I4&@P[JNU=LT]%[57K,+N'<*_U6NZ4:D`VTL8ITQ99F930S+@;U M*H2=-LUVLT\'%_NAW8$=H+_%'IQ1(Q3'$R_^"Z^PC;22X[6J6Z:I=ZM*Z>\, MHN.E2?_"WF&KB1,DR$&!.CP$AR3+`0QZ]$AZ%3L'SV&GY=J6&JUH.S:R'$.$ MS947HKET(]_GJ_"DZ_TJG6AG_JQV&0I6D0OGH$%..UN-TK>W">\Z$QS)(='2 M]N`GS;:;M2U8>%=W4SJ%_)*]S":%ZEB.WCUTHLDIK,M^\GZ#BR-*BMOO=4M:8F%6HKB5]N1;LXVIB574*OPN[0[?I[0U M+_JMM#V2M3`N^NV^.#9YU;]H&@E]%/6]U@T-71UJ*MHV7SY[\4@>#Z.X:!(* M8>7?;1!VVFW[,,OJ2J-]>_1]F+_`^FF_PW"/B?8Q'+%149?:1/E3ZGAJP-

    =3EH[6-MF9+< M>N'^H#5^J<*1JG@#JT%O$:F#4>BL4F1T.7W_$PM&A M&W1*9-W@U2]16!+SMC-$]DJA]7LH'(I`AQ?E@/9$^_&%>7%2XKD]%(.[%VYS M8;Z&?&K0%>ZX6+U(JS5(M09Y>W4G.CI9?NLG?W7&,6-:[,WV*?Y6D-2\Z-8] M'S<\A\V+@74.>HMQ8?3V0S'KPG"/1W=ID)34,U2MT#]%\9CYLWFLV@<+(VVQ M"WR#,1QE-_@-!I%6UJI2X+/7#X'Y>=*[7*$Z!,$W-2*N;_2K-"C>+QHH;UDR MBWU4SVB6RW"T\,T?H3_;1E9[O\UJKTQQK97.FJ^-1HNC$7^\CK3P\@SX/1YV M??NU9>`VJ7#:[5JZO:<4W`.G]TF[,*%=Z-$NU!YXVE_MW7@,P:(*']P9]GU8 MA+%*\'&Q"GQ*2BRLT9N^O MGE%]P!QY;,!65>]R)3\:?_+A'?;9?V*CQ2ZPG^9X&[^<1+`9_DL`H&$V3-@& M2KW3Q@QLJE0J[Y:UVKMN\1I?H^!]5WE]-ZV!;E:53MW.37KWYMOR/JQ[-4%* M20MF7^\/*OK"'J'>I:)JB?OC0%2UNWV]6]6QYM@9M'\\I+33R+',7F>>C-[\ MVAW8`]>6D%."L#ZH3@ZJLQI46P6J;3EFK[=;4,ON8FI0'16HEN,:@UYWYV0U MZY/55<':LX`#W+5!_8V%+/8">/QR-(']`#=L8/GT;,-:IOU><&C$ZMVN$@>[;UA6_W`+47\/='LJ)!S#M&RK MOR$.I1DJFQ'>M)0;H.MTC8(X+)U^/1";D-6TE/SM@,ZS%0@OXQA.5X8>^_>K/&&\&14+4=F8.^W\>!WYG",?_F5V,5EEO$ MX.`$J^:.`L%[_.XGG=]!LDSFD]_)9:'F/24I+QQW MQ]0LHG?T]/2^UZ&GI:3GJR/G\HYNSIZVFCWMEI[-V=-5T[-[+O3$8.Y/,6/7 M&*?$DMG.A*?;5U+3,+N[HF<9>D=(S0*A!N6$TKXG[T(_^-N;63QG;WX^0BP: M[["N^D`US('UFGAB"_*_:ZJI:1@K;P'G3U)=Q)^MBLF?"U>;+-8BJ<%B6L"@6#-\C MC??'N*079//^%D=)LAE5NP,UJUHFW-BWH>>H@=\N=:33"'32V`\3?TA*ZQH2 ML3L8J#UQ=M=QG>T11@GWSLBS0MFKV(4]]6EJFTYO*_J&"MZ]DZ.&4.HJR>%: M3G]A*[8)*\!7;>'8AW:\D%!2;D.,279?V(W@1,`5_CRP-'>(F368G.2RS MZN]*S"A`U`]'#!.8C`O+]<,E=(OAHHU&%J&G_YXG,W_\4FNZ;X^,T/3"%\T; M#J,Y[$!,D=5HCVN4WZ9-^5Y-M/L7+6;#Z"'T_XMY\4,YGH>)<"G^RGP*7\U@ M<`:P3#RT4HX]/]:>2`6-QO2;2+$63X[0(@R_4,;UA29#-F)89@S6+5D8DY[M MT)O%X6,IG9NDE39/$.3_S"/\3N[@FF@@S&E@&XI#+@(44C+(T:AB77@]&$PSQY3K<,*=^JTZ(4BA]J+SX(1433[3=`E\,?L0@/Y'1$M$*CKFZ\Y MX;5%PC][2;[R(V0^HGD$R"/D'WS@Q5D4)Q?:U2.>,4DZK$PU8&F`9^C-@343 MV![^V!_B9-X(MPEG:_':4UJ&ISI,CPPRB!=X$FWGWPHD5/N,3PVI0; M39!K6/R$YW'.+QC*AX*J@S)(F[#98S2ZJ"M9ROY>=?I6'H(EIZA:K34[IO/G MW?P^\4>^%[_<>90#2SFN:*J%E5QEGNWV%6&%)9I%]\)=O"VH#OZE%-QE3>Z^ M21S"-^`W<[-X`,FS;;WY]<;]E]FW/BR@LQ.PCY4\1<>=1!X'R-/[UWF3IHF? M6R*-^THXIXG+5R)/CSCGQ,BSTLY_RR9P[,-Q<05DBKWA;.X%M7=MX^TVFGAN`UP+H6_!/_'*(`+=\*C1YK:O7M]VZGP MQ1E]MV>:]@+$A1F;0U0MP@`BH)(2(K=K]6QW(XB^1#/VP4^&093,XW5*&B6# MOM4W]F"_W9$E$PF@]=YI977'ZO[%2:FR(FA:?4R6K(JN'U88+IL,?0AS[S7P MK>\%VLW\'K[3OH['#'=V'=O+8:FV#8,OFK,"AB8Z?Y9HOB#%E),B$J1`2Y:- MI4OP_U-C*GPG6PNQ0JK'K:FI,2T;17N+QAPTBPF;,KST)7KBI?),AU=3U;5G M+"9"5F-_AB8WA@4.-._A`:V=L`%",M=&0\9&-+TWA4_?R:09O&AOS9YN=*G" MBD8524!:C>9#S"/G%L[GV*4V.P3G^D[.G34:N!?D6.P92S"E1'5P5G-T%CP&I0 MQ:JZ(-#0"[5[)JW:/9L],R:35Y1Q)+P6O^T3RX?9^X+YD=W[%Z;EYOQ^L<[& M7L='=.RBEA>W%BK2E@1LJ10\0JE[S5U<(9G]><<^MMRQC]BMN`=$^6'-,DV] MVS46/%&P(QB(\.B%"2]6ZC<*H["3_J)-:`+:"2CG[U,'RBAUH/`]6&1E]&R$ M#[C;QZ`!H1"W3:VCO1U<=*VU6/H$5NE;J5.N5/07I/4T]6DA>=&GA9ZKW.&F M=%RA#($7O?MH/J-'4.O,7*`DVY@'LHKD2(<[5LEG>J%=SOA/]"1G&;ZN(%KA M-@1G*3RJA3R6"T8<>WQ&X`T`S(.S.7FDTN8"UU2.KD8V=RLBMA_?7W_[<*FC MRXTER21U0X)D]"9X1-!#!+]0ZK5GR_\"P?.W:*I![;V`J*G-50J0*E[&,[*>^^>/)_D MWIL##DDRG@=!IDKQQY$'8(F"V6,T?^"'&_?U\?,J]6FF7L%U6`X5J3":B7F_ M2QQ0?"GEPG3DY;D*PX[\$9(V"IY@,>;W_V:B4*T.`TWA_N[MA_YBP#9>TG2/=^91=-W6C<_%?,2=9:XWN&HF0CB M,Q2%D`3;SPB<&ISMR:@_TL"*E./@8Q77D%9%FY`KEK&7;1%@&#;T)CP8`:2+ MGW!)(7,(OEG@D#D*(5C#12;.8R6DP!$>X`$:--?<`#OF@.(K:1X!%![G_T@`%D`?)K%H&1/^/`N'6><^^`9I`?9F1`"_)DD3.)/ M_,"+M7MTW0.O\Y`*5/AAF&6:@.*)`FT^H=@.X/J0[WM!ZT@[%$UC63\*&7SRR*`H,GUB($\FT`U@Y3BB!L,2#PPD[W"&IZ,<%Y0%BAR31KV-:SBR#S+@?,8OCPM;$&3NTH*/R/Y8 M6Z>D1>=7Q3P891S!M?*93JSRO1%^'XW)3QT99QN<4K\& M;@FY2DNWKNA7ONX&;U`F=L7;%>W+Z[_96>^UQ4;F6T/T"&AI-\%,V2>TP7L+ M;Z+G4P?UX-D[MHV>3GN[JX2H[E%6]UJA'AGJ@IBW'ZX^D[O->-<9AJ?$J M5J-"5SS8*PUNK5AFD_'$?QA&M:2^00>HQQ( MGLMW78:]@J?NLFX(+=K%:[Z-4O;Z7SNSS-OMN_?TGC$W#^^UC[ MF2#B`=6OC!1ITD"!$B*#H/!=&EQ>^)*28UN*E5,,\RX*7U`21DNM,<%R M<%+M794N6XPLA?G\%G*5.Z!E]99"1R,,6E(=NS:J-@)=>2&:H9O*T,WL2D7+ MMM(FM/6KRH83YOSRHZGW5VINVT)/%7#3+DVI`>G"&1P;WZ'._Z8!&_=GU.0-8-+HY!SAW)15%: M?JFP;GNL;H?53-/476.5,ZP5"P<4V]@\LUV?XUT?XZ+?[I]3D'7]BU7A3(]*>M4LBG4;(ND*S36"7MKZK;=U1W7*3_Z MMU)L;>=!Y6M,^$F4')L]8C875BBI5QZ/DY-7E2GM0$7MJPHTYW2V!GK/<'2: MZJWE&/#)U+%3U)3*7+'@I;1JY5IP.NO#V=,=Q^!``KJNW:\!XQ]AUJ5HQ,?L M-)K8H])/)85C"**N:>N.T4U+9_I)7O)G%F$536GRI7Y((7`"B)J>1AFN%]J' MO'0-I^BJVC5R.43J?^5IHM02T$/JXX2PK$1=E"P2Q>FP7*=EZX9MXLLQ&P=4 M=XCW0:/:AT"IM*;BE,64%A$.T[)4@GH7I8*MHG"999QPX;*#UA"]S=NZ43E1 M&375WTUP.JY:E,H\')&&(S>YXU4!1;F^TZWB=*QY.J7!^+4"[Q=95J.&$:\M MO:4\IV?OO@[!+7W[E6<-F$[]D.)NU]+M?:8-',@^5UYN8$G$\E*4HA!?LUU\ M7(Y;Q5T2:Z?O&+*];_N5`%<)4RZO417$1'E4^^*\;/RFQHI7%3^R*JYP]Y@= MG^E?.G'*+G:M-V`K%K)NSZAQAIVRE6P7VGO#*?=HWEFZ^9"=PK*Z>K_G"@N/ M8[BPYMU#6WC*034-W3132&U+=XTZ9AYMV<[3>'JAP*RP^'1MW;7<,S#OF):E M]YWU[#NB?+G*L%#5U4S1M:S8[.P;&SZ&<*`\O-SQ5N')%?44+VMMUJO;_=!P M%&VVW_SJ]&U3ZB"IF'Y-&)T<1F7F MLRA060[8COB-MN+UM#"]^R?2;>CEN_' M.BZ:K5QQ:M]P=G:ARK"/,^SASRFHX*B_&S-L2A%'+UXP>Z%/=&'@!0[2UE3>B.P6B;)I9=83#!OG(##89H4: M4<&==C:>!ZE&O-"K91BSD3][CF+L]()=<-(>4AG,Y5;($K3LC0CX(P`![S>.=O(LA&O=P2RKTRBK'`J&% M4=+>1]C;+248M<<:^T,-2Y[/\"]^,\%7I/8^\B5#OOE@<:6_J+VG%\+_/D2X MFM23B6/!,=+FP2SMUCFD/FHC'[N4:?A=S+MS"=J%V%>'2DL3K^6W(KDS74D? MIXQ<%]JEZHJ(."VY1HI]"Q^]$36!RXA?SF_4+Y.NZ?PFW#=U`V[#"S?AFA)D M&W]+VD@=-6-1,^%]C>@ZR#U>:W3X=BU3V9+J5(025 MG&(;.T(P85_''[/6APVN(CV`U^VW5Y&]J=`'U9;_X/VJ,T[9FZI8"='//6I=1VEFL^U(XP]'E@3MJC]'+"4%$#!>0_JVE[P8 M)\`(2F%25`>%RA*W8X+,2B8HM"AH,&_I.`!@[,P/^OU'HW``VY$_#F]J`74R/Z M`/[*U6YL;\V`%'A-B(4="X?*OLPO64,RPZ9M,6/&>WAF#\Z\[V(2>B;P.1P8 M@^/C/&!I8QPW;,<'L03@5\>QHEOD!M"9.2:73-A[7V8^(Y;`8=12-J M:DJW#[@=A0_\4I(#-9W'PT-%.&BR=:\;1+*\N*8K*\IO/7 M\0<_P(:67`.4XZHVLB1;!8-W41,=].&P[SHYU`TAVS):3>S.EM-7HN7TK;YI M6<>"5A,KM>4,U*O5Z_5,+%KTEO?3>2_PA:*5B MT,VVF&FH+WMUM]@*`'>#9),-9QKVQAON($@VV7ZFX6R\_0ZUDK4WHVFX&V_& MK2&9+`ZRX6EGJX^%1EMQ":ZMHM3HI+/51T*CC;=;E)J=>?\<$WXOG9RQ2>!S0IO.C-SWQT@O<=@D\8%6P^^$#VR(0L<>Q7 M\<2[/^X^_)^?BS_1@#_G(Y;.P`D$6CA33,`_X0,;C)\N0,4,_)&UYI"HU)FR MN%,Q)V_L*KXKC`1K#SPPB^+LQZ:TIC=^KAI1FNX#"Z,)7)HK)UQ%F<49EP=- M?Y7P5I%3[#JB*.TZ*Y>-]*=M_LD-BG?I%?^]%^"-^NZ1L1F<.9>C$=T6O2"/ M'TO>O\`'N$=ZP6]Q-)^B31+NY+"G\!GN5V.CKU/&C2G)Y7<_Z0A7S-?GD(VN M8+?XP]_)8[.PF.BMFKTL4C?U8K%82X:/`&=A5R9L>/$0/?U\=?W_O?G5,`RS M:UI=VTB)DK^\.&S"'A#EQ<4:`1C?IX$_]&<<1FWDPW/H4_S;FU3,[(=L;W[] M]TLX>Z/8!4/TUYZ%L[.RWA9=` M"!9>L#?2I8N.4CVSU(;DE3@T(2D`M<]D?3/2T!LA/JG M_\3NV'`>D\WIXW70^(];].O[HQ>C#36Y83`?O^Y?R`4@T?)Q, M@^B%,7)!?26[VVG+AAT2Z\VOZ21*JAU$*+QN#L[S\F@U6NY=R;VE%&LY=^^< M^T_RA,Q:CEW)L05*M9Q:SJF8HO(-;L%G>J[+Z+4G\7:XY+S.SG(.:4^[^MSQ M?IY0?._E\#]SG[NJB4^^/;*_1WXXN[V]NHKBZ6GSB0))<=TO1;5EEU)V^20B M)Z(XM[3PTX4:%J700J5!N>:<9[Z0_O!*^*46WY9E2GKG% MN#%BDM^][_YD/CEMYLC0R;FA@%?+!:NXP`_/DPMDO%HN*.<"'IUY`X"]?`,9 MFF#%PRA,WK_(OQ";D*&!UV0X<5:IC;-09I$0)"5<]T32 M]BIY\E?)O;++511B%5'N?K_UD[_>O[QGH!AC@C/QS7+>)2=MJGLRB M"8N7GA'O_N[].XK3A[A1_L[__BG/QCYM]EQ%U%SC4%%W%;=N",VRM6[%BFT3 MGN7%3T_-$A9HMRV!8W4,^]0/3L3A>$G:7G+WL[%.APO:2^ZKX8+%V/E3%*]- MXQ-W?-5;(&D;3-=DV[[.8+I7S,'G%1#PZH+I7C'GML%T)Q5,=^R:8/I6IY1\$P;0'-*`33' MQ4RFV3$=^<^[^7T"%T\O?KGS`O9U3-HA\<[US=?3YADE:KG8R7`\$'?0&C1T M8\BO;)L[R(.U;BS0GY^P^CW[C#4=K[,:AY=4XO#]"W?:8X7'0H`';5_,_>'K=$I@/=8BVF=C/L?3.4+D"[ M#18KJ<&?UNDYN-WF(5D"USV15"E9>.VBZ_`;FTS99>S_-PJ]V7++HOLV&%UQ@J^;<]LXP=.)$SP!3FWC!-N3N"&7G-?9>>QQ@L?/ M':I;_P=L@R'/T1CM)/F7LAN67>D'H3CDZ;AZJ-`8W)T+)9(S;+"7D= MWCQ&+/2_`Z6_S8<)/'#^MJ;:Z+=LU8BMQ*X4_2Z_CG,Z?WN,H_G#8S2?"?H" MO:^\P!]'H*7B!VFHK^/79OOP*YV@^YR@YY;":9VXZZS<9M`=91%KEHAL2\A<0X5NEHA<0@A.B&7;"H!'6@'P MA'FGK0#8\HR"9\[L`S;E@G-0XEMU>3TN:*N!GDHUT.-CIE[.3#VL8Y)V MD_P2S5CR.0+*PAT`;AIP-/OA0]YC$@F=_IUYY^`:PF*6S-XS+X:G_P@3S$^% MQ8BCB9_`T?^"PYXVYVU"(,&+3:>,93BF>X4B8R4<. MLH2[[3H<1A.X3L+`B.M[+^#W!L9F6-5@-")UP`ORW0J$A@_3*/&"W^)H/DU@ MB&`^\L,'?`;F\<,Y&W&YC^N2Y45ZX'6$TV;"_9`M;12C(-Z^^-@/ M@5OA_9QM,N**7[;"DC9ORG<2+C6))':QE^`N2-+JE<>D5Q[+VK=ZX=FMN=,Q MNNT]\GCWNUB?PZQ]N]_/<)#5I178U>J>XIW>V:F. MS^]UK>/Y@`R_\]5M'<>'=1P?\W+_F=F-?V/10^Q-'_VA%]#SB]5%6O[8H*:0 MDLP"@')BGRF'7D7A$(#CWH5;/_GK_\5"[5<'U&Q8MN$9WGQ M4X]L"0NQ(+6<'7/O6X MH[TRT:+$_DPY(C.WW@U9Z,%0G`?$AYN8/?G1/`E>;MDTBN$V=MJL4(JMM/@K MT#XS'N#5&JW6[74\;B^Q)+M:;JMC]I3+G5V_L2#&;31[O&$@,3]BO;%IC!W3 M/G^^.F<>J(__81@#%V]7C&'#O_48X]N_D^'GX,0S@1HP0@'?PRP\+LX.%[Z[ M>N$3HH20D7=>^)MW'_LL^(<7!.SE.GP=W%"/"`=CD>[N6,2J*QL$<2[C.'I^ M9-[H%G]\30_8:>:2: M$(=A%6>'RB?JMO58)?7^$IFDF_AK.6EJT>`P#.)*Z?!'S"`*N\:-]X)1/%_0 MAP!/F3AORU%U.6H+EA9NE%6NPCGRM-FOQ].?_#B9?<9XF+_/P^'I%T-LP)DJ MU`_%#F;_>-FA6K)]8O?QW(M?S#[,UVT9:+\2K8SZ+0\WY>&O878RM%Q\`"XN MI__Y\7&WMLWSG__W??;Y-=U!2O$^#"-T=V@#W9`15DFS#VQ(S]FOZK:Q%N]L M79*5T+[EWX;\^W4XBUKV/0C[+I/^++G7K<>]5P'SXAMO]O@/P`.K\[VFLUB- M_,%8PCUFEJA[*KNO2JRMST4[.YK=(Q!N)\W)XI!H&?FPA_29\W%;W>MHHM<4%+B,]&%8H+?#<(U-6*!UOV^#9[:L MJ1R-OWW'7-L[M<)U`NS=D633#NW7M7J.G_9.WD)W]B9D.M3.VUTJT>9L5KN[ MO?GJ6:TIJ5IVVX#=K);=&I+J_-BMWS'5C267]3SJ%G3:;--4M950/LSRXQ(= MW_)77X52([AIO+Z[4`.&V?)-J(SJ9\FS-7T/;6K.":3FX'+NBE5.L9^)N\/^ M!FV?\4.7>]_'ZJIDXRWS\F^2K^,\`_C;(YQ9#X_1?'89^_^-0@\TZ2LO\,=1 M'/KX01KJZYBW?;P.O[$)D)F_<-I,4RU*=T^W5\:(;0&6LUSN#VS,8K@ZW[(G M%LZ!PV&?/)#*FATUN59R\N765V.[I(D=LK[XL3&`H$1;DWQ7W%:3U9H`\5H* MHQ_)7OGLPTW_58G*)8S/=/&;"+VT9\4M"W@S]D=_>N+\T$B.+/8**:%#RR4= MJ>X!%[&OB$-(="@(T+)&KG*].L98"FY\#9S1!C,?:S#SX=:^#68^VS5O&ZZ< M0,.58V&$MN'*,35<.1:N:!NN'+KARK%P0MMPY0P:KAP+,[4-5XZEX".P-2))^ M@_\+'_]_4$L#!!0````(`(5K<$=P-C\P"@X```S=```5`!P`:GEN="TR,#$U M,#DS,%]C86PN>&UL550)``,Z($I6.B!*5G5X"P`!!"4.```$.0$``.U=;6_; M.!+^?L#]!U_VL^JXO7:W1=.%FS2%@;0)TN2P]^G`2+3-K4QZ2@_+WMTTQPFD%V0&>W]\O+WJ1;W3U^]> MG=Y\Z=W?G?=>G@Y>1X-!-'@311_>IPA_?R?^>``,]O@C,2O^>W8RS;+YNW[_ M\?'QQ=,#35\0.NF_/#U]U5])GU3BXMLD6S?8%G[=+[]7J6SR%,Q`AS#*`8Z$+0^]8\>$5B4%6D*:$T)-*B/]% M*[%(?!0-7D:O!B^>6'+RX9__Z/5*ZBA)X2T<]\3?][>C9\_,IO!/@G#V(B:S MOJ#]].VKT[Z0['.M,SB#.(LPR7C_$6`,9BP"\5\YHC")`$[XX\$#2E&&(!/? MYS/^>0(S@%+&\1:/GU(X/COY<\D[6CU`:/B+K?ZSY1R>G3`TFZ?PI+^%.P9I MG*<%SU?\_Y6XP.::@E)%^)1!/NNKL5EIF9)8093XY'\?SQV2XOT@2;$;!NT,6`/A77(630!8%Y,YCY,,[;Z MI*`P.AU41N*7ZF.KL$J1'?*._Z!NDW:>4\H;;'UQ`<>0?Y;I_@HS!V1N/:7;=-U0,H[IU;Q/IJ\*EN>X)#&/4+YWN/LA.]6'B&:3+-J MZU+V`VB\YR(^][LKB3XG;E;T&2'N):[:CRF9.5GPB(H+KJ<6#X,?A@>/-EJ7 M[)<_R6YO?G1)WGJSHTZPO+V&$?=[C1_54NS0ZFH7HDOGJX[1N6\+W,8*6MC8 M3K[^`>SN-E2_[]<%TZR'%U]'D&5H)@+$$9@1FJ&_RQ&`3W.(&6P9533MUETP ML9UF>C%$.P[X)<)\^E^AQ;XS--Q2^%.I[W"<0?I?".@E;R#QV2WTZ'X?8J;T M+9P!),XVKL>7B/%9(P!8H:.QY]!IL3HQNC8G"GU);F<:[';6!?!W_/'VAOY9 M;YV`_TCL@=_T%11T>:Q/KU&8X1M-W8G5$0UI-^:$@/WW.:1HRK$IT%C70]I0 M'IN.!J]/EX9__P`TU"_SN@R\_E$8:)@#CC:F;R+.1$[+_`XR+CYDT1PLQ<:[ MY:[4J$]W6](6:KGS=I6XLO:T9O(6=2D,VNQS<4 MX1C-03K"*O_XL,ZZ`%[J'1_25=#`38($MKH-T\&N?6&)W=D?DC]M'V_;W8,+ MU]DB6B,OV9%K,#B-"A;H4JR6XYP#@-&,.SFS?!:):#M(HQ64:$QH)`XYN3IX M$J7%\49+]\'Z<]VY&$=2W:4;&;BY=0ENO9OJ.00?,MF1W0NQT%#+I84ZV@WN\I9-B/Q`[HG7Z"A7PWA10" M$7\Y#/)^/V%"-G'##^XO3/_;=#DBUB9#2%[Y\5F0KG(AN>M.:*A?]T**<+N@ M0;80AA3B/C(/%L\]7(2[GD^OY98X3MDKB6U9) M?3LNBYZPA?++50;A)>5,3!&#YX1EK$$IK09'4^PKP;&I;OMMW+NRPS@F.3<1 M-^5!S!`G_!.:P^TLSWK2#^C!'\Q;&$.T$'I^A9D>KJ8F'H`D_,WGE@>D-P`E M(WP.YB@#LCHFA;0']9L*>'T7W9;/5\R*.AGWJIX#-N5OFOA+E+,L0"K6^6%V M#BA=B$(BYE[A3:X[SL[YWTAA6)3R(4"0 MKFH.=`>B3MB[\@9#()'W!^$./)66YEWGY[B-!=7<"EX-VGJ(9MF,X%EB3'[$E[5Y/Y:X>I,29I`RH3?EBW5NC"$9&%6>21?1<)BM`Y2L"C-P M4G"K$X(Q:.D#EN2R$7D-FTX3]T!N(ANN<^82WK)4A^6PNT#=K3CUELLT_A_>HJ.YA!XZR9Q4PLJ#;C7[#^-,KI", M=3-4D_3%D$RVW@!J!5A#,N1ZL#039D*RZJ;`Y`DH(=E[/52&V0(A&7X]@,HC MF$!-?QT6]9%EH,9=SU`ZYA[[K@GBL0Z1X(AF01&H+]SZ*V M9N<:(9D)/83*X]"0C(0>I.:DZ)`LA1X>K?J%%N;B>#>WZ^%2'5V%9"ZTT\F( M%@O!&8LV^*3I@1M@WLHIUP+%-7O5%3=-8E%$'[NM_7TY;W45VV@#1#C"_XS;\-*!<,XF?2/@(ZX=[+34[C*6#P M,__WYL-P]6K8R7\@D*8U1PRO^=PL+8XV3[>E8) M`I.F'FXN?Q8/ED"H%_*H;/.N/+<(^+VB"Y'?$TKMIF\ M)5\'N7Z3$@II#_G>,-L,BT3I6AD?J>EX M?4]BJ4_SFZ>4]WA?EY+S!DE/Z>FE(C)U]R4\J6DZ2_0:>0+S#:1K9UR>M]TD MZB.!N=!!-K%WO_:@(%F"-%LVNQWU0AXRIV&QSG'WX0N@WZ&8H,WS6=W`&XAV M#I198P]IXC">8I*2R?(;I`L40];D?2ND0U"_^<50RH>9\[YG=G;/3AKM9TAA M0B62NF4XI!.$)@#-N[V0S@WJ4!@&U$(Z7FP:E*:U,*2LD"8,FF8KI!R0)CBJ ML&=(YS;U4;_&L:E9$T,RP4I$33&VD(;&T+?:S@DV<<="&KOVD,UCOR&MNNUQ MZ^XH6DSLXQU_-\5/]K%U=C9KPJS?=+>8GMX'K.$(*23#J@XH;6&R<=07TJ0T M`F\2?PMIA%T<9A`33H.;!HX94D;,0YH]]4Q67#L[*6LR8XRT"FK0HSL^" MRWV*`9M&XY0\'B_WJ>D1X>0^J;4\*/>)[XK%;?7LDM!;".*_5GWQ.MQ)2=TDK_(UCK]F5<8P`7S M-\4/D.S:"PGD-EWXN[':+*%(L]7/)$M[:8#\]1#NZ3461X;BQWNWKMY8W[LA M@6;6V$LVV\X*K%.++P%[6&Y,%N[:2#`!.U;N\?F"X5;]!`"S)TZ3VUP MDG9A0"HNEMFZ\,P`E:QI",#DU?K:`-5=A`#4\")^D]8AP"NFU^H%DNU,VS8/ M!N#FUPY;S%-E#R'`K.Y87`U%[5V+VHA-.@L!_/.K0OF>=SU:PSA#"[/A-NG, M2P6`4(M[H@N4P.3C\IZ)9?V2;PYQ_$S'NBBTA`0[G09#Q@@O^!A:)L.PTV#( MJ)F]AY-AV.G/0ID&5=?QN"&STNPCWE-TDS1J,N`@`JO>53%Z:R`R^_4Q!#F%3'G&D*XS+^NA-\EB$T:^T7 M7DW(1V<0S7OP`G.!&*>>>S<7)'_(QGFZBH#(<2F;^*A>FE126*#K@7#:H]$(7 MDT85\FU1OM)M0BQ>&^^B!N;H;XTJ\2*D8AK[\Z-A=Q12V8V+%T,W4*W+BXL? MB;#/B[X'J,O#;S^*Y50=U>@2\K:3$\/&P;&V/^8HW=<%13H'LMJ\=-%1M9E[ MITV4B^HM-S:GX=!;FXV..:_'R`W4YJI;3NW!YYG:O+SNUAPZ)+E+FY,WW>+D MT`1B;5ZZZ?JVRWO0)N6W3I)RO`+KP=MNO3VK'EU6AK[LIB-LE`"MS47'G%^; MN2?:''73[]4Y\@BL4M1&\LCSL(OYF6E(A<7'I<3HC+4+9QR'\-(R@:`+)QTV M:=%.'VEQW-$%8NR7RK8PP0!?.E`\@H56F64AKN$?_D_U!+`P04````"`"% M:W!'?'1AC9])``!B1@8`%0`<`&IY;G0M,C`Q-3`Y,S!?9&5F+GAM;%54"0`# M.B!*5CH@2E9U>`L``00E#@``!#D!``#M?5MSXS:V[ONI.O^A3_8ST[=[6R[;G>QYFH))2&)"$1J0M*W\^@.0NEDBP042!!=EO"1N&P#7MW!; M=_S]OY\7T9M'RI.0Q;]\\_[;=]^\H;'/@C">_?+-USMO=#>^NOKFO__Q]__G M>9]H3#E):?#F8?7F?I[%`>7G;$'?_._9[?4;[\V[[__V\=W-YS=?[\=O/KQ[ M_[WW_KWW_@?/^\??HS#^\V_R/P\DH6_$)^,D_^,S]Y^>/?NX]M-ZV_6S>5?@W3;8;_Q]V^+/VZ;'@W]]#%O^_[GGW]^F_]U MVS0)RQJ*0=^__=_/UW?^G"Z(%\9)2F)?TI*$?TOR7UXSGZ0YTVHAO*EL(?_E M;9IY\E?>^P_>Q_??/B?!-__XO__GS9N"=83[G$7TED[?K'_\>GMUS(LP3M\& MX>+MNLU;$D6"Y'R$.:?32E(W#)04?"^__5][/=/5DO[R31(NEA']YFU[H@*V M(&'L+>CB@?*&Y)6.89S0<$%CN2^\XG--::T8QC2Y][,'ZFV_V)!BQ4@= M\IA.21:E[9G\/[][F!(N#(*7B M6ZF833_+?R!QX(G_A^E*'!13QA?YN?`2R!^K6%);C)13K#U0)1*!.(Q#V?1: M_'/=6A+;&::"%/J<4G$%K`^J#341\\NF,)^^A/K?SMCCVX"&DH3OY`^2*]]Y M[]ZO3[W_$K_Z]TC0$$@Z+B,RVWPT(@\T^N6;RK\71$7R6&9\S2"31(TSSN4G MP\0GT;\HX1=Q<"X85T)?7=.N23U?3V-!P`WE(0LNQ>^2$EIKV]HE5G(+1NI1 M2UN$%CRJGGUE.UM$WHOO*&C;_W/7)%WDY\A8?)63Z$J<&,__0U[ MHIT=(G^G4?0_,7N*[RA)6$R#JR3)=L+[$;$U[;LF^IX3N7_O5HL'%I406?KW MID1-2?*0R[99XLT(6>;RV5L:IT'#*%<]+<*92-("T&<7HD?#_=B?<,>B=XP=O0B9ZYTODW/V()#7[Y)N79=KBU/MM*2Y]R MMJ@EFVE-AOBJ16R52G@%LE*Z6>.=#@3[WCC8%Z>5::QF)W3]2Q:G0GN_B'+2 M?ODFH3/Y@S8/]JR$%;"/S[>R!5RR,RU/9ID]40<23!`$@OJ`#I12*0.B^H@( ME4)Z`Z+Y#A$:F+D)".Q[1,!JE3\@IA_088*HWD!P/Z(#I]0S@:A^0H<*I)`" MT?V,#AWAP+#)&T`72Q0:)A$ M#X4G;@?G[V\/T(CA_C3IBDVRY;+094@D].I$\B7CU&-3+V:Q3Y*Y1_PT?!3G MW(;&>K=L@T%MN&@;DP5SUQYS1/[FWY="H?'G84(O*4T^OU@R:W-+73,=ZU`% M$=>A4)+K2*AL9-\\-1:3<1FQI[N]*3O?SEAR+V;D3'SYSPK#E6YW^P#/Z90* M.3:XI8\TSNB(B^F?TMT/3E@_9O?=YMCNS=&#](6XZ=5 MN.I[#-@A<@(0^E]4SJ?C?#KV?#JZ%Z-E!T^]RJ!U!3*HV(C2CZ4Q5^`91N3? MZFBN:^1SNR"=-]9Y8[6PXL?8W:ED=C$[3W0W5CEMU0:?"`&@G+4UDUBT3L8L MI=Y[+R;IVD['EC*-3GPIR?,LDFRQ('PE_Y*$LUB<-CZ1*1B^S[)8.@>])8M" M/Z3;>:XW7IK_I@W;9E=4MS)]WH7/6_E497A4M;.O1HT*GB2WU*?AHSS52BF' M-N_!>,H6RRRE_(Y-TR?"Z978U_$L%)2-DH2F2C1:??N`%OMY0(U3`=2_\>>8PM661H5)!=H-!:`:4SV@!P(8M19L0(^!PT"P M6[(D90O*CXA4']:P7OW!N:51(8/,PV7Y_:_1PWE%&L*XE$(FO0X?:7!PG2=G MJ\_D#\;'$4D2Q4G68`14,'V3 M7C!T?="IMEMUPSZ(?@X7V4+)Y](V/9`JUG(MJ65M[),J=]1D^F*>E=NTMOV` M(?1_IDSXC,3A7[G@(62IA$5AD/]C%``VV#`4/=,SNM4*]G'L08;Y MKE"N7?!L*6<8XC6QFWK>[8(>2"@DQ.6P#U3'#CZ4U:R*.=+V9=@M-&!P#5=H M@NA6;)DRR$!F)Y3K\9CMAW.BTBC1Q7W5S4ZU_1((Q5!BJ<&-T]AE@VYK-?7( MO#@OM:-:4&[+)I,*6Q-P9P^ZS6U@?0`<17:E0$O;`NIT!X(W5`#'I1:XU`(M MK/@Q0N4I_$A:VHSP`^S"L(`?M5W)`C\_S"GD9F\;E_OC7M[.QXSOJQ&I6QH/V;D+$N$O"(D[QW'1L6V4@=V@_N=$*3^ M(ZK*2*P.3ZIIW1_Y8[9X$%*?)*A$K*Q!`^OLDI)U=RI!+&3KE ME"&0@02=)PYN>F.:5G^4L4IUDU0SGP`+'CI?LOX,`ZS*@TV<`EY3:/8IP%O) M-#PW*#=E_9PP?3_H8#.A7#!\)\'.+OB]]YL(812XO1!X_6NX9=#"8-/HW.,8 MPSGGD#Z.8>]92/UM;3L29;!9@2Z=UJ73#B"=UB62N40RETC6YB3!CZ2EA0(_ M0)-V4?QH70*9>TS*)925S.AK22AK$OYK.PWL8_Z_Q./;>F<;>H"I8-4#6$L' MJR.AU8M-LE`*B5>3IY@&A3*L2%6J:6L@:4-H[Y83<&- M6*AADC"^^B)X44UBD_X&R/["XA#TY??5I#<=PR;Y'PR0_Z$Y^6:?^Y+$)->, MQ,DH#M8YK_%L5QGQ;+7[N2;2WL20+I*[.8PE2TCTB;-LF5S%?I0%@NN25B93 MDS,:3+9OX]7&_K8<[97"[S_43I#*%G0KHIV12&P^>C>G-)5&WR#(;^07SUV> MK;30*O:_W8_;9VY^I.6'VSTG@:P!,!'R"]\=9@D\:ZS56#W$_[XXL)5[1]5T M<(3WOZ-=*#/*4.8CY=?%`;LX8-/>%W,"-3HKB_*68$:T*92.*2-3RII<6H.- ML^U#K$2W7]HJ9$S+>H5RZUA>!ZPC=1"=0=_L45QJET,70@G"W-R,.MB(<1?O M@=_%^AKB/6R(2?BY,+@;S_GH<5SISD?_`J@!8ZMME_UWWI(SL5*.XB@]+KMR1^#RD,R86W!?Z M]"OE"564VC>S6HRM&^4%I2WP]=7QA59T,.#C.O[.%_;(KB-%41U@%^/$193P&Y+.?Q/S)<.GKV(PD;5=31-[ M&?)$G%E"-?XUBWVY0H&DUG4T3>@M2^0>AJ\'\`BF2=\\L2)D#O8TIR2XE7^$\QO8ORNR\\V^E)=3Z)_1 M*+IG3S'5IQXVC'$0?R0^_%PK;6V:I-__>;;]-WSU*GN9)#'9GS2Q9SZ1!Q[2 MZ#?4ST=^_TXVJ284T-P<49?T@6>$K][_))K\4$N4 MJKDYHL3=74`',4K1VAQ)DW@S'Q]!1"G;=T'6]YIDE;0W2=9V4F#K2MW!)&$3 M/V4:LUC=O`.BH'-8W=R^$PY<@_G`+Z=9N_DD(/7OHJXIK@T`U'-0W(-&7E)- M:Q<9UG?(Q@E`Z']+NZ@3%W7BGA8V_3164Y,22I]KW:2YIX8U3"UV(P:ZA=K$ M%`+$C_G=N^;V2R!X0R_8V0.O8_X$\L#08V3=\T#3\C[8&#A\$4,`7WNMZL`T MC8$H+^B>@Z)^&,I6A7DBT0DCVJNXWLR.3@K1Q@@Q^0)1_CB4]0MPDZ$3KQI, M;)W1')T4U0!CK7L'"/*GH:Q=:,`*.O&P^0*N=+"@NU=;+."V('\>S`*N"0N# MB@V#,5NI0_30W:W::[@^0@)C@/AK2`HP:7`TJ[ZYL'<7]EZ.3S/L'>1=;:@`QK@?=K,6W%[^89M57$=/A`0X7V4))9FF;'D@51THMJ65M>BB63/F4 M\45119_PBAIPP-;VR;^5286*@^[H[SV1J.1J20OD9/8?(W1+Q:D?^BD-\E-4 M3;BJ;0_A-B2BDVE.BDP#GDSOA8J;D-SXKP[9`G<\*5#]+S87'H@J/%#>/&=$ MJ$[RZ3:ANY-"P]HFF"=GJUV;&[*2O\LEWIW8&P>R=FUM5;@N/^48I_DI!"O/ M!::>0F!J5\2**VS.HH#RY"*W`"Q_=K]>X"8/21A$!*^VKNU542Z& MR\5PE>/3C.%J:$2T'=7UDQ?&HA'U4O),=5_D*^]L+<)+]7GW6K=^Y%'.S'OR MK/.`47V7`7M83P""<]4Y5YV*YE.K(>.TV`$H`.XU;B?SGZ+,#Q>';(OY/WN< M1N(W@;!*VYV!I.[4*K[#>:G8G;Q*/_.BN.L.-U;<>S&(AC>ILYN MY>Q6".U6C=49VV:L]^\\T681IGEPC$?BP)/+/XQG-/9#;?\U=#AKYBP]@FSZ MN,<[LD9Q,-XG"JXV-QO$F<]B1T+E6P1UK< MW3I+6+=['P!CH?:FQ=U^&R9_CCD-PE3^5(FIMD9;O\^(+)"F'RD>Q=7#:KZ+O:!7!`>"S*2&\KS M*$W8N@/VL@_G$V/!4QA%XA06"X;$LU`LG5&2T#39_$DY2=K]>R@"L%B2D$O9 M>L+/PV3)$A)-IMP\XD.H$(""( M!2NMHUA4/\YE;:F."X%&'FYJ&TR+D5P(G`N!:Q0"UPVQ]YP$THLV2>>4KT6P M1!RH-'R4A"EW@59?^]"$>#^97B1IN!"LKEH[Y8U.(!31153ACS9R%:Y>5QP2 M2!M$%X-41_7^4QM`3S`ZC`#"]V`V<:BB6[)ZD.%.'B!0>Z\^Z`)MXFD$@C;T MG(,QT,TCDX"`OT,&N*5W#XCZ>ZRH]8,E@(A_&!3B)L$20$;\B)41T&`#(,Z? MD.)LH),"$?^,%'$#"R]4%L$J?S7S0D!18Q7!@&Y+*$RL`IBFHQD*%YOHU3+8 M`PH;JP#6/NH#R@%LPIAVV@44*%H9#!QS!D6*517.)%LL"%_)O]1E_Z?2'*E=B;2#3]NK6MH9\38KG+J03E0A MG?Z7%D:7%O3`\OS[KP M\.X^U"?3#HF3@0V^N$[/)3X:Y)$W<,XT&JU/^!LEGO&]ZCAZF.%#N,!?%_B+ M*?`7LL[U5[*+CG71L2XZUD7'-H"D.FPL;\9Z2!7$,A,R`KKYTP';0@B$FC%0 MXNY&+;!MV_@@=.[_9&$2%KIY(R.%<@QKU@8`%:U*+6X=@,E5?#-G-`Z?Q2J_ MS_Q$+M;P+Q:3ZC>`M3OW4'$L2\1AG22C'1?S'SFE2F,!N-\)0>K?#E)&8K7> M5-,:!?DWG%TROB!7\53^3_ZJMLY=LU$&;(`[`0C][YT]V85SQL>,7=,B"4?!'EA3%E35L8HV'[),1ZX"7OVAP%4B_FIRN(B1O??`%`L=U M2!["*!=SQ-^RA;:]T.A7G'G-F=><>0V)>0TD8*#3Z>&B*VLGQZ,T+=;-6LVKE8FW=HG#VC1BBV[*TVAZ?;5'Z@\VF^X5'SJJ2Y3)9+;1@O$T_"LW45P\ MR\14O0P2DY]P.I/3F9S.Y'0FIS,YGO,[66J=!-(QRS>;G)MD;Y0_Z_ MQ%N2E:2JF3:I'L2:)@DAPVF13HO\+`N`Y'[\HM;G/>6+<_J0:JJ0>L,XMD%C61$VRK`3_F45;IJIG\7]';FN"O_+Z3^)W$7UZW M\RX5^ZXHWIF,_#1\%$M(4P=H.S`.IMR0E=Q,HR?"@WW:?R-1E@/*XYV+WS5F M4/N/],ZLA\.)WCWAE",:Q<'!;[Z*8Z[5VNKDDTX7=;JHTT6=+NIT4:>+.EWT M->FBYL4Q=#/O_-\^>)DD9^8)Y#) M;U1[U>R;T.4L(LXB4@0G?!:+<9$M;L7B(='Z1D@N&5\_PAW/\K?D='5^`V,[ M#=5IJ$Y#=1JJTU"=ANHTU->DH1H3'BPJ'DFV7!9+G$3BN-U45Y"*>=T2CF79>#7]0+S-SB_T%0H]:.9 MV,1).IK-.)V)N;S)N#^7[T@+G?]0.C,SF`%`+YX_!M0Y/VYF@(C#L&\Q\1%) MDOQFE07WS^F2)6%:NFYT^QH@]UI,05S'L^DJ]C/YJPI1WK>G:G-!4*A>3Z5AHD!N**X`U&6+`;J43@-#_5G?NGY-P_PS$HZ(K MKJ"SZ&H))D?O5%39%5!ZD33F"CS#B+Q+'R3,0>#G M`7+L!V0<:VYW`@+^$1E@DVY4(`M^0L8"$^OX9R283,9U0,4I>R8+Z'Q6FO.A MD+"(B"TB3*PG[7BQ+)*21XFQY?KT*-)9Q/VQ('PE_Y*$XO*9AKZ03CWB^RS+ M$UV\)8O"/->E<6A=]S382PCJ'D6KP+SML?)9J(3S:/69\#^I_/@EI9\X2Y([ M$M%$R)B^C""-1W#9,39+5N1*%UIDPSH9R0F32PI$FV_.A('=J'X4KXH MHP_4P0!AVZD28N(H>!3:9ICH37ZS$0R0_B63!_%DNN71VL292!9)Z>?('ZG; MK0LB2\,.JUL9(&&M),AS9S*]X?0Q9%D2K39R12Y.7$DY\8\LSE^7_#U,YX?< MV3!''EYE"#K[B!$&S,2()#H7(F$DS^#DA>-CS**(RCS:KTL6R^6Z-P_E4%L/ MUPFHG84?1O5Q^X[)6BN=^]Q2'RVM!^L$T/K&R`^V3S265SH-SE:[O:L+JL&` M1H#E"M*>":']&6!B1`/0[L+G[9=44=6J=O8]\*-"[I,:`0T?I2&GE')H\QX` M[&[_=6'U*M(K&_9`=!2Q)[$&Z"7CYRQ[2*=9=,S:*B!:G>V#DP8NZ31X%$>+ M(&F4C@GG*\%V652D"A2L4P]@V&*9I93?L6GZ1#@]T*25FT6K;Q_08GG`%\KA M;9C\>4;%J224PS^5X5O0;B<#J/^PM&,*5UL:%<%>T&XH`-6$=@-Z(("QDYG> M0W&4=$$`I#9T&]!CX#`0;/LL2=F"\B,BU;<.K%=_<&YI5`C?\W!9+B=K]+`/ M0_'6S]GJ,_F#\;&TK2O.L@8CH(*Y(_$+6:CW5\-17@G<_H^8G44ZG,U3]6Y4 MMK5/^M5B24(NK=-%0?V;Z13CIY#J[M4!7H=+O;!UALAO7IKCHJJQOV0?2SK$:BW".E;7H@M2B$)8?6,QG0:2O^]+RY( M*;T*CD9Y-'$LE2O*:9*.?)]GE1G@!D8\@2S3.A$:759IO83'P*Y4E%EXBAEA MC:7$P>92ZGDIT*U6L#ML#S+,BXYR[8)G2SG#$`>;W02S;A?T0/+Y(4Z=?:`Z MGH:AK&95XJRVM\ANRI_!-5RA$*-;L64Z\;[L4VWC0KD>C]E^."^BV5E/7W8OS4CL`"N6V;#*IL#4!]PJBV]P&U@?`HXBN MS(");0$-:[";,^[JX[CZ.%I8\6.$RE/XD;2T&>$'V(5A`3]JNY(%?GZ84\C- MWC:N@%6W!1=TTC_0B80PB`UBSNR:C\R4FJC+*K:KV9M;H."X?;M"NS&`3;+* M@%#156C2#54"XL12F,E`>0P@8BQUF'2K5P#AH2K)I%U"`BH*8"F^9#R=&\H` M+,*0C9H64)Y@D9XTRTA`X:$2F0Q5G(!BQR):F:UK`D6/1>XR798#BA^+,-:P M(!84)BI9K$VU*BA@+*+85I^H*;T^#^0"0:^8!]Z7F^^ MJ#7?`6S`Z/8A'WJY.L`-_81]\!N[Y;[)L@,&Z'S&%A,VQ&T>HS`&&SJP`:!C MT23TK^)[NEC2$0__$II?=9G`^M8&2()?')T?^QL56#X=\55(+.M_[13?6TK6 MKR94,ZWQ(":+0A^_=E9:`[KJ4;161%PS(8G/:"0M)T)N6573H6YIH@@Q35^\ M#"#^?2A-;,^<,@*;]#=8.WD4!+E\3:+2A53Q^&R;(0P2?ZY:^8I'@=L-TDGE MZ@V7Y#,%NV0_%=W0OIV0>\_.Z#A7W6$D'K?OC*S)LK`FCN2-N"3Q:O(4'_(F MYUB2[H5^UI/?;%R#,/=6Y?&2+:=NPC^3F,QH4%RSROKH!H?O!'3IX7(_)^D_ MR2,]HS3>.0C%M?B9K,[H+C*EO:\:8)%@^Z_2'G9[.QXS MOJQ&I6QHOX[!1NW8X]CZ'E+7C@/W.R%(_9O^R-_34:X?(5LHR!\$C_O0D9&"ZG1P`%K#(8"?)7%MJKF<),A4`-5 M/"/8''KMVX0],^.<O&%^0JGLK_R5]=$'$[Q[-DPH4V+^[SS>%Z%\8^W=O& MYV(3C_Q]YU`]FXQ^#BL#UX:$SCG7X#NN/G-#&!5O<1Z0KGRQLT=R%4^XJQ&H MWGY'!DHI,^H_3G]"P/J7AZLSRFHK@.ITQ03,E6UW9=N'5K8])S@J(WAC\ZY2 M!G2ZNGKTKCQXSZ3>D%4>E'#/UJMS(W#3)(^=K:`>VLV5HG:EJ(=6Q_D$(""8 MC4U([2?*9IPLYZ%/(DAEYZKVKIJVJZ9=4YMAT&6D0:X/RT6=ZK,'KKZ(_@P#_,5V4791>$U]3:'9IX"\$*81L(AR4];/"=// M.+%;!,<52"W!BJH`IBN(VOM-A+`RJ+TJ#OK7<,M8?;NUL0P>@+I^.W3GGI:' M[BC3ORKM`>4YIS%7X!G&\UY`)]O:=HPID&7X*L6[)Q;<$PL#>&+!%1=WQ<5= M MF:@]!,6,4NIJ4XP$"AR;$&8R/QO*`Y0RFO$B0U!NH)35NB@]!&4(%O&NP@[5 M#!0J$+3&:GJ"Z4*ZCD-TVNZ-5: MAG($E72GR1%PU6TH,[!(?)U77H%--8I/^)HJ%LC@$??E]->E-Q[!)_@<#Y'_H@/R4[CT;*W3Z ME)/<2[;_&.=+8B$]S).V69ZW8L,#Z"IK;IZH&S%9?K@DT=ZS2D#&U76UGS>[ M>44X)_2:D5@^%G4I;CM!9SS;47ZVVOU<4_O*Q)`]%(\*DR5+2/2)LVPIQ;LH M"P2YXM3MO*AFI530=' M>/][T=5D05F3Y4A?=@5-7$$3TVDDYF3(MG&_Q@U/REN"&=$.+6.&9=@8F5+6 MY-*R&Q%M3?. M++F0;\A^,N#1RS;'309L"#\!",Z6[VSYK\F6[S1K_/I63YJU4X!Z4A"JI0+; M0N7W7KC-,_!(GFC04I[4&-&:**E-4[L@99+,1\&C-)EL"V@<9G,AZG7H( MQ'0OY/8?"^Q>R#VY%W+=0[+N(5GWD"R.AV2=-=!9`YTU\'5:`]T34ZPKG0NE M%?7UO4;EGB-JJ`X=/4?DWB(ZN1<&G3/(.8,P8'3/,+AG&)QC\!B2CEE\H,&1 MG=4E1A4NJ>_+&UC<),@5`L2$J@Y;8[^F;=?]#^O"6TNR,E!9##B:-9>]%CVM MW/6[YU?%4AG/0\[RY`.`?UG5P:2O>_N=+^R174>*FF?`+L:)BRCA-R2=_R;F M3V:#7,5@(FN[FB;V,N2)V/^S>?IK%OM%64$0J74=31-ZR]+Y#8U(?"%CT)=< MJN37UV,@M:#>IDG>V,I^E9M\;5E;EW,%D@T>P33I]W.:?U-(T>QI3DEP*_\( MYS>P?U=DYYM]*3-I0O^,1M$]>XJI/O6P88R#^"/QX>=::6O3)/W^S[/MO^&K M5]G+:/C3_J2)/?.)//"01K\)E8JN8/3J#6&BD-_F/9[MPUF[5X?6.[V,8(UN M!HGO^3:/)#+5&J MYN:($C).`1W$*$5K3A$W\ ME&G,8G7S#HB"SF%U<_ON]S/H&\(''GEPOQ."U']P2AF)U9$>-:W["+A\$(I# MDO),JA"7Q*_BTQTD8GV0E-`P@.Z""NX6'H47J5II$49EU,W:37S M"Y!VT3GR6\ZXPGB)SJ'?`FH3XR(Z/W_;J=;Q"*!S_QL"K^-00!X5=%)4`XRUCD`@2'N/M;=OMEC`;4'^/)@%7!-H"14;!F.V4@>]HKM;M==P?2P-QB2BUY`X9M+@ M:%9]:0)SS^+070/7QFF!"?((['!,X:!.?Y-Y@5<+C*_#)LB"X9D,+ M\`F[IIE0$61B.U7LQ[QZ?KIJF2-6-XRUY#`8(:VRPN[FA-,S(I:;?+E.2":D M6)7;%.OD;)6W>9!M;HJI'ST1'DR6^>,TGT1+64Y&G``A"RZ>Q4$@CC^Q,OQ# MU[ZU[_50&S3X(TO2G/Q[MGLWZ(:$P54\)LLP)5$Y\EMQC`K:Q1%ZES+_SZ]B M^8@M5DAR]([R1X&K@+K.QU0\PM`3%4-B=PYOO9+LL[G1UWM@;Y1_32R&4A07 MS_+'JL`=O3JFDZ)RUXL3;_O'9/W7I*I4 M8ZNQD$#?"-MW\IG(7!@9RSB+X&QU2+D.$_1'M<^."R%JL!7=G!7E6^L+BQ_% M.4Z#?/F*LTF<0_M_'[,D_<+2?]%TE]I?G#J7C.\=/%5+J!\B3HC9NY&*3A,A M"?+[.8G75X)MOD/I.:4IV+N!K;.[Y-L]LG9'36EJ%;B]?0A7-Q,ER4=_MT_B M9_(<+K*%DLS2-CV0*E366E++VM@G55P44\87Q2.M8EN6/XX!;-T#^9SYE`9Y MS.A5DF22LBMYW0GE(7N(0G\RG5+Y$G85(-W^_4+Q#NI66 M"86R%*@^E]L+B4054I@G95Z;:0^`QFI/W&65.;F=?>EX;%MDJ5)2N)` MB#!7L3A/XR3T?R-1Y?M4G7\/(0N3*DP[HV4)W.R,#IJ-K- M!^H!=/:0A$%(^&I/AE?MGKKV)U!``(@17R8B7+5DM;9 MK;"3H5NG9:8R!C*%HUR4QVP_G!.5O0U=$'7=[%3[5.R&3!O<.(IH%'2;IU.= M+86W0[!'ELCB[S9UJ8DW$)V[`H%:X!0:6SMDRR&J@>9UM MC<$#S>_4##<;:`*GT70'(`\L5KMHS@.]O!<@!I"O M;R_]%"JX6+3-65DVP)@:*'NP"79-TANA6+%)=CUDPD!9A4UJ[#,W#LHS;+)G M+WG44&9ADUB1)`%"V8=-%.ZU-,*.:7;*H/SDA;%H1+V4/-.D93$4V>J+H MD`,KC&(H)S&GZIX\KR6`,QH+Y%4O<-6T'G#L_@E`0!"*ZZ)<3R'*=2@!AI)700*";;GR9X_32-H^O"7AZX`!JR\G`*'_G>4T,*>!64R-:7@^65;+`-D9U3<[@PDL M*#7-!O-3,;MX]$YG0'`&A.X-"'9#J@UO4VSN#Y2@V>KA:0JP6$OQ:0 M,[4Z4ZLSM;8Y29P)%<=1J?&4L=*,`P2&)9.M@24(B!!+`AK<5@D$ABU+S(25 M"`@=6\X7P/@'1(8E'4O?B&W1.2/NE4!R.'=')"P*@SSF\X%$L@:(E\PI31// MSSB7K9=YSI>7Q203FZ^(#16_G],T]$FT15WOM.GDLS:<.1T2;C-S:\P6BW5* MZ0WA$UX\:)^GK-]0GH>K5*CG&CWM&QCVB"NJN8RR=,ZX3/FLAU/5`P&,HE@- M%,++U@C(WRN/`,50TL4^D!LQ%A4[.6BR4?0Z]PT.N%U@G7"`46Z:^@XX0-1O M'6"O`3L*3@""\W4X7X>*YIX?D;GG0NO*^&KO"*F@6-'R!%PTSM*,WPKKLH)? MAWVVC1P],(MM$^EZ8"9;7;E[H(9;+6%\H!9:;0O0P.RUVJ8A(#YT56(A=B,@ M-FQU8.'V)"!`+`5=P7*X[02/#QY)$FG[)OY_LE"<@'F.0Q22AS#**R[+OTL' MW2;3`>XL:#>^M12/EA2VRO$XRQ*Q6I)$K/N',%[7\-M4.[P*!(U"_I4BX2@G M<;2FXWPE! MZM\H6T9BM86SIG5_Y.^==V>$SP1K;S+NS\6I]4G\O#L"B[34&G3-!D,!?BS. MM3#((W18G*?>%LK@>SCDVB%0`&U\JQ5-X.PP]*%A,VU<1)/L_>%\;66XI8\T MSJJ\"[W0,&Q67\5"29R%V\;;PN"?&`N>PIUQMD-6@VD8-JN_4(V;P,17ALVN M&\Z6E*J"!8)W:(P<6/&8W M_&.@T6<].EX&&LYFPOD+%=ZP/3[>W`ML.\;O>X\F:;C(,][)@O$T_"NGT*-% MF8:&H7VZPUJ+Z&M&F,T\_DN)EUZ'C\?BZ&B/X'49C=$TI?Q?E/!+T:'"*&M@ M1/OF9CVB;ZGCB-,?!))`$;8H1P9.UN,+HRAK8F<7I:960:'@PT!_+WX MO+FI?S':(.`_,7/@=V.A@EX=<0'K-&`/]`E`<$YTYT17T7QJ3G3G5L/OG^,&<0&YNEIHAO: M-DC_X"U(FO$BNYI-\U\FWI*LY(W;T!JM-:8U4W0#JFS:H:]9/)/%J,_I0^7+ M9R5->GC,;8^*SUN.WM+ENO+[9'K#P]@/ER2ZBNOL8NT&&P+X2JM8FZ%0`]=Q M#I@:=L!6J1.`X`QKSK#F#&O.L.8,:\ZPUI>295:2&*A5K;U,.5"CF@D]8J`V MM6JMT+8MX?T[+\D6"\)74K^>9F(:J+8O)B_+0 MU8;V!N/?M6:3Z(ARFW:+@_>T+G,,ZQ=.-X_!G5<66-'L;5_0!1)X%4MKI3Q8 MJ@3XY@-A!LTR;@;TX4"(0>=7AQ'4QR-AAOW$S(`^&`R&A7VF_L/OUX;'WDO$I#>7%G,C"=,_+ ML"B0DES%-U1LPJJWWJU]]P19VL,Z-D+3\*;BDVB8;C%^XBRI-,YV]Z7AL6WO M8<=.KZG*[PR:93UL;\VO(V1OHK6_NF"Q>0IZ8O-#_3IZT!9W"KNK6%]C%J=< M*)$9B62,6=4S7#U2,CRV5V_?*K`?.F)["TJ&Q_;?:"+P'>#,M_DY22MM#CU] MW3GDG4/>.>2=0]XYY)U#WI8#IV/];J".^EZ4M8&Z]WL1D@8:$M"[[#[0F(+. M37<##3KHS>(QT'`%RRX-()>PO<.`R!,!Y""V=QDZ=NY"94UL3S;TXJJ%,@N+ M9-Y/P`N42R@E]3Z-T/:#V<2QFHIE+E_7*.*^6L>S@4>T&-*F29/-[.=\_=R+ MSRH,CZ5M[!L<;[=[J'IAV?9?KTG;< MQ[X>.?)]EHFCX:9X"D9S*LK:]$SJZ"') M';,0D@_;VB=]3)*Y."3D_Z2`\D@B*9J,TC'A?"5$.%4BBE;?'J"QQ2),VU[#!`J M)0J=+GT">:1Q1J$34=:X=^(UIJ"B?7\0[LESYS[`+5D2BK.R M>#^R?GK4S>T#N!#*)%M1H49'4M$#"]G@?O8A?6(L>`JC*A'T\,_V";R*A09. MQ9*F>[)\!;7*MGV0?O1BZL6S'V72U%7#=YVN]H'M+>`*^DM:]$JF$,]R46?. MHH#RI+"MU=.N[-8K(/6!@^F$.::E1N.I[]`#B/5+15_DR[MK6TD5^8JF]@G/ MJ1#+^)J16,=^`NZ'"5*M2*'3M2=@ZQ4#F)WRECT\T)'.*0_=A'5 M=[`/XH:O9?]:O5_1LA>RER24R572C2(V9LY;B"5/HVKI3F3PF MY(:E-!.)@Z823WV7/@/OV]C]&H[2!]R4A#$-+@B7*3/)R/>S19;K;$*W#OVP M:O;@'0<`*!V2X0%7^0IBMM];HB+@'^?W1)$VJ:]\`UT`?032,8;"LU"%T8+!@V M/!(+7>DP,$:`XPE=K2\P.$U3,+KB7+5`=0-0T979`D]EDP@!=$6RP&BU;83H M*EW!#]G6H.P5G]*8/ZA-%%\I*0.G:Y5?`5\IJ#8G;%N4""4>_>`-*%B$HD\[ M0`C%'5C8&10@(C'G94/DZ@5,.8:&BJ#3D`&$EZA0VDDZZ)1E&&Z=-#5T*U=O M:C5#0]&IR'IH:^-6T&G)>OB`J0GH5.2F**OC_M'IR'H005%*Z#1C/8R&X-G3 MAC7AU<9AHM.,VQXV;855K/(/,%$'GV+<[M`9CFK<^.#!K@;K`0/G@Z(3XZ#N M55CD!CIU"T#X2[NQ.D06G5JEAT^=^HM.H=(#!RJ:@'#_Z6"L"T)"IT7IP=.- MID6G3NG!K0OF0Z=*Z<'32Z?;@>VKGM6V0>*QJ2<]4,6S+P9+6<$_T6,5*UTB M6Q6PNJ6S_,P^%Q)^)+]U264H12[N;SZS7Y()TKZ/\CZ/E*=A(@ZM2:T)L5:V[:7P`Z=^F"\'\7-$\ZLKEK,O=L%?^>\KD.AT M[:$@Q%I"N:$\K^98,RUUS?L'<$:2T!?L/0^CK/I5"V`O^W!>AA944%_>J$=B MU<=/5;,>:H706`@!D=Q]P4)('W+QIN$C70=85=`/[-5799%KEB270KPMK#69 M6-:3K:AS1J>,T[W@SHMG0;R0M\75QE>YF43:Z.3+6BP2],VNXI3*)Y\J6&'A MBST6:%E/Z)F8[VEEIF1-ZQZ2[FFZFY8*HDO;]%$?(%Z+X7+>)3WJG5?;OH=D M^Y?T*'BN:-E3C8""D"IRCUOT2F;Q9*F<[*1&*(%UZ@F,[I*'=>H)S!V)MDIJ M=24`5=,^4N)S&JIVZ>&?^R.P9I57->N!8+8B4;I2"WWEC0:<>7\"$!`4#Z"Y MS">.Z<^$_TGE^:8^#NL[]`:BF3*AU]F5=W#E'2H;]5!D@/KSF$5LMKJC_#'T M::(R4]2TQD"^^@ZK;6\?PL'CV,5[,Y-I;L3:>X<&9@5K-Y@K%]%!)(@K%^'* M1=1=KZ==+D*MYZ`+S*HDE\%T(72S!`&DMNBCB[^"0*HW6J`+N8+`JO/3HPNT M@H`"RF7HHJI4V#2#0M"%5('W6)F)&5T>"NA4+[4(74[QM-YIQ6JSI,A!F1C0! M318$VE5:O4J23#"2\1NRDI^:3._%YY-IX3XH1=)D``.$5_@W]MDXVNW$R73= M3M)4O9&-#=I'NNT?65*46[EGDN38#_/*N3LQ[I[)(OLWG#V&XO`\6WT5!_%5 MO#52C/PT?"Q2T]7APUU^RJ7\VLVC;?&2'?+WZ\K)$\)ER(+#.T0+H7J(/A** MB^M/+_<,V,OE1YO+&!4[7YZ-DUC&ADRF+RJZ;\NY5T#3Z]QCXJ,L+QA618E6 MM.J%W`,A$E)6N!I5B\$P@3]^KP4,M>JIE]Z!2;:_6'>J]\H;C(`!YD%-2#"X MBGXX(.65Y_=>*=%`5=45`[#J(M=@@/5#8`"J?`>J%B/@%:E^X6V5F751O1JE M27\`%"#E'MJ<$E46I*;=T0#?-E-1^@H4&+'.8!C`OWQK M\)+Q$CL$&+S.8'V`+_RN2AG\N$DOE4;*+$2784QB7\<8U7P@S*#+G/"M&:`: M%`TSKN)'L3@-K`#`0)A!MU\!FH.B88:^0;KY0)A!MU\!FH.Z>E,*4K?^K-W! MNB[@*UU>TOVKRE_7[-T;O.2>Y0XN3C>>C/PMU,DT-X47?ZD2+)H,@0!HY<.: M4)BU`_0`DC.?TF`=SQ=%U"_\E0?.VBJ$>KW[A5=B#H=,HOX(OU#Y!-6-75$D5Q2ILE$/Q&;+95$&A$2Y>2EB3U?QE/%%OFIKU"#-WJ[HCBNZ MXXKNN*([AO,LVAICT&5@M`!D-*$&6YV'[L-`T2V%3B&S)FH- M;@-:8:+)'`1T6;!V.-@\]P%=$J6MH^T$BGK88E63F%]TI4'LK2N->'9T)45L M<C.4?/\`,>PHU/0S?#"9'X8.A:UNG;!6:)#N78A@(X/4;VTI*'< MN)J\@&4=#.4VU01O,HEX*#>L)HN:%X,;RA5KA"'*^G_H#,#`*-TF@?7HK@Q= M%&55[\OJMJ&[#UH!K2J.L4/9>;7P6-P^WO>>:$;B62BN((_DSA2/K#5@+Z`I M":/M6JVO#JX]I(UJX`V):E7]^R@2]/.+A;1?#+BF:0\53;,D%=N0Y\X$>>_. MPV4Y_1H][,.XE.N'7H>/\L[93'WA+ASY?K;(?R$+JDRF;3C**X';?T:Q@N"]MYOA*(\> M?+8*9ONB=O4%!VK;0XEDQH*G<)=2=U@$^>#/O=17.YQH(1M'F7QLIH9XG:XX M@=56N-0?8L!U$$X`0O\'KZN&8@I%-]\=P@?9]-$))QTRY,C*B"[RHBWXB2>@GFSCV\XR+^;V? MTR*&J,P%#>MAX#7=]8?&^4:!$Z9L;XZLR9+&.F0IVYLCZXY%P5F6?F'IOVBZ MC88CAPX`G2[V+8(7<1JFJX(4&GP5&TOM,:IMWZ/#"T"^LFU_I#-^'B;RFLHX M5<4`U#3'`4#M&Z[M,&@0_;M4OF1R24^F=^*#E>]:E3<:L"OK!"#TOW2<-\YY MXRQZXT"7&3H##^`"*_.R51 MD2/(.8)PG+'`/%V%7H+.M*^&I&F00F>[AZ,#F2?1&>WA^`!63B`Z+&GQ^B9) M^PZ'I?B?D+1(Y"6R[F[BL:DGNBW$K9'(#'6//DL7"0T\B5R(/5$FQ#$OIJDG M>)MX`DG1L[&7HC,*++HV.L8`\X>8T99'`D=.7_A([Z@OMJ/,4+Y8TU\4^E@L MLW1='.>"\%AL6)FAG1=N?EG*^D#)-CJV?4-"2_+/5N4#*"PI%KZ(A8VUZ4[0 M;B<#J']+Y::N9EZK9+*4BTSMM:IKW\>CJ)O*XCE12O*5;0=L\CX!"/WO!6>U M/PFK?3?$_DXX)W&J/%U*VYR`@\&:C(+.1P&62)C6'8/2[&MCEFL7U>`2AIJL M$*`0AUXS/BRNN";LJ%]U>UL M70)_[R7CM:=-;;T#]SLA2/U;8E3]?7`U+WQP7Q MX/D5#7"E#[<,TI)Y`A#Z/P:<,?8DC+$#L7""KA%TUDFX@,+@DAE*RT7=_-1, M)4#$<<8H9XQRQJ@6&$UN46=)&I(E25NJ1^?8:(]3H9K9MHI])PU"^8ME'HD# MCVZ>*VMH"8,.9\WZI4=0*XM7445$/M+.9ES,?+7)2]W20*F$RE?H"HNM?&P& M3&S;L7J(O]N5+#JG2RZNQMS(*7Z.Z/I!Q_U21K5/]AW&Z1D>WCZ#KN5K27,6 M!5<+L3L>B](KRF`50`_[,";3:>C3+3^5`)1M[9->N2C.5O>"&(4E0*,G(EBJ M9RA@G1"!R1\3KWZA`-P/$22Y=)3&/XV>)P8+@773V9HQV9K9-'TBG.[5+U;> M/+7MG;G@L60WG&ZPDH3-I M-00,O-K0)=EKPC5H!D&7C]^$%0:!.@^9\Y`Y#YG=2]CYRW!(&3!(.M8Q='(% M,+B\$X,Z.JFCY7R76P]M^PM_]*8DY-XCB;+\X?!LD6>DY15.V/K'F M>HLO6/,JMJ:QE:.QR,<1ND8@DR[$74**-2T^.*/%%9$W>9!-;LA*_FHDY/3@ MDO$I#=.,TUL!I\S99WAH^Z:6S^0Y7&0+I46NM$T/I(HE64MJ69L>JF;(Z5?8 MVX[^WA.)ZG(>QRV0DXG`V.U<#YA<#\#3^>SH=!:WU6_RLAKM[JJ+9P%/BESA M8QB(RZCD2K#^W1-AZ6],/N89A>G*-E/+OSQPMMZ&R9^7G-(K(4]QFJ2VF*KZ M;D\L?6@BFBG6RSWEB_?Y=)[/4_9\5HC%Z/R;99(Q`RDA*$WAQVP_ MG!.5>(W.3E@W.]7:K'/".">,<\*TP`@]29Q+!<=1"81D6_,:J%_&LMH_4(>- M+34)7>A(#XNH7B,'<@G5DQ"=.%UL.P;?>W1=]&OWA,'FR8-6[T'H#6OQD8&H@A])0G\4BQ,X?VVB0AD']K)O2H#40T)2\\AY35!Y39S-[Q1L?AU5 M:J?A;"[.M=$CY61&-R^AK4^[_`1,)EDJ#O]8QOA6H&DX"AJX1Q3FI[X>6/48 M)V#-=48I_`:;GHQ2SI33DW8)JJ0R**-+B]-UH`:45I?G0*TB6EJ6;57^@_=` M(A+[5&BRE*8>"?[(DC3/9O,XS>.TO91Y8D!OF7%_3A+Q`P]%>W%`R1L^;%%) MV_RG+5;:[HKX5N'"YW1*.9=5VHO7FNF8)6DRSL3OCFKX$Q]KSIT1]A1V[SBSAS!+.+&'+G:LA/@_41E$NK0[4_`#1 M%.HU\/7OY7^DFU[\YO\#4$L#!!0````(`(5K<$=[))J40&L``-7V!0`5`!P` M:GEN="TR,#$U,#DS,%]L86(N>&UL550)``,Z($I6.B!*5G5X"P`!!"4.```$ M.0$``.V]>W/D-K(G^O^-N-\!.WMCCQU1LKO]FO&+I8/E]?7?_B?__%O_^WBXB>:TBPH M:$2>#N1QLT\CFKUG6TK^][O[&W)!WGS_YV_?W/U,/CU>DF_>O/W^XNW;B[<_ M7%S\Q[\E9YN)___T/FZ+8_?GKKU]>7K[Z_)0E7[%L_?4W M;]Y\^W7U]1_*S^&O45$W:'_\_=?RC_6G9UV_?"N^??OCCS]^+?Y:?YK'71_R M3M]^_;]_OGD(-W0;7,1I7@1I"%CR^,^Y^.4-"X-",&UT"*3W"_B_B^JS"_C5 MQ=MO+KY]^]7G//K#?_R__P\ADG492^@]71'X]]/]=2_-'[^&+[Y.Z1JFZ29X MH@G'++K89'35W2[)LJ-F@.-'P/'V!\#QW[MZ*PX[^N]_R./M+J%_^'HRTCN: MQ2SZD!J&W-VM%>P/19`5-M"?=VP8_R,K@L0L\O,N36/F!HL:QGS6I6','ZEA M^3CMT!Q>!-#B'*0BN@2^NN$_E1]"AP-&5=`K37BK8_JYH'P]*JUFW3<+CP;Q MZR$%H&^_?_/CMV\$3/C-/]ZS<+^E:;%,N;$HXN)PG:Y8MA7VO2(C8,H>E+Z7 ML!)8)5A6#OAHR)K]7B1M;BHQZ9S]&<`\I MNX3!ID4F`-W'^6\_T^T3S4Z$2[.5IH@I]FY;T"KRY(@^`0#D%PGA_SB5-EVN M,R0KW4K>!VYHV8'2AX*%O]WN`-B@S(U^CY2VWGYMRUE%F`C*1)+V*V'C/&;: MC%.5JIZE[R,KZ".[BE.^OXF#A'N;!05#^IX609SDCWQ=W0=)UR*HUQ*S'*I1 ML"U'@((\,E+C(#404B(A)13WBZ3F)+`)G'5KONYI7F1QR-U<(?^#IFOP6Z39 MZNS3MJ@U1$NCY=5:#;.5:?%JHI7**P&]:/T4K]-X%87J1!L<_H!5M=L!V5VXS\ M(DBCBWR_W0;9`?XR)K]%\)2HFT-KA$W93>,`G1E80/Y6XF:K!C4'76)FJT$; M+.'.PP+;$Y,A4VUY[MW:]"5'%,7)OHB?Z0,-]UE<<&`?/H?)/J+1%>?_)=ON M]H48W^WJ0Y"E?`3Y'-D%&WQVZ.UA^CD^5W2%%Y'IC$9EM]6Y3)@UI\@L0 M][.6N9AGYF'R;*VSWW`+\7_W<1Y+2X)8,`=[,+KR=5)RNH1]TP8PNS5I>"9& M%Q<%]MJ2PN\N=AFL9\5!K&64P]B)OR+D4;$OHY(Y0M.IC'Y70>%(:B"SDU75 M61J56BW6N_5RKM,PHT%.WU/Y[W5Z6VQH=BL=MW1]$P=/<2(,?H_7@N@!Z85H M4+(MS0A(PX+M8<1%3VK%P+`%=9*H#LJ2_X21.&:`J;96EN\O8KZ?3-[ M,&H;NTDYM8L_"`0E@-G9Q)&Y&+6'*@QVG%)VFFOT[O".IN%F&V2_#<3\5)MA MD\I&NK>>57:>3%;3]QF"4V8[P_+2EB'\H]@^\ITDP@+VM#5J^DYH.+5Y?Y2D M9V?M^O@^:N8&F6GM6//-11JK1=GO. M^*8%B2,Z`C0[^=6=O?$S0LR4V#O&7V4!M^-QSK=6ZXS*;)N+2";=:1[,JW1E M^*A]B*1;H:Z1-$!*'',29K4Y4CCG5F>\[YCN,@RS/8WX']B6/@:?:7XG'6?E MF.YH#\9BNKV4;,NRI$@*($G*C<5,XIOCW!^,;RJRU/N&Z9$#T-LKG;8PMTVJ M>O:P0P+2,]L%_4S3Q["S@M"I1E36.\Q<^+;IE8!BL&`O&HS8];UN'N_02B? M\7AEQ@^:VR%NVK.Y._X/W[(%B13_'+(Z*WV`^R87M,PPNX`Q7X@C!/X_<">] MUI\IYMD:?<.6W#A.MT:_AB_1LU5I]@%ZA1R`E[@Y[')YF.W"8$]P%-80R]+@ M^/PW$5I"(YDHRO<:$:22TC07QNG#9_BQ;X^IUQA[%JQ$Q%6VD!H:3**0K7$B MMH9 M"_*<]&^]BDI)CF22WDS".GU<'@SF#++.\W8#]OUZ.XWS%J8V&4W/WD(XL]I: M='!Z:%?1QSZ+ESQD6IM(\.?R+4Z%6JFF\/?]EO\>LUU`]V[Z"L<71P2X M"AN'UD)6`IN?/X^?697+)E.FRYZF/`4)U+WD&P'*]P5!].L^+T]2,YJ`AW)1 ML(MB0R]V?-XW4,-RE\7\^T!Z,%!\"Z=$Y@D;UB]S`-VJ7HE;P&ZA+D$7C$.N M$`O`#=XY:J0%,5%05EMS;T^/\_UNEXC?!`E<$;H0Q?$NXE:1/)R>ZG=L6`_5 M`;C5LS8N#DN@:8&:HS(AYE)!6;`3Y#C`)"L#Y/?*`BAI,/2M/(UTAAZNG5MBRUR,JX M7.Y7E,:8RS0YYO)N7KT=P"S..AU:OZ]W2MCOS;T*S?Q68:U)0UWF&YX)YS4- M,)*MVIF;J@8^)+JSK,'\I%EYHO"%#9Q*\0\76Z@X)4,R;'5R-0PCREH]&KXY MJ$#9[47"!A!;M2\5SD^P]:9-X9*A]ERX]6=OLW60QO\4V[5+EN8LB2/Q/\LT MNN/S"[L[6=3IO*9P_C[.PX3E^XSRKQ^:H.O^,C^*W'4?8% M`^F!NX9K6UO;XUF0HQ$1;I5)>TR$K;HJ9N>D&9=HTQH9:89&JK&17V!T1`S/ MS_[!F\RQN0B2O1T/S8MX*P*FP99E13G""UHF..!V/7J=&M[YJ!%WN_NI,;4A ME8CFM[1J3Z#"+@@S*VX7V(^TD)=F;EC>=RNE\QODTG34EZNLM".BF.2SB:B+ MGF?)AAY_H`6!=$BQ5G'*NXQNN,Q`P97$TR#T$^6J07A9/[NEEBGQPUYI`YD" MRW9ER>"PB)_A]CMFQ5'MS'#Q@V&B;JLA""PEE`K)_%86Y8E2J):@PWU[4KP* MXNSB.4CV5":(E'!$/6SYXQI*U2,#R!/Z-RSKVCC7^9;YW*N\V8.J4ZG9F\WCY*U%_U4A5T9@J9VN$# MYKY"=!O:$3QE(+*3=^F M/F,*CJGF-$R4ZX]PE-?UU&:^?.(X..TNZ55OA9'1\=Y=O*F:]SRJ"B_FE##< MGOCH96<.8F+AIC,:^=;O3M]+^\R8/:[XUT8V^7VD_*W MM^W'9&9':W+,B'TLW\GQILD,7^=0D+O!O:HJ8QW?38B>:5;$.??`1PI=]'Z( MO8]PUJ&S`A9GE%'%*@S@QP1Z&K)^*U#TRP-39Q)&V',:?K5FSU^+T$]V`%G_ MMOH?$/-O6V)>_AJJ7ER*'[FZ=5[M'_]04\S[.[1^X8:;SYJDG^O["MQDZBQR M;!%;61RWJ^LZQWTI4MS[K*-2(ZRE'.S)@)X>9X[CCW>UV%\09;+)O M5S<,7MQ[II%4N/^D273%LD^]WK166^Q^5H6&LXVL"AC4#M;.*!%K28,$5A+` M@'8QK(B%^VUU7T!=;YIJ#01NX7'_'Y:T M@I%B0TG[I>S.\7_E/C"K*FH,PVC'Q00RRG4[*C?GRS02K\A*W;[<9W!DV[.$ M:;3$%AD8IV"]X("$4&?0B+0:)MX/#B4"$OC;)^A,`9O`UXG&O,S.X3(OQ/TM M?-%OQ\>_QICP_EZMBU"9D%61)F\7!*CC[;;)L5@QV5$D['60D&`+@1VR2_8Y MWZUPIXH[\G6*&F]\QA1AX4_MO@<3KR"%3',ZS&C1>QI*,F^4U&CH\PEZU-6M M*T6J:).W;PQIDIG16%&E$?TYY\7,%&A0_ICN-!C?5?R4L?U.9T_1T<#,CJ+5 ML9?]A*!O&8Z5ZA^*8,K5?*;2>HUR@-)TZCE.QA+$5D;W-;G@?T@@W.`J1%+5A630:ZLK")C'4K0EY"#K/0!9D#:45KVO&13STIX3-I71CA<5FB20A)%&/P?9 M;[0831D>;X`U];T=6[?:DK*PQ=N*MM_[U0I<9OJLNOWB50.RZ-/E0E M6,7)U$?:?P:IV`Y]`CG2OZM@PB@0S+[`PN@P-SY*%$*G:@@+,CHH:X>JJC+% MT*QTKEW/<1ZS](IE[]G^J5CMDZIR0K]BC3;!ZU1OU_:/\TO:9,4R\A1$)*)/ MW@[O%5C,,'QS*UTG+SDNLXQS7+@P\/C>\G/<)V/J#9&2-D[`MKS5+W:6$$@+ M0_FZ(L#PXZ]J\)_AF3HG81Q\U%.GJ16!=',[Z$PDO;[OJ<5T92GT?XE(*7YF M-/SE-GK5317CA$[%C2E9*J_Y`V$_2_]XI&L^@:IRP_@336D6)%!A*X)Z/KEX M9/>9*D4`%!M/BP:,$'&E$6IH,)IB:YR(RL6/T(3D$M""K"4D67/N"-0L0B.J MXG<>)M'BM>,`M*QQ+$KM'^1_1P/(FLVQ`61%,M8#R$?5M260A7P(XD!^ M*?_U'D#6G1,VE=%N1?9#D,%A=GY',_$$GIJD*K9""NA([[;ELB)/.'WYHN'L MI%*5_PS)5+`/%6-0$;^A3I+1U=6E;Q`3-V4G5('.9#L= M=F]>5'_>D6X/^#0D54H.LI($%.[@A514C(+E.Y!W`W;M]+CZ:7I?&4O:D\,, M<'SBK>]W^SQ.:9YS/^(I3L7MX//K`T%=+''P`L%5\,PR^%;$I3J+XCL@A[EQ M;A&6;?VPC5_[LOL\>/FCY&5*UZ*>N!9+:ZHD>`5/A):P"+KHM805,+ M=O0JUH(T?'W5HC6I"L,]W-M,.S)WW$4$9Q!TS2718C%.YP<._=3863/%!;Y?/"L9$)/V*VQ/D7KFV2` M=/$$F$@;U()(6,+VU,"(0#:W?J#A/A,:?!DD"=0V+K_+RP_[0NN&>L7&,:=1=U9K91I,5%$%UYS! M5&L!C+")+*D3EA%!?D$D4OA;@Y5(L.3I4#7(ZQ9^#AU,"3^S-&^.PROEPYF/ MK/0-M*,KVAU@@RO*A)Q=H%1&A+I):6.\4_9W=_SW&[YRSBV"I"^`;#J7';\? MTSQY=,GR(E<+LBNVPKX@,]R[]1>)6F]6"?JSB[RKLK_[::MQGCH6P<&GBHP\ M2>3VZ2'\$T/8IX2P.1H>JX$/O`[D_16@]W3'\K@8%,S.;]`W+5M]N1+3(Z(8 M:9V(&K%#*"GZ?.RJ>]J9$E=!O;SU)D";YD^ MPV80JOSPF69AG/-=51S2^H]UY..M3H!2M2^38_ ME8YXNI8)#H\TV]ZN+EDZZ/5.Z@Q]I1=#U)4O@D.'<49<\0'AC4AHI,36KL&6 M0U9%":_,V%H00`A^B1HWK-V/GB3+S.S$N#4*/S$6O<1)TJ/FIW]&*F[5C6U5 MK.A@E`J/$:$F:D`MR?O9I+(Q+CB^`,L.05('1-EH#PZA& M,Q*XTFF*+PLX2L)!A<`20YD-Z>^81(OC;`H;9[,`#84@5)N97X2QD8[,*UT/P1FH80\R MPXII;/P(56U'!-2'Z%Y;QX1237^5..VE8FE980'0/-#L.0XIU%_8QCF\I#92 MSE2M[;1:I\,TK)_ZE&]`M5`L2(5C05I(9I/3K3GW;D4$2A!?;F9G_/SNYQ]D-`W>HT M.2+T[-VV!M6/R\:RR'(1?/:43J;*YHXW995XYZ'4_'6>[VGTGJ\P MZ9HO'S&+9#G\C_1%_*EO9Z#7>$J1^5$BKBRX&AK4(YR6QHFPZP(*D5B(!$,D MFH5TR?A.B",B*H.U64M?7?1."^EK\GD.=2];"?;O#LTG9>FBY4N01;*`8?Z3 MN`!XG68RE0K`0-7J+ MX_3QN41+-.9!)9U\%M$,[K]G<*/M/97_7J?U3;?+8!<703(2W-#O`/\$CB(A MZ]55-F"`A"UF]85(F;TC!+=5=45D\T`,D*Y6-.1_%_'!`"HRYB(R[:DN"V+6 MV/2I<.QS[G>[1*P307(9Y)NKA+U4Z,BS7FJVQOJ$:%>LA[A8,$G(< M9,6!D*B.)7D24]U)8!,YZZU2%5\7SE]#ZY%,U6;3JU9U=N_L-OX(#M2]>^-C M0]>^;"T28M'(C][[HPI#M%^R:UB\N@MW*?#5=:9`$<0IC:K#I*-;.:LX[`T^ MJS=$YP>,$;!>:_CH*I8@Z>FP7YG5#,\_MW)W4C'B:E_P=?3G.(VW^VU5G/O] MGOM.5WQV_DZ#K"^BA>\(*9?Z!%VM"?K(,*N$B_$CHDE_/AQVOOCS+7W3`!1VMO-U5EJ[^.&9C18 M\=FS%2W`691,'J&XJF/RJ[X=(JBOO7VX(TO74,#P/7TJ?@Z*,@OWGNY*>/#6>)R&\2Y( M[NF6;[$C>.[M*L[#((&EO2\N::A;;-QR(GEG<\>:;9$T/XR-^_ MCN%A"JMRD!<%E$L%F`O2`(6GM"NH<%98@X4_E'#A]Q(P&1<"6Y%A4PK.;$W= M_!P5'0,ZN3^+SHQ7DXD&:,OA\6=%QDVD1Y=(6>L-\=BQNA=\>_00)&">Q`7# M_O)50Y]BE;2C2TK>RDR6D&UW07H@(>\P#OUD(PXRF^EP M4%6>?CVDA9"2-S]^^T;("/SF'Q\^AS3/JYL1]W0=LS1(X*KI\8W4?]+H1&ZP MS35E29>,;?G2Q:-CSNV/%6&])1Y2W_RI$,FKUR<7M6Y%0:2![2*3PN] M>G!9M926H2=RKDXJIVHF5>N\)^N.:DUQ?JYJ#K)XHD[L"T ME[]SU^T79DRSFZZD8UR=9T$9U&ZKA.9\3)VAL;ON;I4 MA;Q58&I^-?"&95NU'I["A$V,J8_6K-2#R>V"OD7..^N'2ZL0C*,C+)@XW9`U8(;$X9XP5.PG_\:+:>W:P(E_KXQ????K=X\^9- MI:_R4/*!:P[=/G&-__;-@L#DBYR']S0L?_M6_/:[!1B!D.7%EWXR(/JEBJFS M>J)_]I$61P_!-,EVGW8LA0!$G)8O4-3?+=<9E7K?Y8&9Z1'C8TVC[,2+F@91 M>R%WQI$I.@UO#:_JAY?*--3')C'KGO0F7M/N[' M<'N5-7Y-:H1Q'KP70R:"69C)J>9T#RM,B\X-]W'2G.85BN[K#AK-4(9QO'LW MUF\;4R0MT];IBIGI$6-QIE%V8HRF0=368]<< M09BP\SM7$%-JH20O'.:Y?2.OBC&&TV95;F0!&\-3-L*?>]VSRHYZ,)6&C`:S M,+VN3[1_W>>%\!$?V3**1/IRD-P%,8Q!UG;O#HVUCU7NJ4Q]IN7-!1D#:[W' MVGM,[I0Z^NS="4I7T3%'P\&$W&;+:C0$AB,6'3F@!>D[*.%_ M$1'`^A"D'EGUG'-Y&$*4^6XM/\.M(C//,C/9"Z[[A10G^ARS?9X^.[ MAIUU+850L/-WY)_;LEW,C5A,7"#>[?,XI7G.EZNGDL#/XHA,A'/EXM1:^*HG MQ]JOC9V^V=2U1%@D@UDD+,!QLDQ8P*UMYF;!.\124>$F+>`+TH)>N;@M\`M2 MP3]^-W!!JB&0+ZI!C!Q[SY631I:,N.9&5'$#MB*[-O-H_>AB4!19_+0OQ-.+ MY9UF^8J=2!'B+0*^A&Q;,U,N+$%KI_-%O:QP(/M$O)3'5JN<%M#EFK'H)4Z2 M+STL*39M'7,E.FZ7E=-;WQ:6%%42#I:3,2AS7$K&,-LV?N9YYFP).:MXX67U M,,]`FRO'64V+_UHT<-8,N6#H28O;DX3W=,?RN,@ELH^-S0OS#N;5YN8KY'AG>[X_`=39)']I+2FYO+G\4EAZYU8$(W&&./(&?; MHC?G)Z)B.R17"U2D#8L`+B*`$8Z,_"*Q_1]MX^.$`9,M3-P\!$^")[8ORDMP MHK@!@E\>+,,4P6:F)LNDCC\$Z?N8KID`\5Z6`"\C8(KJK=S#9,T>I>18J3D> M(@"5HMJ"!"[%5X;TV<*P7:KR&)<\*[&Z^';JK^;DF%3=RX0&V5U0;/[*Z7'G M(5?7V?&FDY6UGX1C+15`""`A%123VFERG"[5LH\MGM5103([]5!U&MR&XTY] M]>OTGN9\ZQ06-((*OU%1]3/]A+RG"BBS"R_)RZV=\$!XANWZ6U8,&Y(OH5/^A=8A<\Q MB^I`M[:UK"1-^&)2$B??EE4.T&NGT>'86"_3*L=/W(&&"!1YHF0'V>+G?/"P M6JJ(&=-EMDFW]"K.\N(F7F^*OY1)>XI.Z5C#R2YI'P''#JF`000.4@$QY(R: M&Z%+5[2+(;[]T%%A[/1"U?AO4MO^]I_OZO]7W_\-MIJL9YV].U8RCJ&5PVYP MOV=H<"[UZYP7GI5K6/PZ-4N![8;=O>_UW+V.STVX>]][=?>^-^WN31J.49W9 MR4-*<3V#];M]?2R9@>?7)7%]GE\OWTTI357R3%5K!KZ?I#8=_3K4F[KPFSG% M,3(@'YHC-TRG'/&I-T,R=Z8XHWPWK3FJX86![XUHCI\`0U,RT;CFO+(0PRDG MYJ`Q2D&&47Z[C;U?LC1G21P)UO\UR&)`>9T6E,],\2$MXN)PQ_\>'GK"[=KM MD1%V93JVM?$(R()44$B%A4@P"R+AD%_*?Q_IYX*\X^/^;419+06=]2>*3>;^ M1./?5$B0#\4M\YQ;F6-C0!45J:N(2.+$^R@, ME]D+FA$F%I""`1)N M'<_^4+ZR\3NL*S7-%!BI+V5`RESO6^`9D-&7(OH^0^]"CKNSO]EH'CM9D/_O MS5=OWKSE6^",/`/U?^4[7WAMX>C%A7VQ81F4U5F0MV\6W[WY9O'FNS]6?XW% MNU/BXM^/BS_]\*?VW_BF.R_X7\!Q&7RW@7?[]LD2"J6/[&SXMF8XSN]GC[ MN>?[6@C_#=O2Q^"S>%.(QL]P#-'K;6BU-G;QHY.*OYL>G7#,7.V8.M+)=SDD M`%(``J@GJS0Z9W)CG>:I1[*>$%??@,T4MZ3[=!G$;B82CN"P;) MWVEPFAIDH6>D\!I`X&HM,0`5L\YXX=`SS9Z8[O(#XNM%S4V*,;/(^3F;C>6J MH!E`ON(-C)B+SAZ=F(DCRO,T#T<0[9N%B1Q!F8/'#>7N&Q!^!4:A6UC1QF"` MW]X"MA;B#.<.YH)+V?<81UK.=UQ[:/@UH&M#Q*%XQJQ)`FR'!*6 MI!/KW8<=G8=N7U:-N7->G(RN2UZ6I'FO1NX6(L=K$)>^'U_!ZF-NX9G#FG,+ M)91ER*9'83N^0&IAJR?;JB5(5;5,_1RF=_&-*3##=YQZ*8^A,$'J_J;&(M3G M)/R%I\^QF(E-3QKCY,!T17U^0>D!\1J,2(_Q<_(CDVN1J5B6!J39/52'R*_3 M&Y8OTS5-:'X)]`]5(<%E&GVD+W^!J3GTWP8TV"WN(W0\&,;9^"Q)-YGP+9@*ERRS%31KZ%NFWFA9$"X`20DP:Z MV&AP\/SWY/5RS_`5_Q.SOT_[#?\&>/H$/"V.>=I>$;:.+I?/2'VDQ>WJY$TI#J[Z33V.2Y87G;Z];5J& MGOLS@LG7PW]&P)MXP\X3%XT]!GB$G[0&L"!\"/+N[O%S@,*RU;]LZJ:^=I;B MUH^EK%0&K_H=<;)H)-QW?P43!3?YBP-<0)0UJLK[*6??IG*RX9?GKQFF4?/+ MIG9N"'R&-4VL=^4KAZW!S>-A0K.F=^")0@MBZS:N6=_@K+9LHI21K/W0$^-4 M:8*,=PYU[>K4<@@#YK32[)@0:T`%8$&6=41(%JQ2&92E6*^2$#$,%R>?3;:L M67Z[:KNP&=NO-VQ?++/XGRP-N$(W)S?\?Y9-P]N5C&1<;MM'9/]AHCP`6O=8>N1D$*4&)U:\9A_C?UDB@O1P+'-6)T2SJIA,.1N?' M98LUDL%Q$$5FLN.Y.2F=QUE]M/4>F:H%!%Y?X$74(#_U382C5=7A.YLX+^>L MSK2>>1(R0[';CDAR*\S<[[-,ZV1*!%:9F-,@JS(J="30XK@GA4H[#\':AV3J M+I&?T1L)=0;K=2;RW%I!S\X89RL*>F*0SXJ=>HQIZFOT:=@2.6&&S%IGJ/24 M_N.&CMLV7$]3#)P>1:=63@\:6MEMLY#SJW>*#(,V>$-=/7<\#S.HP? M4N5/+>"4R9MH!FOCR[W+$1C]6V=T)QCCITW,MMUKW!K8!XTK/7IWZF#DEC>; M&;TXV0Q&1\SK-@8>%!POT]/R,.I)\MB#Z&X^=E)`R5X\$O2/V8"$4]84A6.SV^.DN*T_$1DM[#WR) M/&SJZ-&V/7C@#(>74]A;P7Y?G]'`IR#TTD MTY@=MX+Z*:>WJP]Y$7/W@IYF``U_A!3/X\YL2R:G!J)3TYO=@U8]O&5J#',K M+!_IR[(N37N7L93_R%4/5A>5$L93NT$*G"XYZZ6-Z0MI`)%C1+.33_1D,5,S MX%C&6=$N5_F1]EV)Z_\0*Z=G';I*#3FGC$D(,8$?$1J\BE.^^P--:FB+?#\_ MZM(O%4R=56Y%OB/_JZE'/F;,]1HC54.-B&UUZ4HZ):W*[;_XMM6:<\&F,7CJ M61%+JT3.=S2`G=NG-*XD.D]D<^.;:1MIGQ5#)C7S-CUS`C%LW!K3U&X?:^LTLM?4;!]J*'KEK;?UFSMIZ*JO:VMHY#;Y+?]UE%)ZHK_+Z MJ_JH:22*EGF@)`-:N(85R?ZRM=*ZWZ_GXQIC_&1=>C85JUK==\8[1G;'>]D MKSA(B;I3[,$E1HDEF\S[R1O7HU"K?`_NBF5WP0%FZW95W6Z]HF?GG_@.<%M6 M#4)N\HYU$"$VJG;&.R7_1V!JU;NM,A+@_^&N$+&I?SITE`_V81R4E*:W MA&\OJ]UNR!]AN[+/#JVG#7OVWP-?(K?;'3W:-@H5R9.'*7V_1CG$6Z;!,./+ M1IWU#DO4)4L2&G)_Y]..I0]!0EM7H-56%>WNS"PZRF0]K4G*^`Q8>(N\,+.B M+5HEL@`CJ4$20$D`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`R]G3'B M;C-S(!<""3EUOA9$HB'CP[2U[]01-S:%OZYO_:?U$X=\U\)M1)F>WZ-VH]^C M:P#T].NN%$`/`%Q%`&.C043U'J%)F;8>"^KDB_+6B9],@G&A8=J\;EE6Q/\4RE@N85JB;I+$1%4P`<6IJ@QM7"%Q4$`F M;,+TXY?*?1E/*`U0--_A&L`G-F0 MEU$N/-/LB>DZAESP?IA9?$M%')4"7LK<=;RU/]X`WK"\+U=VX$OL)OZ\1U?J MUD$:HTQ&1H"(<0$A`B),R@T\2_UDKPT)!=/@T^Q7,DY>_RQ&J3=WJQE0G?%Z M!O`W.G"DX$)VO?@,Z-^J- MXP-6N__T2K3[2"0G*?CV^\./P>_LNPR"?)\^3GNO?>EWX-Y+3ZE9#V5 M?3!4`Y?X!1XB`)%?`)*G+'?$[*@)]##+'><>E`\6/G!YZKWAW_T1-LO@J#-G MJ05'5%'Y!!-QRW>M'HH@*S0/JA+Y6!;?9*4D@'H7ZS@5;_"Q%>)],+/C^9!J M%CFJ1A.GS:X11@5/?U&H]+="OGMF:ERH%5BF>X3FQF8K"Z1;DYD:^V:SP#;V M\V.PI>_9-HA3_45VJ!?S"VT7-;^+[>)HJ054Y!>):W8K[N!4J:VZX_QW*]YW M&=B(XG#'9ZQ8IM&'_[N/=U`00OT2$*8+I&#KD+(MU166!1%H1('8&L^LK@BA M)HB9X+J?2[GM,_RAC<_(YQ.OYIYVZ^IV[DFBAL>MRQA_.^[H#C/-OS@-+_*C M#0R*E*.ENUNHO*[/XUP>$2S_JVY])3WZQ#T%Q?(!7=].+1_0[M-9^0!XS#Z> M3?F`3K9VE0_HYY5;X?F0%G%QD,>(*@(T^CU2B'K[M2U(DC"I*,]!FL9YS+09 MYSK7?+O;%S1[8*OB)=I>P`Z4/-'N.0RK*B[X+N%4&Y#3-19CK(TN?:BSA@?&#EP4]D,35QZX8,3 ME1U:P_.SF/O1KL_ M-L!9+0'F9\/K:M"U$+0[DXV(O&-<\&$2I4EY;>N"LFUPL43HB=CO9;6`)PM\ MK0P=M&>W"K0POGZ+WQK,O*S[)"[/SY+#<'ZG%KM+9YU8YUX1P5CBG(9?K=GS MUQ&-P0A_!S^`[?VN97OYK_ZQW-(T@A/?JR18G]C'WK]KVK"S?FS;F9H8`6I. MY;.?9VR4$3T;Z.8>4V*)8UD(/H_+0M3>4Q77V=Z0,U/W8GG]!R&=>UCG'V"@;/,SYH/9W?#%E MWMUH?CGS/I.GNOAV.ONF=%YU<_&^?(+NBCLD02(OU87[4WU7^!*QX>CIT?J; M%B59(ND2($P$9>?;D#&>,@U&N?82()6^+&<]=,.Q_T.TOW#:H;/"XQ[7C0$V M,G7>N+,DU5FGBBWI^':R-6GUZ=J>E(?I<[`H79SMM"F][')\%378TMO5D10/ M)GV/?H^]H-K7KSM3X]-1&6)>SCJ_:!A2 M&N57?%S7>;Z'YVZN(0&)6_[]4Q*'MZL57P'2T^,%='O\%4,U.JZ.094!88XR M+8X6<1Q9H9'EW"H\I`1$)"*B-EY[=RDUQ9!-YK8_16V?-G[X3+,0KL$H*.A@ M.P.*V=F_#X7L!#)5$0V-;K("'IW?$\7A.="[8>GJT3<%IKK8FMY5]4K>!\6I MUSCZW80MZ5%_SK:CY3Z4DR5`U]M6M)N;3)E%-B7CN0D!P*@G=\@E^&COJRGZ``Q`M1\!CZ[ MV<>4>.+Z$F=>W*[*W=[R*2^R("QZA&+P6_0ES8X^[5_*S,M=O"";_]G3S[Y:Q2&MB[H,GKL.?HLM?=[5I_5GRP315L$>K^D8PVQE6KRRZ:O( MF^OE,GA/=U`2-5T_%$'1><:B\CG"9QGJUE'M@6[-,BR`Y7<<+WJ;W"T_,=6FI.^G,D+C55(LEZ$I,^9C)E#MD7#$'UDCO5 M:Y8=>L6B\RNT4!SUYD@D!$U2$?4D$-UL9(J\<>NFW+!T_4BS[7OZU.?2=GV" M=$K:7;D*++9I8F*(TS!CGQ?VXC!USC13885;H:W*J;QO#A8'_>O1[Y'BW-NO M;=FN"),69;^^]CB+F3;?7$2.(;XP$#!N_WE"G!BZ<18>!F+>8L)'#&-C7+"3 M.U(E%7S:L709\EU=+BIRW*Y:\G8?KS?%J8-LME.#62CJQ&U+F1F4IC);K/#E M1\F7E*ZAD)S>VMV3R=/*="'['12.;\!"D*V=(9/-GT.3$H0>H6!^0L58BTW` M!TQW_'/^O_E9RA":??/))T+8C9&D(^R4NO71WM,5S3(:=:?RC7R%],=.>G.U MPS@AB]ED3$:.2$NH:!(EW);\QCX!8(J\<;SQZ*PXL,PRN.$#>I>_.S3?W`4' M^)TXQVH.L]((*KZ/OFUADQ1VNV,!DO6X$+>/Q4%6U_";>VUU0IG+6;(?KOP; M39+_E;*7]($&.4MI!'E]9]M[Y>_1(?AT%,X'ZQ6]`GE3TB03@*;`YQF:F MS;O78K[+%+>?^)=%?IW*I*:_4?"R:+1\IEFPIE7^VUT6AWW^C@<$SHV]-E)7 M?IK#(6%\P%ES'.%?"CC<9/$MWC;(?J,%V0%M\D6[BWFB1\P_2: M-DA.I,6$R3`O`HYO)(4A%%;0V3^I-,'>5QKHVOKUI9)V:^>T("D=2>ZS=8M) MA<<,P[B)N3&7['9WM4^C_"8.GN*D25'ORGD9_1B3R]+;J?VK2Q=L1U9`FB05 M;>V$"H/PD954UNM,Y*"0,,BR@W`?Z^(JG6,D7T1[2E[B8L-7$)92`@32N(521@WH=F7'E(GQL6/Z4V*8S>/3ZQ8>QY! MG_O\KLZ/L([046?6LTTK:N070<_3^6DW`YD:5QR76JVM.QRG#I[S#WV*+;[: MT:7]$E9U%--O*=8A=C(='KVNK6)KW^MA4ZA)W=/V3Q'E[&.5>L-Q&G^SS6F[ M$4O=3?>K9)ZE^.7O)&"A:\D,AB90\SYQEUCE5EYQD.&&DX`Z"OE'SN?^S:)J M&\R><:QOZY=HJIS8506`A(!`!!A@WZ5U0.MD@+C-Y7V3=`^[PJ@:=UHC$2,N M-YQ?L"Q>QY"8+[A!@NC7O7BU#!X6YAT]QVR?)X=VGCYOR3GT3_F.&9=J$F]W M09P!TB])D`,O@?!3D(AJA/F&D*`U.4&C M7603/`L3E9(XY>.)TYAW)FT>4'NB*?]EX6%[JZPP#"4D?N*0XL!?G/8OT^B* MRT8::S69F*&.*.ATMEM9_P8BI4H- MS*U\CB*F?;D:2_7%-N>WIU;:=NWX4@M^N:^=E/1UC*M/DE.OH=E[PG2BW&Y=! MON$K-_P#F3C/00)F:%E8EZG?&%)\S@%__Z2I:(:^CY(H'CC-Y9?QC\%OL"657 MGZ[>$0H$<3]/?PPSDVEQR'5\-('*D7=!5AP>N5KD'`^HB#B#R6]7K=_UQD:U M>T#'194IN5K[-"!AUBRK(T:L-24>(@"1%O4%*3'!<87RH*T%B_4EDAE@^NL* M8)2)>N):EY6J$&-T/`4LSO"\ED#%&7`?`0H#W$/8G1;5WUM9@E$M,1A5&)D\ MM_:K^Q1.7FR^3L.,\D'PS8SXM\"DVH>S9Q.HATJ MHAV79Z[54KC!9UM:7P@?B=N-?(TT8CV]6L]Q%&1)Z])^1=G/W8$QYC)-CKVN M\[E^7>F+=K^U=#XW`8FG\SD$XM=R/H<8FH_S.21) M=UQ=FA:PY[O+V',C=X1,?UG5:WR9;AD7\'!]N9?4C/M@> M8VNF4VQ=ZDG$79G`:2@QULPU7Y#1%(B@D#WD:%89.AV:E9DZ%(W+/)4$1IT&18XXL)DQ%7X&9J,G0E>MQDH*9C M%B;CMBJC:-)D:'9JUF0H$O=L,A11&C09UOABPF0TU3SG:3)T)7K<9*"FPU-9 MT)\H6V?!;A.'03)0!F7T^ZG%0D_[M:W#;7H^JY>,,[:KB.@PM]R*4KE+OUTU MSG4:/10L_`T>U8/""T-7^#5;(\5,D8JKA4,1#F:%,#_2*4^.U^5-V(K_("HZ MCP_,DJ;I2AJ;R%2W6OANG\NH*+V\#/7&BV1VJ=`P7Y-`UE1 MPU\Q?ATVLPF\>UT)(Z-/7EA*%5&F.]?78-R^^/*:,RW5I]KE4RYS72OXED:> M=-^PO,]GTVYO8=TXHN/*;U,&A/'<+(X6<8H)V_AD="0>ULIN`5-<,0?XZ$<% MN75YXCXE@*PP7JJ;PSX%!/AD7L(4U*A)BW8"\*!$X&KI55\$D.^$EK``1&L"`J MC+1LHJ*0K:NH^9D%$N5=T6VQHUM30S=_'>JS:I+Z3E0M&T;9T$J`41L!9$`!-U4`4TTL)&&G#D%X!'!#X_,<]I MT\>,SLGKVBY;?]E[C([_HE.OZPZGWP>ZS7'O]_<:MVG>_-?3VQI6Q$[E+/]W M7#OVGAT>VYA[@^S%7)1EB)IMRUOO%EIX>G8+Y9./Q+<_@YVOX:"%^B2\$A_F M(TNESL(5V.)PG>9%)IX4R$6E4&H\UJ],T+57,PIL]N[-Z`B5-\8CUYJD/<,>')6SQGU8\M'WX6(V! ML(S`*'X?IY`3E$_[,'*J%#A.7<_*_&3A<`F;GT-&;V\H8KP!-D&]MV/;%N>! M9C'-R1*>6"R3M86WO"CWJB06,+SO7A58S_3YZ5_>EOMBPS)XSE)#YLX;&92[ MIG/OLA?44&8I?QW3,"*#?;Q]Q3NZ#Y]W%()>?V4)[R;AFU57>[IARG/8U74C MM*U6%57R7)-]_9N[D)?(P?ZEE1=2];8%.;^#C9@ M[V.H0I)&KK=?773GM/EJXW.V2D8E43\7Z-S-L^U]5__D>3]6N^0P.39YL5<\ M$B7=\)LX>(*=(M]]7*.9[JJL6W5*8D3+DH5>?+V3^+"T0_D%XEAY!:%_2%%+!09 MOT(B-/*O=_ROD"A,B@VW"P,C_E]%W!/0[9.(4GD.N*< MCU=Q M"`2&]C%SXHBQC5`S*-(>U>E!A2B`T@YXE$-;G!]N+,I"*04?(*E&.)=ME0,- M'-Z7N1(BWS?X1AY@'&]@[$:?JV<8'SJNP_UY)O?AAMY@5.781%>V0Q=^I@$4 M$0+_2=;O7/ZZSPM1BKV4Z9$GS,UWC'&/C0"P+9WFD&H[W)[X8VR);($E$BVI MX2[J%0Y6PO)1]2\JT%K%=WSRRL@V)H@J8*1@9%V"(]%>U*B'+[8M3LH"/V3% M,O&GIXKU83-R#WL?L\:$V9O5U[N?NLO@\9KB<,=EJ8`ZSOS;'0SG%57?FR>#[)C/IJD:%/\)AK407WY08_DKV"R-JYFE39*B ML+AP9>O%,+\*GEEV`R8\-^;/:O5NS:E50C$?SU8)KAV7S1*GK/JX#>8%$:B) MA.W0T[7$-B/N;EPS(:J8`'[O"H"*U2`1:$E0%%G\M"_$[_@'T):N5C0LX"9\ MR,U5$*==KG'C3^?DBY>XV(BF',(^$2__L=6*&\2VK_WE7#UF/7.EY38C1.3U M^L[R$P>.\C&A&7C%\A./"9(3D?MVH['\0U<'DT%F0<_0XM%"?] M.9**DBH19`FGZTDN^KC)E%GDUK?A)F\;2^^+FS/Y'O.:IF&L\_`(KA.D3Z)' MS/J#@`T:$0(ZPC.KYT60D\3,<'YBP$;6L+]=77%K&F[BG,(.X8:ON^NC'6![ M>ZK8!!-:&>G:2;QD!(/V;M[XF#"OZPD,L*ENH5CP?3J9T\",Q![2>JBK!A>A M4"T3(@-)C8_4<8.0;7=!>O`0(5!5)89A^>O=RU_"7:FT:/VA>MA;[6EIIQAF M$`$8Q?H:@P.C@_(=-S#)=2./WF]%7@VG]A^H,!"HWPD8&!SEV%"00$\B`KGDD4 MI/WDF*]ZFII3P'!\?;V^UD?J(KNH164&_A)'\QH](@[;]X*.XASBH`1NW/_> MCDG:.F!IK3R;GMG$//4#G/:BF:Y#EV&;^-Q"E)KQ2*]/>C?RWB-.'5]@G]]N M>G*U5+1(8LS\),3HL^Q$%;0ER>Z:<:;`%+>2*]X,!XL-#X@WSX5S<_V1R.DV1LJY"PGJ)'8Z!9#7M!4FI3`(K-]D[EHF@+=A3"/=FSWZVUEK3P:;P MV/$UQ7!#HWU";U'C4PLLS%;;G6FBD,]!I^E;]Y:;;AB7P[:=;W& M2#U0(V);XNN8:!%\EKLZ7GN&][-/@MNJI` M1Y_VUU!)B_P"U#RM@H/,9%H<,75^@RWIV>[+E$<4HX434 MZ"!OM5=3J1EGJ_IHY^0S)=[X\:[N,OH'.XI;')IU%F=5+?91%^KKWMW M+E>#@%00%"N66G:]1CG?X8&IL=-[=LB[(%MS]_"NK&'_$_^Y.6->;ME>I\2, M1F?F05O00!@*T]T023& MN62BZ"CB<,*)]L2XM6C2>[UA>7[%>2+S$?9QNK[=E:\XY._HBF6T]G)I_N%S MD04LB_@`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`;ED37 M6S@%%C?8\\$K3`HML$>'_3W;5I6:-&G3]GMC2871#,$]/_>4ELVV>R!R./+U MQ)M&)[U:OTI474!IT?49$AQC;L?MD4&.^1'8HU9D_(GP#'/63:7VX8MFGM'R]%J[*9D M<)L?*\)%K<&(6',-1]:EJ`#5KTIX3?96%L&.%'`]7CO>[L7YCN5!\E/&]CNH MB9'LH8@7O+$F;PK1J+DH!$]+#BX?$WO#;AAQ5*WO*$M81.`2#XCZ75^FS@XS MS'(?%\;JRF/O`CY9(7W84`I1F&44"9T,DN9YP?S=06N<`ZZZ6^*3KK39!NE% M[?SM(QS/_-F].[?3Z:G0X^WJ*D[YZ.(@J1;7D4L4.DVGEH$<(&&]QDR%03QT M6:&HG2NN&"40SP4C56:AJWZD,FM]E0Z_VA=0]Q`WY.+B4_`X+*JN(1)2IQ$`B7U@3IL/VJL1(*=7VEQ$_/= M66/A_^&*L'G9W:-^J<\>0)R(J'>BNZI"QO MX4=,A_G+])CF5I!NBPW-E*L"C'R-%*6>7FW+DB`[FZOU8ZQEFOR:24+'IYRN M]LE-O!I(8U-M:3JAHZ'@+*EV'`HJU=3&"#$9IL-Y*Q(-&1^EZZR5#E%3R5KI MXZZWG2`DMEXE[&7L&KU*D^D[O[.NG>[X1!JS(#^CG5X_M[MW>",L="MH\)*) MD2H.^(Z00JE/T+:H"NE<">D$89E1-84)D\/,<=QUXM]3<9UR''M0NZK$VSU7 M0Z&+T1WEL\BWANL^)T:_`W2"H"HA=W>251'AD@CMC1>56/A4D`;/HGDT`"`M MB`1%5,=L+<]06QK9=)8[7HQ:!3"&]ZP#7V*7D_,>G58NF4DZZQ!C3]^Z'.*6 MJN#\>N`M01S>_/CM&R$,\)M_?-Q#ZN+MZF>6%IOD4$7O3J1!Y5--<1CJTK8\ M#-'6L;-FQX"PJ)(V..PE=>)_&!$+A>WK"),.C.0>2DGD(J8>IRN6;'W:<3_`A\E$&@FP3JC8@OPE5/-5E(2IL-NMXO"WVB\ MWO`E:OG,W(Z=GS65&H5G$A]D$<;70N::AO, MRC;6MY,E;@R$]B)A?E2(1>_DO'51KWT`A,QG:),70EC1JL5.^*OE,9TX=88_ M-G$/L?!Y6.Z458BAV#S1*`@#!)=U:-9YV6KX(XS:GW5F/6K;$%2\1V4'-4[8 MKUNN7D83L?TO&`GDNE@.BR^3(.QP8!VD!P]"WB\A3(V!;OVXGQB+7N(DD:\2 MSW&5N^"D(Z^,+:V.=&XL9-MWZBQ`W]Z3'A*6,Q$0$&^CY?`AL5F-[0;A_G M'-]-X&MBG(GCSJS*P+Y=09WC&ZCS(]59K0KFE*ZP]P80)*V_E%-C(MS+KN\$ ML!4!7!<"6+TRS&P]F#2%S.2\^+BA(QX*N@OBOI!4SU>3[KS4O3DY\JZKZ\6M MYYQ\O^%TQ,ONUYO.&>1:/H[]FZLXC0LJ9'G0$U9NAY:AD?[M/PMVYNQ*#-+. MS<_`*4\(0W/9N6B*$^)!NW7^"5[@ZJY<6RR51R7MB.1K+0X7:WET&6V]6'($OC=)W?T4P$(`:W1D;[1HJ? M$0RVY?93^LQ%092_XKY^',*/N;@XX?O`QNP4,JOS,HNCR_*@28#,6P=1>F>6 M8[V8/:SLH^8JUJ`)"Q."L#YR1&3B[)"6.Z];5ND[80T<+BU=\Z?D'4V[GB8Y<:5U#$:-04_`B=$60(PIH;=X8/)[GTUN" M'UR'FKQ/N-075&,S3W'(O^GAJ1/N[5E0O30QZC2]-',N4AF^LZ MN$Z^*#.NOB1//D>#MPCE6*`N8DF=?%'2]Z/V8Z+?=8`PQ+=97.(L2PE-O\2I MT)'92YP#!%U?XEQ54.9ZB5-E)GPWU82/4_H^4Y M=M8-RF#DS-2H;K^(!1O#,-LKQ&. M0/2`/1M2IV1;G2LH]8U1\?"X1%/EX/L)6F"F@QG@L5NQ+=]MN:B-*-: M!IMR.Z2(CO9O6S!+`*2%8'8I&NJ3P-"<=2N.CUD0@:Z(PF&5"C4/#`YF$&FU M18JE$@W;HBE`"$,I"\/5-K0!,CM1U9L<-HGCOLK(CL3,-`O'HGJ;7"I6BZK+ MXK`5,"A90@2T!6EBL"6\^96#QW'6=M5SFV87U[V55SPA:D?#_>--YBV:^KHV-$F M"3;V%6G?I0(5N'R^&1IEG5O1$J^KIQ'\`Y4RGX,$KH*K[7^TVB(%3HF&D]`Q M++'BAQ:.V;F8>E/")O'9K:#"2L_M\8D6'=0D5:\Q4E35B+A(01#K;H-C=E*J M.1UL&H_G8%#OZ]SN(473LK-Z71HUOVJD/5KE!B!Y[;9;'-SV5\Q!=,>4TQ%AXYMX:ZQR,-J MCH8(.*3&0P0@PA'A"['8';&%RGR!>#$6-@$K#09YJ.&"DEDV>5I<'YQ4-1%O M5^W"H;WG)<.?HX])NKMU=0K?1Q]SX&Y@+%-2T1KRA*MSG9&!(;I MJZU?7U]%6JW:OK->DO#Y4TJ1MY>KAR#]*7C*8IK\-4@2>KA.531%KXM)ZJ-&RIE.Y:=^#(=$2DQ$ M@B(?FJDIQ&?JBID@0V79EX+A<`>[PO+(WM-GFK!=E]YJ M-)M2KGV@>Z>EVP=PH.N?&QW;I)+N%1+2LDD%([,:H)$:MTUI]]712".)RF,5 M=Q4].JWHKLQ?D[[O/2LV=Y0S^0.4,MEE0%8]AJ/4>K)O/$C%L:\,6(@`0UIH M#'K/A@?KTIL6O/D?P7;WK^< MTV>7SJ@Y79UYC)@Y\"7ES3/HY:M!RY<@BT1BW.T.K%+.=Z9[89^6 M>;[?RM]IZH!)(I,UQ`08E_HC\%X\`>#J02XB("_*[,L2]8+4N$D+^/Q4S*@T M="J@^2GVKYY0-(^FN0#='DEY\_>`5DE$IU:Y-E.&NT8__3(=@/112 M4R-\%Z/_4I:W81H)-JZ.1P^O"T44O%N^8Y,?!'%&GOEBT[RSE;>,2M@:LZ^W MB`R*.;,YJ<:L13B(Z`MXPA&6!TH)$L(IP)K]LXG!#UGSD!:4Y"2'H)X^"FC4D MAZ+B-(,G9$11?+Z3$3WQ_5]9=+Q\DES08N5VL%U$!3*GR^?+DP.AK7EN7D&6 MUZ8";C?.`GG?U2#&/ND3\[@M,?$[0H#6YU M_B=Y4@]5S:)MG,9@A>!%FY.GR$]T0[$54O-&>K>M/"5Y6<#N"(#?.G:J3&=( M3GJJ+7,3I_2:_SA:5.;LPZG59.H.K9OCBB+Y!6@20=1S'9ES;G85D.EAD6-1 MV3_E<10'V>$A$!9XK`S1V/=8P>GKU[K\!.52[KT*T2AGF3:[YA$/>'=H_V5` MN/0[,!P-."?D-AC@4?P0O%?8[8\QU+&Q:W3E8[#E/[:@OF?;($[[K)YR0ZSY M&R7@V`Y*HIXLH3JW&9Z%_FSCH*CU?VC`UKD1I1.;YE.4!KC98[W\B\KUW6UG M:G[OW['/\U3]V)8'3D@QZ]Z2%)QSC(VRP=1EJ)]96FR2P\]!]AN%>E17E/Z4 ML3P'5U0^!M2UD:-."MO;H:5J$@-BW!< M1``C`AF9]=B-I$?M:@#@G:S%V',Q]J!U3VP7'')Q@KTM6;:M6;:"P^^`-RKB MW5XN3'$JNN90XC!(6MT$ZXR*O;G/&V6ZVGYVKPPUH5-3H^+/-7TZ<+5LZ#M4 M\E%'?]9=Y?@S:1'%WR@S`QZG9M>M^Y>M^U\Y']NJP>0C46-(0I@RY]SZ;#_1?IRG7VZJF_521Q3W,K0*!!K[BU?9@*Q7`@,HD)D6A"E ML5AR6H?%A&EQS5#QCZ:"0)=I[_]J2FF/IC>GE3P:LNBZ%E.03ZK3X1F[M1(< M'NMN=,CT:9F-/I9-U+UKSLAT'L[-J@'`]\-JV0FC-9;N+B MTZ39"'2+\MRJ?B;N;;$DH2)G>+]C,G!-/]-P+UJV]T=-]-J'&@S)UWGE,SNJ M\)ZN:-:N='C)\B+_2`NX.+7F',Z+Y9HS"0J?W_$IV@0YOB:2`L1^(@$2$J$I(9(*HQD]NPP$KV)*@8UQBD4 M#$HE@X*20?!M4#-I5S%I!]#!MHG[JKEX?]F'39MN`IC9"9QH'Y?1,]SNS:]8 M=D];O.7N]J,H."$F_79U7Q8`?%_5_Y.5];JLI*$N,;9R(FDG%G,B1FU#X8XG MTUX1:4$3.]RB`0=Z?UZ!DF1S9XBQ*!?GB`1=EWO)T/SR8#1-601F8P8G!^/# M#$[;WE/Y[W5ZR6YW5_LTRF_BX"E.XN+TC3[M=K@@_'C_C@+PXT`0(6D;HT/X M?9?L@NW("@B39&;#,>*WQ24T\D54@OL2DJ7"KG%#S6&Q8Y5)6C&+O,39-12+ MH2?`N-GH]@?53,=P6S/FHYN&)Q/2#<:`WDT>Y;$3]#AA)WFR49K#X&P;EI;] MR*@H,\3_3UH2602OFS6SL#(C.MAO:51FQ>UI'E255J_8,_(U\E2NIU?[KP,\ M%;.JN3/&7:;)LHGKUCT[!`G4(%=Y2EVC!6:-&N[9^I6FBCK^46@'8\*9ZI8" MB)!;]7(ZV).6?NNW1BV:RE3LWPDN(Y0U%/,: M;'.T]A2W(W;K*9,%(9-L(NLGZ^`S3?<4\L5^#M)`%E75U$-,#SA=U*%D7Q\E M&K%@-'AL**7=85OV>=MLVC9L$BNK<(/A*RA6%Z0'$G+B<>A'=5%BS`Q,TO0S M:9H5<0[W5/=II*"R:BV0)\H#/=M6R19U`N2-JJ'IH=E5NZ#%"CAV\'.,J2)E M#,%?4PF?2\!K MJC2-)+GSBA(SJR2AHNAGN;G*LS_1C-7E*40%U<9ZJM?'P?6`,6UZE)P8.3U( MVL;`]H@1AJ^I@@/.^)&W9*XJCNUQNS2'VR.&'?E4E'JP2TA]90:FQG2L+R^M MI"`J*T%SIK\[-)?`ATV7D0Z-1`1U"#LQ;),03H\9VN4'PNR=1T[SVO.3YJY& M29X.K>(/4\R@8[98L(K2'J[;K*F]LZB*U)1^6UQ%83N"L>*Z.84"]6T'GXF/G&WR^;&>C)7Q!E,>ZNGLV,TC/4E#VM_S/,., M/7V:1X%;QE?JYO;MI:37OH6HNTIK=F9FA58DZFEU5D1G8`FRQ@=#JW+KLCTI M$;9N",)O7P<[\,]5'B_!HL;FAJ;5^Y#'-YL[U]I=<(!U-FA?ZI_%6JNK^/WK M+&K:)B>@E'*@UPJ>8#'3O*+Q]`@,B[-CH>5#4H@:!E M:6H,9`Y#,I0_+@X#;H/+`$LR`E'`/U=,R/U6B5G>")[O9^GS?4E^NS03V_JIM9=8_DR7=.$YI>PFA\&BJ\-?HFJP-;9 MH_4R;"PG)5DBZ4XHQF9H!!8K6)T/=T$N@R3FWZ=QX*-&V[`<,0W63BVE38NC M^B[\_ZLK@642WC+Z=9\7V_.`)KH]JORV!ATWA;DU`.F7O;8Z6DPQ;UJX%4#JJN1-?'1>2\E$V'*.E M;/*\N+XX?`1J]"!F]'OTY>&>?NU?'SZ6QH40/BZL5;Q37&IGJ:>KQ&/<9MHL MM%*>L6N5,U_BPF-!"T/E*TR-P&"]0V]C,%ND4)8FC*7,1S)9*N-_CS,:%LFA M?8.RS"CLT[8Y MD$1)3=7OVZC#;&5:O#+^P-`C>T?EHTPT6N;E!:O;EU2^@M"\_;44H9RV&3AR M<0WV:^81(WWZGIX]T@=JX+$A%]PQ]+02K`;O**G0PJEUB?>"`6`9'6P@DU?' M*&OO./$_!`41#UH\59%7R<'R:(.T.'ATO%W*23&WZ[N,O!7BL,=GS-A#'<=)S6XQLA538V( M;7.DAP;S.+#Q<4ZI8`]@"$O%+1/0S5T)1@2/J-HP+:WMFD+'IG'8T&J_C"*1 MCA$DG](J'3@ZMPM#B[YF%U/6?D523ET`14SHY=':F"L1G.^OR%H.'-OL6;#C?"H].@J[6GO@-J=JQ$*R\3E@];J*'OS447 M9;\>HX82@*$@%W8T>*MR>[3->!11OED,R6(\CD$@+A2X9K&!Z-"/X:!8%T\G M:OEE(JX(RY[?BUKUW/;>B3HP75JN\CU&RX?Z=:+E0P"T5<+0:*;X[I+V^?,E MOL9B1[VK&^YASV@]Z+F2AC!MYKH-"%S"(-,B$]-T'^>_77+W(B[@IYXH@$(+ MY-9_H&?;EN&(-`&*"R*IE_^#K5UH:5>L,@D,P5DSB\SMCJ8ZB\S@]Q,6FQ0G68/>G2Z,BR##],K;F M,Y'WW[P:_A)57+FS1^M%E055<9.OI(N_>65J!!9O7@7U<'?F4$K@>E$:QKL@6:;1=BC":35'Q;#42;D+; M:ECT0\*VQH@)>`,6TH!9D!J..,>N`"UP=62L#=7(S@Q>4"?LF3N;+YLXW,!5 MP=;0XQ*@\"ME>'P7Q%Z"XYIZQZ9P?^J&K960*MW:?@=S[%O4%JVG3_O!L';B M=[E30[N9YD9A1%&J%)?60S?E0.46S<<6:TQVF!8K)TK]49H,5Z\Z4^;#YS#9 M1U"P6GG;-;4OC-9@:=K6J@H77Y8`F;#+-392@R,FMWCN>&%Q$[BK&;>K&5?G MI"T(K3DWB]WB9)%G1N?.[8[SW3Z/4XZ$&ZJG.!63N6R*$Y4/7'9=D\9W@-R7 MJA-RM5551X39O=H<+\)7K^"0%IX%:2&J'\M5&+&ES2Y"%METAALY9+A.'^EV M1T>+QXU_C3]:Z.K5T:D"7P$$;0/5X$R.Q5+YM[!GT-X."P;EB6DR=J(^=*@A MWT6R=1K_DT;7$6=KO(IA1RD7TRK!DJ^WK>+N_&]\XJ)/Z2IX9AE\?4.#G';6 M^G!"$*.55H$Y"6)9'8&V99@+/Z?DCK7HDN1UL\%DC&!_QA:PK@%YJKR6L!FL M!ROKQL0P]Q-L]CB@B@O><[U0.`+H^MQ`V+_=K8]0?YO^U)CWM+$8">E7$(C_ M\9AZY8D$:;K?-C%Z*(=`\J)ZB#,5/,AJT/Z#]IV:TA.H[V>QK^I^:2&3'S4* M_/4WF5SC[[QKAV7^('PVRQI_`PSO+/,WQD6S"\LE2\59]CY(%(^7>UH86%Y. M>O:QPIQ`F&J4)X_(R#K30F'DN'CRJ/!)B&%K*.*8^'AMF=72TJ- MOP`W_"?^R^I7 M_#]/?$/%?_/_`U!+`P04````"`"%:W!'T(4)3<1+``#_JP8`%0`<`&IY;G0M M,C`Q-3`Y,S!?<')E+GAM;%54"0`#.B!*5CH@2E9U>`L``00E#@``!#D!``#M M?5MWVSB6[OM9Z_R'G)IG=N*D4E7IU36S9-E.N\:)O&RG:OII%DQ"$BH4H>;% MMNK7'X#4S1(!;I`$04)X260)`/?^B,N^XQ__];((WSSA."$T^O6'L[^]^^$- MCGP:D&CVZP_?[KW1_?CZ^H?_^L]__#_/^XPC'*,4!V\>5V\>YED4X/B"+O"; M_SF_NWGCO7GW\>\?WMU^>?/M8?SF_;NSC][9F7?VD^?]YS]"$GW_.__G$27X M#7MDE.1__OK#/$V7?W_[]OGY^6\OCW'X-QK/WKY_]^[#VTWK'];-^:]!NNVP MW_CCV^+';=.CH9\_Y&W//GWZ]#;_==LT(64-V:!G;__GR\V]/\<+Y)$H25'D MV7OOP]G?7I+@A__\O__GS9L" MNIB&^`Y/W_#_O]U=OWIF.L=_4A*E?_/IXBV'_=VG#^_>\I9O&=4I7N`H]0+J M9_D'%`4>^Y^D*\;5E,:+G`G&6/Z<>8RGO_[PYXHUW(S$2?D/Y8'2U1+_^D-" M%LL0__!VCY-EC!/6+6]\P[Y8M^?D:N.J(`:_I)C-V#6N&WI"ZK_B?7]Z)=C_ MVXP^O0TPX23\R#]P7'[TWIVM7])_L*_^=\1H"#@=5R&:;1X:HD<<_OJ#\/>" MJ)#/(AJO(6J3J'$6Q_R1)/%1^"^,XLLHN&#`E=!7U50WJ1?KUU@0<(MC0H,K M]EU20FMEVVZ)Y6C!2#UJV16A!4;BMR]MUQ61#^PY$MKV?]9-TF6^CXS94V,4 M7K,=X^6_\:J$-FF[CHBDBP6-[E/J?[^?([:S3K*4GU3\]!93#.C4$?G%OG.' MES1.V=/OV<9>NI(@S;LA^8J$.!ZS!3*CL7A2E+;JAL`[/",)FY%1^A4MRI:4 MK%DW)/Y.PXQ)`'$!D_A]"]IU0^0?.`S_.Z+/T3U&"8UP<)TD&8Z%Q%:TUTWT M0XSX^KU?+1YI6$)DZ>\J1!W+A/R;[08]BH("A^MC\6M-!KA]7:RF*'G,1>LL M\68(+7.Q\2T.TV3S3<[`'G+KK__WWL<18J??MRA98I],"0Z87H/((0O@]@98 MV`C%3*C&U^SCX;JJ;FB0Z`V@HQ=227=96X.D/Z#'\'"?E3>2$;NO'HUB_PV- MF8[]ZP],*V>_3#$[`(.;XAE"G3+7D7)"V`-SO?CO?D@3'/SZ0QIG6RI0[!\I M7:\'6K=XNT3\V/7\.0F#3>]I3!SM:!4P%X/0R:+L4>G7D0C'R5S#_DI>6)[_X;*ZHB(&H-V M$QU1FS!8I(3`(W#%U',V61)\A7'R!2\>CYPF5: MXN2!7I&(L4E0N%TCR>B16S#\M(PB>*_N#=YC-E^N0OI\OS>K+K:3*GE@D^:< M/?F[P!2NVKU[!B_6.^P=?L)1AD,>^,25U537U^P!:\^!W*D.$[P38_L@37T&%OV&X@&2IN: M3#HUJ$9,70Y@;LO72QS-CI<4^GZ3/;VJ[9.HAFA%$V2A*<2KE1ZFN" MM_(;)[* MMPEIV^Y)+X!<;UVR>2=N:(+H%[+(%E*<2]L8()7-X4I2R]IT3RI?29/IJ_F3:8E:NCLR6.O[G78]VBK7 MMVO=NBJ.Q109W0-^Q\VWDEWCZ'=#)$K77TD+%QOA8B,D=+O8B-[8S5UL1$.W M4Y5@9PL2$CXIV#I\.BY^-;N?+9,$S#55--+(8B"4;)[6Y:<+ MIXU`5;!EDARS1T$6`%M.'#G_8F.-=04)A`N@MF77EB52!X!7YXZR0]F6Q=40 M.8!-VA;QI>D<@SKYP'@-I7B(BP5VL<"USG:A==66S5=N6%#TEM@"2AU%6BUV MRA;-J.G9W<1);O%LDVK@T``J,#Y#*7?ED@\JF'7)!PK)!V;]W-TG,;SWD/_O MC"0D%_TWU`"S$Y`6&.A'01^:C)BN$>(DGSPK254?:4O+2OL(2%S/ MAO5VP+;H[3QYF,U-[E++BSX'(6JKQ5(/W>%CBJF*6*EFI; MG+Y07`#&.5L@4?#SRH]@6]9.-;M4P25@2[R6BT4>4D1MS_>3$N+^94\V)`NC MUB_:4`3,;!$/T&%V2Q41C6[`X*4E4+2:/$4!0EHRA84QK-=N78SE>[SQ6AW&T,.?`@8DO8,!D+ MSYTJ@X4;CM8]^XQ$NL#;G>(< MA6SYX/LYQBFWFP=!KLN^NJ?L?*7$I60%=_OP[L'--Z5B5XY1P'.G)TQ(BG?; M40)/+&HTEH'`WE=;KG3-R)JZ4%\7)RNAV\7)]D;M=G&R#:U6[8FSMF#6"B*T M%6W.%F-S]30T(9/9,F$[QHXJ6;%LF<)F=H52$Y4M;KQ6(:UOL+0%3A=OTH=X MDYY'/;:UYN!:M"T'0/>G;*O6/5LFL//#.S^\!C]\"W;.[MWR/WK+F+*5GZX\ M%`4>_G=&EOQ71>=\U3`=NNAAI#1RU-OGY'2^O7[Y]F[74_@VY+5JH^!R,XOA M;I&S)ZKHX[/=#I@1KTP/J"5_?JWT>/;--7 M/)3GKRAJ?I(1.E3Z*JEHI._M\K4!1>?;KSC?)W536.9]5E@NUP4DXJ(BR75T M6/#F'D47!,\H6Q=?\?-O?)>35-!O<=B^%45VE9Y=I>>^L^$J/;M*SVT';;^F M#F[.4NCIK%C.BN6L6$/0L)P5RU50-%+'08]V<3J&,5<-3[T:GM7U)IW!W1G< M7=&=WNU`]6TO+MC/.7F

    H?BB;([KW[?RTKE6S1*L:Y78$O3OTZ4@I:,>? M<\6FP'A.8IK'14-N%)9T:,&-_99'/9RB0U*J.;1-Z1]/Y+0Y1=,E3D98QUQIN M;L9`:D&]VR9YHQOGEY^L-6F^AN'S`3Q"VZ1OKFQATA!]GF,4W/$?X7@#^^LB M.U_L2WY`$?\\29B+`'-VR/J"C_& M&8I79[^P)C]5$B5KWAY13+PH6`?=.1G!Q[P._HV)1<-,LB9V^5870 M#<1//2KD\%2T'GAXD25LF(R2#M/JZP!-W-S(<#L!U*HVL<;;X M)FOA)+'MV!(I-(Q10+1FKXMSRU8_8%`];SZ_1J`:;HGK!E M+W=`$NI M9KR"=6J4RVUQN2WMY;:`HDZZSV?Y.:_EG*XV=``360Z[=9C!4OYH5WKZ]?VZ MSR@.*BIBE;89>-B0)6R8C'ZZ9&N8KC"^3QE!DZ4PL0?#EI26!K;LG_X[GCTMV M[*/?#9$H1;6DA0$R,=M(B9_B(-^6Y`3+VAH()40AGDQS4GC9A>(Z13\@D7,D"WTE6W1A^1\M6MSBU;\NUS&V@E:4<#K M%U=6'M3Y*!>+[&*1:\4BZR*6;5=S&C*-/[G,]3JN5L&3.93[&V`Q>TQ(0%"\ MVMNA9=.IJKV+&'<1XVISQ1I`*MFEE5J>=5%0PLDA4!=LF0S'[%&00FK+!)#S M+[8=G(ZC1F+AM&41E+-(E>0DJ:B:KFU+L+:A=JX4)OV0FUJV@2[#[[YQ2,1 M:X2]%+U@U3L"RSMW&(@C(\"%X[@8EQ['N%SG$_1L);VWE?1=Q77:F]/>=%P"`A6TNE?8/GDQ#MDW@NK/3 MJ*IOD*$Z5.;@Y%BCV@E(S.V7A?5`7)A8V&C@2IDE;)C4+>^*=73+EY%4%Q,W M-$OTGO$Y.5_M_R(+35<>H#],PHT`-49P-@%G$W`V@2'(J\XFT#3>L.898`M" M-?BG,'GR!$T&SJYTJG:E>LL(*E7;$JGDK&_.^J;!^E9;P^G>&'?VSF-M%B3- MQ3,/10'[.TI)-,-,=%..IX`.UZ%13HTD:PQS[>@TXQURHR@8[^,&5_CK#3)P MZYDE;)@T`KKR'JX^AHQ(TT@Z&Z&S$3H;H;,1=F\C=#G)-AOXM.?>&2Z=X5*#X;*)I:93VV5"9A';XGS$/B/?IUE.J;>D(>'$ M;C_`S9>J(W9CP:Q'52,CYBAXPG%*$O:"Z"WP3`M,/$5\:M[)M/)$L?Y)($3KMBU!6+O\(P] M!H7KVR5QK`2T>N]62'["48;Y!O8%1:A(J5G/8);V,\`Q7AMU3=KFFIL*Q7=S#`Q&Z['M,D3>333+%7]^R"UX)VX4P>>*$25>!4M_N66-"_61ZF:1DP:`6S9WR1I8%G[;B?7)A MJ2(47%3>J:8=N[BT&G%I0%72EK53I?COWST$=)_;`@V`WSUTZCBO;=EHU)"" M^^%L"1!6Q:>.#QF,5=]O;`%A53\"#XQ3SV\::;#FX%YB,%@?K0)+/58'#-1/ M]@-5)\0'C-_/5N$'C:P!P_.+3?#4L."`@?ID$U`U?`]PT=,J*;V>6PT.EE6" M.C#^`(Z.56*Z8J`)'"4K!/2&,6)PM*P2TYO'F,&!LT)D5TYY@^-CEZ0.CJ>% M`V25*%X=K08'QBHA7#%G7ITZ\O.BZ,GV6*!XA7_I2HD M,N4^$>42\1H>W64Y>6WD-ZK:5!;1JHW>JD(NFH%R61Z*+,QQD(5LSQXQ<`,2 M9OQ0N\=^%A.NNER^^&'&YMT5V__X09@5RX5M\0=>""\X>#/-`5CDRMT4RROS$FT7BO`J`:S_`A7"Z0RP7J4RX09)[W92;7(!:6 MK#RL4&H#0HE+!!*AX!*!7"*02P0")P+)=V=;EHS@P*1MB(ZV+!\5C!JH%'!K MG3UPZ=%-NS?AO6>BR;\SDI!"A*EEBY..T:%1#4!'(^O8-B(BN8YNYQ1'Y(4M MD(?,3_@L)W_1")5>-U:OLZ9RR]5(@>QR`*R[5%O.LX0=B4DRVA&5?XPQEAK: MP/WZP9)80:]HW0OR;V-Z1>,%NHZF_#_^565EY7JC.`MO,V-E'--X3-DQ7=PX MS#:J6T9KS$XO0H-1\&>6%-=[*%@L:P]I$HAU6-Q?.+@.N!>7OZ8BEGF]2P2, MCQN"'DF8G__LMVRA;,UM]2G.^.F,G\[XZ8R?VHR?\B^-%;KHM/Y!$.>%-YHIZS`#A:AVX#)8KTA-<"20!9YI78Z<7%`K6O M%.B!R<`&NZ^SWSG[G;/?G8K]#GH^.$N>L\DXFXRS.#B+0TMJGZH8V[VF]]$C MVU)G'LI-(/64O.J!.M3OH,3H4>VJGP[2ZJ!,.-VG9JC'89$_MD`W=?X4PSF4 M1S+'-IWN%7\\J@N9\1R7T8+&*?DK7X^7+[R^@5KB7IN/<+JQTXV=;NQT8VVZ M,>"4=6JQ4XN=6NS48J<6M^Y!KBDXV[**X%"U+U-W;VOX*?\O\99HQ>FJ9V>0 M#]*AC0%"B![[@OS)(-L"A'AG5ZAI5_C"*T7D<4-%/?P''"\N\&.J:%10&\8I MRDY1=HJR4Y2U*4KNJI=8+> M'>IS4@KT*'*"1X(T."FY3G6KJ;J55W:_3]GZ*LJ[)R,_)4\,=T5EKNG`_0#E M%JWX#!P]HSC8I_UW%&;%!LP398KO:@/4_"'&P7H\?-&[>X9SCD91:6ED9-5'*11&L#QV')2;3+>I$5G;Q"3S3F;8MY5Z;*:GP<3"`#PG*QWB>VM:#'-$F3 MKSA-&3$S=CPEZ6@VB_&,O0U2%F;!1"P1\9:+W`[UB MBX4)V2CY2WCV]H(QC1(2K.\L?6`S,5D?U[O%?QWY M&?]*H*0U&[3>U-$&1^VM<3.4!!5:BP M!1D%OH_N11/9.6QQTM3`IL("9`LRSL?9!Q]GST,LU99/?37(%KR<3[B&3]B( M74??-GX2."L;*?6M\-[BK6*/`,/S8?#P=.T\!D/[X^"A[87O!XSW1VOP;F*> M`\/UDS5PM>O8!0/XLS4`MK4"?QD\(NT&Y8"!^S1XX$`.'[B0/'QMI%%X^\M:4CR,/_: MH9GZ:>@RM5`_'XT".[?[VA<:I?-P]07%WS%_^!7&GV.:)/,)Q2A*U*:`V0JO$]S'R441JQFW^D^GVE:[]`0E_HUQ:/7+20[NUB^CA M\TKC;(];M4K$6JGDV^5D>AOC)T*S)%QMY+%<#+OFLOV?6>3S5G^0='Z(T`8@ MON>6\=#Z0UJ&8,;&1.$%$\5#?G@DKWQK8QJ&F)<3^+:D$5]A>^^BG-G:PVEF M:^<6@]&]:]\986M3Q3YB\AVQ]F":65H?=_F._!E'7"+!P?EJMXI5V5(8L&76 M<@5US_C4?#=H,F*KS-V3E^VS9"D%LG;=Q]N,"M&5JS:8/'$C8"GET.8&&-B) M+NL+9T2D'S4T&1HW"D/ZS&8!OJ+Q!TVD6'H,K8@74V21[W,3)G6U/;(MA M1(W2,8KC%8.>UW42L27O9)0=NEAF*8[OZ31]1C$^,`Q(EXQ27Q.L17RK+[3< M.Y)\/\=L;V):[G=IJ":T6Q\86FUID\1!0KOU@J&*>'I`CQZPL1,RSJ!\['4Q MNQTV2S*;I_)I*6W;/>G7BR4B M,;>R%5=_Y&@7&/\3AP&30;\)A6Y07Y-;^<:CO.*DL`TM3MDT>4`OM]RQP[>$ MM>(OX`_:W22+Q4)8;W6R?4/^&2)3.\Y(6 M+NW0I1U*Z+8Z[5`/L=^B>&OO9K+&.8[PE'"OE\\V:"Y\,$3#/&8SXE(QCG&2 MCGP_SH0)Q0U&M+9:ILN_;);:4B5-VH*$A$\*=OF<3AJAFIW5EDD"YGH/*9BO M[71RY.G'^QA4A?'EC? M%D!M=X`M2Z0.`*_.'64'OBV+JR%R`$>&+>)+TSD&]43J2Z?LV[;EZHV48'): M]4:D9[O0U&S+YBLW+"BZ:&P!I8XBK1:K9HMFU/3L;A)98?%LDVK@T"@O?5G^ MO3W%!?XI?4=X[U**M[-$*PM4C5`A?4=Z[U!JI8(`&*_AU^E1+PT`!L>2DCTUTN7! M$`V_.(^&3%>X5#E\N;N;L@%P1(\@&,W M?!&__4H/XB7.EZ_U88E)F&#=5@K4H4@6-''_121!/M_F]&GM[F% M+EYQ4CYL_N`X?=A+#EE_S6U\X_PC+\U=EO54W;"%8D@*-9WSDMB'=X1$07D5 MWP->M#ZKU>I0)41^P8A?"\\G4W$+P"CX,TO2O'3X`8ULJ<>\FOT%+OX'PM#@ M"2:9SROX%]7[-3`N&=TDTX=.=@V<5SW")/L;B_N^L5T#!)#'=`_#AKS-%2&M M,5XU<*NLCED3XE]'#WBQQ*.8_,5447$9O.K6+9`$/T0Z.`(V6CF_6.,;$P36 M?^UT\3N,UK="B&&K/4B;=9N/+\/;)['R-L%&1-Q0)N;.<,A-04QZ68GID+=L MH^@N3E_='\#^/I0MMCM/&8$J_4^]_O(H"'(9&X6ELUYP87*=(;349;Z0+53) M9=;U!M%<6GJ#%+\"89?7*J.\JJ]F@A_H.1[GJCR,R%W[#@B;+`NK[(@?Y4L4 MK2;/T2$^.6H)G[QP!M3&U<+HWNP\GKKE]$WB+RA",QP4\H&TC'D+PVMFNW2C M>9BC])_H"9]C'.W\V^P\_X)6Y_@.YS3(IVH[3]#"?(504FQ3#W-I]L\ZKE36/:3:;TRQ=RZP,U3$*R93&$>%_C'8=)U,UD;B[I[8`$0/^-VXC MN[L;CVF\%',E;=A]\92-WK2'V/I,DE<:!/?K!TOBRCL5KP&1]KQ(JSU',[R/;*`&?V>==?,]HP;46.,N`P7K&OLA**RH'K#+$ M0%@MN="P.?.`6Q(-PW$;TRL:+]!U-.7_\:\N$3O*HEDRB9G>S@Z_S>9Z3R(? M[RWG"[:81WZ)?JK[#N[O!%4%W1=!= M$?13+8(.TKVA*>VV')P`P4365!*V;,NB<<7/NU8-ZD<[@?%RQ=#M*X;>)*9; MWT(;$ESM!NCJ.P`&CFGS@'%]9I'>0=LH^5>?E-8[G.H&;.E3@'L'D;8,9WUB MQY`P+$]S!V,S_#*-;92(`,,U_/J-C0N7@+$:?OW&3JO3P85A>Y2'.O'\<)SL MT1KJ).K`<1J^)M!.E1TX8I8)^,T*=;S>9&XZ@9>J`A@)`<"PM4POT ME!2"PSE\34)@`3_E:N\*I37AL`Q?,9`<`S6JN,!-MO9(_O5+_L#1&K[\WU6% M9#BFEN@*BIBJ%MZ&XVF))J&(IT()=SB4P]5#_E_BQ;M;?IO=Q`(?L,/;6%2)@MW((BIWOZ=5%LJDI-A]1=L6ZG%N+OXY MQXB;6[Y%"?;9+`W8>;X@24+C%<\7%I-8IW\KI<@C`GKRF9CTNF-T2?[[%LA_ MKX'\X12"YRM[=TGYF/)KWO,X"VZ.$)$H[M%Z0?V]1VW6TAT#!4#9?G.=9-VR MN>63)0KW[@D#@B?J:K*2S.;F^IS4&XHB?O_9>D9&LQWMYZO=YXH*=&T,::`V M'4F6-$'AYYAF2RX1AUG`R&5?^VS.$R;6!84QE*_G&*?Y)94;ES[G@`F4;%]-SE=*7$IF3+23T3?@J#JK].TK@X`& MZB3K/OSC1V^Y#NOS4!1X>!/8US`(1'78#D-!ZI'6*""DC\[TEAR,F+T@1AE_ M/2*OX5X3DXX?YS]Q_A/G/W'^$V=3L=2FTG/+@%-):V7,B86'[H7ECQ[9YFMX M*$_8:"@G*XS8H8BL3%6S<&F4S$?!$[>3;:L<'>;%E,G&D'ZM!DU>OO@XVXSHZO+WE M'D47!,\H4^>_XN??^.ZY$H/;XK`&8FD7-$[)7Z@H1%^Q+F&=>G0%M5!G=7=F MNSNSW<72[F+I/4*MO%C:6<6<5D8VMR5;NI7 MNEE]::(SX#L#OKLYIG<[4'V=W\4QGK#32,WZ>(*AC%JK8UL2W%C'NW1"48Y` M2SD8$4MJK#7P\77OSOYI711KB58MU/T"CM:A&UN)HD8N[-W%UVS"C.A)**9,`NK1,78A3?HG3^.WM_/"WF.@(36=FU;6*O M2)RP76`V3W_+(K\H_0T71^BT,47?*H\V7,%?F;FS&06E#OMDG> MF*M^XXM\;=Q:EYH%D@T>H6W2'^8X?R934.CS'*/@CO\(QQO87Q?9^6)?\JP? MXI_C,'R@SQ%6IQXV3.M,_)GX\'VMM'7;)/WQS_/MW_#9*^W5:CC0_DMC:^8S M>HP)#G]'88A7,'K5ACBM8*+MS6';JPUWMZNM-Z52.JN[M5L)\.CR-QE5NU:M M$G%;2&@7V,\GS-D[WD0\_P#-VR/J"C_&&8I79[^P)C]5$B5KWAY13"0K6`??Q$IM"X7O74&RN"):&VH#[]8,E/3!E(TCCC$L`5\G%Q M?XJ`?E%SLV&A^S3MIU[GDDUPBV.?6U-FXA!7Z``FV;RAT8PG2G-JOR"FW.?7 MG=WAY?I:Y,ETFUI]'?T+H_CAF0H8KC/40%B_PWP["'(!C20^"CGYS6$H'=8% M*[I@11>L.*S(#A>LV(*C'23%V`)'%;-'X6&*YF);XEEJX20Q/MH24*>,2QU+ MHBU!/O4FD8JO0)\;?D!(J?@EP(`I7V8V`,`4_6>V[.4N"%@E"%C)O@Q&1?GJ M[`$L)YC/W[I5!)DXUFJJ(G(7+ M>SW7%.JC(PQYMD6V45I0U=%,MIQ1YA),>ZX[`992S>`0Z]0HEP^IDJ,%BU\Y MH4Q(8%#KJ24]U@@^/LF4#JDKWDB?#FH#A,+(M>ZS2W_.K]9(5PW3 M2JN&Z3"?%$:*=3>%"$B]G[/I?8[8^N!7?.(H62_`;6V.Y'R5MWGD;6Z+N3IZ M1G$P6>9WD'UF+7F]*K9=$AIF8BF$"GC.XGDW=`ZWT=*,`A_G3V(0HY>/RA7\4Q6+".AMEC^\I%<67 M2]MT3VI>4VHR_0/Q73*=%"4"7^U\VQ^3]:^)J))MK;%,OJ=2@C<:SCV_]S>7 MH\8\Q"PX7QW2K@(#?%23@%PR&8FN\&;/*%]@7VGTQ'9T'.13F.U1;#_:_WU, MDY3)&O_"Z:Z42;'[7-%X;P,23:-NB;`2[MU(1:<)$V'CASF*UH=#U\A7T6/G M2]@[C3L'?._9O0!W1T]I;B:X??%+=SLX59?CD.L+4!\F/J8QSD8?/729)QRJ[YH<=4B>PQ M)/YD.F4'8C03,03M;W)_V2=R?\_;2)V'URR!^YEDZH[;*R2JP]'OADB4KH>2 M%@;(?&UYD!,L:VL@+1&%3%W*2>$E?R?3!Z8E)"B/#I:GM(([NO3<.BQ4&1G7 M-L9SD(WQYR59057M7E0*P M;JW+PA2'.\+FBS6`5+)+*VUWUF5:"B>'P)1@RV0X9H^"S(RV3``Y_V*+\.D$ M@TO<\+8L@G(6]S``.EUL6125>(!,^;8LD4HT`'91ZS*I77T/@SE8/5\PTC-5 MZ/6P98E4;A?ZS8:VG$-*FHJJ5\>Z*@XNG:^"V5>0U+'UG5!R7[71_X3R^AH' M?)Q@@E]S$_,))OHI!]V<8"9?R\'C8`25"\\,"T'5+`0P;LKU17J+6P?A)F!4 MEY-[!P;='ZS)"1BC;"7HA><-"S``ANL MPS(L*@195XREI:S'',`']+(6],YQA*=$=/^AH+6["Z%/19GJY%4X%(";BA&, M%G\H)S,Y7^W_(JL.H3R`4\Z<8&:0M"-?BG,"GF!'4W MI^"?JH)?;QE!96M;LF6<&:2&&:2!JM*]:>3LG%;;8ZN=N)WFMXP MA&:HQ(@`Z=(NDNMG?6$3:1ZNUM&+A[J:K&FKY$R6.$9\1N=S9_VD._:8\E+] MH#XFK2PY2:,HX.2@4'[?0&E;L\0G;.YQLABX^]'$KQ%/^(U`D^F8`1^SPT+( M79W!3++OJAV[HK,R(DTCZ8R;SKCIC)O.N&G&N.D*>MELF=1>T*OG_#O+;!\L MLSVW.6JNT--S[IW%M>Z=UA4&%'U[:#]A4;7?Z%M`_<0':%`%PV)/VF`[-B4P MI*7S#%F!XF? MQ3D.RSP1T,LBE+&MHPBI9=_/<4I\%&XYK_:,:7EL-QXSC:3#/&GM6&S&=+%8 M9SG?HG@2Y_,XR*M'W.(XCY,1F'$4>G9OB-HCKJAE-/6"C M*-4%9>%UZQZ0OU>I!,I#21<3U_.MCY\Z"T6MLVGF@,L%UJD?S$@7376'?C!1 MO72`O9PCZ>0<24SFW#@B;FF2*WNCQT3F35?IZCQDYCUD>HA]B)D>E\6KO0U% M0+&DI3V.O5J+PWGVG&/#A9P/Q[1O"`FI.:V.!F'=7%%`2*Z.6.<@4T:F3+_1 M9]X?"BI"74F?`;^/T"C;]?39\7L.3TO;C'+)\D'`TFB/4:Y&/@A(FF\PRO7$ M^XA+I:[8?>[7>P\E"??7(/_?&6'@YLE/(4&/),SO*>"_YT[Q=0H4W,75;/P. ML[\:TM@H_>L\2]B,21*V9!Z91ET4)-T4?KT.&(U,)^*ZPB@G<;2FP?(NFW0)S]$`O:A.;.YS/T\+JDNQY MU9.'>4RSV9QFZ8@=RS1"C+PQ"LF4QA'A?XQV'2?3,7L4\:^C![Q8XG4'?L4]_^Z-U;6C<+;V^2K!<7 MEKI*P/WZP9+83%_1VASY>UOA.8IG#-+;+/;G;$/[S#[O=LL[9)+=!W`6/GL[J&M6)'F%XL+[3%,M(N` M&:3_5Y?BZJ)-#E``Z96VP%'%+(7;>VP)'X!"TK5ASQ9\7;Q7'^*]>AZI`EB$ M-0V:MB#D(N+4?,@&]#[K=NS.`%8T]EBWIJ5`-\1`/=F>W[7:I]SH[LSC&N+X M/A6@1GC&@^3Z!*L!?[[&A/Y3F+0E9EP-,80G-&,K0G,T1"/V%]Q^N,PT!#H. M$O(ZSG\P=I]L$(OJQPYT'SWZT<-)2A9Y_0^TH'%*_BHJNN!UX9MZ0:.JPW88 M*UJ/M$8AHD)CN2HMH-"Q>@QVZ4:Y(A%)\0UY.M:O1GL$KVLOC:8ICO^%47S% M.@A\+@U&]`S&[ZB1?8>Y$2G(ZS"1Q$*;ML?],>\J\."9)WLEDB)$+,S%,M`LS&:13I64A MUT67B%!POFU7RZ1_GMLG'#_2?E7"U:A;Z9M1UN`HD$SU>5SM0JY,I='GJ;4* MNS)U6%]=%;N@*S&DZ'.U6@.=U$"IKSA+;UW5:MI]]UZ4GSRFB61Q$=].I_F7 MB;=$*RY7U72A*(W9H?^D!EUZG"=*A(`\)S58Z_3.61K-^'4=%_A1>)/L7A.3 M1J]].KYL,;W#R_6]/I/I;4PBGRQ1>!U5&7#K#6;2A*E.L=!\6V>H@;"NXL]J M.JQ)2)P%V%F`G06X;0NPVF'MS+_._.O,O\[\V\8%<2V+(B=I^VU#K#U)TV\[ MRM`)YNC(5./N+49G[[PD6RQ0O.*RRS1C+Q)[B^+R=(\SC$)O\TJ]*8T]NKFV MTPN+C(!Z5J76G]NAY4D3[7JL4ZT3"[)@:8*H2]7GX'[:JYR'+P4+FVNA+X1E MU8"]3=K&@"1>1]SXSW=PD"9!<$9>9^1U1MZVC;SMR[/. M$.P,P+!HV=5*;79_JU`#.A^J?1ZCMXU(3&`GV1 MOA:`)C(LZ8OQ'3IH8I7]!.-Z:UIKNW?7_,P4$^I_9^I%7F/70WY*GDBZJNF% M@0[7H7-%C:1&/I/\WL1S]L(#1A6/=U]/\!A%LYRB\]6NR7H:C)Y1'$P*VBY? M<.R3A,NJ?V`RFZXY12VI[S!RLT_4O^#8FOM#>ULW3APSP%8VGF/"C M.N$EAU^6I*AKEEQ'MY@MP$`3M.#G6@BI@9G<"DW#>Q6?6<-TR^/GF"9"=T+[ M3QKRMK!W1;C6P^KH.=Z/#C1UT#Y:`9J!?1'X=$MF98\![O,,3I3V?AT@MT>! M\4/IL7HN/2J+XX5OALVQ,8W2F*F]&0IY?+#H1F`#E`P9>/$B%K'[7A/P-2@9 M,O"_XX1Q>,!IOM@O4"JTD'7\=*,`NS`G%^;4KS`GL!'612^)4'#12RYZJ7_1 M2\MJ\4\%5Q8<$UU?L2631'CP&!]6>#!=#861PJ(>O`)H*ZH5C[%2_%IV?)H+^ MV1-2MLSX)4.%@;YQW#]XQ$Y#_Q6ITE,Q28$,8&2[(EM=.L7RQ?'`'BOQXY6V MZ9[4NRV*]QS$+U@2IB9MZU((N@SE^DJC8O.]_'?&IOQUQ-Y,EELV^BFPJ,'&6PX$&@'&6:X.SNBX#9$T5>TP/*M3^.C7(R/B_%Q M,3X*XJ@+\SE`02(*VP)".8M42;8^P9`>%_=UJG%?E0M&OTBC+]RFM^M-(">Y M$+H.M;L3K!C6G55"WYJVT^':0)7NU*3OTRC@=ZL&_%-"0Q(@_O8?$=O??>PE MS>%=>%J$L('O&LFI#?SO/Z<;\WR:MC9P"8SI97F51D-P0]$A" M-H_&Q4/++/Z5C5LHOG.Q7MA7;/ZSM97@,4W21$(4J(,VPM@B]%5I.^YCP`WB M^S1C6\5M<6T;$[?8-VP?##:OEF`!Z`U&,,?F'?8Q> M0X@^;-L]Z6.4S-E&P?_C0LL3"KFX,DK'*(Y73%J1)<@J]37`&ETL2)J+7YQ* M&O'JBCCRV2XH8JBZAQDV:)3;N:0O0]"L>X(W1^P=PW',_B<5VWME^SZP()0J M5+J89.0)1QF&OHBRQL:)5W@%@O;F6'A`+\7&OR>*5D"6%[94X< MX/7(FW?/P"53*>D*,V4ZY,H>6-`&]^N>I<^4!L\D%(FAAS]W3^!UQ+1PS*8T MWI/G!=1*VYH@/471C'#5JIC".+U\\<.,6W4J<%?IVCUC>Q-80/]>"Y."]AX9 M3$#+A9TY#0,<)X7%K9KZTFX]84F^Z1PW[!?9%7I/=0<#3*SOP?U*4[RQFHC( MES3MGO"<"C:5;RB*5"PIX'Y]8JE2L%#I:HBQ]8P!O)WRE@9N,DSG.`9O3A6M MS9-?.8FJ.W3/Q.W&IU:I_4M:&B%[B0C/H>4.%;8P M!9'R'&$F.RRYL8AM-$)^JKN8S&)H8OVK.8H)=E-$(AQQ0*6U M7VKJ,365L[VJ0_=,/,08)5F\JA2GCAMZT<\0N@<>5@O9F5Q`O@@%%W]]JO'7 M?0X:[F.Q)D`0A"V`R%G=PZ2&%F7+\@%CU$CGM"5#`8P6/&Y.7P7/GD(#\"SJ MJZ_94TP4G0/Z*F7V#!_5F&9;BEJ")TZ=.!5;BE."05(V;>NK(FG@#FSXF26+ MZ=57`+*WDP;J/]!8K;&GV*A[?3467^P91C5273262^P9./5CLC26.^PI1DUQ ML$4VAL6NPG%1KQ[?^S.[]F'=\\T69M&"AK?98M8"\%MBB5#.3+1E$L'@4DGI MM<6:I3:1%"/O;;%KJ8%4&4=HBVE+#19@GIDM=JVZX(ASOVPQ;*DA`PIMU6?. M,B#XJ>%3G9>@SY+5YWE3G3%@BSFKZ3;<7)VR2E@&IK%:8\UJMAT;L&<-:4NN MKY5;)1*#*SO8HE8!*YT!@S1ML5H`^'WMLI,GU=ABG5"#15YIQ)X%I(()J+R3 M!FO$IP*:",]R9Q MD+FZN7G,.B,&W-Y$`<8G'*W5#;LG^CQC9.`D84+4(XGR=WR.XAD[ M`6ZSV)^C!']FG^^P3V<1^0L'HP5WG`D8:S:8B5)V23J9RE_6JS8F,]Y>$5*1 M["9M:Z0P5XQ]DD\(]CG$^>$7\??/UL%?^?<"3E2Z&BC8M9:1;G&<5^"N>"U5 MS^A`_;JGIW7H64"ZLL;&216O@&)FAFHY88C)@:$?/4% M"Q(1/GE3\H37,<0"^H&]3%5^NZ%)?CLN#1E]L^LHQ?PJ*0$4&I]H\F0JR-U:^"HVP8K6!BL` MKF?D.9NP4V$1#D%K8#ZVII)..-U-+0'=K]J8G"UL_J[5"3Y[.47R_4/8WB03 MD]<427`O:6F4<.ZN*D@1$7S.%)QBJ@X+.!?Z MV.[V!<7?,=\6Y+M(=0=C3-33)F"=S58F&G(9,5=M2V_%)^S/(QK2V>H>QT_$ MQXG,4E'1N@_DR[?^RO;=L_`')K-YBH/1$]M`9KBX_6XRS>U8>[?BP0QAS0:S MKW!7E6[O:G6)4'"UNERM+E>K"Q(C*-=^;,%"R"6%*5:VK`X(#G(/B2T!@!`D MJBTNMF0@0M"HBK.P);X/@@50$KAL%9B# M;3E78;(6(([(%H%+SFJ9M%%BB[%E=H#!`%FH]$E@!C8/,#32P$%;Q#`P&E!' MA"TR&1@8]0!'6V0T,$1*$61695RH+B]%MYA54AT8*T!$CBTV`YB4IQ(W8XNX M!^1Y#Z4VDAMLD0_5T5,)9[)*7E2'"ASPJ$^('`1.'493:Y!*369*U\6Z.NK9 MJF3@&DM7%F1MB\X'$RI@N4ZVB!.5W$J0D4:'V"(QJ`#41E1-_[+)?93,O6E( MG_5ED\L>T:-L\FHR&V63CX(G%/DXN:+Q'4;^OS.ROCDP"GC]N[7LSE7%`Q?0 M'9]VA[%X;0Q9,SE(P!\[87CM$GR!B_^OH^,2O65,0/IY[[426GX%`(S8\KY> M]$N+%+/S>SM\X1#<:'/?EC1Z]:JW[4:S&!=SNXR/9B.V.W'RRH^[FRFNDR1C M<-+X%JV*RS8?&`7)M/"%EC*C,D"[M`O\M?M@CG;KGK_6@SAFN6<]Y*44!8P( M6ADA]T!NAMQU(N:JQF#U=`C=[!]?JPIF=M>UIK:AD3>._:O)MU)E43Y"']@\ M*$`.9D[0KQ\LY?=W[=VYJ<#58=>>S4KQG3A@'L5#]&MSD5[;7,EE:>^>ON(%Q=W$=Q@%XPR=?29K<0V=#J=N\-@]LW46=%"D?HUX*\+6XUWKR,TMN- MP3Q#!NO9K8P!P`#]9GIYG,`.&@/YX"Z M0;[^0'UFNOD<``YJ>`XH%FLT*&%M/7N[#79=RY\[_[A/7%:_!MC;J'UO36/R M0'-77XPW#AW,+V"?3'-[>?&+2,90&:)?O+ZRM_(8MPI[+7P`LWS&U,% MAB'V"__M@?]:Q*1:;[/LE=C-(>]1?00C;#Z1A$'/-(\+FCVFTRS-^M))+?2BIH;75(V%$]41;RR/>9\MEF!."PLWKOXZF-%X4XMMWWE]T"+Q]7@$Z'@ M:O"Y&GRN!A\DN:>I^4D?6BF.$]QMFE@#,(2I8^\M7V?2V:4_VMB6U:H5*5I' MK]8P4TUFRNH&6%,:@H8,>NO?0LN9.AJR?>U_!8WRBVPI'=75IMZ+RE,VS^G- MNK9&7K?%;(_=!0^NH4IG)+V6Y@]']Q4QOJC3BMFF5U`XTU:'ZOU_U# M]P:(&EA(D:P5]ZE=\;,`6$!"D7;-S0(887D3VA4P"Y"L%>&NO1C:8(!M5JE$ MNS8U&!S%O0');OK4)`.^!%TGCDJ^K@;5:&B`UJZ7I$^Q&0QVXM[PK$XPC)]. M$$9P*AY<).^YFTL+@A4)FW#P>NYSU7"D0$H&P/'KN3VB?9%&4I4`CMH0:CHW M@Z[=%!\-ZF"/S6-- ML67+CMD2D'53IFP)2V@?1G!RG09+F3FAJ!TP`B%-[ M0*VHJZU/+BK0O(P&N7O6*N.M#\L^BD"U4F4UR#UF(%)DONP>M+(ZSQI$F>'A M(RJWMP.G@PN9(B8S>1\]U@Q%,\(%)U0$#Z"->2[`*2+A=FU47\"D/&0W%R[5 M)*O1!4M'^4=?,+^A:_.$=58^I&D+%\/LH&@`RC[)K0QHX&J(+$G9UA3GSG4N MR<[)LOS%*/3HG@UVU),4WY`G?NYOT"XB?T:^GRVR/'0`<&N"^D`FZZQ)J#U? M?4%_TG@L?DY%I?#J^K6TS>W0_TK6F!IN:2:H_2*72:\JW/' M.AE]>YL03QYX%G3?;J)3<"6'8CT'/FRP#EWW*@0UMM+T6RB9+'*E0)FW?'EGW-`S.L_0K3?^%TVT4*SKTJJATT1F3 M`9OMH&@,E873I?G[,DI)NBIPQ<$W=G3+O8J5[0TZ10'D2]N:(YW&%R3AIV\6 M8UG01$7S?C`@CQRH[&#@BL.,SX+)])X]4'C?\.M&WMFPR/UQ6.1^-$>N5W29+_B[D[NVJ]MVSL+O>*B=*2KZTK?.E.5_:J?K2]!#[ M!XIC%*72)5G:YG3YX?V_&R4U.J;=G;^NR/[I/M7Z/=KGLGP7LOV:OAZBUC MZN7E6SVR*^-:T_I?9^@.S?KUR6MDKW^8X]\X@7=WXS&-E^*"J-*&.E-OZ@`# M\@C41[Q+R\+Y^JJNT=X]4T4(@=P2"^[7#Y;$9JF*UKT@/[F-Z16?,T4>*EW@ M&W%14'!_DQ40940>7`"IP%[IU9'.#NWLT*=GAQZ6**KA)'56VP,40`>=+7!4 M,4OA8JO> M@O8C%[_RZWT]%`4>WMZ27,]J!AVN0TN9&DF-K&-%<:GKB+WK&>-#"_ZQ1Q&-_PBSCD-@^L%>XU/1:4`:8@5H$?W;$RF4^+C M+:12!J1MNR==."_.5P^,&(D11Z%GC]B2W>4D[V325BND;,(.U5A\NU%EOUXR MQ:>/U&:KT-,9H.NP0*?I,Q.L]^KF2_>TRO;.ANYLZ"=O0P>+JLYN?H""LJAA M"S0JC%,E&=,6:VE-A,!JA"TVTYHX`4]V6\(^%5%JT=2BK]I%_Q%L%9^>[U?. M!=@'%Z!R=91>+Z+::K$MAUN?'8*]]7BI6;LT[+^OBU4]]!4G;89V?:MO>'-. M9(_LWKOZLS=%)/:>4)CE%^!FBSS',$]FINN/,YXC=WP?+M#AVN`)'?I@&U/9 MR"U;9%$Q'2W@*2TX2M9K@CUPAHN3,&_RR)O"*QE-,TBS&=XR= M,E=BRT/K])0V>`<@YVGC=]REA?$+>B&+;"$U1)>V,4`JB:I)+6MCH.(,G_42 M,_/1[X9(E)?".6[A_#YU6`!NC>='6R/;1G[GN\AHMXE^47_H=DG35-:CE3QXXK';=S$R'?>:(/4!"(P[8`<,P>!6DLMGAGY/R+ ME4M;^'?>J3YXIWKN;9$N$J$J;@OW??8U]3'YK',UU+J]N'MXQ:83ZU9Q-;@= M:*BVA$\9F++5-A1;(JL`]\-H<6UU[X(]\_"Z=-VN+O2FCG2CRV'4ANWTQI<5C"$R7$'T7L+,RKE`M,2Q6]3*9700J5]:88F0W. M,V?ZM<'TJ^GV"$QF<[8AC)YPC&9XIO(MXYDDJ5LUXQXQ+B`&\513"YH M`:E'-.8;IAJ[Y6/`F!V6IMWRF>JL^A;FHUJ3L?_N/[O1:`%WD-[(/7:S7S57,:)N3!(]IDB;C M+.83NLSV(^U03Q51OTB@?2A!YBU][[!+G6WS!M$G:`2#*5`02\[Z%_X/C^QAW_Q_ M4$L#!!0````(`(5K<$>L"G;<,A4``#OT```1`!P`:GEN="TR,#$U,#DS,"YX M/R4 M?6!LQW%FDIK,EFS'64\YMLMV9G:?MF`2DC!#`5J`M*WY]=L-D!1)@1=)2$2- M]61:Q*4O'QJ-9@/XZ1_/D\A[I%(QP3_N';X^V/,H#T3(^.CCWM<[?W!W>G&Q M]X^??_I_W_],.94DIJ'W,//NQPD/J3P3$^K]Z^3VTO.]@^,/1P MFX/#8__PT#]\Y_L___2LP@\J&-,)\:`_KCX$(N&QG'W<&\?Q],/^_O.#C%XK M&KP>B6XO0Y&-O+ MXQM+!<8?J8KM5_S_B\RM/3T^MX3'\7C,>O`S'!\L<'[X\.LM(1XW^4 M2NM.A!Q!R8.C?7S]0!3-BG/"`F4G2+_"]@_+]'#!>3*Q]Q'&3>D^%/*A M%)4LR.NU5RI74"RP4P8O+'2I>"IKRL,;2X5$^2-"IGF=(5$/FJ#TA9;M0A4I M(JJL=?0;>R5DSUY)O[%40@;""E12+1[OFY?%HJQ!YXRKF/`@U_GS`D:>CG3I MP_?OW^_KMWE1%=H*0K.'^__Z1^)8LH?_^YOG:9/!)E,A8X\O5&Z6 ML[$TER(@L;9J14E;H;!/HUCE;?GSMEX#%7O[2Q*TB);5"=)MK4)0RSBLH:BQ M%I!Q\-X_?`,VO3,9[?:Y23;6BOE__KR9U>A9L.5=:,DKZ:=5:*B.X_?[J.5] M3D#B>!7KI!B\0`Z`:50+_O'GS>R&C'52:D+(5D= M?/#GE5?&2-'6=U&*KH+_^5D]U,D1ZF15,5CLS35-)E>8(J"M8% M*VD*&[B'`AZ#50K,7[%>8OBA"!+]0'CHPU\6SWP]GSL-[7VXOV188A ML7O+.7T9A7.-F055EY7YSP<'!Y[OG:5]%1\'//0^Z6Z]BWFW/^U7^EH@(U$T MO.8_Z^?*R$@KIR6:*I;1U[U>5'`(Z[C"AX/LW(PJ><+._$ MD.7=:;*\5Z>&+N]&T^5]S>CZ^PY)JRG4GQ+\?4QC!D)1&P-6E0Y7.'OC&&?> MJYL2H3O@516>%U"^&/HX">O.U;>T7AWZ=`6HHVZ`RHLH3PR]ZYPB[]7.9G54 M8T#4V!]&XND[0L?:IROHO%T%.J=`D7>.%.V@@VI4R71J`O(D\D.F@DBH1%)4 M'A=%6"D047P#J+@27&/5&Z14O%Q`^MU7FLK*O`14`N`TE?CF;DXE8"RCTKM)J7SA<'L#FOMOPI0F M;6W<5%IS!8`?K`!`AWA0Z.Z%:_)(_U&^I`%EC^0AHNMJT]*B*XW^:-7H4?J@ MO-N\RQ>NU;=^&OZ;F7@7P'V*;]?5;6V[KC3\WJIA=!QOTHZUH?Z4=?S"]7SL M@]H('S&`O$^4@K7[NBJV->E(NX<'5NVBWW>1]^D-=)\O7+'O4B,Z)3,7-KG: MG"N%'EH5^BXWR#>FOQ>NS!^TH5QK/59NQY7ZWEC5AW[3)]W1"]?;CV`*02G4 MC\GS^JNC2FNN='ADU>&/VJ9B=]X]=O?"-?D>O-&(I&%V<%YB2;C"`(:#U4MC MVZZT_-:J9?26;DWG8&K1.;HO=/["=7YXX(/N)BPVP4WT5P.A5_&4.XEVM+7O M2O<+<3$3R#C0$=2<`.T7GQ8)>+GZ;PDQN0AX=>["%0H6PEDM$2KO5?;T@H/E M[L*2,&N#(]N/$&E&BRMHV0-ECB*EWJM[3>U+1V$YR.D(3O9&7>'"'FZK!E!W M"FZ.C3E2=5OSKI2^;`1NI_[:N)DCS3>T[$CI;Y8(S.WT;0VI.=)U3:NN]-PQ M7K?3<3G@YDBYU>9<:;4MC+=39[<5NRL?OV,WKM1OCP"VQP=VL%@FST/6"X:0PV6].X1]0Z)<`;`F MJNDJZ+`#:`4+0TEX,&8*EA`C2=.,WU2YZR.ML757D'E7R1_.$7.>]>X-\MYS M".Q43XGD,#J4#V--X%32H?WZA((^3MN M8M&>$+1_AY3LH)&K;`I_P'2"'Z)U9/8`I$J+1?"'3Y^#*`EI""-<3,!9B1+\ MTLEI/%>R8Q2Y)\D5X'ZL`]Q-1K+!E]FWD`(.2?8^I21[2#),>YID[XK&'B)4 M`W2'S(;`MF//J*5U5WBQAU(7X^<[7Z6J'1/DU$J2,+;198T8>6`1PPWM^#Z9 MP.^.;,[R'3I"R-&!S:)H@)A8ZR`E2+N_EW."\#T2M+,7N0I+^VQ]$OZ>J#0` MDZ7GQ,('3/C31`9CD+\_E0S*DRA*SQ!Q!R>'M+A"6G6_>8ZTTLY?;S"G-<\L MBH4'M'HW*:W>#=+J#7):=R#,%5^*[$RE\/5)#\6#)MR!;(F^7(&HNID\!U$I M>'0CA8>'!9+B21<[D-1NCW'MW73HP14@[*%GVX:)\,'3M@U&2-.9XLVIIW!0-[O-22G;:;)"KZF>`G MX2I>N\&&-/R(\SH$D M[UO+]N<*+34[X3ML MI=DAIJK!PAZ#8:+W(4R`U$DR\66:LT!F1K]#(;,-"GSD1Q24X2XUW1DAKC!F MSR+5`8_Y_H9S3:CWQ1`*MLID5J2$>D!HMCF"C[Q+3>B+\&=^VJ_>T)3^4K[) M2=_CE-Y;J>&)E]W\9Q"&FEP2&8FE271[^LZICWOUKUD488#IXUXL$[R?+7E0 M,8L3+/Q9BF3Z<4]?Y/F!@5+W/'/Q3?H++#I'5%[`"^1BSS,_F]L?[G7!,#%[ M7(H74UE(?\0L+74NY"TM)*\.>'A/)>!9-W$]O*4CS<$9?:010OF6C<9X*&3& MXKK-K"Z*B>"`3SFKRB)-EONX%T@*"EA'1'C?D8(1<9[P4&\%FJ$Y/HG`[2]( MH+G4*@R:>W4_Q%DSJZJ;0%\2G)"L\SEO^HO8!;^18@2C1WVADP/O)MBO?/CM16OK9",S=1?IXN5/Z9KE M7J1L51L3=65ZP\2=B,*3)+X2 M\;]A39>=$8)AYQ(?#<6^*2N=#)NXGF+\064&>I;>N)GST%"@;^:ZWH:)R93P MV?43X,DHI6+!ZM]OWGXU!QXV$398RU&Q$UQ!75NA[6+NBL8Q>$$C@DT,1B-) M1R2FV3Y6O8VUF?%N#6R94`0/NBB]5*YG+-8:G"Q>C:[O5QYF_^6P:)L'2LTWE7.*:-)!T_DB+F-IN2J]B[#6JC,?2,A*&97V5_U#Y)Q. M*2:G8R:%)J2.&7NA;6#K2CR*RRAH8ZQ:K.^L193(&Q*/?X4ZB=2!]R86FXKW MG-5S)E5\B1;^EX0')IA9RVA#X9ZS>2OB\0T%>P7&G\JIQ&GZ\O*T@=>V&CUG M^([P,T9'XA=,?2E,YLU([E*KYXS?CZFF?B"E>!I3$M[BRV9=M]?9$J:UL9UB M>1:Y/\WC]JZDIN/B^1D?1$\ M'D>S+T3^03$/#?PW($&I.Q)1=4-E@$E>([K`7O=Z*S$+G$Y-(^Y8O14S$L6S M3NPUE]T02^WP5$7#`7/&9_(@&8U^)5%$9_58[5RMQR,34Z?&@G+VC'EP2:`$ MMWYP6:9"G]FMXVKSQ.?$7MRGZ?EF]P:(^4X,XR<-A=: MG;V,1@=`+7]7OZ5!1)1B0X;J$),S.A6*%977N?RVA)HO<`E)57Q""08+OW)% M@P30<0/L,*6$G&%B?]G4+EFG?W/()0OPX)7%()[M10_)%VK`1U!,G>*-$;,* M#W5O-S\=YKXRS&;%#/9FCWOI6IOVM\W-']?#^;T?C3-]]^(;_Q1P1>-2G'L> MQO\Z%;RT]V+1[N=F=.U6^CLS`FNE[ZKP?S57/\]=+8ACF3J]8[[63ET)SCI- M%8=E"[9"O?X9Z]9CZF]^( M_N%!3?/3@''S+/(/U!4]W]92/7!]*S1F+MTMB+Z&C4J1C4^R%>J42L`)%S+= M7'H]S/9,X0Q3QU);I=[9VCKV8>*`L3,E$?A(F:(:(-E0?'/8;+0FRF8@RGJM M*[$IJ[$"/X.T2CM?A9*;MXH)3D37PRS[>1Z*NQ?IE[J`OU$IRZR]V.JLZ*@7>]0N@D-,SA%5R\1Z]MWQ&%HUY7O( MV[TXH6:#2#T_I3(]Y<&$6V@X4,7\_;(&S`5GC<-HM;9Z(Y/T*W9V)$N5S<77 M_3%XA6EF<0ZR:^1:?B&:0GE/+YI`9+ M@B]D=D)OJ;X9:W&8.VNU-W)J296OV6>VFHOT+\R6TGM.'V0"@CS\$>A]9V6I MIDAO6;H2CT8%M4JRE^@M0]<\0]51+4MU9;:`J>,.3!UO"U,YM.K'4VVA'K-U M'<2B!7_6(OUGJ0E]UB(]9"D]Q^8&YKZX>)B-N7,;OWXW'IZV1OW^":-TJ)\J M+;;&0-%H+)(XS50$5D])Q(9"LY+9?IV+DPGWM+#18HJ7,QD7*>!3>=;+-*>[A#2^9>?*3?!T9/9 MW(7J(H#E&MF\$"JG%ZSH-*W92N^FCJJ`E`[W8E@<7W=PDY:LU0]724.7M?'6 M5JH7O-R-B:0G1*'+/L'0KJXRD(!#HXV3F2Z"I_^'Z=>@P1.1F#PUI`P3F(NI M8^Z:V_2(;^5$U;&27MFE;VS#9;?N^=,ST,4JIS9]XS[6$*'NU:$,@T8TG-2P MES*$3/Q&T5^DX>`19HH1Q0OS]'UYBZ+\EEUM2J*U'KIN=2RBD,JROVU[T;]X MSQU[+J2E5#BPO^L?$]GNX=O;TU,A*P?JU+WL'QOSBV>J5]#XE$C.^$CYD5#* MAY[T]4:"^PI1-K_JQK#LHJ'>I6XV,#7,4.J3?*_*$C)IJ;Y-DN!Z0Y.Y237; MTJ1OORI<8:08N+Y#%L#$Y9,@P#4_7E8T1?<(K\:*D=LN0I_..ZP M-:-&WUR;#2-]2275D7\:`K3$Q`]9E."E=>#_SX?=L@/W6_2Y13)ON\^M*V@[ MM[-5LG%U4UJ[])SUM#WR?>,7/U1U15I=K:WB6W^W]+-T*CU'\!ST-X"7TW5A>++]-O`X)D_XCQN"-BVY"]B;T8QY'^"%D"2.Y6IO;)#/< MV0\>-S)@(C1XBNXC0J"[C+JTL4TR,4QD^EU!(*T-;(4TVJ*BV4.30)9HX[O) MQ%REKH(QG1#X]W]02P$"'@,4````"`"%:W!'`K0(/+WM``#\V0D`$0`8```` M```!````I($`````:GEN="TR,#$U,#DS,"YX;6Q55`4``SH@2E9U>`L``00E M#@``!#D!``!02P$"'@,4````"`"%:W!'<#8_,`H.```,W0``%0`8```````! M````I($([@``:GEN="TR,#$U,#DS,%]C86PN>&UL550%``,Z($I6=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`A6MP1WQT88V?20``8D8&`!4`&``````` M`0```*2!8?P``&IY;G0M,C`Q-3`Y,S!?9&5F+GAM;%54!0`#.B!*5G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`(5K<$=[))J40&L``-7V!0`5`!@````` M``$```"D@4]&`0!J>6YT+3(P,34P.3,P7VQA8BYX;6Q55`4``SH@2E9U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"%:W!'T(4)3<1+``#_JP8`%0`8```` M```!````I('>L0$`:GEN="TR,#$U,#DS,%]P&UL550%``,Z($I6=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`A6MP1ZP*=MPR%0``._0``!$`&``` M`````0```*2!\?T!`&IY;G0M,C`Q-3`Y,S`N>'-D550%``,Z($I6=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``&X3`@`````` ` end XML 33 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Restricted Stock Activity (Details) - Restricted Stock [Member]
    9 Months Ended
    Sep. 30, 2015
    shares
    Outstanding at December 31, 2014 (in shares) 662,375
    Restricted stock awards granted (in shares) 8,000
    Outstanding at September 30, 2015 (in shares) 670,375
    XML 34 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Supplemental Disclosure of Non-cash Activity
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Cash Flow, Supplemental Disclosures [Text Block]
    Supplemental disclosure of non-cash activity:
     
    In connection with our acquisitions of franchises during the nine months ended September 30, 2015, we acquired $1,539,321 of property and equipment, intangible assets of $1,531,041, goodwill of $2,312,259, favorable leases of $17,469 and assumed deferred revenue associated with membership packages paid in advance of $117,301 in exchange for $4,652,525 in cash and an aggregate amount of $744,350 in notes payable to the sellers. Additionally, at the time of these transactions, we carried deferred revenue of $976,500, representing franchise fees collected upon the execution of franchise agreements, and deferred costs of $478,200, related to our acquisition of undeveloped franchises. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 2).
     
    In connection with our reacquisition and termination of regional developer rights during the nine months ended September 30, 2015, we had deferred revenue of $914,000, representing license fees collected upon the execution of the regional developer agreements. In accordance with ASC-952-605, we netted these amounts against the aggregate purchase price of the acquisitions (Note 5).
      
    As of December 31, 2014, we recorded a deposit of $507,500 for the reacquisition and termination of regional developer rights, which were paid in advance. During the nine months ended September 30, 2015, we reclassified $507,500 from deposits to intangible assets.
    XML 35 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 4 - Property and Equipment (Details Textual) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Depreciation $ 257,197 $ 52,823 $ 532,682 $ 141,707
    XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 6 - Notes Payable (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Schedule of Maturities of Long-term Debt [Table Text Block]
    2015   $ 231,500  
    2016     272,850  
    2017     130,000  
    Total   $ 634,350  
    XML 37 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 4 - Property and Equipment (Details) - USD ($)
    Sep. 30, 2015
    Dec. 31, 2014
    Office Equipment [Member]    
    Property and Equipment, Gross $ 470,251 $ 209,575
    Leasehold Improvements [Member]    
    Property and Equipment, Gross 2,330,927 665,961
    Software Development [Member]    
    Property and Equipment, Gross 688,471 564,560
    Property, Plant and Equipment Excluding Assets in Progress [Member]    
    Property and Equipment, Gross 3,489,649 1,440,096
    Accumulated depreciation (838,325) (305,644)
    Property and Equipment, Net 2,651,324 $ 1,134,452
    Assets in Progress [Member]    
    Property and Equipment, Net 950,893
    Property and Equipment, Net $ 3,602,217 $ 1,134,452
    XML 38 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 10 - Commitments and Contingencies (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
    2015   $ 431,526  
    2016     2,548,329  
    2017     2,513,975  
    2018     1,948,791  
    2019     1,601,175  
    Thereafter     8,443,060  
        $ 17,486,856  
    XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Nature of Operations and Summary of Significant Accounting Policies
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
    Note 1:
    Nature of Operations and Summary of Significant Accounting Policies
     
    Basis of Presentation
     
    These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”) and its wholly owned subsidiary The Joint Corporate Unit No. 1, LLC (collectively, the “Company”). These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary consolidated financial statements and the notes thereto as set forth in The Joint Corp.’s Form 10-K, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company’s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended September 30, 2015 and 2014 is unaudited.
     
    Principles of Consolidation
     
    The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the “Company”), which was dormant for all periods presented.
     
    All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation.
     
    Comprehensive Loss
     
     Net loss and comprehensive loss are the same for the three and nine months ended September 30, 2015 and 2014.
     
    Nature of Operations
     
    The Joint Corp., a Delaware corporation, was formed on March 10, 2010. Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.
     
    The following table summarizes the number of clinics in operation under franchise agreements or that are company-owned or managed for the three and nine months ended September 30, 2015 and 2014:
     
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Franchised clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     239       215       242       175  
    Opened during the period     13       16       36       57  
    Acquired during the period     (2 )     -       (23 )     -  
    Closed during the period     (2 )     (1 )     (7 )     (2 )
    Clinics in operation at the end of the period     248       230       248       230  
     
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Company-owned or managed clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     23       -       4       -  
    Opened during the period     4       -       4       -  
    Acquired during the period     2       -       23       -  
    Closed during the period     -       -       (2 )     -  
    Clinics in operation at the end of the period     29       -       29       -  
                                     
    Total clinics in operation at the end of the period     277       230       277       230  
                                     
    Clinic licenses sold but not yet developed     180       248       180       248  
     
    Variable Interest Entities
     
    An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a variable interest entity (“VIE”) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.
     
    Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs. Such PCs are VIEs. In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice.  The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the PCs. As such, the activity of the PCs is not included in the Company’s consolidated financial statements.
     
    Cash and Cash Equivalents
     
    The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its IPO in short-term bank deposits. The Company had no cash equivalents as of September 30, 2015 and December 31, 2014.
     
    Restricted Cash
     
    Restricted cash relates to cash franchisees and corporate clinics contribute to the Company’s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.
     
    Concentrations of Credit Risk
     
    From time to time the Company grants credit in the normal course of business to franchisees related to the collection of royalties and other operating revenues. The Company periodically performs credit analysis and monitors the financial condition of the franchisees to reduce credit risk.  As of December 31, 2014, six franchisees represented 56% of outstanding accounts receivable. The Company did not have any customers that represented greater than 10% of its accounts receivable or revenues during the three and nine months ended September 30, 2015 and 2014.
     
    Accounts Receivable
     
    Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees and marketing and advertising expenses. The Company considers a reserve for doubtful accounts based on the creditworthiness of the franchisee. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management’s best estimate of uncollectible amounts and is determined based on specific identification and historical performance that the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of September 30, 2015 and December 31, 2014, the Company had an allowance for doubtful accounts of $85,376 and $81,032, respectively.
     
    Deferred Franchise Costs
     
    Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.
     
    Property and Equipment
     
    Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.
     
    Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.
     
    Software Developed
     
    The Company capitalizes most software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally 5 years.
     
    Intangible Assets
     
    Intangible assets consist primarily of re-acquired franchise rights and customer relationships.  The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from six to seven years. The fair value of customer relationships is amortized over their estimated useful life of 2 years.
     
    Goodwill
     
    Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note 2.  Under ASC 350-10, goodwill and intangible assets deemed to have indefinite lives are no longer amortized but are subject to annual impairment tests. As required, the Company performs an annual impairment test of goodwill as of the first day of the fourth quarter or more frequently if events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.
     
    Long-Lived Assets
     
    The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. No impairments of long-lived assets were recorded for the periods ended September 30, 2015 and 2014.
     
    Advertising Fund
     
    The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee was increased to 2% in January 2015. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense properly eliminating intercompany transactions. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company’s consolidated balance sheets.
     
    Co-Op Marketing Funds
     
    Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops’ officers. The marketing funds are included in restricted cash on the Company’s consolidated balance sheets.
     
    Deferred Rent
     
    The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which may include rent holidays and rent escalation clauses.  It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.  The Company records tenant improvement allowances as deferred rent liabilities and amortizes the allowance over the term of the lease, as a reduction to rent expense.
     
    Revenue Recognition
     
    The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.
     
    Franchise Fees.
    The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of ten years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.  The Company’s services under the franchise agreement include: training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.
     
    During the three and nine months ended September 30, 2015, the Company terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, the Company recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.
      
    Regional Developer Fees
    . During 2011, the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from $7,250 to 25% of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from $14,500 to $19,950 which are collected upon the sale of franchises within their region and a royalty of 3% of sales generated by franchised clinics in their region. Regional developer fees are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. When the Company anticipates that the number of franchised clinics to be opened will exceed the contracted minimum, the license fee on a per-clinic basis is determined by dividing the total fee collected from the regional developer by the number of clinics expected to be opened within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the fee per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. The franchisor’s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer’s license.
     
    Revenues and Management Fees from Company Clinics.  
    The Company earns revenues from clinics that it owns and operates or manages throughout the United States.  In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.  Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.  In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor’s PC.  Under the management agreement, the Company provides administrative and business management services to the doctor’s PC in return for a monthly management fee.  When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.
     
    Royalties.
    The Company collects royalties, as stipulated in the franchise agreement, equal to 7% of gross sales, and a marketing and advertising fee currently equal to 2% of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly two working days after each sales period has ended.
     
    IT Related Income and Software Fees.
      The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic’s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue upon receipt of equipment by the franchisee.
     
    Advertising Costs
     
    The Company incurs advertising costs in addition to those included in the advertising fund. The Company’s policy is to expense all operating advertising costs as incurred. Advertising expenses were $377,122 and $853,110 for the three and nine months ended September 30, 2015, respectively. Advertising expenses were $53,691 and $93,730 for the three and nine months ended September 30, 2014, respectively. 
     
    Income Taxes
     
    The Company accounts for income taxes in accordance with the ASC 740 that requires the recognition of deferred income taxes for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
     
    The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
     
    At September 30, 2015 and December 31, 2014, the Company maintained a liability for income taxes for uncertain tax positions of approximately $142,000 and $122,000, respectively, of which $36,000 and $30,000, respectively, represent penalties and interest and are recorded in the  “other liabilities” section of the accompanying condensed consolidated balance sheets. Interest and penalties associated with tax positions are recorded in the period assessed as general and administrative expenses. The Company’s tax returns for tax years subject to examination by tax authorities include 2011 through the current period for state and 2012-through the current period for federal reporting purposes.
     
    Loss per Common Share
     
    Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.
     
       
    Three Months Ended
    September 30,
     
    Nine Months Ended
    September 30,
        2015   2014   2015   2014
                     
    Net loss   $ (1,656,722 )   $ (202,373 )   $ (5,416,317 )   $ (464,019 )
                                     
    Weighted average common shares outstanding - basic     9,844,964       4,828,122       9,777,119       4,819,861  
    Effect of dilutive securities:                                
    Stock options     -       -       -       -  
    Weighted average common shares outstanding - diluted     9,844,964       4,828,122       9,777,119       4,819,861  
                                     
    Basic and diluted loss per share   $ (0.17 )   $ (0.04 )   $ (0.55 )   $ (0.10 )
     
    The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:
     
        Three Months Ended
    September 30,
      Nine Months Ended
    September 30,
        2015   2014   2015   2014
    Unvested restricted stock     393,339       542,354       393,339       542,354  
    Stock options     524,600       266,555       524,600       266,555  
    Warrants     90,000       -       90,000       -  
     
    Stock-Based Compensation
     
    The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Prior to the IPO the grant date fair value was determined by the Board of Directors. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.
      
    Use of Estimates
     
    The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs and the related deferred tax assets and liabilities as long-term or current, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets and purchase price allocations.
     
    Recent Accounting Pronouncements
     
    In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
     
    In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern: Disclosures about an Entity’s Ability to Continue as a Going Concern.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The new guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU No. 2014-15 on its consolidated financial statements.
     
    In April 2015, the FASB issued ASU 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.”  The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.  Debt disclosures will include the face amount of the debt liability and the effective interest rate.  The update requires retrospective application and represents a change in accounting principle.  The update is effective for fiscal years beginning after December 15, 2015.  Early adoption is permitted for financial statements that have not been previously issued.  ASU 2015-03 is not expected to have a material impact on the Company’s consolidated financial statements.
     
    In April 2015, FASB issued ASU No. 2015-05, “Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.”  The guidance provides clarification on whether a cloud computing arrangement includes a software license.  If a software license is included, the customer should account for the license consistent with its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a service contract.  The update is effective for reporting periods beginning after December 15, 2015.  The Company is currently evaluating the impact of the adoption of ASU No. 2015-05 on its consolidated financial statements. 
     
    In September 2015, the FASB issued Accounting Standards Update ("ASU") 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the three months ended September 30, 2015. Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the three months ended September 30, 2015 with no material effect on previous-period or current-period earnings. See "Note 2—Acquisitions" for more information regarding adjustments to provisional amounts that occurred during the three months ended September 30, 2015.
    XML 41 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
    Sep. 30, 2015
    Dec. 31, 2014
    Series A preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
    Series A preferred stock, shares authorized (in shares) 50,000 50,000
    Series A preferred stock, shares issued (in shares) 0 0
    Series A preferred stock, shares outstanding (in shares) 0 0
    Common stock, par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized (in shares) 20,000,000 20,000,000
    Common stock, shares issued (in shares) 10,402,047 10,196,502
    Common stock, shares outstandig (in shares) 9,868,047 9,662,502
    Treasury stock, shares (in shares) 534,000 534,000
    XML 42 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Significant Accounting Policies (Policies)
    9 Months Ended
    Sep. 30, 2015
    Accounting Policies [Abstract]  
    Basis of Accounting, Policy [Policy Text Block]
    Basis of Presentation
     
    These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”) and its wholly owned subsidiary The Joint Corporate Unit No. 1, LLC (collectively, the “Company”). These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary consolidated financial statements and the notes thereto as set forth in The Joint Corp.’s Form 10-K, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company’s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended September 30, 2015 and 2014 is unaudited.
    Consolidation, Policy [Policy Text Block]
    Principles of Consolidation
     
    The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the “Company”), which was dormant for all periods presented.
     
    All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation.
    Comprehensive Income, Policy [Policy Text Block]
    Comprehensive Loss
     
     Net loss and comprehensive loss are the same for the three and nine months ended September 30, 2015 and 2014.
    Nature of Operations Policy [Policy Text Block]
    Nature of Operations
     
    The Joint Corp., a Delaware corporation, was formed on March 10, 2010. Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.
     
    The following table summarizes the number of clinics in operation under franchise agreements or that are company-owned or managed for the three and nine months ended September 30, 2015 and 2014:
     
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Franchised clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     239       215       242       175  
    Opened during the period     13       16       36       57  
    Acquired during the period     (2 )     -       (23 )     -  
    Closed during the period     (2 )     (1 )     (7 )     (2 )
    Clinics in operation at the end of the period     248       230       248       230  
     
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Company-owned or managed clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     23       -       4       -  
    Opened during the period     4       -       4       -  
    Acquired during the period     2       -       23       -  
    Closed during the period     -       -       (2 )     -  
    Clinics in operation at the end of the period     29       -       29       -  
                                     
    Total clinics in operation at the end of the period     277       230       277       230  
                                     
    Clinics licenses sold but not yet developed     182       248       182       248  
    Consolidation, Variable Interest Entity, Policy [Policy Text Block]
    Variable Interest Entities
     
    An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a variable interest entity (“VIE”) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.
     
    Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs.  In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice.  The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the VIE.  As such, the activity of the PCs is not included in the Company’s consolidated financial statements.
    Cash and Cash Equivalents, Policy [Policy Text Block]
    Cash and Cash Equivalents
     
    The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its IPO in short-term bank deposits. The Company had no cash equivalents as of September 30, 2015 and December 31, 2014.
    Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
    Restricted Cash
     
    Restricted cash relates to cash franchisees and corporate clinics contribute to the Company’s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.
    Concentration Risk, Credit Risk, Policy [Policy Text Block]
    Concentrations of Credit Risk
     
    From time to time the Company grants credit in the normal course of business to franchisees related to the collection of royalties and other operating revenues. The Company periodically performs credit analysis and monitor the financial condition of the franchisees to reduce credit risk.  As of December 31, 2014, six franchisees represented 56% of outstanding accounts receivable. The Company did not have any customers that represented greater than 10% of its accounts receivable or revenues during the three and nine months ended September 30, 2015 and 2014.
    Trade and Other Accounts Receivable, Policy [Policy Text Block]
    Accounts Receivable
     
    Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees and marketing and advertising expenses. The Company considers a reserve for doubtful accounts based on the creditworthiness of the franchisee. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management’s best estimate of uncollectible amounts and is determined based on specific identification and historical performance the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of September 30, 2015 and December 31, 2014, the Company had an allowance for doubtful accounts of $85,376 and $81,032, respectively.
    Revenue Recognition, Services, Commissions [Policy Text Block]
    Deferred Franchise Costs
     
    Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.
    Property, Plant and Equipment, Policy [Policy Text Block]
    Property and Equipment
     
    Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of three to seven years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.
     
    Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.
    Internal Use Software, Policy [Policy Text Block]
    Software Developed
     
    The Company capitalizes most software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally 5 years.
    Intangible Assets, Finite-Lived, Policy [Policy Text Block]
    Intangible Assets
     
    Intangible assets consist primarily of re-acquired franchise rights and customer relationships.  The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from six to seven years. The fair value of customer relationships is amortized over their estimated useful life of 2 years.
    Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
    Goodwill
     
    Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note 2.  Under ASC 350-10, goodwill and intangible assets deemed to have indefinite lives are no longer amortized but are subject to annual impairment tests, and tests between annual tests in certain circumstances, based on estimated fair value in accordance with ASC 350-10, and are written down when impaired.
    Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
    Long-Lived Assets
     
    The Company reviews our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. No impairments of long-lived assets were recorded for the periods ended September 30, 2015 and 2014.
    Advertising Fund, Policy [Policy Text Block]
    Advertising Fund
     
    The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee was increased to 2% in January 2015. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense properly eliminating intercompany transactions. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company’s consolidated balance sheets.
    Cooperative Advertising Policy [Policy Text Block]
    Co-Op Marketing Funds
     
    Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops’ officers. The marketing funds are included in restricted cash on the Company’s consolidated balance sheets.
    Lease, Policy [Policy Text Block]
    Deferred Rent
     
    The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which may include rent holidays and rent escalation clauses.  It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.  The Company records tenant improvement allowances as deferred rent liabilities and amortizes the allowance over the term of the lease, as a reduction to rent expense.
    Revenue Recognition, Policy [Policy Text Block]
    Revenue Recognition
     
    The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.
    Revenue Recognition, Services, Franchise Fees [Policy Text Block]
    Franchise Fees.
    The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which has an initial term of ten years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.  The Company’s services under the franchise agreement include: training of franchisee and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.
     
    During the three and nine months ended September 30, 2015, the Company terminated 10 and 30 franchise licenses, respectively, that were in default of various obligations under their respective franchise agreements. In conjunction with these terminations, during the three and nine months ended September 30, 2015, the Company recognized $290,000 and $870,000 of revenue, respectively, and $153,000 and $389,750 of costs, respectively which were previously deferred.
    Regional Developer Fees, Policy [Policy Text Block]
    Regional Developer Fees
    . During 2011, the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from $7,250 to 25% of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from $14,500 to $19,950 which are collected upon the sale of franchises within their region and a royalty of 3% of sales generated by franchised clinics in their region. Regional developer fees are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. When the Company anticipates that the number of franchised clinics to be opened will exceed the contracted minimum, the license fee on a per-clinic basis is determined by dividing the total fee collected from the regional developer by the number of clinics expected to be opened within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the fee per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. The franchisor’s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer’s license.
    Revenues and Management Fees, Policy [Policy Text Block]
    Revenues and Management Fees from Company Clinics.  
    The Company earns revenues from clinics that it owns and operates or manages throughout the United States.  In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.  Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.  In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor’s PC.  Under the management agreement, the Company provides administrative and business management services to the doctor’s PC in return for a monthly management fee.  When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.
    Royalties, Policy [Policy Text Block]
    Royalties.
    The Company collects royalties, as stipulated in the franchise agreement, equal to 7% of gross sales, and a marketing and advertising fee currently equal to 2% of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly two working days after each sales period has ended.
    IT Related Income And Software Fees, Policy [Policy Text Block]
    IT Related Income and Software Fees.
      The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic’s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue upon receipt of equipment by the franchisee.
    Advertising Costs, Policy [Policy Text Block]
    Advertising Costs
     
    The Company incurs advertising costs in addition to those included in the advertising fund. The Company’s policy is to expense all operating advertising costs as incurred. Advertising expenses were $377,122 and $853,110 for the three and nine months ended September 30, 2015, respectively. Advertising expenses were $53,691 and $93,730 for the three and nine months ended September 30, 2014, respectively. 
    Income Tax, Policy [Policy Text Block]
    Income Taxes
     
    The Company accounts for income taxes in accordance with the ASC 740 that requires the recognition of deferred income taxes for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
     
    The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
     
    At September 30, 2015 and December 31, 2014, the Company maintained a liability for income taxes for uncertain tax positions of approximately $142,000 and $122,000, respectively, of which $36,000 and $30,000, respectively, represent penalties and interest and are recorded in the  “other liabilities” section of the accompanying condensed consolidated balance sheets. Interest and penalties associated with tax positions are recorded in the period assessed as general and administrative expenses. The Company’s tax returns for tax years subject to examination by tax authorities include 2011 through the current period for state and 2012-through the current period for federal reporting purposes.
    Earnings Per Share, Policy [Policy Text Block]
    Loss per Common Share
     
    Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.
     
       
    Three Months Ended
    September 30,
     
    Nine Months Ended
    September 30,
        2015   2014   2015   2014
                     
    Net loss   $ (1,656,722 )   $ (202,373 )   $ (5,416,317 )   $ (464,019 )
                                     
    Weighted average common shares outstanding - basic     9,844,964       4,828,122       9,777,119       4,819,861  
    Effect of dilutive securities:                                
    Stock options     -       -       -       -  
    Weighted average common shares outstanding - diluted     9,844,964       4,828,122       9,777,119       4,819,861  
                                     
    Basic and diluted loss per share   $ (0.17 )   $ (0.04 )   $ (0.55 )   $ (0.10 )
     
    The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:
     
        Three Months Ended
    September 30,
      Nine Months Ended
    September 30,
        2015   2014   2015   2014
    Unvested restricted stock     393,339       542,354       393,339       542,354  
    Stock options     524,600       266,555       524,600       266,555  
    Warrants     90,000       -       90,000       -  
    Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
    Stock-Based Compensation
     
    The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Prior to the IPO the grant date fair value was determined by the Board of Directors. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.
    Use of Estimates, Policy [Policy Text Block]
    Use of Estimates
     
    The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs and the related deferred tax assets and liabilities as long-term or current, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets and purchase price allocations.
    New Accounting Pronouncements, Policy [Policy Text Block]
    Recent Accounting Pronouncements
     
    In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
     
    In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern: Disclosures about an Entity’s Ability to Continue as a Going Concern.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The new guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU No. 2014-15 on its consolidated financial statements.
     
    In April 2015, the FASB issued ASU 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.”  The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.  Debt disclosures will include the face amount of the debt liability and the effective interest rate.  The update requires retrospective application and represents a change in accounting principle.  The update is effective for fiscal years beginning after December 15, 2015.  Early adoption is permitted for financial statements that have not been previously issued.  ASU 2015-03 is not expected to have a material impact on the Company’s consolidated financial statements.
     
    In April 2015, FASB issued ASU No. 2015-05, “Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.”  The guidance provides clarification on whether a cloud computing arrangement includes a software license.  If a software license is included, the customer should account for the license consistent with its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a service contract.  The update is effective for reporting periods beginning after December 15, 2015.  The Company is currently evaluating the impact of the adoption of ASU No. 2015-05 on its consolidated financial statements. 
    In September 2015, the FASB issued Accounting Standards Update ("ASU") 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the three months ended September 30, 2015. Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the three months ended September 30, 2015 with no material effect on previous-period or current-period earnings. See "Note 2—Acquisitions" for more information regarding adjustments to provisional amounts that occurred during the three months ended September 30, 2015.
    XML 43 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Document And Entity Information - shares
    9 Months Ended
    Sep. 30, 2015
    Nov. 09, 2015
    Entity Registrant Name JOINT Corp  
    Entity Central Index Key 0001612630  
    Trading Symbol jynt  
    Current Fiscal Year End Date --12-31  
    Entity Filer Category Smaller Reporting Company  
    Entity Current Reporting Status Yes  
    Entity Voluntary Filers No  
    Entity Well-known Seasoned Issuer No  
    Entity Common Stock, Shares Outstanding (in shares)   9,906,491
    Document Type 10-Q  
    Document Period End Date Sep. 30, 2015  
    Document Fiscal Year Focus 2015  
    Document Fiscal Period Focus Q3  
    Amendment Flag false  
    XML 44 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Schedule of Franchisor Disclosure [Table Text Block]
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Franchised clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     239       215       242       175  
    Opened during the period     13       16       36       57  
    Acquired during the period     (2 )     -       (23 )     -  
    Closed during the period     (2 )     (1 )     (7 )     (2 )
    Clinics in operation at the end of the period     248       230       248       230  
        Three Months Ended
     September 30,
      Nine Months Ended
     September 30,
    Company-owned or managed clinics:   2015   2014   2015   2014
    Clinics open at beginning of period     23       -       4       -  
    Opened during the period     4       -       4       -  
    Acquired during the period     2       -       23       -  
    Closed during the period     -       -       (2 )     -  
    Clinics in operation at the end of the period     29       -       29       -  
                                     
    Total clinics in operation at the end of the period     277       230       277       230  
                                     
    Clinic licenses sold but not yet developed     180       248       180       248  
    Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
       
    Three Months Ended
    September 30,
     
    Nine Months Ended
    September 30,
        2015   2014   2015   2014
                     
    Net loss   $ (1,656,722 )   $ (202,373 )   $ (5,416,317 )   $ (464,019 )
                                     
    Weighted average common shares outstanding - basic     9,844,964       4,828,122       9,777,119       4,819,861  
    Effect of dilutive securities:                                
    Stock options     -       -       -       -  
    Weighted average common shares outstanding - diluted     9,844,964       4,828,122       9,777,119       4,819,861  
                                     
    Basic and diluted loss per share   $ (0.17 )   $ (0.04 )   $ (0.55 )   $ (0.10 )
    Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
        Three Months Ended
    September 30,
      Nine Months Ended
    September 30,
        2015   2014   2015   2014
    Unvested restricted stock     393,339       542,354       393,339       542,354  
    Stock options     524,600       266,555       524,600       266,555  
    Warrants     90,000       -       90,000       -  
    XML 45 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Revenues:        
    Royalty fees $ 1,150,574 $ 871,462 $ 3,264,278 $ 2,233,053
    Franchise fees 638,000 $ 435,000 1,862,259 $ 1,469,500
    Revenues and management fees from company clinics 1,198,397 2,368,866
    Advertising fund revenue 330,502 $ 88,031 955,480 $ 204,141
    IT related income and software fees 197,569 218,400 598,758 629,225
    Regional developer fees 531,350 152,250 799,600 377,000
    Other revenues 91,623 51,452 223,419 148,347
    Total revenues 4,138,015 1,816,595 10,072,660 5,061,266
    Cost of revenues:        
    Franchise cost of revenues 697,170 556,495 1,948,328 1,505,569
    IT cost of revenues 48,312 97,900 134,233 233,563
    Cost of revenues 745,482 654,395 2,082,561 1,739,132
    Selling and marketing expenses 693,953 324,177 2,450,976 723,955
    Depreciation and amortization 421,390 52,823 822,489 141,707
    General and administrative expenses 4,328,089 1,096,025 10,528,817 3,146,666
    Total selling, general and administrative expenses 5,443,432 1,473,025 13,802,282 4,012,328
    Loss from operations (2,050,899) $ (310,825) (5,812,183) $ (690,194)
    Other income (expense):        
    Bargain purchase gain 384,214 384,214
    Other income (expense), net 16,111 $ (54,599) 17,800 $ (58,399)
    Total other income (expense) 400,325 (54,599) 402,014 (58,399)
    Loss before income tax (expense) benefit (1,650,574) (365,424) (5,410,169) (748,593)
    Income tax (expense) benefit (6,148) 163,051 (6,148) 284,574
    Net loss and comprehensive loss $ (1,656,722) $ (202,373) $ (5,416,317) $ (464,019)
    Loss per share:        
    Basic and diluted loss per share (in dollars per share) $ (0.17) $ (0.04) $ (0.55) $ (0.10)
    Weighted average shares (in shares) 9,844,964 4,828,122 9,777,119 4,819,861
    XML 46 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 6 - Notes Payable
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Debt Disclosure [Text Block]
    Note 6:
    Notes Payable
     
    On February 17, 2015, the Company delivered a $155,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and a license to develop one additional franchise from Roth & Pelan Enterprises, LLC.  This note bears interest at 1.5% per annum with a principal payment of $25,000 plus interest due on June 17, 2015, and the remaining principal and interest due February 17, 2017.  While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.
     
    On March 3, 2015, the Company delivered a $60,000 note payable as a portion of the consideration paid in connection with the acquisition of four existing franchises and a license to develop one additional franchise from TJSC, LLC. This note bears interest at 4.5% per annum with a principal payment of $30,000 plus interest due on July 30, 2015, and the remaining principal plus interest due on January 30, 2016.
     
    On March 6, 2015, the Company delivered a $30,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop seven additional franchises from The Joint San Gabriel Valley Inc. This note bears interest at 1.5% per annum with principal and interest due on November 19, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.
     
    On March 23, 2015, the Company delivered a $10,000 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Arrowhead Ranch LLC. This note bears interest at 1.5% per annum with principal and interest due September 20, 2016.  The seller fully performed its duties under the agreement and one half of the principal plus interest was paid on September 21, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.
     
    On April 1, 2015, the Company delivered a $58,500 note payable as a portion of the consideration paid in connection with the acquisition of an existing franchise from The Joint Chiropractic Bell Towne LLC. This note bears interest at 1.50% per annum with the principal and interest due September 30, 2015.  The seller fully performed its duties under the agreement and $25,000 plus interest was paid on August 18, 2015. While this is a below market interest rate loan, the Company did not impute interest as the effects are immaterial.
     
    On May 1, 2015, the Company delivered a $80,900 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop six additional franchises from San Diego Joint Development Inc. This note bears interest at 4.25% per annum with the principal and interest due April 30, 2016.  The seller fully performed its duties under the agreement and $25,000 plus interest was paid on September 1, 2015. An additional $15,500 plus interest is payable on November 1, 2015 and $40,450 plus interest will be paid on April 30, 2016.
     
    On May 18, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop two additional franchises from First Light Junction. This note bears interest at 4.0% per annum with the principal and interest due November 18, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable September 18, 2015, $25,000 plus interest will be paid on February 18, 2016 and $25,000 plus interest will be paid on November 18, 2016.
     
    On June 3, 2015, the Company delivered a $100,000 note payable as a portion of the consideration paid in connection with the acquisition of two existing franchises and licenses to develop four additional franchises from WHB Franchise, Inc. This note bears interest at 5.25% per annum with the principal and interest due April 3, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable October 3, 2015, $25,000 plus interest will be paid on December 3, 2015 and $50,000 plus interest will be paid on April 3, 2016.
     
    On June 5, 2015, the Company delivered a $75,000 note payable as a portion of the consideration paid in connection with the acquisition of three existing franchises and licenses to develop three additional franchises from Clear Path Ventures, Inc. This note bears interest at 4.25% per annum with the principal and interest due June 4, 2016.  If the seller has fully performed its duties under the agreement, $25,000 plus interest is payable on October 5, 2015, $12,500 plus interest will be paid on December 5, 2015 and $37,500 plus interest will be paid on June 4, 2016.
     
    On July 1, 2015, the Company delivered a $53,000 note payable as a portion of the consideration paid in connection with the acquisition of one franchise from Chiro Novo, LLC. This note bears interest at 4.00% per annum with the principal and interest due January 1, 2016. If the seller has fully performed its duties under the agreement, $15,000 plus interest is payable on November 1, 2015.
     
    On August 10, 2015, the Company delivered a $46,950 note payable as a portion of the consideration paid in connection with the acquisition of three franchises from Chiro Group. This note bears interest at 4.25% per annum with the principal and interest due June 10, 2016. If the seller has fully performed its duties under the agreement, $25,000 plus interest will be paid on December 10, 2015.
     
    Maturities of the Company’s notes payable are as follows as of September 30, 2015: 
     
    2015   $ 231,500  
    2016     272,850  
    2017     130,000  
    Total   $ 634,350  
    XML 47 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 5 - Intangible Assets
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Intangible Assets Disclosure [Text Block]
    Note 5:
    Intangible Assets
     
    During the nine month
    s ended September 30, 2015, the Company entered into several agreements to repurchase regional developer licenses, reacquiring rights in Los Angeles County, San Diego, and Orange County, all located in the state of California, Erie County, Monroe County, Nassau County, Suffolk County, and Albany County, all located in the state of New York, and the regional developer license in New Jersey in exchange for cash consideration of $1,583,000, of which $507,500 was recorded as a cash advance at December 31, 2014.  The Company carried a deferred revenue balance associated with these transactions of $914,000, representing license fees collected upon the execution of the regional developer agreements.  In accordance with ASC 952-605, the Company accounted for the development rights associated with the unsold or undeveloped franchises as a cancellation, and the respective deferred revenue was netted against the aggregate purchase price or recognized as revenue to the extent deferred revenue was in excess of the cash consideration paid.   During the nine months ended September 30, 2015, the revenue recognized as excess deferred regional developer fees totaled $254,250. The remaining balance was accounted for as consideration paid for the reacquired development rights. As the deferred revenue with respect to these regional developer rights had previously been taken into account for income tax purposes, the tax basis in the reacquired development rights is equal to the cash consideration paid.
     
    Intangible assets which remain subject to adjustment upon receipt of final valuation information consisted of the following:
     
     
        As of September 30, 2015
       
    Gross Carrying
    Amount
     
    Accumulated
    Amortization
     
    Net Carrying
    Value
    Amortized intangible assets:                        
    Reacquired franchise rights   $ 1,296,248     $ 108,916     $ 1,187,332  
    Customer relationships     387,793       101,652       286,141  
    Reacquired development rights     923,250       79,239       844,011  
      $ 2,607,291     $ 289,807     $ 2,317,484  
    Unamortized intangible assets:                      
    Goodwill                     2,948,363  
    Total intangible assets                   $ 5,265,847  
     
    Amortization expense was $164,193 and $289,807 for the three and nine months ended September 30, 2015, respectively. There was no amortization expense for the three and nine months ended September 30, 2014.
     
    Estimated amortization expense for 2015 and subsequent years is as follows:
     
    2015   $ 129,101  
    2016     518,896  
    2017     368,634  
    2018     325,000  
    2019     325,000  
    Thereafter     650,853  
    Total   $ 2,317,484  
    XML 48 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Equity (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
        Nine Months Ended September 30,
        2015   2014
    Expected volatility     45% - 50%       43% - 46%  
    Expected dividends       None           None    
    Expected term (years)     5.5 - 7       5.5 - 7.5  
    Risk-free rate     1.66% - 1.92%       0.07% - 2.05%  
    Forfeiture rate       20%           None    
    Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
        Number of
    Shares
      Weighted
    Average
    Exercise
    Price
      Weighted
    Average
    Fair
    Value
      Weighted
    Average
    Remaining
    Contractual Life
    Outstanding at December 31, 2014     314,775     $ 2.23     $ 0.92       9.2  
    Granted at market price     211,660       8.35                  
    Exercised     -       -                  
    Cancelled     (1,835 )     3.49                  
    Outstanding at September 30, 2015     524,600     $ 4.69     $ 2.21       9.0  
    Exercisable at September 30, 2015     111,502     $ 1.81     $ 0.82       8.4  
    Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]
    Restricted Stock Awards   Shares
    Outstanding at December 31, 2014     662,375  
    Restricted stock awards granted     8,000  
    Awards forfeited or exercised     -  
    Outstanding  at September 30, 2015     670,375  
    XML 49 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 2 - Acquisitions (Tables)
    9 Months Ended
    Sep. 30, 2015
    Franchises in Phoenix and Tucson, Arizona [Member]  
    Notes Tables  
    Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
        December 31, 2014
        As reported   As revised
             
    Deferred franchise costs - current portion   $ 668,700     $ 622,800  
    Goodwill   $ 677,204     $ 636,104  
    Deferred revenue - current portion   $ 2,044,500     $ 1,957,500  
    Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
    Property and equipment   $ 297,630  
    Intangible assets     153,000  
    Goodwill     636,104  
    Total assets acquired     1,086,734  
    Unfavorable leases     (227,834 )
    Net assets acquired   $ 858,900  
    Property and equipment   $ 1,539,321  
    Intangible assets     1,531,041  
    Favorable leases     17,469  
    Goodwill     2,312,259  
    Total assets acquired     5,400,090  
    Deferred membership revenue     (117,301 )
    Net assets acquired   $ 5,282,789  
    Bargain purchase gain     (384,214 )
    Net purchase price   $ 4,898,575  
    Business Acquisition, Pro Forma Information [Table Text Block]
        Pro Forma for the Three Months Ended   Pro Forma for the Nine Months Ended
        September 30, 2015   September 30, 2014   September 30, 2015   September 30, 2014
    Revenues, net   $ 4,159,975     $ 2,668,562     $ 11,030,264     $ 7,465,179  
    Net loss   $ (2,064,297 )   $ (814,369 )   $ (6,338,663 )   $ (2,811,855 )
    XML 50 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 9 - Related Party Transactions
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Related Party Transactions Disclosure [Text Block]
    Note 9:       Related Party Transactions
     
    The Company entered into consulting and legal agreements with certain common stockholders related to services performed for the operations and transaction related activities of the Company.  Amounts paid to or for the benefit of these stockholders was approximately $100,000 and $471,000 for the three and nine months ended September 30, 2015, respectively. Amounts paid to or for the benefit of these stockholders was approximately $293,000 and $671,000 for the three and nine months ended September 30, 2014, respectively.
    XML 51 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 7 - Equity
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Stockholders' Equity Note Disclosure [Text Block]
    Note 7:       Equity
     
    Initial Public Offering
     
    The Company completed its initial public offering of 3,000,000 shares of common stock at a price to the public of $6.50 per share on November 14, 2014, whereupon it received aggregate net proceeds of approximately $17,065,000 after deducting underwriting discounts, commissions and other offering expenses. The Company’s underwriters exercised their option to purchase 450,000 additional shares of common stock to cover over-allotments on November 18, 2014, pursuant to which it received aggregate net proceeds of approximately $2,710,000, after deducting underwriting discounts, commissions and expenses.  Also, in conjunction with the IPO, the Company issued warrants to the underwriters for the purchase of 90,000 shares of common stock, which can be exercised between November 10, 2015 and November 10, 2018 at an exercise price of $8.125 per share.
     
    Stock Options
     
    In the nine months ended September 30, 2015, the Company granted 211,660 stock options to employees and certain non-employee members of its board of directors with exercise prices ranging from $6.31 - $9.62.
     
    The fair value of the Company’s common stock prior to its IPO was estimated by the Board of Directors at or about the time of grant for each share-based award. At each grant, the board considered a number of factors in establishing a value for the Company’s common stock including its EBITDA, assessments of an amount its shareholders would accept in the private sale of the company, discussions with its investment bankers regarding pricing of the Company’s common stock in an initial public offering and the probability of successfully completing an IPO. Although the methods for determining the fair value of the Company’s common stock are not complex, the board’s estimate of the fair value of the common stock did involve subjectivity, especially assessments of value in a private sale and estimates of value in the public stock market.
     
    Upon the completion of the Company’s IPO, its stock trading price became the basis of fair value of its common stock used in determining the value of share based awards. To the extent the value of the Company’s share based awards involves a measure of volatility, it will rely upon the volatilities from publicly traded companies with similar business models until its common stock has accumulated enough trading history for it to utilize its own historical volatility. The expected life of the options granted is based on the average of the vesting term and the contractual term of the option. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury 10-year yield curve in effect at the date of the grant.
     
    The Company has computed the fair value of all options granted during the nine months ended September 30, 2015 and 2014, using the following assumptions:
     
        Nine Months Ended September 30,
        2015   2014
    Expected volatility     45% - 50%       43% - 46%  
    Expected dividends       None           None    
    Expected term (years)     5.5 - 7       5.5 - 7.5  
    Risk-free rate     1.66% - 1.92%       0.07% - 2.05%  
    Forfeiture rate       20%           None    
     
    The information below summarizes the stock options:
     
        Number of
    Shares
      Weighted
    Average
    Exercise
    Price
      Weighted
    Average
    Fair
    Value
      Weighted
    Average
    Remaining
    Contractual Life
    Outstanding at December 31, 2014     314,775     $ 2.23     $ 0.92       9.2  
    Granted at market price     211,660       8.35                  
    Exercised     -       -                  
    Cancelled     (1,835 )     3.49                  
    Outstanding at September 30, 2015     524,600     $ 4.69     $ 2.21       9.0  
    Exercisable at September 30, 2015     111,502     $ 1.81     $ 0.82       8.4  
     
    The intrinsic value of the Company’s stock options outstanding was $1,336,454 at September 30, 2015.
     
    For the three and nine months ended September 30, 2015, stock based compensation expense for stock options was $129,704, and $240,701, respectively.  For the three and nine months ended September 30, 2014, stock based compensation expense for stock options was $7,440 and $15,538, respectively.  Unrecognized stock-based compensation expense for stock options as of September 30, 2015 was $613,406, which is expected to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $23,031 to reflect accounting for certain performance based options.
     
    Restricted Stock
     
    The information below summaries the restricted stock activity:
     
    Restricted Stock Awards   Shares
    Outstanding at December 31, 2014     662,375  
    Restricted stock awards granted     8,000  
    Awards forfeited or exercised     -  
    Outstanding  at September 30, 2015     670,375  
     
    For the three and nine months ended September 30, 2015, stock based compensation expense for restricted stock was $226,875, and $405,376, respectively.  For the three and nine months ended September 30, 2014, stock based compensation expense for restricted stock was $10,115, and $32,508, respectively.   Unrecognized stock based compensation expense for restricted stock awards as of September 30, 2015 was $663,525 to be recognized ratably over the next 2.7 years. During the three months ended September 30, 2015 the Company made a cumulative adjustment to stock-based compensation expense in the amount of $122,841 to reflect accounting for certain performance based awards.
    XML 52 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 8 - Income Taxes
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Income Tax Disclosure [Text Block]
    Note 8:      Income Taxes
     
    During the three and nine months ended September 30, 2015, the Company recorded income tax expense of approximately $6,100 due to state tax expense stemming from current year state income taxes and  an increase to uncertain tax positions related to unresolved state apportionment of taxable income. 
    XML 53 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 10 - Commitments and Contingencies
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Commitments and Contingencies Disclosure [Text Block]
    Note 10:      Commitments and Contingencies
     
    Operating Leases
     
    The Company leases its corporate office space with 66 monthly payments increasing from $10,500 to $22,000, beginning February 3, 2014, the date it took occupancy of the new office space.  Between December 31, 2014 and September 30, 2015, the Company assumed 46 additional leases for clinic locations.  These leases vary in length from 18 to 124 months and have monthly payments ranging from $1,432 to $13,213.
     
    Total rent expense for the three and nine months ended September 30, 2015 was $402,061 and $756,678, respectively. Total rent expense for the three and nine months ended September 30, 2014 was $33,860 and $100,942, respectively.
     
    Future minimum annual lease payments are as follows:
     
    2015   $ 431,526  
    2016     2,548,329  
    2017     2,513,975  
    2018     1,948,791  
    2019     1,601,175  
    Thereafter     8,443,060  
        $ 17,486,856  
     
    Litigation
     
    In the normal course of business, the Company is party to litigation from time to time. The Company maintains insurance to cover certain actions and believe that resolution of such litigation will not have a material adverse effect on the Company.
      
    On July 7, 2015, a group of 13 franchisees, whose licenses had been terminated by the Company due to defaults in performance, commenced a collective arbitration proceeding in San Diego, California. The claimants’ demand for arbitration asserts claims for breach of contract, promissory fraud, negligent misrepresentation, breach of the implied covenant of good faith and fair dealing, wrongful termination of franchise agreements and “wrongful competition” pursuant to unspecified state business practices, unfair competition and franchise statutes. The claimants also seek “a preliminary and permanent injunction prohibiting the Company from seeking to operate corporate clinics within 25 miles of any franchise clinic.” Although commenced in California, the arbitration proceeding has been moved to Arizona, pursuant to the franchise agreements in dispute, which include clauses that make it mandatory for any arbitration proceeding to be conducted in Phoenix, Arizona. Each agreement also requires claims to be arbitrated on an individual, not class-wide basis. Additionally, some of the claimants may be unauthorized assignees of franchisees and, therefore, may not have standing to assert certain claims. The Company does not believe any of the claims, either collectively or individually, have any legal merit and intends to vigorously defend the arbitration proceeding.
    XML 54 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 3 - Notes Receivable (Details Textual) - USD ($)
    1 Months Ended
    Jul. 31, 2015
    Jul. 31, 2012
    Sep. 30, 2015
    Dec. 31, 2014
    Non-interest Bearing Unsecured Promissory Note 2 [Member]        
    Notes Receivable, Contractual Term 2 years      
    Financing Receivable, Net $ 29,925      
    Non-interest Bearing Unsecured Promissory Note 1 [Member]        
    Notes Receivable, Contractual Term 2 years      
    Financing Receivable, Net $ 10,000      
    Interest Bearing Unsecured Promissory Note [Member]        
    Notes Receivable, Contractual Term 1 year      
    Financing Receivable, Net $ 29,925      
    Notes Receivable, Interest Rate 4.00%      
    Company-owned Clinic [Member]        
    Notes Receivable, Contractual Term   4 years 180 days    
    Financing Receivable, Net   $ 90,000    
    Notes Receivable, Interest Rate   6.00%    
    Notes Receivable, Principal and Interest, Term   3 years 180 days    
    Financing Receivable, Net     $ 87,557 $ 59,269
    XML 55 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 5 - Intangible Assets (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Schedule of Intangible Assets and Goodwill [Table Text Block]
        As of September 30, 2015
       
    Gross Carrying
    Amount
     
    Accumulated
    Amortization
     
    Net Carrying
    Value
    Amortized intangible assets:                        
    Reacquired franchise rights   $ 1,296,248     $ 108,916     $ 1,187,332  
    Customer relationships     387,793       101,652       286,141  
    Reacquired development rights     923,250       79,239       844,011  
      $ 2,607,291     $ 289,807     $ 2,317,484  
    Unamortized intangible assets:                      
    Goodwill                     2,948,363  
    Total intangible assets                   $ 5,265,847  
    Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
    2015   $ 129,101  
    2016     518,896  
    2017     368,634  
    2018     325,000  
    2019     325,000  
    Thereafter     650,853  
    Total   $ 2,317,484  
    XML 56 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)
    1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
    Jan. 31, 2015
    Sep. 30, 2015
    USD ($)
    Sep. 30, 2014
    USD ($)
    Sep. 30, 2015
    USD ($)
    Sep. 30, 2014
    USD ($)
    Dec. 31, 2014
    USD ($)
    Six Franchisees [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]            
    Number of Franchises           6
    Concentration Risk, Percentage           56.00%
    Minimum [Member] | Franchise Rights [Member]            
    Property, Plant and Equipment, Useful Life       6 years    
    Minimum [Member]            
    Property, Plant and Equipment, Useful Life       3 years    
    Regional Developers, Franchise Fees Collected Upon Sale of Franchise   $ 14,500   $ 14,500    
    Maximum [Member] | Franchise Rights [Member]            
    Property, Plant and Equipment, Useful Life       7 years    
    Maximum [Member]            
    Property, Plant and Equipment, Useful Life       7 years    
    Regional Developers, Franchise Fees Collected Upon Sale of Franchise   19,950   $ 19,950    
    Computer Software, Intangible Asset [Member]            
    Property, Plant and Equipment, Useful Life       5 years    
    Customer Relationships [Member]            
    Property, Plant and Equipment, Useful Life       2 years    
    Cash Equivalents, at Carrying Value   0   $ 0   $ 0
    Impairment of Long-Lived Assets Held-for-use       0 $ 0  
    Allowance for Doubtful Accounts Receivable   $ 85,376   $ 85,376   81,032
    Franchise Monthly Marketing Fee Gross Sales Percentage 2.00%          
    Initial Franchise Agreement Term       10 years    
    Number of Franchise Licenses Terminated   10   30    
    Revenue Recognized in Conjunction with Franchise License Terminations   $ 290,000   $ 870,000    
    Recognition of Previously Deferred Costs in Conjunction with Franchise License Terminations   153,000   389,750    
    Regional Developers License Fee   7,250   $ 7,250    
    Regional Developers License Fee Current Franchise Fee Percentage       25.00%    
    Regional Developers Royalty Sales Generated by Franchises Percentage       3.00%    
    Franchise Royalty Gross Sales Percentage       7.00%    
    Marketing and Advertising Fee Gross Sales Percentage       2.00%    
    Advertising Expense   377,122 $ 53,691 $ 853,110 $ 93,730  
    Liability for Uncertain Tax Positions, Current   142,000   142,000   122,000
    Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued   $ 36,000   $ 36,000   $ 30,000
    XML 57 R49.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 10 - Summary of Future Minimum Rental Payments for Operating Leases (Details)
    Sep. 30, 2015
    USD ($)
    2015 $ 431,526
    2016 2,548,329
    2017 2,513,975
    2018 1,948,791
    2019 1,601,175
    Thereafter 8,443,060
    $ 17,486,856
    XML 58 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 6 - Maturities of Notes Payable (Details)
    Sep. 30, 2015
    USD ($)
    2015 $ 231,500
    2016 272,850
    2017 130,000
    Total $ 634,350
    XML 59 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
    9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Cash flows from operating activities:    
    Net loss $ (5,416,317) $ (464,019)
    Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
    Provision for bad debts 4,344 $ 91,831
    Regional developer fees recognized upon acquisition of development rights (254,250)
    Net franchise fees recognized upon termination of franchise agreements (480,250)
    Notes receivable issued for payment of transfer fees (49,850)
    Depreciation and amortization 822,489 $ 141,707
    Gain on sale of property and equipment (11,500)
    Deferred income taxes 147,800
    Bargain purchase gain (384,214)
    Stock based compensation expense 646,077 $ 42,047
    Changes in operating assets and liabilities, net of effects from acquisitions:    
    Restricted cash 36,145 (158,950)
    Accounts receivable 94,684 (8,582)
    Income taxes receivable (53,989) (320,290)
    Prepaid expenses and other current assets 224,131 (45,230)
    Deferred franchise costs (18,100) $ 178,000
    Deposits and other assets (125,594)
    Accounts payable and accrued expenses 164,945 $ 450,515
    Co-op funds liability (26,834) 44,971
    Payroll liabilities 779,271 188,159
    Other liabilities (35,294) 56,547
    Deferred rent $ 62,549 543,563
    Income taxes payable (419,297)
    Deferred revenue $ (134,925) (435,354)
    Net cash used in operating activities (4,008,682) $ (114,382)
    Cash flows from investing activities:    
    Cash paid for acquisitions (4,652,525)
    Reacquisition and termination of regional developer rights (1,075,500)
    Purchase of property and equipment (1,461,125) $ (538,323)
    Proceeds received on sale of property and equipment 11,500 2,500
    Payments received on notes receivable 21,562 19,301
    Net cash used in investing activities $ (7,156,088) (516,522)
    Cash flows from financing activities:    
    Deferred offering costs $ (511,921)
    Repayments on note payable $ (110,000)
    Net cash used in financing activities (110,000) $ (511,921)
    Net decrease in cash (11,274,770) (1,142,825)
    Cash at beginning of period 20,796,783 3,516,750
    Cash at end of period $ 9,522,013 2,373,925
    Supplemental cash flow disclosures:    
    Cash paid for income taxes $ 420,250
    Cash paid for interest $ 1,445
    XML 60 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 4 - Property and Equipment
    9 Months Ended
    Sep. 30, 2015
    Notes to Financial Statements  
    Property, Plant and Equipment Disclosure [Text Block]
    Note 4:
    Property and Equipment
     
    Property and equipment consists of the following:
     
        September 30,
    2015
      December 31,
    2014
             
    Office and computer equipment   $ 470,251     $ 209,575  
    Leasehold improvements     2,330,927       665,961  
    Software developed     688,471       564,560  
          3,489,649       1,440,096  
    Accumulated depreciation     (838,325 )     (305,644 )
          2,651,324       1,134,452  
    Assets in progress     950,893       -  
        $ 3,602,217     $ 1,134,452  
     
    Depreciation expense was $257,197 and $532,682 for the three and nine months ended September 30, 2015, respectively. Depreciation expense was $52,823 and $141,707 for the three and nine months ended September 30, 2014, respectively.
     
    Assets in progress relate to the ongoing development of company-owned or managed clinics, which are not yet placed in service.
    XML 61 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 1 - Franchise Agreements (Details)
    3 Months Ended 9 Months Ended
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Sep. 30, 2015
    Sep. 30, 2014
    Franchised Units [Member]            
    Clinics open at beginning of period 239 215 242 175    
    Opened during the period 13 16 36 57    
    Acquired during the period (2) (23)    
    Closed during the period (2) (1) (7) (2)    
    Clinics in operation at the end of the period 248 230 248 230    
    Total clinics in operation at the end of the period 239 215 242 175 248 230
    Entity Operated Units [Member]            
    Clinics open at beginning of period 23 4    
    Opened during the period 4 4    
    Acquired during the period 2 23    
    Closed during the period (2)    
    Clinics in operation at the end of the period 29 29    
    Total clinics in operation at the end of the period 23 4 29
    Clinics in operation at the end of the period 277 230 277 230    
    Total clinics in operation at the end of the period 277 230 277 230 277 230
    Clinic licenses sold but not yet developed         180 248
    XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 148 314 1 false 58 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.thejoint.com/20150930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.thejoint.com/20150930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.thejoint.com/20150930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.thejoint.com/20150930/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.thejoint.com/20150930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Supplemental Disclosure of Non-cash Activity Sheet http://www.thejoint.com/20150930/role/statement-supplemental-disclosure-of-noncash-activity Supplemental Disclosure of Non-cash Activity Notes 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies Sheet http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies Note 1 - Nature of Operations and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Acquisitions Sheet http://www.thejoint.com/20150930/role/statement-note-2-acquisitions Note 2 - Acquisitions Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Notes Receivable Notes http://www.thejoint.com/20150930/role/statement-note-3-notes-receivable Note 3 - Notes Receivable Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Property and Equipment Sheet http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment Note 4 - Property and Equipment Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Intangible Assets Sheet http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets Note 5 - Intangible Assets Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Notes Payable Notes http://www.thejoint.com/20150930/role/statement-note-6-notes-payable Note 6 - Notes Payable Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Equity Sheet http://www.thejoint.com/20150930/role/statement-note-7-equity Note 7 - Equity Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Income Taxes Sheet http://www.thejoint.com/20150930/role/statement-note-8-income-taxes Note 8 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Related Party Transactions Sheet http://www.thejoint.com/20150930/role/statement-note-9-related-party-transactions Note 9 - Related Party Transactions Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://www.thejoint.com/20150930/role/statement-note-10-commitments-and-contingencies Note 10 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.thejoint.com/20150930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies 17 false false R18.htm 017 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-tables Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies 18 false false R19.htm 018 - Disclosure - Note 2 - Acquisitions (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-2-acquisitions-tables Note 2 - Acquisitions (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-2-acquisitions 19 false false R20.htm 019 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment-tables Note 4 - Property and Equipment (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment 20 false false R21.htm 020 - Disclosure - Note 5 - Intangible Assets (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets-tables Note 5 - Intangible Assets (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets 21 false false R22.htm 021 - Disclosure - Note 6 - Notes Payable (Tables) Notes http://www.thejoint.com/20150930/role/statement-note-6-notes-payable-tables Note 6 - Notes Payable (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-6-notes-payable 22 false false R23.htm 022 - Disclosure - Note 7 - Equity (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-7-equity-tables Note 7 - Equity (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-7-equity 23 false false R24.htm 023 - Disclosure - Note 10 - Commitments and Contingencies (Tables) Sheet http://www.thejoint.com/20150930/role/statement-note-10-commitments-and-contingencies-tables Note 10 - Commitments and Contingencies (Tables) Tables http://www.thejoint.com/20150930/role/statement-note-10-commitments-and-contingencies 24 false false R25.htm 024 - Disclosure - Supplemental Disclosure of Non-cash Activity (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-supplemental-disclosure-of-noncash-activity-details-textual Supplemental Disclosure of Non-cash Activity (Details Textual) Details http://www.thejoint.com/20150930/role/statement-supplemental-disclosure-of-noncash-activity 25 false false R26.htm 025 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-tables 26 false false R27.htm 026 - Statement - Note 1 - Franchise Agreements (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-1-franchise-agreements-details Note 1 - Franchise Agreements (Details) Details 27 false false R28.htm 027 - Statement - Note 1 - Earnings (Loss) Per Common Share (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-1-earnings-loss-per-common-share-details Note 1 - Earnings (Loss) Per Common Share (Details) Details 28 false false R29.htm 028 - Statement - Note 1 - Potential Shares of Common Stock Excluded from Diluted Net Loss Per Share (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-1-potential-shares-of-common-stock-excluded-from-diluted-net-loss-per-share-details Note 1 - Potential Shares of Common Stock Excluded from Diluted Net Loss Per Share (Details) Details 29 false false R30.htm 029 - Disclosure - Note 2 - Acquisitions (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-2-acquisitions-details-textual Note 2 - Acquisitions (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-2-acquisitions-tables 30 false false R31.htm 030 - Statement - Note 2 - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-2-assets-acquired-and-liabilities-assumed-details Note 2 - Assets Acquired and Liabilities Assumed (Details) Details 31 false false R32.htm 031 - Statement - Note 2 - Balance Sheet Adjustments Related to the Purchase Price Allocation (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-2-balance-sheet-adjustments-related-to-the-purchase-price-allocation-details Note 2 - Balance Sheet Adjustments Related to the Purchase Price Allocation (Details) Details 32 false false R33.htm 032 - Statement - Note 2 - Supplemental Pro Forma Information (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-2-supplemental-pro-forma-information-details Note 2 - Supplemental Pro Forma Information (Details) Details 33 false false R34.htm 033 - Disclosure - Note 3 - Notes Receivable (Details Textual) Notes http://www.thejoint.com/20150930/role/statement-note-3-notes-receivable-details-textual Note 3 - Notes Receivable (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-3-notes-receivable 34 false false R35.htm 034 - Disclosure - Note 4 - Property and Equipment (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment-details-textual Note 4 - Property and Equipment (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment-tables 35 false false R36.htm 035 - Statement - Note 4 - Property and Equipment (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment-details Note 4 - Property and Equipment (Details) Details http://www.thejoint.com/20150930/role/statement-note-4-property-and-equipment-tables 36 false false R37.htm 036 - Disclosure - Note 5 - Intangible Assets (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets-details-textual Note 5 - Intangible Assets (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets-tables 37 false false R38.htm 037 - Statement - Note 5 - Intangible Assets Acquired (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-5-intangible-assets-acquired-details Note 5 - Intangible Assets Acquired (Details) Details 38 false false R39.htm 038 - Statement - Note 5 - Estimated Amortization Expense (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-5-estimated-amortization-expense-details Note 5 - Estimated Amortization Expense (Details) Details 39 false false R40.htm 039 - Disclosure - Note 6 - Notes Payable (Details Textual) Notes http://www.thejoint.com/20150930/role/statement-note-6-notes-payable-details-textual Note 6 - Notes Payable (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-6-notes-payable-tables 40 false false R41.htm 040 - Statement - Note 6 - Maturities of Notes Payable (Details) Notes http://www.thejoint.com/20150930/role/statement-note-6-maturities-of-notes-payable-details Note 6 - Maturities of Notes Payable (Details) Details 41 false false R42.htm 041 - Disclosure - Note 7 - Equity (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-7-equity-details-textual Note 7 - Equity (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-7-equity-tables 42 false false R43.htm 042 - Statement - Note 7 - Fair Value Assumptions of Options Granted (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-7-fair-value-assumptions-of-options-granted-details Note 7 - Fair Value Assumptions of Options Granted (Details) Details 43 false false R44.htm 043 - Statement - Note 7 - Stock Options Activity (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-7-stock-options-activity-details Note 7 - Stock Options Activity (Details) Details 44 false false R45.htm 044 - Statement - Note 7 - Restricted Stock Activity (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-7-restricted-stock-activity-details Note 7 - Restricted Stock Activity (Details) Details 45 false false R46.htm 045 - Disclosure - Note 8 - Income Taxes (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-8-income-taxes-details-textual Note 8 - Income Taxes (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-8-income-taxes 46 false false R47.htm 046 - Disclosure - Note 9 - Related Party Transactions (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-9-related-party-transactions-details-textual Note 9 - Related Party Transactions (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-9-related-party-transactions 47 false false R48.htm 047 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://www.thejoint.com/20150930/role/statement-note-10-commitments-and-contingencies-details-textual Note 10 - Commitments and Contingencies (Details Textual) Details http://www.thejoint.com/20150930/role/statement-note-10-commitments-and-contingencies-tables 48 false false R49.htm 048 - Statement - Note 10 - Summary of Future Minimum Rental Payments for Operating Leases (Details) Sheet http://www.thejoint.com/20150930/role/statement-note-10-summary-of-future-minimum-rental-payments-for-operating-leases-details Note 10 - Summary of Future Minimum Rental Payments for Operating Leases (Details) Details 49 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets (Current Period Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 2, 3 are contained in other reports, so were removed by flow through suppression. In ''Note 2 - Assets Acquired and Liabilities Assumed (Details)'', column(s) 2, 4 are contained in other reports, so were removed by flow through suppression. In ''Note 2 - Balance Sheet Adjustments Related to the Purchase Price Allocation (Details)'', column(s) 1 are contained in other reports, so were removed by flow through suppression. In ''Note 5 - Intangible Assets Acquired (Details)'', column(s) 2 are contained in other reports, so were removed by flow through suppression. jynt-20150930.xml jynt-20150930_cal.xml jynt-20150930_def.xml jynt-20150930_lab.xml jynt-20150930_pre.xml jynt-20150930.xsd true true XML 63 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 5 - Intangible Assets Acquired (Details)
    Sep. 30, 2015
    USD ($)
    Franchise Rights [Member]  
    Amortized intangible assets:  
    Gross Carrying Amount $ 1,296,248
    Accumulated Amortization 108,916
    Net Carrying Value 1,187,332
    Customer Relationships [Member]  
    Amortized intangible assets:  
    Gross Carrying Amount 387,793
    Accumulated Amortization 101,652
    Net Carrying Value 286,141
    Development Rights [Member]  
    Amortized intangible assets:  
    Gross Carrying Amount 923,250
    Accumulated Amortization 79,239
    Net Carrying Value 844,011
    Gross Carrying Amount 2,607,291
    Accumulated Amortization 289,807
    Net Carrying Value 2,317,484
    Goodwill 2,948,363
    Total intangible assets $ 5,265,847
    XML 64 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Note 4 - Property and Equipment (Tables)
    9 Months Ended
    Sep. 30, 2015
    Notes Tables  
    Property, Plant and Equipment [Table Text Block]
        September 30,
    2015
      December 31,
    2014
             
    Office and computer equipment   $ 470,251     $ 209,575  
    Leasehold improvements     2,330,927       665,961  
    Software developed     688,471       564,560  
          3,489,649       1,440,096  
    Accumulated depreciation     (838,325 )     (305,644 )
          2,651,324       1,134,452  
    Assets in progress     950,893       -  
        $ 3,602,217     $ 1,134,452